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 Introduction and overview of the thesis 
 
PERIPHERAL ARTERIAL DISEASE (PAD) affects 
more than 30 million people worldwide. In the United 
States, more than 8 million people suffer from this 
disease. The American College of Cardiology and the 
American Heart Association have recognized the 
importance of identifying and treating this disease and 
have initiated national campaigns to increase its 
awareness. Many patients, however, do not exhibit 
warning signs of the disease and remain undiagnosed. 
These missed diagnoses create a major health burden. 
When left untreated, PAD can lead to walking 
impairment and in more severe stages, to gangrene and 
leg amputation. Patients with PAD often have 
atherosclerotic disease in other parts of the body, which 
places the patient at risk for myocardial infarction, 
stroke and death. Especially coronary artery disease has 
been recognized as a complice of PAD. This thesis 
provides an insight in the prognosis of patients with 
peripheral and coronary artery disease and attempts to 
find solutions in improving the identification and 
management of this disease.   
Peripheral arterial disease encompasses a range 
of disorders affecting the arterial beds exclusive of the 
coronary arteries. The most common disease process 
underlying PAD is atherosclerosis. Major risk factors of 
atherosclerosis are tobacco use, diabetes and 
hypertension. The ankle-brachial index is currently the 
standard diagnostic test for PAD in epidemiological 
surveys, vascular laboratories and in office practice. The 
ankle-brachial index can also be used as tool to monitor 
the efficacy of therapeutic interventions and for 
prognostic purposes. Prognostic information in patients 
with PAD may provide the basis for optimal 
management strategies. A risk index for long-term 
mortality, based on clinical risk factors, laboratory 
values, electrocardiography and ankle-brachial index 
values is presented in chapter 2. The prognostic value of 
postexercise ankle-brachial index values in addition to 
resting ankle-brachial index values is evaluated in 
chapter 3. Since coronary artery disease is highly 
prevalent among patients with PAD, refinement of risk 
stratification may be accomplished by routine cardiac 
testing. In chapter 4, the prognostic value of left 
ventricular ejection fraction and stress-induced ischemia 
is evaluated in addition to ankle-brachial index values 
and clinical risk factors. Chapter 5 presents a study in 
which serial ankle-brachial index measurements over 
time are correlated with mortality and cardiac outcome.  
Although identification and risk stratification 
are important steps in the management of patients with 
PAD, it is treatment that will reduce the morbidity and 
mortality associated with PAD. Lifelong treatment 
should include modification and elimination of risk 
factors and promotion of daily exercise and use of a 
nonatherogenic diet. Underlying risk factors, such as 
dyslipidemia, diabetes and hypertension, should be 
optimally treated. Chapter 6 presents data from an 
observational study in which different cardiovascular 
medications are systematically evaluated for their 
cardioprotective and life-prolonging effect. Chapter 7 
evaluates the effect of intensified lipid-lowering therapy 
on long-term prognosis and examines whether higher 
doses of statins and lower LDL-cholesterol levels are 
both independently associated with improved outcome. 
Renal dysfunction has been identified as a major risk 
factor in atherosclerotic disease. Chapter 8 evaluates 
whether statins and angiotensin-converting enzyme 
inhibitors are associated with a lower progression rate of 
end-stage renal disease in patients with PAD. Diabetes 
is another major risk factor, with dysglycemia 
contributing to atherosclerotic progression and 
development of micro- and macrovascular 
complications. Chapter 9 evaluates the potential of lipid 
lowering treatment in improving glycemic control and 
prognosis of diabetic patients with PAD. 
Surgical interventions are indicated for 
individuals with claudication symptoms who have 
functional disability which is unresponsive to exercise 
or pharmacological therapy and have a reasonable 
likelihood to improve symptomatically. In patients with 
aortic aneurysms, reparative surgery may be indicated to 
eliminate the risk of rupture. Despite the various 
advantages of surgical intervention, mortality and 
cardiovascular morbidity are high in the perioperative 
period. Preoperative screening is essential in identifying 
patients at increased risk who benefit from perioperative 
protective medication. Chapter 10 reports the incidence 
of perioperative myocardial ischemia and relates the 
location of perioperative ischemia with the culprit 
coronary lesion as assessed with preoperative 
dobutamine stress echocardiography. Chapter 11 
evaluates the prevalence of and prognosis of 
unrecognized myocardial infarction and silent 
myocardial ischemia in vascular surgery patients. The 
prognostic value of impaired fasting glucose and 
glycemic control for perioperative cardiac ischemic 
events is presented in chapter 12. N-terminal pro-B-type 
natriuretic peptide (NT-proBNP) has emerged as a 
10 
  11 
marker of left ventricular dysfunction and has 
prognostic value in patients with congestive heart 
failure and coronary artery disease. Chapters 13 and 14 
evaluate the prognostic role of NT-proBNP in vascular 
surgery patients. The relation between NT-proBNP 
levels and the extent of myocardial ischemia, heart rate 
variability and changes in left ventricular function is 
evaluated in chapters 15, 16 and 17. Chapter 18 
discusses preoperative risk stratification in patients with 
renal dysfunction and chapter 19 evaluates the impact of 
glomerular filtration rate on minor troponin T 
concentrations for cardiac risk stratification. 
 Beta-blockers have been demonstrated to 
protect vascular surgery patients from adverse 
perioperative cardiac events and mortality. However, 
optimal management strategies are essential in this 
setting, since inadequate management may compromise 
efficacy and safety. Chapter 20 provides a review of 
perioperative management to address current issues and 
controversies.  Chapter 21 evaluates the effect of 
different cardiac medications that protects vascular 
surgery patients with left ventricular dysfunction. 
Chapter 22 evaluates the effect of high doses of beta-
blockers and tight heart rate control on the incidence of 
perioperative myocardial ischemia, troponin T release 
and cardiovascular events. The effect of beta-blockers 
on in-hospital and long-term survival in patients with 
severe left ventricular dysfunction is examined in 
chapter 23. Selective or non-selective beta-blocker 
therapy may interfere with the interpretation of 
dobutamine stress echocardiography, which is 
recommended as screening tool for high-risk vascular 
surgery patients. The hemodynamic responses and long-
term follow-up results of patients using selective or non-
selective beta-blockers are presented in chapter 24. 
Recently, statins have emerged as medication with 
cardioprotective effects. Chapter 25 evaluates the 
intensity of statin therapy in relation to myocardial 
ischemia, troponin T release and clinical cardiac 
outcome in patients undergoing major vascular surgery.  
With the safety of current surgical procedures, 
elderly patients are now commonly referred for surgical 
intervention. Perioperative management and risk factor 
control in elderly patients is discussed in chapter 26 and 
27. Chapter 28 gives a comment on the use of 
preoperative revascularization before major vascular 
surgery. Finally, chapters 29 and 30 evaluate 
perioperative cardiac outcome between different 
surgical procedures for carotid artery stenosis and 
abdominal aortic aneurysm.  
Atherosclerosis is a leading cause of death in 
industrialized countries. Hopefully, the results of these 
studies will contribute to our understanding of 
peripheral and coronary artery disease for the 
improvement in management and outcome of these 
patients 
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A prognostic risk index for long-term mortality in 
patients with peripheral arterial disease 
Harm H.H. Feringa, MDa, Jeroen J. Bax, MDb, Sanne Hoeks, MSca, Virginie H. van Waning, MDc, Abdou Elhendy, 
MDd, PhD, Stefanos E. Karagiannis, MDa, Radosav Vidakovic, MDa, Olaf Schouten, MDe, Eric Boersma, PhDa, 
Don Poldermans, MDc 
 
 
Background:  Prognostic information in patients with 
peripheral arterial disease (PAD) may provide the basis 
for optimal management strategies, including risk factor 
modification and pharmacologic treatment at an early 
stage. This study aimed to develop a prognostic risk 
index for long-term mortality in patients with PAD. 
Methods: In a single-centre observational cohort study, 
2,642 patients with ankle-brachial index ≤0.90 were 
randomly divided into derivation (n=1,332) and 
validation (n=1,310) cohorts. Cox hazards regression 
analysis with stepwise backward elimination identified 
predictors of 1-year, 5-year and 10-year mortality in the 
derivation cohort. Weighted points were assigned to 
each predictor. Discrimination of the index was 
determined in both the derivation and validation 
cohorts. 
Results: During 10-year follow-up, 42.2% and 40.4 % 
of patients died in the derivation and validation cohort, 
respectively. The risk index for 10-year mortality 
(+points) included renal dysfunction (+12), heart failure 
(+7), ST-changes (+5), age>65 (+5), 
hypercholesterolemia (+5), ankle-brachial index <0.60 
(+4), Q-waves (+4), diabetes (+3), cerebrovascular 
disease (+3) and pulmonary disease (+3). Statins (-6), 
aspirin (-4) and β-blockers (-4) were associated with 
reduced 10-year mortality. Patients were stratified into 
low (<0 points), low-intermediate (0-5 points), high-
intermediate (6-9 points) and high (>9 points) risk 
categories, according to risk score. Ten-year mortality 
rates were 22.1%, 32.2%, 45.8% and 70.4%, 
respectively (p<0.001) and comparable to mortality 
rates in the validation cohort. C-statistics demonstrated 
good discrimination both in the derivation (0.72) and 
validation cohort (0.73). 
Conclusion: A prognostic risk index for long-term 
mortality stratified patients with PAD into different risk 
categories. This may be useful for risk stratification, 
patient counseling and medical decision making. 
_____________________________________________________________________________________________
LOWER EXTREMITY peripheral arterial disease 
(PAD) is a manifestation of systemic atherosclerosis 
and is associated with increased cardiovascular 
morbidity and mortality [1-3]. Patients with PAD have a 
3-fold increased risk to die from all causes and a 6-fold 
increased risk to die from cardiovascular disease within 
a period of 10 years, as compared to patients without 
PAD [1]. The prevalence of PAD has been reported to 
range from 4% in patients aged 40 years and older, to 
over 20% in patients aged 70 years and older [4-9]. It 
has been estimated that approximately 8 to 12 million 
people in the United States suffer from this disease [4]. 
However, prevalence values may even be higher since a 
substantial proportion of the population has undetected 
PAD [3,4,7].  
An increased awareness of PAD may help to 
improve identification of patients with underlying PAD. 
Patients who present with PAD may benefit from 
antiplatelet therapy, walking exercise, risk factor 
reduction and life-style modifications [10,11]. Many 
clinical risk factors have been identified as predictors of 
adverse events, however, to our knowledge, a 
prognostic risk index including clinical risk factors, 
electrocardiographic data, ankle-brachial index values 
and chronic cardiovascular medication has not yet been 
developed in patients with PAD.  
A comprehensive prognostic risk index may 
provide an overall framework for physicians to identify 
risk factors and to help making predictions based on 
these risk factors at an early stage of the disease. After 
risk factors in the individual patient have been 
identified, a risk score can be calculated and the patient 
can be classified into a particular risk category. 
Prognostic information may help the clinician in the 
decision for targeted treatment interventions. The 
objective of this study was to develop and provide an 
accurate and easy-to-use prognostic risk index for long-
term mortality that could stratify patients with PAD into 
different risk groups. This risk index was validated in 
two independent patient samples. 
 
 
 
 
Department of Cardiology (a), Anesthesiology (c) and Vascular 
Surgery (e), Erasmus MC, Rotterdam, the Netherlands. Department of 
Cardiology (b), Leiden University Medical Center, Leiden, the 
Netherlands. Department of Cardiology, Marshfield Clinics, 
Marshfield, WI, USA 
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METHODS 
 
The Erasmus Medical Center in Rotterdam, the 
Netherlands, serves a population of approximately 3 
million people and acts as a tertiary referral center for 
approximately 30 affiliated hospitals. A total of 2,642 
consecutive patients with PAD were referred to our 
department of Vascular Medicine between January 1983 
and August 2005 for the evaluation and management of 
their disease.  
 
Ankle-brachial index 
The ankle-brachial index at rest was measured in each 
patient by trained technicians, using a Doppler 
ultrasonic instrument with an 8 MHz vascular probe 
(Imexdop CT+ Vascular Doppler, Miami Medical, 
USA). The ABI in the right and left leg was calculated 
by dividing the right and the left ankle pressure by the 
brachial pressure. The higher of the two brachial blood 
pressures was used if a discrepancy in systolic blood 
pressure was present. Again, the higher of the dorsalis 
pedis and posterior tibial artery pressure was used if a 
discrepancy in systolic blood pressure between the two 
arteries was measured [11]. Of the ABI values obtained 
in each leg, the lower was used and PAD was defined as 
a resting ankle-brachial index of ≤0.90. An ankle-
brachial index of <0.60 was considered as severe PAD.  
 
Clinical variables 
A detailed cardiovascular history was obtained, 
including a history of stable angina pectoris, myocardial 
infarction, coronary artery bypass grafting, congestive 
heart failure, and cerebrovascular event. Patients were 
also screened for the following clinical risk factors: 
diabetes mellitus, hypertension, hypercholesterolemia, 
renal dysfunction, current smoking and chronic 
obstructive pulmonary disease. Diabetes mellitus was 
recorded if patients presented with a fasting glucose 
level of ≥7.0 mmol/L, or in those who required medical 
treatment. Hypertension was recorded if patients 
presented with a blood pressure ≥140/90 mmHg or if 
patients received medical treatment. 
Hypercholesterolemia was recorded if patients 
presented with a plasma cholesterol level ≥5.5 mmol/L, 
or if the diagnosis was established by the referring 
physician. Renal dysfunction was recorded if patients 
presented with a serum creatinine level ≥ 2.0 mg/dL 
(177 μmol/L) or in those who required dialysis. The 
body mass index (Quetelet-index) was calculated as 
weight in kilograms divided by the square of height in 
meters. Patients with a body mass index >0.30 were 
considered obese. Baseline 12-lead electrocardiography 
was evaluated for Q-waves, ST-segment depression or 
elevation, left ventricular hypertrophy, right bundle 
branch block, left bundle branch block and atrial 
fibrillation. All patients were assessed for cardiac 
medication use, including aspirin, angiotensin 
converting enzyme inhibitors, β-blockers and statins. To 
ascertain the long-term use of cardiovascular 
medication, medication had to be documented at least at 
2 months after the first visit. 
 
Definition of outcome 
The median follow-up period was 8 years (interquartile 
range: 4-11 years). End-point was all-cause mortality at 
1-year, 5-year and 10-year. Mortality data was collected 
by reviewing the medical records, by approaching the 
Office of Civil Registry, and through follow-up 
interviews with patients, family-members and referring 
physicians.  
 
Development of the prognostic risk index 
A random sample of 1,332 patients (50%) of the total 
cohort was assigned to the derivation cohort, which was 
used for developing the prognostic index (Rotterdam 
derivation cohort) [12,13]. A total of 1,310 patients 
(50%) were assigned to the validation cohort 
(Rotterdam validation cohort). A descriptive 
comparison between the derivation and validation 
cohorts was performed using the chi-square test for 
categorical variables and the Student t test for 
continuous variables. Cox proportional hazards 
regression analysis was used to analyze the association 
between clinical variables and mortality. A prognostic 
risk index was developed for 1-year, 5-year and 10-year 
mortality. To select a final set of significant (p<0.05) 
risk factors in the derivation cohort, all baseline clinical 
variables were entered into a multivariate Cox 
proportional hazards regression model with stepwise 
backward elimination of the least significant variable. 
The non-modifiable variables age and gender were 
always entered into the multivariate regression model, 
despite the level of significance, and were eliminated at 
the final model if non-significant. Separate risk scoring 
systems for 1-year, 5-year and 10-year mortality were 
then constructed by assigning weighted points to each 
independent and significant predictor in the derivation 
cohort. Weighted points were calculated by multiplying 
the coefficient of the predictor by 10 and by rounding it 
off to the nearest integer. In each patient, a risk score for 
1-year, 5-year and 10-year mortality was calculated by 
adding up the points for each risk factor present. Based 
on their risk score, patients were divided into four 
different risk groups (low, low-intermediate, high-
intermediate, high), using the quartiles as cut-off values.  
 
Validation of prognostic risk index 
The 1-year, 5-year and 10-year prognostic risk index 
was applied to the Rotterdam validation cohort and 
predicted 1-year, 5-year and 10-year mortality rates 
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Table 1. Baseline characteristics of the derivation and 
validation cohorts 
Characteristic Rotterdam 
derivation 
cohort 
(n=1,332) 
Rotterdam 
validation 
cohort 
(n=1,310) 
p 
value 
Age >65 years, No. (%) 686 (51.5) 636 (48.5%) 0.13 
Male gender, No. (%) 964 (72.4) 934 (71.3) 0.56 
Angina pectoris, No. (%) 317 (23.8) 316 (24.1) 0.85 
Previous MI, No. (%) 506 (38.0) 481 (36.7) 0.50 
Previous CABG, No. (%) 266 (20.0) 223 (17.0) 0.051
CAD (summary variable), No. (%) 601 (45.1) 584 (44.6) 0.78 
History of CHF, No. (%) 105 (7.9) 119 (9.1) 0.27 
History of CVA/TIA, No. (%) 101 (7.6) 99 (7.6) 0.98 
Diabetes mellitus, No. (%)  229 (17.2) 234 (17.9) 0.65 
Hypercholesterolemia, No. (%)  291 (21.8) 274 (20.9) 0.56 
Hypertension, No. (%)  609 (45.7) 627 (47.9) 0.27 
Current smoking, No. (%)  461 (34.6) 464 (35.4) 0.66 
Renal dysfunction, No. (%) 67 (5.0) 66 (5.0) 0.99 
COPD, No. (%) 149 (11.2) 171 (13.1) 0.14 
Obesity, No. (%) 160 (12.0) 148 (11.3) 0.57 
ABI <0.60, No. (%)  590 (44.3) 589 (45.0) 0.73 
Electrocardiography, No. (%)    
  Q waves  373 (28.0) 341 (26.0) 0.25 
  ST segment changes 204 (15.3) 195 (14.9) 0.76 
  Left ventricular hypertrophy 74 (5.6) 72 (5.5) 0.95 
  Right bundle branch block 20 (1.5) 27 (2.1) 0.28 
  Left bundle branch block 50 (3.8) 47 (3.6) 0.82 
  Atrial fibrillation 21 (1.6) 38 (2.9) 0.021
Medication    
  Aspirin, No. (%) 291 (21.8) 284 (21.7) 0.92 
  ACE-inhibitors, No. (%) 340 (25.5) 347(26.5) 0.57 
  β-blocker, No. (%) 335 (25.2) 319 (24.4) 0.63 
  Statins, No. (%) 257 (19.3) 258 (19.7) 0.80 
Enrollment after 1995, No. (%) 553 (41.5) 585 (44.7) 0.10 
MI = myocardial infarction, CABG = coronary artery bypass grafting, 
CAD = coronary artery disease, CHF = congestive heart failure, 
CVA/TIA = cerebrovascular accident/transient ischemic attack, 
COPD = chronic obstructive pulmonary disease, ABI = ankle-brachial 
index, ACE-inhibitors = angiotensin converting enzyme inhibitors. 
were compared. The prognostic risk index was also 
validated in an independent cohort outside the Erasmus 
Medical Center (Netherlands Heart Survey cohort). This 
cohort constituted of 688 patients with PAD who came 
from 11 hospitals in the Netherlands. Five hospitals 
were located in the centre part of the country, three 
centers in the northern region and three in the southern 
region. The participating sites included 2 small centers 
(<400 beds), 5 of intermediate size (400 to 800 beds) 
and 4 large centers (>800 beds). Two centers were 
university hospitals. Data collection in this cohort was 
part of a survey of clinical practice supported by the 
Netherlands Heart Foundation in the context of the Euro 
Heart Survey Programme. Since follow-up in this cohort 
was 1 year, only the 1-year prognostic risk index was 
validated in this Netherlands Heart Survey cohort. To 
examine the discrimination of our prognostic risk 
indexes, we determined the area under the receiver 
operating characteristic (ROC) curve, which is 
comparable to the C-statistic [13]. C-statistics in the 
validation cohorts were calculated based on the 
mortality risk score system created from the derivation 
cohort. Hazard ratios are given with corresponding 95% 
confidence intervals. For all tests, a p value <0.05 (two-
sided) was considered significant. All analysis was 
performed using SPSS-11.0 statistical software (SPSS 
Inc., Chicago, Illinois). 
 
RESULTS 
 
Baseline characteristics are presented in Table 1.In the 
Rotterdam derivation cohort, median age was 65.2 years 
(interquartile range: 57.3 to 72.1 years), 72.4% were 
male and the median ankle-brachial index was 0.60 
(interquartile range: 0.50 to 0.75). In the Rotterdam 
validation cohort, median age was 64.7 years 
(interquartile range: 56.5 to 72.1 years), 71.3% were 
male and the median ankle-brachial index was 0.60 
(interquartile range: 0.45 to 0.75). No significant 
differences in baseline characteristics between the two 
cohorts were observed, except for atrial fibrillation 
which was less frequently determined in the derivation 
cohort compared to the validation cohort (1.6% vs. 
2.9%, respectively, p=0.021). During 1-year, 5-year and 
10-year of follow-up, 81 (6.1%), 298 (22.4%), and 562 
(42.2%) patients, respectively, died in the derivation 
cohort and 88 (6.7%), 306 (23.4%), and 529 (40.4%) 
patients, respectively, died in the Rotterdam validation 
cohort. At 1-year follow-up, 74 (10.8%) patients died in 
the Netherlands Heart Survey validation cohort. 
 
In univariate analysis, risk factors associated with 
increased 1-year, 5-year and 10-year mortality included 
age above 65 years, previous myocardial infarction, 
history of congestive heart failure, history of 
cerebrovascular events, renal dysfunction, ankle-
brachial index less than 0.60 and electrocardiographic Q 
waves and ST segment deviations (Table 2). Angina 
pectoris and a history of coronary artery bypass grafting 
were associated with an increased risk of 1-year 
mortality. Diabetes mellitus and chronic pulmonary 
disease were associated with an increased risk of 5-year 
and 10-year mortality. Hypertension and right bundle 
branch block were associated with an increased risk of 
10-year mortality. Univariate analysis also demonstrated 
that statin therapy was associated with a reduced risk of 
1-year, 5-year and 10-year mortality, aspirin with a 
reduced risk of 5-year mortality and β-blocker therapy 
with a reduced risk of 1-year and 10-year mortality. 
 
Multivariate proportional hazards regression analysis 
using stepwise backward deletion of the least significant 
variables identified 10, 12 and 13 clinical variables as 
independent and significant predictors of 1-year, 5-year 
and 10-year mortality, respectively (Table 3). A risk 
score for 1-year, 5-year and 10-year mortality from each  
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Table 2. Univariate analysis of clinical variables and mortality in the derivation cohort (n=1332). 
Characteristic Hazards ratio (95% 
CI) for  
1-year mortality 
p- value Hazards ratio (95% 
CI) for  
5-year mortality 
p- value Hazards ratio (95% 
CI) for  
10-year mortality 
p- value 
Age >65 years 4.59 (2.63-8.02) <0.001 2.10 (1.66-2.65) <0.001 1.65 (1.39-1.95) <0.001 
Male gender 1.02 (0.63-1.66) 0.93 0.81 (0.64-1.03) 0.080 1.01 (0.83-1.22) 0.93 
Angina pectoris  1.71 (1.09-2.68) 0.019 1.26 (0.99-1.60) 0.063 1.16 (0.96-1.41) 0.12 
Previous MI 2.20 (1.43-3.38) <0.001 1.61 (1.29-2.00) <0.001 1.53 (1.30-1.81) <0.001 
Previous CABG 2.01 (1.28-3.16) 0.002 0.87 (0.66-1.15) 0.32 1.08 (0.88-1.32) 0.47 
History of CHF 2.71 (1.55-4.74) <0.001 3.07 (2.30-4.09) <0.001 3.01 (2.35-3.85) <0.001 
History of CVA/TIA 2.41 (1.37-4.25) 0.002 2.34 (1.71-3.19) <0.001 1.70 (1.28-2.25) <0.001 
Diabetes mellitus   1.41 (0.84-2.37) 0.20  1.61(1.23-2.10) <0.001 1.45 (1.17-1.80) 0.001 
Hypercholesterolemia  1.29 (0.76-2.19) 0.35  1.25 (0.93-1.66) 0.14 1.21 (0.97-1.51) 0.097 
Hypertension  1.41 (0.92-2.15) 0.12  1.14 (0.91-1.42) 0.25 1.23 (1.04-1.46) 0.015 
Current smoking  1.05 (0.68-1.63) 0.83 1.01 (0.81-1.27) 0.91 1.02 (0.86-1.22) 0.79 
Renal dysfunction 5,49 (3.22-9.35) <0.001  4.99 (3.60-6.93) <0.001 4.11 (3.07-5.51) <0.001 
COPD 1.16 (0.62-2.15) 0.64 1.38 (1.01-1.88) 0.045 1.41 (1.11-1.79) 0.005 
Obesity 1.38 (0.40-4.69) 0.61 0.80 (0.39-1.65) 0.55  0.72 (0.40-1.27) 0.26 
ABI <0.60 3.02 (1.91-4.79) <0.001 2.19 (1.75-2.73) <0.001 1.62 (1.38-1.92) <0.001 
Electrocardiography       
  Q waves  2.88 (1.88-4.41) <0.001 1.75 (1.40-2.19) <0.001 1.71 (1.44-2.04) 0.001 
  ST changes 2.18 (1.33-3.57) 0.002 1.73 (1.33-2.26) <0.001 1.71 (1.36-2.13) <0.001 
  LVH 0.62 (0.20-1.96) 0.41 1.12 (0.71-1.79) 0.62 1.38 (0.99-1.91) 0.059 
  RBBB 1.70 (0.42-6.91) 0.46 1.90 (0.90-4.02) 0.093 2.48 (1.43-4.31) 0.001 
  LBBB 0.62 (0.15-2.52) 0.50 1.19 (0.71-2.00) 0.51 1.20 (0.81-1.76) 0.37 
  Atrial fibrillation 2.48 (0.78-7.84) 0.12 1.21 (0.54-2.72) 0.64 1.39 (0.72-2.69) 0.33 
Medication       
  Aspirin 0.58 (0.32-1.07) 0.080 0.72 (0.54-0.95) 0.021 0.86 (0.70-1.06) 0.16 
  ACE-inhibitor 1.69 (1.09-2.61) 0.019 0.94 (0.73-1.20) 0.60 1.14 (0.94-1.37) 0.19 
  β-blocker 0.26 (0.12-0.57) 0.001 0.77 (0.58-1.01) 0.059 0.68 (0.54-0.84) <0.001 
  Statins 0.43 (0.21-0.89) 0.023 0.65 (0.48-0.89) 0.008 0.63 (0.49-0.80) <0.001 
Enrollment after 1995 1.04 (0.68-1.60) 0.85 0.93 (0.74-1.17) 0.53 0.56 (0.46-0.69) <0.001 
MI = myocardial infarction, CABG = coronary artery bypass grafting, CHF = congestive heart failure, CVA/TIA = cerebrovascular 
accident/transient ischemic attack, COPD = chronic obstructive pulmonary disease, ABI = ankle-brachial index, LVH = left ventricular 
hypertrophy, RBBB = right bundle branch block, LBBB = left bundle branch block, ACE-inhibitors = angiotensin converting enzyme inhibitors. 
 
multivariate model was calculated for each individual 
patient and scores ranged from -25 to 59 for 1-year 
mortality (median: 13, interquartile range: 0 to 22), from 
-11 to 32 for 5-year mortality (median: 7, interquartile 
range: 0-14) and from -13 to 38 for 10-year mortality 
(median: 5, interquartile range: -1 to 9). Figure 1 
summarizes the proportion of patients who died within 
1-year, 5-year and 10-year in the derivation cohort 
stratified according to the four different risk 
classification groups. One-year, 5-year and 10-year 
mortality rates increased significantly from the low risk 
group to the high risk group (all: p<0.001, Figure 1).  
 
The mortality rate in each category in the derivation 
cohort was comparable to those in the Rotterdam 
validation cohort (Figure 1). Kaplan Meier curves 
stratified according to the four risk groups showed that 
Kaplan-Meier survival curves in the derivation cohort 
were comparable to survival curves in the Rotterdam 
validation cohort (Figure 2). The C-statistic 
discrimination of the final multivariate model for 1-year 
mortality was better in the derivation cohort (0.80), 
compared to the Rotterdam validation cohort (0.74) and 
the Netherlands Heart survey cohort (0.73). Also for 5-
year mortality, a better discrimination of the final model 
was observed in the derivation cohort (area under the 
ROC curve: 0.74 and 0.73, respectively). Interestingly, 
the discrimination of the final model for 10-year 
mortality was less in the derivation cohort (0.72), 
compared to the Rotterdam validation cohort (0.73). 
 
DISCUSSION 
 
In this study, we developed a prognostic risk index for 
1-year, 5-year and 10-year mortality that can be used as 
a point scoring system to stratify patients with 
peripheral arterial disease into low, low-intermediate, 
high-intermediate, and high risk groups. The risk 
scoring system included non-modifiable variables, such 
as age and gender, and modifiable clinical variables 
obtained from medical history, physical examination, 
laboratory testing, electrocardiography and ankle-
brachial index measurements. Chronic cardiac 
medication use was also included in the risk scoring 
system. 
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Table 3. The prognostic risk index for 1-year, 5-year and 10-year mortality. 
One-year risk index Hazards ratio (95% CI) for 
1-year mortality* 
p value Coefficient Points 
Age >65 years 4.47 (2.54-7.88) <0.001 1.50 + 15 
Renal dysfunction 4.37 (2.38-8.02) <0.001 1.48 + 15 
Hypercholesterolemia 3.60 (1.91-6.78) <0.001 1.28 + 13 
History of congestive heart failure 2.58 (1.42-4.69) 0.002 0.94 + 9 
Ankle-brachial index <0.60 2.26 (1.41-3.60) 0.001 0.81 + 8 
Q-waves 1.98 (1.24-3.15) 0.004 0.68 + 7 
Diabetes mellitus  1.77 (1.02-3.04) 0.041 0.57 + 6 
β-Blockers 0.53 (0.29-0.95) 0.034 -0.64 - 6 
Aspirin 0.46 (0.24-0.87) 0.018 -0.77 - 8 
Statins  0.17 (0.07-0.44) <0.001 -1.78 - 18 
Area under the Receiver Operating Characteristic Curve: 0.80      Total points:_______+ 
In multivariate regression analysis with stepwise deletion. 
 
Five-year risk index Hazards ratio (95% CI) for 
5-year mortality* 
p value Coefficient Points 
Renal dysfunction 4.30 (3.05-6.08) <0.001 1.46 + 15 
History of congestive heart failure 2.19 (1.58-3.02) <0.001 0.78 + 8 
Ankle-brachial index <0.60 2.08 (1.64-2.62) <0.001 0.73 + 7 
Age >65 years 1.93 (1.51-2.45) <0.001 0.66 + 7 
History of cerebrovascular events 1.92 (1.37-2.69) <0.001 0.65 + 7 
Hypercholesterolemia 1.67 (1.14-2.45) 0.008 0.51 + 5 
ST segment changes 1.62 (1.23-2.14) 0.001 0.48 + 5 
Diabetes mellitus 1.51 (1.14-1.99) 0.004 0.41 + 4 
Q-waves 1.34 (1.05-1.71) 0.020 0.29 + 3 
β-Blockers 0.70 (0.52-0.93) 0.013 -0.36 - 4 
Statins  0.53 (0.35-0.80) 0.003 -0.64 - 6 
Aspirin 0.49 (0.36-0.67) <0.001 -0.71 - 7 
Area under the Receiver Operating Characteristic Curve: 0.74       Total points: _______+ 
* In multivariate regression analysis with stepwise deletion. 
 
 Ten-year risk index Hazards ratio (95% CI) for  
10-year mortality* 
p value Coefficient Points 
Renal dysfunction 3.27 (2.40-4.46) <0.001 1.19 + 12 
History of congestive heart failure 2.10 (1.60-2.75) <0.001 0.74 + 7 
ST segment changes 1.60 (1.26-2.02) <0.001 0.47 + 5 
Age >65 years 1.59 (1.33-1.89) <0.001 0.46 + 5 
Hypercholesterolemia 1.56 (1.17-2.08) 0.002 0.45 + 5 
Ankle-brachial index <0.60 1.51 (1.28-1.80) <0.001 0.41 + 4 
Q-waves 1.48 (1.23-1.78) <0.001 0.39 + 4 
Diabetes mellitus 1.39 (1.11-1.74) 0.004 0.33 + 3 
History of cerebrovascular events 1.40 (1.04-1.88) 0.029 0.33 + 3 
Chronic obstructive pulmonary disease 1.34 (1.05-1.72) 0.019 0.29 + 3 
Aspirin 0.69 (0.55-0.87) 0.001 -0.37 - 4 
β-Blockers 0.62 (0.50-0.78) <0.001 -0.47 - 4 
Statins  0.54 (0.39-0.75) <0.001 -0.62 - 6 
Area under the Receiver Operating Characteristic Curve: 0.72      Total points: _______+ 
* In multivariate regression analysis with stepwise deletion. 
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Figure 1. Mortality rates at 1-year, 5-year and 10-year follow-up in the 
derivation and validation cohort, stratified according to four different 
risk classification groups (low, low intermediate, high intermediate 
and high risk group). 
 
Risk factors in PAD 
Results from the Framingham Heart Study identified 
age, male gender, serum cholesterol, hypertension, 
smoking, diabetes mellitus and coronary artery disease 
as risk factors for the occurrence of intermittent 
claudication [15]. The National Health and Nutrition 
Examination Survey revealed diabetes mellitus, 
hypercholesterolemia, low kidney function, coronary 
artery disease, smoking and black race/ethnicity as risk 
factors for prevalent PAD in adults aged 40 years and 
older [8]. The Rotterdam study showed that age over 75 
years, smoking, diabetes mellitus, hypertension, low 
HDL cholesterol levels and increased fibrinogen levels 
were significant determinants for PAD [9]. Independent 
risk factors for PAD in the Cardiovascular Health Study 
included age, diabetes mellitus, smoking, hypertension, 
hypercholesterolemia, increased creatinine levels, low 
body mass index, and non-white ethnicity [16]. The 
above-mentioned risk factors are common to the 
development of atherosclerosis, and most were included 
in our risk index. In our study, coronary artery disease 
was present in almost half of the study population 
(49.2% in the derivation cohort and 48.0% in the 
validation cohort). ST-changes and Q-waves were 
strong predictors of long-term outcome. This finding 
supports the use of routine ECG screening for 
prognostic risk assessment in PAD patients.  
  
Renal dysfunction 
Incidental atherosclerotic renal artery stenosis is a 
frequent finding in patients with PAD, with prevalence 
values of 33% in patients with chronic ischemic PAD, 
as detected by angiography [17]. Atherosclerotic renal 
artery stenosis may lead to ischemic nephropathy and 
impaired renal function. Renal dysfunction is a strong 
predictor for cardiovascular disease and mortality. 
Moreover, it was one of the strongest predictors in our 
study cohort, associated with a 4.4-, 4.3- and 3.3-fold 
increased risk of 1-year, 5-year and 10-year mortality, 
respectively. 
 
Ankle-brachial index and long-term mortality 
PAD is characterized by narrowing of the leg arteries. A 
decrease in the ankle-brachial index, a ratio of ankle 
systolic to brachial systolic blood pressure, is commonly 
used for the diagnosis of PAD [18]. An ankle-brachial 
index of ≤0.90 or ≤0.85 has been associated with an 
increased risk of overall and cardiovascular mortality, 
compared to ankle-brachial index values above 0.90 or 
0.85 [1,16,19-23]. In our derivation cohort, we observed 
1-year, 5-year and 10-year mortality rates of 6%, 22% 
and 42%, respectively. These values are in accordance 
with previously published studies reporting long-term 
mortality rates in patients with PAD. In a study by 
Newman et al, mortality during a mean follow-up of 16 
months occurred in 27/392 (6.9%) patients with PAD 
[19]. McKenna et al showed estimated 5-year and 10-
year mortality rates of 37% and 54%, respectively, in 
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One-year risk index applied to the Rotterdam derivation cohort 
 
Five-year risk index applied to the Rotterdam derivation cohort 
 
Ten-year risk index applied to the Rotterdam derivation cohort 
 
 
 
 
 
One-year risk index applied to the Rotterdam validation cohort 
 
Five-year risk index applied to the Rotterdam derivation cohort 
 
Ten-year risk index applied to the Rotterdam validation cohort 
Figure 2. Kaplan-Meier curves for 1-year (a), 5-year (b), and 10-year (c) survival in the derivation and validation cohort stratified according to 
four different risk classification groups (low, low intermediate, high intermediate and high risk group). 
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Figure 3. One-year survival in the Netherlands Heart survey cohort 
according to four different risk classification groups (low, low 
intermediate, high intermediate and high risk group). 
 
patients with ABI values ≤0.85 [20]. Leng et al 
demonstrated an all-cause 5-year mortality rate of 
63/288 (22%) in patients with ABI ≤0.90 [21]. Criqui et 
al found a 10-year mortality rate of 32/67 (48%) in 
patients with PAD [1]. The Edinburgh Artery Study 
found a 12-year mortality incidence of 119/245 (49%) 
in patients with ABI ≤0.90 [22]. In addition, 
significantly higher mortality rates have been reported 
in patients who had ankle-brachial index values less 
than 0.40 [20], and less than 0.70 [21], compared to 
patients within higher ankle-brachial index categories. 
This study demonstrated that measurement of ABI, even 
in patients who already present with ABI ≤0.90, was a 
consistent independent step-wise increased risk factor 
for mortality and therefore highly important in risk 
stratification. 
 
Medication therapy 
In our analysis, we included the use of cardiac drugs 
that have been demonstrated to improve prognosis in 
patients with peripheral arterial disease. Antiplatelet 
drugs are established agents for the prevention of 
cardiovascular and cerebrovascular events and form the 
cornerstone of pharmacologic intervention in PAD. The 
Anti-Thrombotic Trialists collaboration showed in a 
meta-analysis a proportional reduction of 23% in 
serious vascular events among 9214 patients with PAD 
using antiplatelet therapy (primary aspirin), compared to 
those using no antiplatelet therapy (5.8% vs. 7.1%, 
p<0.004) [24]. HMG-Co-A reductase inhibitor drugs 
(statins) have been demonstrated to improve leg 
functioning, walking performance, ABI values and 
symptoms of claudication [25-27]. The Heart Protection 
Study demonstrated that simvastatin significantly 
lowered the risk of vascular events in patients with PAD 
with or without clinically evident coronary heart disease 
[28]. Although β-blockers were relatively 
contraindicated in patients with PAD, Aronow et al 
showed that β-blocker therapy was associated with a 
53% significant reduction in new coronary events, 
independent of other confounding variables [29]. This 
was confirmed in 78 post-infarction patients with 
intermittent claudication who demonstrated a 3-fold 
reduction in cumulative cardiac mortality when treated 
with β-blocker therapy [30]. As demonstrated in our 
prognostic risk index, patients with statin, aspirin and 
beta-blocker therapy were at significantly lower risk for 
1-year, 5-year and 10-year mortality. 
 
Risk classification model in PAD 
A risk classification system in patients with PAD may 
help identify those at increased risk for long-term 
mortality and subsequently may improve management 
and treatment strategies [12]. A multivariate Cox hazard 
model showed in male patients with intermittent 
claudication that older age, history of stroke, lower 
ankle-brachial index values and diabetes mellitus were 
associated with long-term mortality [31]. To the best of 
our knowledge, no other risk indices have been 
developed in patients with PAD. We aimed to develop a 
simple risk scoring system in patients with PAD in 
which points are assigned to prognostic clinical 
variables obtained through medical history, laboratory 
testing, electrocardiography and ankle-brachial index 
measurement. The chance of 1-year, 5-year and 10-year 
mortality can then be estimated. Our risk index for 1-
year, 5-year and 10-year mortality had good 
discrimination and was successfully validated in two 
independent patient samples, suggesting its 
generalizability to other PAD patient groups.  
 
Limitations 
Several limitations in our study should be addressed. 
Unfortunately, our study did not include recently 
emerging risk factors, such as fibrinogen, homocysteine, 
C-reactive protein and lipoprotein (a), which may have 
prognostic value in PAD patients [32]. Secondly, we 
used mortality from all causes as end-point. A better 
discriminatory capacity may have been achieved if 
mortality from cardiovascular causes was used as 
endpoint, especially because peripheral arterial disease 
is closely associated with the risk of myocardial 
infarction and death from vascular causes. Thirdly, 
interpretation of this index in non-caucasians should be 
done cautiously.  
 
In conclusion, a prognostic risk index for long-term 
mortality based on cardiovascular risk factors, ankle-
brachial index measurements, electrocardiographic 
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abnormalities and cardioprotective medication stratifies 
patients into different risk categories. This index may 
offer practical help to physicians in risk stratification, 
patient counseling and medical decision making at an 
early stage of the disease.  
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Background: Peripheral arterial disease is associated 
with a high incidence of cardiovascular mortality. 
Peripheral arterial disease can be detected by using the 
ankle-brachial index (ABI). This study assessed the 
prognostic value of the postexercise ABI in addition to 
the resting ABI on long-term mortality in patients with 
suspected peripheral arterial disease. 
Methods: In this prospective cohort study of 3209 
patients (mean ± SD age, 63±12 years; 71.1% male), 
resting and postexercise ABI values were measured and 
a reduction of postexercise ABI over baseline resting 
readings was calculated. The mean follow-up was 8 
years (interquartile range, 4-11 years). 
Results: During follow-up, 1321 patients (41.2%) died. 
After adjusting for clinical risk factors, lower resting 
ABI values (hazard ratio per 0.10 lower ABI, 1.08; 95% 
confidence interval [CI], 1.06-1.10), lower postexercise 
ABI values (hazard ratio per 0.10 lower ABI, 1.09; 95% 
CI, 1.08-1.11), and higher reductions of ABI values 
over baseline readings (hazard ratio per 10% lower ABI, 
1.12; 95% CI, 1.09-1.14) were significantly associated 
with a higher incidence of mortality. In patients with a 
normal resting ABI (n=789), a reduction of the 
postexercise ABI by 6% to 24%, 25% to 55%, and 
greater than 55% was associated with a 1.6-fold (95% 
CI, 1.2-2.2), 3.5-fold (95% CI, 2.4-5.0), and 4.8-fold 
(95% CI, 2.5-9.1) increased risk of mortality, 
respectively. 
Conclusions: Resting and postexercise ABI values are 
strong and independent predictors of mortality. A 
reduction of postexercise ABI over baseline readings 
can identify additional patients (who have normal ABI 
values at rest) at increased risk of subsequent mortality.
_____________________________________________________________________________________________
 
PERIPHERAL ARTERIAL DISEASE (PAD) is a 
manifestation of systemic atherosclerosis and is 
associated with a significantly increased risk of 
cardiovascular morbidity and mortality [1-3]. In the 
Netherlands, the combined prevalence of symptomatic 
and asymptomatic PAD in the population of those 55 
years and older is 19% [4]. In the United States, 
different prevalence values for PAD have been 
reported, ranging from 4% in patients 40 years and 
older to 29% in patients either older than 70 years or 
aged 50 to 59 years with a 10–pack year history of 
smoking or the presence of diabetes mellitus [1,5-8].  
Management of PAD comprises walking 
exercise, modification of cardiovascular risk factors, 
and antiplatelet therapy [2,9]. Although the prevalence 
of PAD is high in industrialized countries, it is believed 
that PAD remains an underdiagnosed and undertreated 
disease in primary care [3,6,8]. Therefore, the 
identification of patients with suspected PAD who are 
at increased risk for cardiovascular events is necessary 
for disease control and appropriate application 
of treatment strategies. 
The ankle-brachial index (ABI), a ratio of 
ankle systolic–brachial systolic blood pressure, is a 
simple, effective, and noninvasive test used for the 
assessment of lower extremity arterial obstruction and 
for the screening of patients with suspected PAD [8]. 
Several studies have demonstrated that low ABI values 
at rest predict cardiovascular and overall mortality [10-
16]. Most studies have used a cutoff of 0.90 to define a 
low ABI value. However, knowledge about the 
association of long-term mortality across the whole 
range of ABI values at rest and after exercise is limited.  
The ABI is commonly measured at rest, but 
ABI measurements coupled with exercise testing may 
enhance the sensitivity of the test and may identify 
additional patients with PAD who have normal resting 
ABI values [2,17]. In this study, we assessed the 
association of long-term mortality across the whole 
range of resting and postexercise ABI values, and 
hypothesized that a reduction in postexercise ABI over 
baseline resting readings may identify patients at 
increased risk of long-term mortality. 
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METHODS 
 
Patients and assessment of baseline characteristics 
The Erasmus Medical Centre serves a population of 
approximately 3 million people and acts as a tertiary 
referral center for approximately 30 affiliated hospitals. 
This cohort study prospectively included consecutive 
patients with suspected or known PAD referred to our 
university clinic of vascular surgery between January 
14, 1983, and January 1, 2005, for the evaluation and 
management of their disease. Patients with suspected 
PAD had a typical history of intermittent claudication 
or other symptoms of chronic arterial insufficiency, 
including ulceration of the foot, hair loss, or reduced 
capillary refill. Patients with known PAD had a resting 
ABI of 0.90 or less. Excluded were patients who were 
unable to perform exercise and those who underwent 
previous vascular surgery. The hospital’s Medical 
Ethical Committee approved the study protocol, and 
patients who fulfilled the inclusion criteria agreed to 
participate in the study. Based on hospital records and 
personal interviews at the visit, a medical history was 
recorded. Diabetes mellitus was recorded if patients 
presented with a fasting glucose level of 126 mg/dL or 
more (>7.0 mmol/L) or in those who required 
treatment. Hypertension was recorded if patients 
presented with a blood pressure of 140/90 mm Hg or 
higher or if patients were medically treated for 
hypertension. Hypercholesterolemia was recorded if 
patients presented with a plasma cholesterol level of 
212 mg/dL or more (>5.5 mmol/L) or if patients were 
taking lipid-lowering agents. Renal dysfunction was 
recorded if patients presented with a serum creatinine 
level of 2.0 mg/dL or more (>177 μmol/L) or in those 
who required dialysis. Cigarette smoking included only 
current smoking. Patients were assessed for cardiac 
medication use. A baseline12-lead electrocardiogram 
was obtained, and the ABI at rest and after exercise 
was measured in each patient. 
 
Measurement of the ABI 
Trained technicians, using a Doppler ultrasonic 
instrument with an 8-MHz vascular probe (Imexdop 
CT Vascular Doppler; Miami Medical, Glen Allen, 
Va), measured systolic blood pressure readings in the 
right and left brachial arteries, right and left dorsalis 
pedis arteries, and right and left posterior tibial arteries. 
The ABI in the right and left legs was calculated by 
dividing the right and the left ankle pressure by the 
brachial pressure. The higher of the 2 brachial blood 
pressure readings was used if a discrepancy in systolic 
blood pressure was present. Again, the higher of the 
dorsalis pedis and posterior tibial artery pressures was 
used when a discrepancy in systolic blood pressure 
readings between the 2 arteries was measured. If no 
pressure in the dorsalis pedis artery was obtained 
because of an absent dorsalis pedis artery, the pressure 
in the posterior tibial artery was used. The ABI at rest 
was measured after the participants had been resting in 
the supine position for at least 10 minutes. 
Measurements were then repeated at both sides with 
the patient in the supine position, after 5 minutes of 
walking on a treadmill at 4.0 km/h. No inclining plane 
or graded inclines were used with treadmill testing, and 
the treadmill tests were performed without continuous 
electrocardiographic monitoring before, during, and 
after the testing. Of the ABI values obtained in each 
leg, the lower was used in all analyses. Interobserver 
and intraobserver agreement for resting ABI was 97% 
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Figure 1. The estimated incidence of overall mortality and cardiac death in patients with varying resting ankle-brachial index (ABI) values, 
postexercise ABI values, and percentage decrease values of postexercise ABI according to different periods (January 14, 1983–December 31, 
1993, January 1, 1994–January 1, 2005, and January 14, 1983–January 1, 2005). The mortality rate was calculated at the 75th percentile of 
follow-up. A, Data for resting ABI values from 1983 to 1993. B, Data for postexercise ABI values from 1983 to 1993. C, Data for percentage 
decrease values of postexercise ABI from 1983 to 1993. D, Data for resting ABI values from 1994 to 2005. E, Data for postexercise ABI values 
from 1994 to 2005. F, Data for percentage decrease values of postexercise ABI from 1994 to 2005. G, Data for resting ABI values from 1983 to 
2005. H, Data for postexercise ABI values from 1983 to 2005. I, Data for percentage decrease values of postexercise ABI from 1983 to 2005. 
 
 
and 98%, respectively; and for postexercise ABI, 96% 
and 97%, respectively. Although an ABI of greater 
than 1.30 has been used as a marker of calcified 
atherosclerosis, we considered patients with values 
greater than 1.50 to have calcified atherosclerosis, 
resulting in high ABI readings. These patients were 
excluded from the study. 
 
Follow-up 
We included 3209 patients who were examined during 
a median follow-up of 8 years (interquartile range, 4-11 
years). No patients were lost to follow-up. Follow-up 
ended at the date of the last visit or the date of death. 
Information about the patient’s vital status was 
obtained at the Office of Civil Registry. For patients 
who died at our hospital during follow-up, hospital 
records and autopsy results were reviewed. For patients 
who died elsewhere, general practitioners were 
approached to ascertain the cause of death. A cardiac 
cause of death was defined as death caused by acute 
myocardial infarction (postmortem evidence of acute 
myocardial infarction or definite criteria for myocardial 
infarction within the 4 weeks before death), cardiac 
arrhythmias, congestive heart failure, or sudden death. 
 
Statistical analysis 
Continuous data are expressed as mean and SD or 
median (interquartile range), and compared using the t 
test or Mann-Whitney test when appropriate. 
Categorical data are presented as percentage 
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frequencies, and differences between proportions were 
compared using the Chi-2 test with Yates correction. 
The primary end points were overall mortality and 
cardiac death. We used univariate and multivariate Cox 
proportional hazards models to analyze the effect of 
clinical characteristics and ABI values on survival. 
Hazard ratios are given with 95% confidence intervals 
(CIs). In multivariate analyses, all clinical variables, 
including medication, were entered, irrespective of the 
significance level in univariate analysis. The Kaplan-
Meier method with the log-rank test was used for 
comparing survival curves in 2 or more groups. The 
reduction of the postexercise ABI compared with the 
resting ABI was calculated and expressed as a 
percentage. The prevalence of clinical risk factors, 
medication use, and mortality rate might have changed 
during the 22-year period in which the study was 
conducted. Therefore, we evaluated differences in 
baseline characteristics and mortality results between 
patients enrolled from January 14, 1983, to December 
31, 1993, and those enrolled from January 1, 1994, to 
January 1, 2005. In multivariate analyses, the relation 
between ABI values (resting ABI, postexercise ABI, 
and reduction of postexercise ABI) and survival was 
evaluated separately for the periods from 1983 to 1993 
and from 1994 to 2005, and an interaction term was 
evaluated to reveal possible heterogeneity between the 
different periods. In addition, tests for heterogeneity 
were used to evaluate the effect of a reduction of 
postexercise ABI in patients with different resting ABI 
values. For all tests, P <.05 (2-sided) was considered 
significant. All analyses were performed using a 
commercially available software program (SPSS-11.0 
statistical software; SPSS Inc, Chicago, Ill). 
 
RESULTS 
 
The mean age of the patients was 63 ± 12 years, and 
71.1% were male. The baseline characteristics of the 
3209 patients are presented in Table 1. Patients 
included from 1994 to 2005 compared with those 
included from 1983 to 1993 more commonly presented 
with a history of myocardial infarction, percutaneous 
transluminal coronary angiography, and 
hypercholesterolemia, and less commonly smoked. 
Aspirin, angiotensin-converting enzyme inhibitors, -
blockers, digoxin, diuretics, nitrates, and statins were 
more frequently prescribed in patients who were 
included from 1994 to 2005, compared with patients 
included from 1983 to 1993. 
 
 
Figure 2. Kaplan-Meier survival curves in patients with varying 
resting ankle-brachial index (ABI) values (A), postexercise ABI 
values (B), and percentages of reduction of postexercise ABI 
compared with resting ABI (C). Subgroups were defined by using the 
quartiles as cutoffs. 
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Figure 3. Kaplan-Meier survival curves in patients with a resting 
ankle-brachial index (ABI) of greater than 0.90, stratified according 
to varying percentages of reduction of postexercise ABI compared 
with resting ABI. The lower and middle quartiles were used as 
cutoffs. 
 
The median ABI measured at rest was 0.65 
(interquartile range, 0.50-0.90) (P = .80). A resting ABI 
of greater than 0.90 was measured in 789 patients 
(24.6%). The median ABI measured after exercise was 
0.45 (interquartile range, 0.25-0.75) (P = .90). A 
postexercise ABI of greater than 0.90 was observed in 
443 patients (13.8%). Baseline characteristics of the 
443 patients with a postexercise ABI of greater than 
0.90 were different compared with those of patients 
with a postexercise ABI of 0.90 or less. Patients with 
an ABI of greater than 0.90 were younger (mean age, 
60 ± 13 vs. 64 ± 12 years; P<.001) and had a lower 
prevalence of coronary artery disease (35% vs. 43%; 
P<.001), hypertension (29% vs. 36%; P = .002), and 
smoking (27% vs. 35%; P<.001). A reduction of the 
postexercise ABI over baseline resting readings was 
observed in 2559 patients (79.7%), and was observed 
in 444 (56.3%) of 789 patients who had a normal 
resting ABI. The median reduction of ABI over 
baseline resting readings was 25% (interquartile range, 
6%-55%). The postexercise ABI was similar to the 
resting ABI in 552 patients (17.2%), and was higher in 
only 98 patients (3.1%). 
 
Follow-up data 
During a median follow-up of 8 years (range, 0.1-22.2 
years), death was recorded in 1321 patients (41.2%); 
671 (50.8%) of these deaths were because of cardiac 
causes. Figure 1 shows the incidence of overall 
mortality and cardiac death in patients included from 
1983 to 1993, from 1994 to 2005, and from 1983 to 
2005, across the whole range of resting ABI values, 
postexercise ABI values, and reductions of ABI values 
over baseline resting readings. Tests for heterogeneity 
revealed no significant difference in unadjusted risk of 
resting ABI values, postexercise ABI values, and 
reductions of ABI over baseline readings for predicting 
overall (P = .60, .34, and .15, respectively) and cardiac 
mortality (P = .40, .15, and .09, respectively) between 
patients included from 1983 to 1993 and those included 
from 1994 to 2005. The unadjusted risk of overall 
mortality and cardiac death increased with decreasing 
resting ABI values (hazard ratio per 0.10 decrease, 1.11 
[95% CI, 1.09-1.13] and 1.15 [95% CI, 1.13-1.18], 
respectively), with decreasing postexercise ABI values 
(hazard ratio per 0.10 decrease, 1.16 [95% CI, 1.13-
1.18] and 1.10 [95% CI, 1.09-1.13], respectively), and 
with increasing reductions of ABI over baseline resting 
readings (hazard ratio per 10% decrease, 1.11 [95% CI, 
1.09-1.14] and 1.17 [95% CI, 1.14-1.21], respectively) 
(P<.001 for all differences). In patients who died and 
who had normal resting ABI values and no reduction in 
the ABI after exercise, a cardiac cause of death was 
noted in 38.2%; in patients who died and who had 
normal resting ABI values and reductions in the ABI 
after exercise, a cardiac cause of death was noted in 
55.1% (P<.001). 
 
Kaplan-Meier survival curves for patients with varying 
resting ABI values, postexercise ABI values, and 
reductions of ABI are presented in Figure 2. Worse 
survival was observed in patients with lower resting 
ABI values, lower postexercise ABI values, and higher 
reductions of ABI values over baseline resting readings 
(P<.001 for all). 
 
Multivariate analysis 
We found that decreasing values of resting ABI, 
decreasing values of postexercise ABI, and higher 
reductions of ABI were significantly associated with an 
increased risk of overall mortality and cardiac death 
(Table 2). In a final multivariate model, we assessed 
the value of a reduction of the ABI with adjustment for 
clinical risk factors and resting ABI values, and 
observed that an increased reduction remained 
significantly associated with overall mortality and 
cardiac death (Table 2). Tests for heterogeneity 
revealed no significant difference in adjusted risk of 
resting ABI values, postexercise ABI values, and 
reductions of ABI over baseline readings for predicting 
overall and cardiac mortality between patients included 
from 1983 to 1993 and patients included from 1994 to 
2005. 
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Table 3 shows the relative risk ratios of a reduction of 
ABI in patients with resting ABI values of greater than 
0.90 and those with resting ABI values of 0.90 or less, 
with adjustment for clinical risk factors and age. In 
both subgroups of patients, a 6% to 24%, a 25% to 
55%, and a greater than 55% reduction of ABI over 
baseline resting readings was associated with an 
increased risk for late mortality, using a reduction of 
less than 6% as the comparator. More important, in 
patients with a resting ABI of greater than 0.90, the 
relative risk ratio for late mortality was 1.6 times 
greater for a reduction of 6% to 24%, 3.5 times greater 
for a reduction of 25% to 55%, and 4.8 times greater 
for a reduction of greater than 55% when a reduction of 
less than 6% was used as the comparator. Tests for 
heterogeneity revealed a significant interaction 
between resting ABI values and reductions of ABI over 
baseline readings (P = .03). Kaplan-Meier survival 
curves for patients with resting ABI values greater than 
0.90 show a significantly worse outcome for those with 
a 6% to 24% and a greater than 25% reduction of the 
ABI (P<.001) (Figure 3). 
 
COMMENTS 
 
The present study shows that lower resting and 
postexercise ABI values and an increased reduction of 
ABI over baseline readings are significantly associated 
with an increased incidence of long-term overall 
mortality and cardiac death. In addition, in patients 
with resting ABI values of more than 0.90, a reduction 
of ABI over baseline readings identified those at 
increased risk for late mortality. These findings were 
independent of the presence of established clinical risk 
factors. The present study shows that lower resting and 
postexercise ABI values and an increased reduction of 
ABI over baseline readings are significantly associated 
with an increased incidence of long-term overall 
mortality and cardiac death. In addition, in patients 
with resting ABI values of more than 0.90, a reduction 
of ABI over baseline readings identified those at 
increased risk for late mortality. These findings were 
independent of the presence of established clinical risk 
factors. 
 
Peripheral arterial disease 
In the United States, different prevalence values for 
PAD have been reported, ranging from 4% in patients 
40 years and older to more than 20% in patients 70 
years and older [1, 5-8]. PAD is a manifestation of 
atherosclerosis, and its presence should be regarded as 
a marker for atherosclerosis in other vascular beds [17]. 
Important risk factors include cigarette smoking, 
hypercholesterolemia, and hypertension, and 
modification of these risk factors is a substantial part in 
managing PAD. In our study, patients included from  
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1994 to 2005 compared with those included from 1983 
to 1993 more commonly presented with a history of 
myocardial infarction and hypercholesterolemia, less 
commonly smoked, and more commonly received 
cardiovascular medication. This may reflect the trend 
in increasing awareness of detecting and treating 
clinical risk factors. 
 
The ABI to predict mortality 
The ABI is commonly used for the assessment of lower 
extremity arterial obstruction and for the screening of 
patients with suspected PAD [8]. The ABI correlates 
with the extent of angiographic coronary artery disease, 
reflecting the concept that PAD is a marker of 
generalized atherosclerosis [18]. It is well established 
that low ABI values at rest predict cardiac and overall 
mortality. A resting ABI of 0.90 or less has been 
associated with an increased risk of 2 to 7 for overall 
mortality and 2 to 4 for cardiovascular mortality, 
compared with a resting ABI of more than 0.90.10-16 
Knowledge about the risk of mortality across the whole 
range of ABI values is limited. The Honolulu Heart 
Program study [19] compared the adjusted risk for the 
composite end point of cardiac death and nonfatal 
myocardial infarction in patients with an ABI of less 
than 0.80 and 0.80 to 1.00 vs. those with an ABI of 
1.00 or more, and found a higher risk in patients with 
an ABI of less than 0.80 compared with patients with 
an ABI of 0.80 to 1.00. Another study [10] used resting 
ABI values of 0.40 and 0.85 as cutoffs to divide its 
population into subpopulations; the highest risk-
adjusted relative risk for mortality was observed in 
patients with an ABI of less than 0.40. Leng et al [16] 
used resting ABI cutoff values of 1.10, 1.00, 0.90, and 
0.70, and found a significant linear increase in 
mortality across decreasing ABI categories. In the 
present study, we found that the adjusted risk for 
overall mortality increased by 8% for every 0.10 
decrease of the resting ABI, and by 9% for every 0.10 
decrease of the postexercise ABI. The adjusted risk for 
cardiac death increased by 12% and 15% for every 
0.10 decrease of the resting ABI and postexercise ABI, 
respectively. 
 
The ABI after exercise 
A healthy person can maintain ankle systolic pressures 
at normal levels during modest workloads. In patients 
with PAD, however, a decrease in systolic pressures is 
often measured during low levels of workload [20-21]. 
In a previously published study, Ouriel et al [22] 
investigated whether the diagnostic accuracy for PAD 
could be improved through the use of postexercise ABI 
measurements, and they suggested that postexercise 
ABI values may especially be useful in patients with 
normal ABI values at rest. To our knowledge, no 
studies have been published about the predictive value 
of postexercise testing on long-term mortality. Our 
results demonstrate that reductions of the postexercise 
ABI offered additional mortality information in 
patients with abnormal resting ABI values. More 
important, in symptomatic and asymptomatic patients 
with resting ABI values above 0.90, a reduction of ABI 
over baseline resting readings can also identify those at 
increased risk for mortality. 
 
Clinical implication 
Although the prevalence of PAD is high in 
industrialized countries, PAD remains an 
underdiagnosed and undertreated disease in primary 
care [3, 6, 8]. Therefore, the identification of patients 
with suspected PAD who are at increased risk for late 
events is necessary for disease control and selection of 
appropriate treatment strategies [23]. During recent 
years, more attention has focused on the identification 
and treatment of underlying cardiovascular risk factors 
in patients with PAD, which may have resulted in an 
increased prescription of statins, angiotensin-
converting enzyme inhibitors, aspirin, and -blockers. 
Measurements of resting and postexercise ABI values 
are simple, inexpensive, and noninvasive, and can be 
performed when patients are assessed for their risk 
factors. A recent study [13] showed that the 
measurement of resting ABI in addition to 
conventional risk factors significantly improved the 
prediction of fatal myocardial infarction. Results from 
this study suggest that measurement of ABI at rest may 
be incorporated among other tools for identifying 
patients at increased risk for cardiovascular events. 
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These patients may subsequently benefit from 
preventive pharmacologic and nonpharmacologic 
interventions, to reduce their risk of complications of 
systemic atherosclerosis. 
 
In conclusion, this long-term prospective cohort study 
shows that resting and postexercise ABI values are 
independently associated with late overall mortality 
and cardiac death. In addition, in patients with normal 
resting ABI values, a reduction of the postexercise ABI 
over baseline readings can identify those at increased 
risk of long-term mortality. 
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Purpose:  The study’s objective was to evaluate the 
prognostic value of left ventricular ejection fraction and 
stress-induced ischemia during dobutamine stress 
echocardiography in addition to ankle-brachial index 
measurements and clinical risk factors in patients with 
suspected or known peripheral arterial disease. 
Methods: In 852 patients with suspected or known 
peripheral arterial disease (mean age 63 years, 70% 
male), the ankle-brachial index was measured, left 
ventricular ejection fraction was assessed and all 
patients underwent additional stress testing. Endpoints 
were all-cause mortality and hard cardiac events 
(cardiac death or non-fatal myocardial infarction).   
Results: During a mean follow-up of 7.6 ± 4.4 years, 
death occurred in 288 patients (34%) and hard cardiac 
events occurred in 216 patients (25%). Mean left 
ventricular ejection fraction was 50 ± 17% and stress-
induced ischemia was observed in 352 patients (41%). 
In multivariate analysis with adjustment for clinical risk 
factors and ankle-brachial index, each 5% decrease in 
left ventricular ejection fraction was associated with 
increased all-cause mortality (HR: 1.05, 95% CI: 1.02-
1.09) and hard events (HR: 1.14, 95% CI: 1.08-1.21). 
Stress-induced ischemia also independently predicted 
all-cause mortality (HR: 2.01, 95% CI: 1.38-2.79) and 
hard events (HR: 2.06, 95% CI: 1.39-3.08). Left 
ventricular ejection fraction and stress-induced ischemia 
provided incremental prognostic information over 
clinical data and ankle-brachial index values (p<0.001).  
Conclusions: Left ventricular ejection fraction and 
stress-induced ischemia independently predict long-term 
outcome and improve prognostic risk assessment in 
addition to ankle-brachial index and clinical risk factors 
in patients with suspected or known peripheral arterial 
disease.
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LOWER EXTREMITY peripheral arterial disease is a 
manifestation of systemic atherosclerosis and has been 
recognized as a growing health burden worldwide.1 
Prevalence rates up to 29% have been reported for 
peripheral arterial disease in the United States, 
depending on the age of the study cohort, the underlying 
atherosclerosis risk factor profile, and the presence of 
cardiovascular co-morbidities.2-7 A high prevalence of 
left ventricular dysfunction among patients with 
symptomatic peripheral arterial disease has been 
observed.8 Moreover, coronary artery disease frequently 
co-exists with peripheral arterial disease since both 
conditions share the same atherosclerotic risk factors. 
More than half of patients who present with peripheral 
arterial disease may have evidence of coronary artery 
disease based on electrocardiography or medical 
history.1,9,10 The prognosis of patients with peripheral 
arterial disease is therefore characterized by a 2- to 6-
fold increased risk of cardiovascular death.11-17 
The American College of Cardiology/American Heart 
Association has emphasized in their guidelines for the 
management of patients with peripheral arterial disease 
the importance of identifying and treating underlying 
cardiovascular risk factors and obtaining ankle-brachial 
index data for prognostic risk stratification.1 Although 
the detection of coronary artery disease and left 
ventricular dysfunction in this particular patient 
population may be important because of the benefit 
from subsequent medical therapy or coronary 
intervention, evidence-based recommendations for 
cardiac assessment in literature are limited.  
Dobutamine stress echocardiography is an accurate, 
safe, and widely used non-invasive imaging technique 
for evaluation of coronary artery disease and for risk 
assessment.18,19  However, because ankle-brachial index 
data can risk stratify this population, it is not known 
whether stress testing can further provide prognostic 
information in addition to ankle-brachial index values. 
The purpose of this study was to determine the 
prognostic value of dobutamine stress echocardiography 
in addition to ankle-brachial index measurements and 
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clinical risk factors in a large cohort of patients with 
suspected or known peripheral arterial disease. 
 
METHODS 
 
The study population consisted of consecutive patients 
referred for evaluation of peripheral arterial disease at 
the outpatient vascular clinic of the Erasmus MC, 
Rotterdam, the Netherlands between January 1990 and 
January 2005. The Erasmus MC is a metropolitan 
university hospital in the South-western area of the 
Netherlands, serving a population of approximately 3 
million and acting as a tertiary referral center for 
approximately 30 affiliated hospitals. Patients with 
suspected peripheral arterial disease had a typical 
history of intermittent claudication or other symptoms 
of chronic arterial insufficiency, including ulceration of 
the foot, hair loss or reduced capillary refill. Patients 
with known peripheral arterial disease had a resting 
ankle-brachial index ≤0.90. Dobutamine stress 
echocardiography was performed to assess the presence 
and extent of concomitant coronary artery disease. 
Specific indications for stress echocardiography 
included typical or atypical chest pain, assessment for 
coronary artery revascularization and (pre-surgical) 
prognostic risk stratification. The hospital’s Medical 
Ethical Committee approved the study protocol. Patients 
who fulfilled inclusion criteria agreed on participation 
in the study. Based on hospital records and personal 
interviews at the time of the visit, a medical history was 
recorded and data were prospectively entered into a 
computerized database. Diabetes mellitus was recorded 
if patients presented with a fasting glucose level of ≥7.0 
mmol/L or in those who required insulin treatment. 
Hypertension was recorded if patients presented with a 
blood pressure ≥140/90 mmHg or if patients received 
anti-hypertensive drugs. Hypercholesterolemia was 
recorded if patients presented with a plasma cholesterol 
level ≥5.5 mmol/L or if patients were taking lipid-
lowering agents. Patients were considered to have  renal 
dysfunction if they presented with a serum creatinine 
level ≥2.0 mg/dL (177 μmol/L) or if they required 
dialysis. Cigarette smoking included only current 
smoking. Patients were assessed for cardiac medication 
use and a baseline 12-lead electrocardiography was 
obtained. 
 
Ankle-Brachial Index Measurement 
Systolic blood pressures in the right and left brachial 
artery, right and left dorsalis pedis artery and right and 
left posterior tibial artery were measured by trained 
technicians using a Doppler ultrasonic instrument with 
an 8 MHz vascular probe (Imexdop CT+ Vascular 
Doppler, Miami Medical, USA). The ankle-brachial 
index in the right and left leg was calculated by dividing 
the right and the left ankle pressure by the brachial 
pressure. The higher of the two brachial blood pressures 
was used if a discrepancy in systolic blood pressure was 
present. Again, the higher of the dorsalis pedis and 
posterior tibial artery pressure was used when a 
discrepancy in systolic blood pressure between the two 
arteries was measured. The ankle-brachial index was 
measured after the participants had been resting in the 
supine position for at least 10 minutes. Of the ankle-
brachial index values obtained in each leg, the lower 
was used in all analysis. Inter- and intraobserver 
agreement for the ankle-brachial index was 97% and 
98%, respectively. We considered patients with values 
greater than 1.50 to have calcified atherosclerosis. 
These patients were excluded from the study.   
 
Dobutamine Stress Echocardiography 
The dobutamine stress echocardiography was performed 
as previously described.20,21 Patients underwent a resting 
two-dimensional echocardiographic examination. Left 
ventricular end-diastolic and end-systolic volumes were 
obtained from the apical four- and two-chamber views 
by using the Simpson’s rule formula, from which the 
ejection fraction was calculated. Dobutamine 
hydrochloride was then administered intravenously by 
infusion pump, starting at 10 μg/kg/min for 3 minutes, 
and increased by 10 μg/kg/min every 3 minutes to a 
maximum of 40 μg/kg/min. The dobutamine infusion 
was stopped if a target heart rate was achieved (85% of 
a theoretic maximal heart rate). If the target heart rate 
was not achieved and patients had no symptoms or signs 
of ischemia, atropine sulphate (starting with 0.25 mg, 
increased to a cumulative maximum of 2.0 mg) was 
given intravenously. Patients were excluded from the 
study if the test was prematurely terminated because of : 
(1) symptomatic decline in systolic blood pressure >40 
mmHg from the resting value, or a systolic blood 
pressure <100 mmHg, (2) blood pressure >240/140 
mmHg, (3) occurrence of cardiac arrhythmias, (4) 
intolerable adverse effects from dobutamine or atropine 
and (5) poor echocardiographic images. Off-line 
assessment of echocardiographic images was performed 
by two experienced investigators without knowledge of 
the patient’s clinical data. From 1990 to 1993, a 14-
segment 4-point ordinal scale was used . After 1993 a 
16-segment 5-point score was used.21-23 Stress-induced 
myocardial ischemia was considered if new wall motion 
abnormalities occurred (i.e., if wall motion in any 
segment worsened by ≥1 grade(s) during the test, with 
the exception of akinesis becoming dyskinesis). The 
extent and location of ischemia were evaluated and a 
wall-motion score index (total score divided by the 
number of segments scored) was calculated, both at rest 
and during peak stress. When there was disagreement  
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Table 1. Baseline Characteristics According to Groups Defined by Ankle-Brachial Index Values and Dobutamine Stress Echocardiography 
Characteristic DSE with no 
ischemia, 
Normal ABI 
(n=154) 
DSE with no 
ischemia, 
Abnormal ABI 
(n=346) 
DSE with 
ischemia, 
Normal ABI 
(n=77) 
DSE with 
ischemia, 
Abnormal ABI 
(n=275) 
P-value 
Demographics      
Age (years) (+/-SD) 59 ± 12 63 ± 11 62 ± 12 65. ± 11 <0.001 
Male gender  61.0 74.0 68.8 70.9 0.027 
Angina 20.8 27.5 29.9 19.3 0.046 
Previous myocardial infarction  23.4 41.6 31.2 34.5 0.001 
Previous CABG  13.6 19.4 22.1 14.2 0.13 
Previous PTCA 1.3 6.1 2.6 2.9 0.041 
Known CAD (summary variable) 35.7 55.8 46.8 45.1 <0.001 
History of congestive heart failure  8.4 8.1 3.9 6.5 0.53 
History of stroke or TIA  3.2 9.0 7.8 5.8 0.11 
Diabetes Mellitus  12.3 17.3 18.2 15.3 0.50 
Hypercholesterolemia   22.7 20.5 27.3 16.0 0.11 
Hypertension  27.9 41.3 20.8 37.5 <0.001 
Cigarette smoking   28.6 37.9 29.9 26.2 0.013 
Renal failure  3.9 4.0 1.3 6.2 0.26 
Abnormal electrocardiography 31.8 47.7 45.5 45.1 0.01 
   Q waves  19.5 28.9 24.7 26.5 0.17 
   ST segment changes 1.9 2.3 6.5 5.8 0.042 
Medications       
   Aspirin  13.0 24.9 16.9 22.2 0.018 
   ACE-inhibitor 22.7 28.0 22.1 24.4 0.48 
   Beta-blocker 28.6 28.9 27.3 22.9 0.37 
   Calcium channel blocker 20.1 30.3 24.7 25.5 0.11 
   Digoxin 4.4 7.2 6.5 5.5 0.65 
   Diuretic  8.4 15.0 14.3 13.5 0.25 
   Nitrate 23.4 26.6 22.1 23.6 0.74 
   Statin  23.4 20.5 27.3 16.0 0.094 
Ankle-brachial index 1.02 ± 0.07 0.62 ± 0.17 1.01 ± 0.06 0.60 ± 0.20 <0.001 
Rest wall motion abnormalities 37.0 47.7 35.1 37.8 0.022 
Left ventricular ejection fraction 53 ± 16 51 ± 17 49 ± 18 47 ± 17 0.12 
DSE = dobutamine stress echocardiography; ABI = ankle-brachial index; CABG = coronary artery bypass grafting; PTCA =  percutaneous 
transluminal coronary angioplasty; CAD = coronary artery disease; TIA = transient ischemic attack; ACE = angiotensin converting enzyme. 
Values are expressed in percentages or mean ± SD. Abnormal ABI = ankle-brachial index ≤0.90. The p-values reflect overall differences in the 
four groups as compared by the Chi square test for categorical variables and analysis of variance techniques for continuous variables. 
 
between the two assessors, a third investigator viewed 
the images and a majority decision was reached.  
Follow-up 
During follow-up, study endpoints were all-cause 
mortality and hard cardiac events (cardiac death or non-
fatal myocardial infarction). Survival status was 
obtained by approaching the referring physician or the 
municipal civil registries. Clinical information was 
obtained by outpatients visits, mailed questionnaires, 
telephone interviews and reviewing hospital records. 
Non-fatal myocardial infarction was diagnosed when at 
least two of the following were present: elevated cardiac 
enzyme levels (CK level > 190 U/L and CK-MB >14 
U/L, or CK-MB fraction >10% of total CK, or cardiac 
troponin T >0.1 ng/mL), development of typical 
electrocardiographic changes (new Q waves >1 mm or > 
30 ms), and typical symptoms of angina pectoris. Death 
certificates and autopsy reports were reviewed and 
general practitioners were approached to ascertain the 
cause of death. Cardiac death was defined as death 
caused by acute myocardial infarction, cardiac 
arrhythmias, or congestive heart failure. Sudden 
unexpected death in a previously stable patients was 
considered as cardiac death.  
  
Statistical Analysis 
Continuous data were compared using the Student t test 
or ANOVA techniques when appropriate. Categorical 
data were compared using the Chi square test. A final 
set of independent predictors of left ventricular ejection 
fraction <35% and stress-induced myocardial ischemia 
was obtained by multivariate analysis with stepwise 
deletion of the least significant variable. The Kaplan-
Meier method with the log-rank test was used to assess 
differences in survival between different groups of 
patients. Univariate and multivariate Cox hazard 
regression analysis was used to evaluate the prognostic 
value of dobutamine stress echocardiography, ankle-
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brachial index and baseline clinical variables. The 
incremental value of dobutamine stress test results over 
clinical variables and ankle-brachial index values in the 
prediction of events was determined according to 3 
models. In the first model, clinical variables, baseline 
electrocardiography and ankle-brachial index values 
were entered. In the second and third model, left 
ventricular ejection fraction and stress-induced 
ischemia, respectively, were added to the first model. 
Tests for heterogeneity were used to reveal a possible 
interaction between dobutamine stress 
echocardiography and ankle-brachial index values. For 
all tests, a p-value <0.05 (two-sided) was considered 
significant. Analysis was performed using SPSS-11.0 
statistical software (SPSS Inc., Chicago, Illinois). 
 
RESULTS 
 
A total of 944 patients were referred for ankle-brachial 
index measurement and dobutamine stress 
echocardiography. A total of 30 patients (3%) were 
excluded because of ankle-brachial index values >1.50 
and 62 patients (7%) were excluded due to termination 
of the stress test prior to an ischemic endpoint (cardiac 
arrhythmia in 8 patients, hypotension in 14, chills and 
intolerable adverse effects in 11, and poor 
echocardiographic images in 29 patients). The 
remaining 852 patients were considered for follow-up 
and constituted our study population (Table 1). Follow-
up was successful in all. Mean age was 63 years and 
598 patients (70%) were male. Mean ankle-brachial 
index was 0.72 ±0.24, and 621 patients (73%) had an 
ankle-brachial index ≤0.90. During dobutamine stress 
echocardiography, no fatal complications occurred. 
Mean left ventricular ejection fraction was 50 ±17%, 
and 105 patients (12%) had an ejection fraction <35%. 
A total of 122 patients (14%) had an ejection fraction 
<40%. Rest wall motion abnormalities were observed in 
469 patients (55%). Ischemia (new wall motion 
abnormalities) was detected in 352 patients (41%). In 
the patients who presented with left ventricular ejection 
fraction <35%, stress-induced ischemia occurred in 79 
patients (75%, 9% of the total study population). In the 
current patient cohort, the prevalence rate of coronary 
artery disease by medical history alone (angina pectoris 
or history of myocardial infarction) was 47% and 
combined with dobutamine stress echocardiography 
70%. Variables independently associated with left 
ventricular ejection fraction <0.35% included male 
gender, history coronary artery disease, history of heart 
failure, diabetes, renal failure and hypercholesterolemia. 
Variables independently associated with stress-induced 
myocardial ischemia included age, low ankle-brachial 
index values and ischemic baseline electrocardiogram 
(Table 2).  
 
Prognostic Value of Dobutamine Stress 
Echocardiography 
During a mean follow-up of 7.6 ± 4.4 years, death 
occurred in 288 patients (34%) and hard cardiac events 
in 216 patients (25%) (cardiac death in 145 patients and 
non-fatal myocardial infarction in 71). Kaplan Meier 
curves stratified according to ankle-brachial index and 
dobutamine stress echocardiography demonstrated that 
in patients with an ankle-brachial index ≤0.90, those 
with stress-induced ischemia had a decreased survival 
(annual mortality rate of 5.7%), compared to patients 
without ischemia (annual mortality rate of 3.2%, 
p<0.001), and compared to patients without ischemia 
and ankle-brachial index >0.90 (annual mortality rate of 
2.5%, p<0.001) (Figure 1).  
 
 
Table 2. Variables Independently Associated with Left Ventricular Ejection Fraction <0.35% and Stress-induced Myocardial Ischemia During 
Dobutamine Stress Echocardiography Identified By Stepwise Multivariate Analysis. 
Characteristic Odds ratio (95% CI) left ventricular ejection 
fraction <0.35%  (n=105) 
Male gender 2.08 (1.25-3.49) 
Coronary artery disease 4.07 (2.60-6.36) 
History of heart failure 3.48 (1.75-6.91) 
Diabetes mellitus 2.48 (1.49-4.12) 
Renal failure 3.54 (1.27-9.88) 
Hypercholesterolemia 1.84 (1.14-2.97) 
C-statistic: 0.76 
 
Characteristic Odds ratio (95% CI) for stress- induced 
myocardial ischemia during DSE (n=352) 
Ankle-brachial index (per 0.10 decrease) 1.06 (1.01-1.13) 
Age (per year increase)  1.02 (1.00-1.03) 
Ischemic baseline electrocardiogram 1.48 (1.10-2.01) 
C-statistic: 0.60 
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Table 3. Univariate and Multivariate Predictors of All-cause Mortality 
Multivariate Characteristic Univariate 
 
HR (95% CI) Model 1 
HR (95% CI) 
 Model 2  
HR (95% CI) 
Clinical Characteristics     
   Age (per year increase) 1.06 (1.04-1.07) 1.05 (1.03-1.07) 1.04 (1.02-1.06) 1.04 (1.02-1.06) 
   Male gender  1.38 (1.05-1.80) 1.26 (0.95-1.66) 1.21 (0.84-1.73) 1.25 (0.60-2.57) 
   Previous myocardial infarction 1.53 (1.21-1.93) 1.32 (0.99-1.69) 1.15 (0.82-1.62) 1.08 (0.57-2.04) 
   Congestive heart failure 2.35 (1.64-3.37) 1.87 (1.22-2.88) 1.60 (0.99-2.41) 1.25 (0.48-3.24) 
   History of stroke or TIA 1.52 (1.01-2.29) 1.17 (0.77-1.78) 1.15 (0.72-1.84) 1.48 (0.49-4.52) 
   Diabetes mellitus 1.40 (1.03-1.90) 1.49 (1.09-2.05) 1.31 (0.87-1.95) 1.05 (0.50-2.05) 
   Hypercholesterolemia   0.76 (0.55-1.05) 0.94 (0.67-1.31) 0.90 (0.61-1.34) 0.96 (0.46-2.03) 
   Hypertension 1.09 (0.86-1.39) 1.01 (0.78-1.27) 0.98 (0.72-1.33) 1.04 (0.56-1.94) 
   Cigarette smoking   1.22 (0.96-1.55) 1.25 (0.98-1.60) 1.19 (0.88-1.61) 1.49 (0.81-2.75) 
   Renal failure 4.59 (3.12-6.76) 3.16 (1.80-5.55) 2.86 (1.63-5.01) 2.63 (1.50-4.62) 
Ischemic baseline electrocardiogram  1.45 (1.13-1.85) 1.64 (1.21-2.22) 1.50 (1.10-2.04) 1.48 (1.08-2.01) 
ABI (per 0.10 decrease)  1.14 (1.09-1.20) 1.06 (1.01-1.12) 1.05 (1.01-1.11) 1.05 (1.01-1.11) 
Stress test results  ______________   
   LVEF (per 5% decrease) 1.07 (1.03-1.11)   1.06 (1.02-1.11) 1.05 (1.02-1.09) 
   Angina pectoris during test 0.98 (0.65-1.48)   ____________ 1.01 (0.47-1.89) 
   ST changes during test 1.26 (0.89-1.79)    1.05 (0.67-2.01) 
   New wall motion abnormalities 2.20 (1.57-3.08)    2.01 (1.38-2.79) 
Global X2  78 85 102 
Incremental value    p=0.01 p<0.001 
TIA = transient ischemic attack; ABI = ankle-brachial index; LVEF = left ventricular ejection fraction. 
 
 
Table 4. Univariate and Multivariate Predictors of the Composite Endpoint of Cardiac Death or Non-fatal Myocardial Infarction 
Multivariate Characteristic Univariate 
 
HR (95% CI) 
Model 1 
HR (95% CI) 
 Model 2  
HR (95% CI) 
Clinical Characteristics     
   Age (per year increase) 1.03 (1.02-1.04) 1.03 (1.01-1.05) 1.03 (1.00-1.05) 1.03 (1.00-1.05) 
   Male gender  1.46 (1.07-2.01)  1.24 (0.89-1.71)  1.09 (0.71-1.68)  0.67 (0.29-1.55) 
   Previous myocardial infarction 2.04 (1.56-2.67)  1.51 (0.97-2.37)  1.32 (0.79-2.23)  1.37 (0.60-3.10) 
   History of heart failure 2.41 (1.58-3.66) 1.99 (1.20-3.30) 1.70 (0.95-3.45) 1.31 (0.46-3.78) 
   History of stroke or TIA 1.17 (0.68-2.02) 1.05 (0.55-1.95) 1.00 (0.42-2.01) 1.03 (0.40-2.15) 
   Diabetes mellitus 2.02 (1.46-2.79) 1.63 (1.08-2.47) 1.52 (1.03-2.20) 1.73 (0.77-3.92) 
   Hypercholesterolemia   1.37 (1.01-1.88) 1.38 (0.99-1.94) 1.25 (0.84-1.88) 0.95 (0.43-2.11) 
   Hypertension 1.32 (1.00-1.71) 1.08 (0.81-1.44) 1.11 (0.77-1.59) 1.64 (0.81-3.32) 
   Cigarette smoking   0.97 (0.73-1.30) 1.02 (0.76-1.38) 1.06 (0.73-1.53) 1.03 (0.50-2.13) 
   Renal failure 5.40 (3.45-8.45) 3.21 (1.60-6.46) 2.87 (1.43-5.78) 2.92 (1.45-5.90) 
Ischemic baseline electrocardiogram   1.71 (1.30-2.25) 1.65 (1.16-2.33) 1.45 (0.95-2.57) 1.40 (0.80-2.97) 
ABI (per 0.10 decrease)  1.15 (1.08-1.21) 1.07 (1.00-1.13) 1.03 (0.98-1.10) 1.03 (0.97-1.11) 
Stress test results  ______________   
   LVEF (per 5% decrease)   1.17 (1.13-1.25)   1.15 (1.09-1.22) 1.14 (1.08-1.21) 
   Angina pectoris during test 0.87 (0.53-1.41)   ____________ 1.13 (0.46-2.76) 
   ST changes during test 1.42 (0.96-2.11)    1.76 (0.74-4.19) 
New wall motion abnormalities 2.34 (1.58-3.47)    2.06 (1.39-3.08) 
Global X2  53 80 93 
Incremental value    p<0.001 p<0.001 
TIA = transient ischemic attack; ABI = ankle-brachial index; LVEF = left ventricular ejection fraction 
 
 
Comparable results were obtained for the endpoint of 
hard events (Figure 1). In univariate analysis, left 
ventricular ejection fraction and stress-induced ischemia 
were significantly associated with adverse outcome 
(Table 3 and 4). In multivariate analysis, left ventricular 
ejection fraction and stress-induced ischemia 
independently predicted all-cause mortality and hard 
cardiac events, and provided significant incremental 
prognostic information over clinical data and ankle-
brachial index values (p<0.001) (Table 3 and 4). In a 
similar model including clinical baseline characteristics, 
electrocardiography, ankle-brachial index values, and 
left ventricular ejection fraction, a higher number of 
ischemic segments was also significantly associated 
with mortality (HR per ischemic segment: 1.06, 95% 
CI: 1.01-1.12, p=0.01) and hard cardiac events (HR per 
ischemic segment: 1.08, 95% CI: 1.02-1.14, 
p=0.006).Tests for heterogeneity revealed no evidence 
for a differential effect of dobutamine stress 
echocardiography results among patients with different 
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ankle-brachial index values (all interaction terms: 
p>0.05), indicating that decreased left ventricular 
ejection fraction and an ischemic stress test predicted 
the risk of death and hard cardiac events across the 
entire spectrum of ankle-brachial index values. 
 
 
 
Figure 1. Kaplan Meier Curves in Patient with Suspected and Known 
Peripheral Arterial Disease Stratified According to Stress-induced 
Myocardial Ischemia (DSE+) and Ankle-Brachial Index Values ≤0.90 
(ABI+). 
 
 
DISCUSSION 
 
Atherosclerosis has a common systemic pathogenesis 
and simultaneously affects multiple vascular beds.24 
Prevalence rates up to 75% of concomitant coronary 
artery disease in peripheral arterial disease have been 
published in literature, based on coronary angiography 
or clinical history.9,10 The current results demonstrate 
that coronary artery disease, cerebrovascular disease 
and renal disease were remarkably high in our study 
population, with prevalence rates of 70%, 7% and 5%, 
respectively. In addition, 12% of the current study 
population presented with left ventricular ejection 
fraction <35%. The high risk of death and the impaired 
health-related quality of life in patients with peripheral 
arterial disease poses a significant health burden 
worldwide.25 In the current study, death occurred in 
34% and hard cardiac events occurred in 25% during a 
mean follow-up of 7.6 years, reflecting the significant 
adverse consequences of peripheral arterial disease. It is 
well established that low ankle-brachial index values 
predict overall and cardiovascular mortality and that 
ankle-brachial index measurements can be used for 
prognostic risk stratification.26 The current study 
demonstrated supportive results and showed that each 
decrease in ankle-brachial index of 0.10 was associated 
with a 6% and 7% increased risk of all-cause mortality 
and hard cardiac events, respectively, independent of 
clinical risk factors and baseline electrocardiography. 
 
Current Recommendations 
The prognostic value of dobutamine stress 
echocardiography has previously been demonstrated in 
patients with suspected or known coronary artery 
disease.27 A major finding in our study is that 
dobutamine stress echocardiography improves risk 
stratification in patients with suspected or known 
peripheral arterial disease in addition to ankle-brachial 
index values and clinical risk factors. Each 5% decrease 
in left ventricular ejection fraction was associated with a 
5% and 14% increased risk of all-cause mortality and 
hard cardiac events, respectively. Stress-induced new 
wall motion abnormalities during dobutamine stress 
echocardiography were associated with a 2.0-fold and 
2.1-fold increased risk, respectively. Furthermore, the 
extent of ischemia was also significantly associated with 
adverse outcome.  The American College of 
Cardiology/American Heart Association has provided 
useful evidence-based guidelines regarding the 
management of patients with peripheral arterial disease 
and accentuate the frequent coexistence of coronary 
artery disease in these patients. Because of the paucity 
of published data, recommendations for cardiac risk 
assessment are limited. An improvement in the 
detection of (sub) clinical coronary artery disease and 
identification of those at increased risk for adverse 
events appears essential in order to obtain reductions in 
morbidity and mortality. The implication of dobutamine 
stress echocardiography in the work-up of patients with 
suspected or known peripheral arterial disease should 
therefore be considered. 
 
When Should Dobutamine Stress Echocardiography  
Be Performed? 
Although dobutamine stress echocardiography is a safe 
and accurate non-invasive procedure, the question 
remains whether all patients should undergo routine 
screening with this technique. This will probably 
depend on the availability of dobutamine stress 
echocardiography in the clinical practice, the presence 
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and local expertise of assessing and scoring 
echocardiographic images, and the consideration of 
costs versus benefit. The current results demonstrate 
that male patients with coronary artery disease, history 
of heart failure, diabetes, renal failure and 
hypercholesterolemia were more likely to present with 
left ventricular dysfunction. A subgroup of patients with 
advanced age, lower ankle-brachial index values and 
ischemic baseline electrocardiography were more likely 
to have stress-induced myocardial ischemia. Of note, 
lower ankle-brachial index values were directly 
associated with the severity of new wall motion 
abnormalities during dobutamine stress 
echocardiography. A limitation which should be 
addressed is that our study cohort consisted of patients 
referred to a tertiary referral centre with specific 
indications for stress echocardiography, and that it may 
not reflect “real-world” patients with peripheral arterial 
disease. Furthermore, it remains to be elucidated 
whether other non-invasive modalities such as exercise 
electrocardiographic testing and myocardial perfusion 
imaging are superior to dobutamine stress 
echocardiography for prognostic cardiac risk assessment 
in patients with suspected or known peripheral arterial 
disease. Exercise electrocardiography may not be 
suitable as test of screening for coronary artery disease, 
since patients with peripheral arterial disease often have 
limited exercise capacity and often present with baseline 
electrocardiographic abnormalities.  
 
Conclusion 
The current results reveal that decreased left ventricular 
ejection fraction and stress-induced myocardial 
ischemia during dobutamine stress echocardiography 
independently predict long-term outcome and improve 
prognostic risk assessment in addition to ankle-brachial 
index and clinical risk factors in patients with suspected 
or known peripheral arterial disease. The use of 
dobutamine stress echocardiography makes it possible 
to detect left ventricular dysfunction and coronary artery 
disease in an early stage, to identify patients at increased 
risk for future adverse events, and therefore to 
implement adequate preventive interventions. 
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Prognostic significance of declining ankle-brachial 
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Background: Peripheral arterial disease (PAD) is a risk 
factor for late cardiovascular events. This study assessed 
the prognostic significance of repeated ankle-brachial 
index (ABI) measurements at rest and during exercise in 
patients with PAD receiving conservative treatment. 
Methods: In a cohort study of 606 patients (62 ±12 
years, 68% male), ABI at rest and after exercise was 
measured at baseline and after 1 year. Patients with 
reductions in ABI were dived into three equally-sized 
groups (minor, intermediate and major reductions) and 
were compared to patients without reductions. During a 
mean follow-up of 5 ± 3 years, all-cause mortality, 
cardiac events, stroke and progression to kidney failure 
were noted.  
Results: Death was recorded in 83 patients (14%) of 
which 49% was due to cardiac causes. Non-fatal 
myocardial infarction occurred in 38 patients (6%), 
stroke in 46 (8%) and progression to kidney failure in 
35 (6%). In multivariate analysis, patients with major 
declines in resting (>20%) and post-exercise (>30%) 
ABI were at increased risk of all-cause mortality (HR: 
3.3, 95% CI: 1.5-7.2, HR: 3.0, 95% CI: 1.4-6.4, 
respectively), cardiac events (HR: 3.1, 95% CI: 1.3-7.2, 
HR: 2.4, 95% CI: 1.1-5.6, respectively), stroke (HR: 
4.2, 95% CI: 1.6-10.4, HR: 3.9, 95% CI: 1.4-10.2, 
respectively) and kidney failure (HR: 2.7, 95% CI: 1.1-
7.5, HR: 6.9, 95% CI: 1.5-31.5, respectively), compared 
to patients with no declines in ABI.  
Conclusions: This study shows that major declines in 
resting and post-exercise ABI are associated with all-
cause mortality, cardiac events, stroke and kidney 
failure in patients with PAD. 
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AS A MANIFESTION of systemic atherosclerosis, 
peripheral arterial disease (PAD) is significantly 
associated with an increased risk of vascular morbidity 
and mortality despite medical treatment [1-3]. In the 
Netherlands, the combined prevalence of symptomatic 
and asymptomatic peripheral arterial disease (PAD) in 
the population of 55 years and older is 19% [4]. In the 
United States, prevalence rates for PAD have been 
reported that range from 4% in patients aged 40 years 
and older to 29% in patients aged 70 years and older or 
aged 50 to 59 years with a history of smoking or 
diabetes mellitus [1,5-8]. Therefore, the identification of 
patients with PAD who are at increased risk of late 
events is necessary for disease control and selection of 
appropriate treatment strategies [3,9,10]. 
The ankle-brachial index (ABI) is a simple, 
inexpensive and non-invasive test used for the 
assessment of lower extremity arterial obstruction and 
for screening of patients with suspected PAD [8-10].  A 
resting ABI of less than 0.90 has been associated with a 
2- to 7-fold  increased risk of overall mortality and a 2- 
to 4-fold increased risk of cardiovascular mortality, 
compared to a resting ABI higher than 0.90 [11-17]. 
The prognostic value of declines in ABI over time is not 
well known. In this study, we assessed the association 
between changes in resting and post-exercise ABI over 
time and long-term outcome in patients with known or 
suspected PAD who are receiving conservative (non-
surgical) treatment.  
We hypothesized that a larger decline in both 
resting and post-exercise ABI can identify patients at 
increased risk of all-cause mortality, cardiac events, 
stroke and end-stage renal disease, irrespective of 
baseline ABI values and clinical risk factors.  
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METHODS 
 
Study participants 
We have prospectively included consecutive patients 
with suspected or known lower extremity PAD who 
were referred to our university clinic of vascular surgery 
for the evaluation and management of their disease 
between January 1996 and January 2005. Patients with 
known PAD had a resting or post-exercise ABI ≤0.90. 
In patients with suspected PAD, the diagnosis was 
based on a typical history of intermittent claudication or 
other symptoms of chronic arterial insufficiency, 
including ulceration of the foot, hair loss or reduced 
capillary refill. Patients unable to perform exercise, 
patients who underwent previous vascular surgery and 
patients who had foot or leg amputations were not 
included. We further considered patients with ABI 
values greater than 1.50 to have calcified 
atherosclerosis, resulting in high ABI readings. These 
patients were also not included in the study. The 
hospital’s Medical Ethical Committee approved the 
study protocol and patients who fulfilled the inclusion 
criteria agreed on participation in the study. 
   
Co-morbidities 
Based on hospital records and personal interviews at the 
time of the visit, a medical history was recorded 
including details of a previous myocardial infarction, 
angina pectoris, coronary artery revascularization, 
congestive heart failure, previous stroke or transient 
ischemic attack, diabetes mellitus, hypertension, 
smoking, hypercholesterolemia and renal dysfunction. 
Diabetes mellitus was recorded if patients presented 
with a fasting glucose level of ≥7.0 mmol/L, or in those 
who required medical treatment. Hypertension was 
recorded if patients presented with a blood pressure 
≥140/90 mmHg or if patients received antihypertensive 
treatment. Hypercholesterolemia was recorded if 
patients presented with a plasma cholesterol level ≥5.5 
mmol/L, or if patients were taking lipid-lowering 
agents. Renal dysfunction was recorded if patients 
presented with a serum creatinine level ≥2.0 mg/dL 
(177 μmol/L) or in those who required dialysis. Patients 
were assessed for chronic cardiac medication use. A 
baseline 12-lead electrocardiography was obtained and 
the ABI at rest and after exercise was measured in each 
patient. 
 
 
Table 1. Baseline characteristics of patients with peripheral arterial disease receiving conservative management (n=606) and patients receiving 
lower extremity revascularization surgery (n=974). 
Characteristic Conservative 
management 
(n=606) 
Surgical 
treatment (n=974) 
P value 
Age (years), mean +/- SD 62 ± 12 63 ± 12 0.2 
Male gender, No. (%) 414 (68) 709 (73) 0.06 
Angina pectoris, No. (%) 112 (18) 250 (26)  0.001 
Previous myocardial infarction, No. (%) 200 (33) 351 (36) 0.2 
History of heart failure, No. (%) 40 (7) 64 (7) 0.9 
History of stroke, No. (%) 51 (8) 101 (10) 0.2 
Diabetes mellitus, No. (%)  112 (19) 155 (16) 0.054 
Hypercholesterolemia, No. (%)  147 (24) 292 (30) 0.02 
Hypertension, No. (%)  222 (37) 470 (48) <0.001 
Current smoking, No. (%)  169 (28) 289 (30) 0.5 
Renal dysfunction, No. (%) 31 (5) 59 (6) 0.5 
Chronic pulmonary disease, No. (%) 57 (9) 145 (15) 0.002 
Rest ankle-brachial index, mean +/- SD 0.69 ± 0.23 0.65 ±  0.24  0.03 
Post-exercise ankle-brachial index, mean +/- SD 0.48 ± 0.29 0.46 ± 0.29 0.3 
Aspirin, No. (%) 179 (30) 297 (30) 0.7 
Angiotensin-converting enzyme inhibitors, No. (%) 174 (29) 290 (30) 0.7 
β-blockers, No. (%) 193 (32) 355 (36) 0.07 
Statins, No. (%) 218 (36) 329 (34) 0.4 
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Measurement of the ankle-brachial index 
Trained technicians, using a Doppler ultrasonic 
instrument with an 8 MHz vascular probe (Imexdop 
CT+ Vascular Doppler, Miami Medical, USA), 
measured systolic blood pressures in the right and left 
brachial artery, right and left dorsalis pedis artery and 
right and left posterior tibial artery. The ABI in the right 
and left leg was calculated by dividing the right and the 
left ankle pressure by the brachial pressure. The higher 
of the two brachial blood pressures was used if a 
discrepancy in systolic blood pressure was present. 
Again, the higher of the dorsalis pedis and posterior 
tibial artery pressure was used when a discrepancy in 
systolic blood pressure between the two arteries was 
measured. If no pressure in the dorsalis pedis artery was 
obtained due to an absent dorsalis pedis artery, the 
pressure in the posterior tibial artery was used. The ABI 
at rest was measured after the participants had been 
resting in the supine position for at least 10 minutes. 
Measurements were then repeated at both sides with the 
patient in the supine position, after 5 minutes of walking 
on a treadmill with a speed of 2.5 miles/hour. No 
inclining plane or graded inclines were used with 
treadmill testing, and the treadmill tests were performed 
without continuous electrocardiographic monitoring 
before, during and after the testing. Inter- and 
intraobserver agreement for rest ABI was 97% and 
98%, respectively and for post-exercise ABI 96% and 
97%, respectively.  
 
Figure 1. Kaplan-Meier survival curves in 1580 patients with 
peripheral arterial disease according to conservative treatment or 
surgical intervention. 
 
 
 
Conservative versus surgical management 
The decision for conservative management or surgical 
intervention was at the discretion of the treating 
physician. In general, surgical treatment was indicated 
when a significant improvement of symptoms could be 
expected and when the expected benefits would 
outweigh the risk of surgery. In patients who received 
conservative treatment, i.e. walking exercise and/or 
pharmacotherapy, ABI measurements were repeated at 
least every year after enrollment. Patients who died 
before the second ABI measurement and in whom an 
ABI change over time could not be determined were 
excluded from the study (n=13).  
 
Follow-up 
Follow-up ended at the date of the last visit or the date 
of death. Information about the patient’s vital status was 
obtained at the Office of Civil Registry. For patients 
who died at our hospital during follow-up, hospital 
records and autopsy results were reviewed. For patients 
who died outside our hospital, general practitioners 
were approached to ascertain the cause of death. A 
cardiac cause of death was defined as death caused by 
acute myocardial infarction (postmortem evidence of 
acute myocardial infarction or definite criteria for 
myocardial infarction within the four weeks before 
death), cardiac arrhythmias, congestive heart failure, or 
sudden death. Details on non-fatal myocardial 
infarction, stroke and end-stage renal disease were 
obtained by regularly scheduled follow-up visits. 
Additional information was obtained by approaching the 
general practitioners or referring clinicians. Non-fatal 
myocardial infarction was diagnosed when at least two 
of the following were present: elevated cardiac enzyme 
levels (CK level >190 U/L and CK-MB >14 U/L, or 
CK-MB fraction >6% of total CK, or cardiac troponin T 
>0.1 ng/mL), development of typical 
electrocardiographic changes (new Q waves >1 mm or 
>30 ms), and typical symptoms of angina pectoris. 
Stroke was diagnosed when patients presented with 
typical neurological symptoms lasting for more than 24 
hours. In all cases of stroke, the diagnosis was 
established by a neurologist. End-stage renal disease 
was defined as an estimated glomerular filtration rate 
less than 15 ml/min per 1.73 m2 or a need to start kidney 
replacement therapy, which included dialysis or renal 
transplantation. The estimated glomerular filtration rate 
was calculated using the following equation: glomerular 
filtration rate (ml/min/1.73 m2) = 186 x (serum 
creatinine level)-1.154 x (age)-0.203 x (0.742 if female) x 
(1.210 if of African descent) [18]. 
 
Statistical analysis  
Continuous data are expressed as mean (+/- SD) or 
median (+/- interquartile range) and compared using the 
Student t test or Mann-Whitney U test as appropriate. 
Categorical data are presented as percent frequencies 
and differences between proportions were compared 
using the chi-square test with Yates’ correction. 
Comparisons of categorical variables with continuous 
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measures were calculated with analysis-of-variance 
techniques. Initially, we compared patients receiving 
conservative treatment (n=606) to patients receiving 
lower extremity surgical revascularization (n=974). We 
then focused our analysis on the 606 patients receiving 
conservative treatment to assess the prognostic value of 
declines in ABI. The change of the serial ABI 
measurements was calculated in each leg and expressed 
as a percentage value. Of the changes in ABI obtained 
in each leg, the lower was used in all analyses. Although 
repeat ABI measurements were obtained annually, the 
change in ABI was calculated over the first year and 
expressed as both percentage and absolute change. Only 
1-year changes were used in our analysis. Patients with 
declining ABI were compared to patients with no 
declines in ABI. Patients with declining ABI were 
further divided into minor, intermediate and major 
decline according to the tertiles as cut-off value (5% and 
20% for the decline in resting ABI and 6% and 30% for 
the decline in post-exercise ABI). For the prediction of a 
major decline in ABI, a final set of baseline variables 
was identified by multivariate analysis with stepwise 
deletion of the least significant variable. Only variables 
with a p ≤0.20 were retained in the final model. The 
primary endpoints were overall mortality and cardiac 
events (cardiac death or non-fatal myocardial 
infarction). Secondary endpoints were stroke and 
progression to end-stage renal disease. For the outcome 
analysis, we used univariate and multivariate Cox 
proportional hazard regression models to analyze the 
association between ABI decline and outcome. In 
multivariate analyses, all clinical variables were entered, 
irrespective of the significance level in univariate 
analysis. Hazard ratios are given with 95% confidence 
intervals. For all tests, a p value <0.05 (two-sided) was 
considered significant. All analyses were performed 
using SPSS-11.0 statistical software (SPSS Inc., 
Chicago, Illinois). 
 
RESULTS 
 
Conservative treatment versus surgical treatment 
Baseline characteristics of patients receiving either 
conservative or surgical treatment are presented in 
Table 1. Patients receiving surgical treatment were more 
likely to present with hypercholesterolemia, 
hypertension, angina pectoris, chronic pulmonary 
disease and lower resting ABI values. Mean follow-up 
was 5.3 ± 3.3 years. In patients receiving surgical and 
conservative treatment, death was recorded in 293 
patients (30%) and 83 patients (14%), respectively. As 
shown in Figure 1, survival was significantly lower in 
patients receiving surgical treatment. 
 
Declines in ABI 
In the 606 patients receiving conservative treatment, the 
mean baseline ABI at rest (the lower of the right and left 
ABI) was 0.69 ± 0.23. A resting ABI >0.90 in both legs 
was measured in 99 patients (16%). The mean ABI 
measured after exercise (the lower of the right and left 
ABI) was 0.48 ± 0.29. A post-exercise ABI >0.90 in 
both legs was observed in 59 patients (10%). A total of 
29 patients (5%) had both a resting and post-exercise 
ABI of more than 0.90. These 29 patients all had a 
typical history of claudication and all had  signs of 
arterial insufficiency, including weak peripheral pulses 
and reduced capillary refill. A total of 459 patients 
(76%) had declining ABI values at rest and 456 patients 
(75%) had declining ABI values after exercise. 
Declining ABI values at rest were observed in 67 (68%) 
out of 99 patients with a normal resting ABI (ABI 
>0.90). Declining ABI values after exercise were 
observed in 40 (68%) out of 59 patients with normal 
post-exercise ABI (ABI >0.90). The median change in 
resting ABI in patients with no declining ABI was 
+13% and in patients with declining ABI -12%. The 
median change in post-exercise ABI in patients with no 
declining ABI was +21% and in patients with declining 
ABI -17%. 
 
Predictors of declines in ABI values 
Significant predictors of major declines in resting ABI 
values (>20%) were age (p=0.003), cigarette smoking 
(p<0.001), history of stroke (p<0.001) and a previous 
myocardial infarction (p=0.042) (Figure 2). Significant 
predictors of major declines in post-exercise ABI values 
(>30%) were age (p<0.001), diabetes mellitus 
(p<0.001), cigarette smoking (p<0.001) and a history of 
stroke (p=0.031) (Figure 2).  
 
 
 
 
 
 
 
 
 
 45
Figure 2. Baseline clinical variables associated with a major 1-year decline in resting ankle-brachial index (ABI) 
(decline of more than 20%) and post-exercise ankle-brachial index (decline of more than 30%) in patients with 
peripheral arterial disease receiving conservative management. 
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Figure 3. Absolute event rate during follow-up according to the 1-
year decline in resting (minor decline: 1-5%, intermediate decline: 6-
20%, major decline: >20% ) and post-exercise ankle-brachial index 
(minor decline: 1-6%, intermediate decline: 7-30%, major decline: 
>30% ) in patients with peripheral arterial disease receiving 
conservative medical management. 
 
 
 
Predictive value of declines in ABI 
Of the 83 patients receiving conservative treatment who 
died during follow-up, 49% was due to cardiac causes 
(41 patients). Non-fatal myocardial infarction occurred 
in 38 patients (6%), stroke in 46 patients (8%) and 
progression to end-stage renal disease in 35 patients 
(6%). Figure 3 shows the incidence of overall mortality, 
cardiac events, stroke and progression to end-stage renal 
disease in patients with no, minor, intermediate and 
major declines in resting and post-exercise ABI. In 
univariate analysis, patients with major declines in 
resting and post-exercise ABI had the highest hazard of 
all-cause mortality, cardiac events, stroke and end-stage 
renal disease (Table 2). Patients with intermediate 
declines in resting and post-exercise ABI were also at 
significantly increased risk of death and hard cardiac 
events (Table 2). After adjustment for baseline clinical 
variables, baseline ankle-brachial index values, β-
blockers statins, aspirin and angiotensin-converting 
enzyme inhibitors, major declines in resting and post-
exercise ABI remained significantly associated with all-
cause mortality, cardiac events, stroke and kidney 
(Table 2). Intermediate declines remained significantly 
associated with death and hard cardiac events (Table 2). 
As demonstrated in Table 3, absolute declines in ABI 
(per 0.10 decline) were significantly associated with all-
cause mortality, cardiac events, stroke and end-stage 
renal disease. 
 
DISCUSSION 
 
The current study found that major declines in resting 
and post-exercise ABI values are significantly 
associated with increased long-term mortality, cardiac 
events, stroke and progression to end-stage renal 
disease. These findings were independent of baseline 
ABI values, established clinical risk factors and 
cardiovascular therapy. 
  
Given the fact that the presence of PAD should be 
regarded as a marker of atherosclerosis in other vascular 
beds, it is not surprising that many of these patients die 
due to cardiovascular disease, stroke or renal 
dysfunction [10]. The management of PAD comprises 
of walking exercise, aggressive management of risk 
factors, life-style modifications, antiplatelet therapy and 
statins [19]. Patients who have extensive functional 
disability, who are unresponsive to exercise or 
pharmacotherapy, and who have a reasonable likelihood 
of symptomatic improvement may benefit from surgical 
intervention [19]. The higher mortality rate in patients 
undergoing surgery in relation to conservative 
management may be explained by the presence of more 
co-morbidities. The high prevalence and associated 
morbidity and mortality of PAD in the general 
population warrants the identification of patients at 
increased risk so that preventive measures can be 
applied to reduce the incidence of atherosclerosis 
related complication. 
 
Large cohort studies have consistently demonstrated 
that lower ABI values are associated with increased 
mortality and cardiovascular events. In a study of Leng 
and colleagues, a significant linear increase in mortality 
across decreasing ABI categories was observed using 
resting ABI cut-off values of 1.10, 1.00, 0.90 and 0.70 
[17]. We have previously demonstrated that the adjusted 
risk for overall mortality increased with 8% for every 
0.10 decrease of the resting ABI, and with 9% for every  
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Table 2. The long-term prognostic value of percentage declines in ankle-brachial index values in multivariate analysis in patients with peripheral 
arterial disease receiving conservative management. 
HR (95% CI) for  
all-cause mortality 
HR (95% CI) for  
cardiac events 
HR (95% CI) for  
stroke 
HR (95% CI) for  
end-stage renal disease 
  
 
 
N Unadjusted Adjusted * Unadjusted Adjusted * Unadjusted Adjusted * Unadjusted Adjusted* 
TOTAL 
POPULATION 
         
ABI at rest          
No decline** 147 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 
Minor (1-5%) 153 1.8 (0.9-3.7) 2.0 (0.9-4.6) 1.4 (0.6-3.0) 1.5 (0.6-3.8) 1.1 (0.4-3.4) 1.2 (0.4-3.5) 1.1 (0.4-3.4) 1.2 (0.4-3.7) 
Intermediate (6-20%) 153 2.4 (1.2-4.8) 3.0 (1.3-6.7) 2.3 (1.1-4.8) 2.5 (1.03-5.8) 1.5 (0.5-4.2) 1.5 (0.5-4.2) 1.3 (0.4-3.8) 1.4 (0.5-4.1) 
Major (>20%) 153 2.5 (1.2-4.9) 3.3 (1.5-7.2) 2.4 (1.2-4.7) 3.1 (1.3-7.2) 4.3 (1.7-11.0) 4.2 (1.6-10.4) 2.4 (1.1-3.4) 2.7 (1.1-7.5) 
Post-exercise ABI           
No decline** 150 1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 
Minor (1-6%) 152 1.2 (0.5-2.7) 1.4 (0.6-3.2) 1.7 (0.8-3.7) 1.0 (0.4-2.6) 1.8 (0.6-5.5) 1.7 (0.6-5.4) 5.2 (1.2-24.2) 4.8 (1.01-22.8) 
Intermediate (6-30%) 152 2.4 (1.2-5.2) 2.1 (1.03-4.8) 2.3 (1.1-4.8) 2.2 (1.05-5.2) 2.7 (0.9-7.8) 2.7 (0.9-7.9) 5.1 (1.1-22.9) 4.7 (1.01-22.6) 
Major decline (>30%) 152 2.6 (1.3-5.8) 3.0 (1.4-6.4) 3.2 (1.6-6.7) 2.4 (1.1-5.6) 4.2 (1.5-11.4) 3.9 (1.4-10.2) 6.9 (1.5-31.2) 6.9 (1.5-31.5) 
ABI = ankle-brachial index. *Adjusted for age, gender, coronary artery disease, history of heart failure, history of stroke, diabetes, 
hypercholesterolemia, hypertension, smoking, renal dysfunction, baseline ankle-brachial index values and cardioprotective medication.  
** Reference category 
 
 
0.10 decrease of the post-exercise ABI. The adjusted 
risk for cardiac death increased with 12% and 15% for 
every 0.10 decrease of the resting ABI and post-exercise 
ABI, respectively [20]. The concept that PAD is a 
marker of generalized atherosclerosis has been reflected 
by the fact that ABI values correlate with the extent of 
angiographic coronary artery disease [21]. The 
prognostic value of post-exercise ABI has been 
supported by the view that a healthy person can 
maintain ankle systolic pressures at normal levels 
during modest workloads, but that larger falls in systolic 
pressure in the legs are measured during low levels of 
workload in patients with more extensive PAD [22-24]. 
Based on the greater accuracy of the postexercise ABI 
to detect PAD, the American College of 
Cardiology/American Heart Association has 
recommended its use, especially in patients with 
suspected PAD who have normal resting ABI values 
[19]. 
 
Important predictors of declining ABI values in our 
study included advanced age and smoking. The 
association between a history of myocardial infarction 
or stroke and declining ABI may signify the systemic 
nature of atherosclerosis. Our results are supported by 
the Cardiovascular Health study, which found that 
advanced age, smoking, male gender, hypertension and 
higher LDL-cholesterol concentrations were risk factors 
for declines in ABI [25]. Smoking was also identified as 
a strong predictor of large vessel peripheral arterial 
disease in a study by Aboyans and colleagues [26]. We 
found that diabetes only predicted major declines in 
post-exercise ABI in contrast to resting ABI. Similarly, 
diabetes was not a significant predictor of ABI decline 
[25], of large vessel PAD progression [26] and of 
declines in post-exercise ABI [27]. In the current study, 
however, a significant correlation between diabetes and 
major declines in post-exercise ABI was found. 
Concomitant arterial wall stiffening, medial calcinosis 
and higher ankle systolic pressures in diabetic patients 
may mask arterial occlusive disease, leading to pseudo-
normal resting ABI values. We speculate that the value 
of postexercise ABI lies in its ability to measure larger 
decreases in ankle systolic pressures in the presence of 
atherosclerotic obstructive lesions, and that obstructive 
arterial disease can become more evident after exercise 
in diabetic patients. 
 
To our knowledge, the current study is the first to 
describe the association between declines in ABI and 
prognosis in patients with PAD receiving conservative 
treatment. Declines in ABI may reflect active and 
progressive atherosclerosis, precipitating acute coronary 
and cerebrovascular events. The association between 
progression in atherosclerosis and progression to kidney 
failure is less well-defined.  The Atherosclerosis Risk in 
Communities Study showed that patients with an ABI of 
0.90-0.99 and <0.90 were at increased risk of serum 
creatinine increases over a 3-year time period, compared 
to patients with ABI values above 1.00 [28]. It has been 
proposed that atherosclerosis has indirect effects on the 
kidney because of atherosclerotic lesions in the renal 
artery and that atherosclerosis or atherogenic factors 
may induce directly intrarenal microvascular disease 
and renal injury [29]. 
   
Repeated measurements of resting and post-exercise 
ABI values are simple, inexpensive and non-invasive. 
Results from this study suggest that repeated ABI 
measurements at rest and after exercise may be 
incorporated among other tools for identifying patients 
at increased risk of late events. Either resting and post- 
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Table 3. The long-term prognostic value of absolute declines in ankle-brachial index values in multivariate analysis in patients with peripheral 
arterial disease receiving conservative management. 
 Resting ABI per 0.10 decline Postexercise ABI per 0.10 decline 
All-cause mortality   
• Unadjusted Hazard Ratio (95% CI) 1.12 (1.01-1.26) 1.12 (1.02-1.25) 
• Adjusted Hazard Ratio (95% CI)* 1.13 (1.01-1.26) 1.11 (1.01-1.23) 
Cardiac events   
• Unadjusted Hazard Ratio (95% CI) 1.17 (1.05-1.31) 1.15 (1.03-1.30) 
• Adjusted Hazard Ratio (95% CI)* 1.18 (1.05-1.33) 1.17 (1.04-1.33) 
Stroke   
• Unadjusted Hazard Ratio (95% CI) 1.30 (1.14-1.48) 1.24 (1.09-1.40) 
• Adjusted Hazard Ratio (95% CI)* 1.35 (1.18-1.55) 1.22 (1.06-1.38) 
End-stage renal disease   
• Unadjusted Hazard Ratio (95% CI) 1.20 (1.02-1.41) 1.19 (1.03-1.38) 
• Adjusted Hazard Ratio (95% CI)* 1.20 (1.03-1.41) 1.18 (1.02-1.36) 
*Adjusted for age, gender, coronary artery disease, history of heart failure, history of stroke, diabetes, hypercholesterolemia, hypertension, 
smoking, renal dysfunction, baseline ankle-brachial index values and cardioprotective medication.  
 
 
exercise ABI declines after 1 year can already identify a 
subgroup of patients at increased risk. Post-exercise 
ABI testing may be useful in patients with no declines 
in serial resting ABI. Therefore, both methods may be 
recommended.  
Especially patients with major declines in ABI values 
may be referred for further cardiovascular, 
cerebrovascular or renal evaluation and may 
subsequently benefit from preventive pharmacologic 
and non-pharmacologic interventions.  
 
Several limitations should be addressed. It should be 
emphasized that the event rate in the groups of patients 
with different declines in ABI was relatively small 
which may have affected the statistical power of the 
study. However, the hazard of adverse events was 
consistently increased in those with major declines in 
resting and post-exercise ABI. Secondly, the results 
apply to patients referred to a university hospital. These 
patients may have a higher risk profile compared to 
patients with suspected or known PAD in the general 
population. 
 
In conclusion, this observational cohort study of patients 
with PAD receiving conservative treatment shows that 
major declines in resting and post-exercise ABI are 
associated with late overall mortality, hard cardiac 
events, stroke and end-stage renal disease. The results 
support the view that progression of atherosclerosis in 
the lower extremities is associated with morbidity in the 
coronary, cerebrovascular and renal circulation. 
Repeated measurements of resting and post-exercise 
ABI are simple and non-invasive and should be 
considered in the follow-up of patients with PAD 
receiving conservative treatment for identifying those at 
increased risk of adverse events and for enabling 
optimal prevention of complications. 
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Cardioprotective medication is associated with 
improved survival in patients with peripheral arterial 
disease 
Harm H.H. Feringa, M.D.a, Virginie H. van Waning, M.D.a, Jeroen J. Bax, M.D., Ph.D.b, Abdou Elhendy, M.D., 
Ph.D.c, Eric Boersma, Ph.D.d, Olaf Schouten, M.D.e, Wael Galal, M.D.a, Radosav V. Vidakovic, M.D.c, Marco J. 
Tangelder, M.D., Ph.D.e, Don Poldermans, M.D., Ph.D.a 
 
Objectives: To investigate the effect of cardiac 
medication on long-term mortality in patients with 
peripheral arterial disease (PAD). 
Background: PAD is associated with increased 
cardiovascular morbidity and mortality. Treatment 
guidelines recommend aggressive management of risk 
factors and life-style modifications. However, the 
potential benefit of cardiac medication in patients with 
PAD remains ill defined.  
Methods: In this prospective observational cohort 
study, 2420 consecutive patients (age: 64 ±11 years, 
72% male) with PAD (ankle brachial index ≤0.90) were 
screened for clinical risk factors and cardiac medication. 
Follow-up endpoint was death from any cause. 
Propensity scores for statins, β-blockers, aspirin, 
angiotensin-converting enzyme (ACE) inhibitors, 
calcium channel blockers, diuretics, nitrates, coumarins 
and digoxin were calculated. Cox regression models 
were used to analyze the relation between cardiac 
medication and long-term mortality. 
Results: Medical history included diabetes mellitus in 
436 patients (18%), hypercholesterolemia in 581 (24%), 
smoking in 837 (35%), hypertension in 1162 (48%), 
coronary artery disease in 1065 (44%), and a history of 
heart failure in 214 (9%). Mean ankle brachial index 
was 0.58 (± 0.18). During a median follow-up of 8 
years, 1067 patients (44%) died. After adjustment for 
risk factors and propensity scores, statins (HR 0.46, 
95% CI 0.36-0.58), β-blockers (HR 0.68, 95% CI 0.58-
0.80), aspirins (HR 0.72, 95% CI 0.61-0.84) and ACE-
inhibitors (HR 0.80, 95% CI 0.69-0.94) were 
significantly associated with a reduced risk of long-term 
mortality. 
Conclusion: Based on this observational longitudinal 
study, statins, β-blockers, aspirins and ACE-inhibitors 
are associated with a reduction in long-term mortality in 
patients with PAD.  
_____________________________________________________________________________________________
PERIPHERAL ARTERIAL DISEASE (PAD) is a 
common manifestation of systemic atherosclerosis and 
carries a poor prognosis due to the frequent association 
with cerebral, renal and coronary artery disease [1-4]. 
Although patients with PAD may present with 
symptoms ranging from pain on exertion that is relieved 
by rest (intermittent claudication), to pain at rest, 
ulceration, or gangrene (critical limb ischemia), the 
majority of patients with PAD are asymptomatic [1]. 
The prevalence of PAD ranges from 4% in patients aged 
40 years and older to over 20% in patients aged 70 years 
and older [5-10].  
PAD remains an underdiagnosed disease in the primary 
care and patients with PAD are not treated as 
aggressively as are patients with other manifestations of 
atherosclerotic disease [7,11]. The management of PAD 
comprises of walking exercise, aggressive management 
of risk factors, life-style modifications, and antiplatelet 
therapy [12,13]. Cardiovascular events are a major 
cause of morbidity and mortality in patients with PAD. 
However, the potential benefit of cardiac medication 
therapy remains ill defined. β-Adrenergic receptor 
blockers were considered relatively contraindicated in 
PAD, however, several studies revealed that β-blockers 
do not adversely affect walking capacity, symptoms of 
intermittent claudication and peripheral skin 
microcirculation [14-16].  
We sought to determine the effect of chronic treatment 
with cardiac medication, including statins, β-blockers, 
aspirins, angiotensin-converting enzyme (ACE) 
inhibitors, calcium channel blockers, diuretics, nitrates, 
coumarins and digoxin on long-term mortality among 
patients with PAD. In this observational cohort study, 
we used propensity analyses to adjust for selection bias 
in the comparison of treatments. 
aDepartment of Anesthesiology, Erasmus MC, Rotterdam, the 
Netherlands. bDepartment of Cardiology, Leiden University Medical 
Centre, Leiden, the Netherlands. cInternal Medicine, Section of 
Cardiology, University of Nebraska, Omaha, NE. dDepartment of 
Cardiology, Erasmus MC, Rotterdam, the Netherlands. eDepartment 
of Vascular Surgery, Erasmus MC, Rotterdam, the Netherlands 
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METHODS 
 
Assessment of baseline characteristics 
The Erasmus Medical Centre is serving a population of 
approximately 3 million people and acts as a tertiary 
referral centre for approximately 30 affiliated hospitals. 
Patients with suspected or known PAD, who were 
referred to the Erasmus Medical Centre, Rotterdam, the 
Netherlands, between January 1983 and January 2005 
for the diagnosis and management of PAD, were 
evaluated. The ABI at rest was measured in each patient 
and patients with PAD (an ankle brachial index (ABI) 
≤0.90) were included in the study.  
Based on hospital records and personal interviews at the 
time of the visit, a medical history was recorded. 
Information on the presence of previous myocardial 
infarction, angina pectoris, previous coronary artery 
revascularization, congestive heart failure, previous 
stroke or transient ischemic attack, diabetes mellitus, 
hypertension, current smoking, hypercholesterolemia 
and renal dysfunction were obtained. Diabetes mellitus 
was recorded if patients presented with a fasting glucose 
level of ≥7.0 mmol/L, or in those who required 
treatment. Hypertension was recorded if patients 
presented with a blood pressure ≥140/90 mmHg or if 
patients were medically treated for hypertension. 
Hypercholesterolemia was recorded when patients 
presented with the diagnosis, made by the referring 
physician, or if patients were taking lipid-lowering 
agents. Renal dysfunction was recorded if patients 
presented with a serum creatinine level ≥ 2.0 mg/dL 
(177 μmol/L) or in those who required dialysis. A 
baseline 12-lead electrocardiography was obtained and 
was considered abnormal in the presence of one or more 
of the following; Q-waves, ST-segment depression or 
elevation, left ventricular hypertrophy, right or left 
bundle branch block and atrial fibrillation. 
 
Medication use 
All prescription and over-the-counter medications were 
noted at the time of the visit and were classified as 
follows: statins, β-blockers, aspirins, ACE-inhibitors, 
calcium channel blockers (dihydropyridines or non-
dihydropyridines), diuretics, nitrates, coumarins and 
digoxin. To ascertain the long-term use of 
cardiovascular medication, medication had to be 
documented at least at 2 months after the visit. 
 
Follow-up 
Patients were followed-up during a median time of 8 
years (interquartile range: 4-11 years) for the occurrence 
of all-cause death. Endpoint was mortality. Information 
about the patient’s vital status was obtained by 
approaching the Office of Civil Registry. For patients 
who died at our hospital during follow-up, hospital  
 
Table 1. Baseline characteristics of the 2420 study participants. 
 
Characteristic Total 
population 
(n=2420) 
Demographics  
     Age (years) 64 +/-11  
     Male gender  1748 (72%) 
Cardiovascular history   
      Angina pectoris  567 (23%) 
      Previous myocardial infarction 923 (38%) 
      History of congestive heart failure 214 (9%) 
      History of cerebrovascular disease 195 (8%) 
      Previous coronary revascularization 464 (19%) 
Clinical risk factors  
      Diabetes Mellitus  436 (18%) 
      Hypercholesterolemia  581 (24%) 
      Hypertension  1162 (48%) 
      Current smoking  837 (35%) 
      Renal failure  127 (5%) 
      Chronic pulmonary disease 288 (12%) 
Ankle brachial index >0.70 and ≤0.90 557 (23%) 
Ankle brachial index ≤0.70 1863 (77%) 
Electrocardiography  
      Q waves  630 (26%) 
      ST segment changes 382 (16%) 
      Left ventricular hypertrophy 113 (5%) 
      Left bundle branch block 98 (4%) 
      Right bundle branch block 56 (2%) 
      Atrial fibrillation 54 (2%) 
Values are expressed as number (%) or mean +/- SD. 
 
records and autopsy results were retrieved and 
reviewed. For patients who died outside our hospital, 
general practitioners were approached to ascertain the 
cause of death.  
 
Statistical analysis  
Continuous data are expressed as mean (+/- SD) or 
median (+/- interquartile range) and compared using the 
Student t test or Mann-Whitney U test when 
appropriate. Categorical data are presented as percent 
frequencies and differences between proportions were 
compared using the chi-square test with Yates’ 
correction. The Kaplan-Meier method with log-rank test 
was used to compare survival curves in two or more 
groups. We applied univariate and multivariate Cox 
hazards regression analyses to study the relation 
between cardiac medication therapy and long-term 
survival. Cardiac medication use was not randomly 
assigned in these patients, and the impact of selection 
bias may profoundly distort the results of our study.  
 53
14
26
13
32
0
5
10
15
20
25
30
35
1983-1989 1990-1994 1995-1999 2000-2004
St
at
in
 u
se
 (%
)
 
28
21
40
17
0
5
10
15
20
25
30
35
40
45
1983-1989 1990-1994 1995-1999 2000-2004
B
et
a-
bl
oc
ke
r u
se
 (%
)
 
27
21
27
15
0
5
10
15
20
25
30
1983-1989 1990-1994 1995-1999 2000-2004
A
sp
iri
n 
us
e 
(%
)
 
30
22
30
12
0
5
10
15
20
25
30
35
1983-1989 1990-1994 1995-1999 2000-2004
Study period (years)
Figure 1. The prescription of statins, β-blockers, aspirins and 
angiotensin-converting enzyme (ACE) inhibitors in patients who were 
included in different periods of time. 
Propensity analyses are reliable tools to correct for 
selection bias and the rationale for using propensity 
scores has been described previously [17]. Therefore, 
we calculated separate propensity scores for statins, β-
blockers, aspirin, ACE-inhibitors, calcium channel 
blockers, diuretics, nitrates, coumarins and digoxin, 
which were constructed using multiple logistic 
regression analyses. Variables (including baseline 
characteristics as listed in Table 1 and medication use as 
listed in Table 2) that were independently associated 
with the decision to prescribe statins, β-blockers, 
aspirin, ACE-inhibitors, calcium channel blockers, 
diuretics, nitrates, coumarins and digoxin (p<0.25) were 
included in the multivariate propensity score. In 
multivariate analyses we adjusted for baseline clinical 
variables, irrespective of the significance level in 
univariate analysis. Propensity scores were added in 
separate multivariate models. Hazard ratios are given 
with 95% confidence intervals. For all tests, a p value 
<0.05 (two-sided) was considered significant. All 
analyses were performed using SPSS-11.0 statistical 
software (SPSS Inc., Chicago, Illinois). 
 
RESULTS 
 
Baseline characteristics of the 2420 study participants 
are presented in Table 1. The mean age was 64 +/-11 
years and 1748 patients (72%) were male. Severe PAD 
(ABI was ≤0.70) was identified in 1863 patients (77%). 
The mean ABI was 0.58 +/-18. An abnormal 
electrocardiogram was observed in 1127 patients (47%). 
Table 2 shows cardiac medication in the study 
population. As demonstrated in Figure 1, the 
prescription of statins, β-blockers, aspirin and ACE-
inhibitors has increased from 12%, 13%, 15% and 17%, 
respectively, in the period 1983-1989, to 30%, 32%, 
27% and 40%, respectively, in the period 2000-2004 (all 
p-values <0.001). 
During follow-up, death occurred in 1067 patients 
(44%). The unadjusted and adjusted associations 
between clinical variables and long-term mortality are 
presented in Table 3. In a multivariate model that 
mutually adjusted for clinical risk factors and propensity 
scores, statins, β-blockers, aspirin and ACE-inhibitors 
were independently associated with a reduced incidence 
of long-term mortality (HR: 0.46 (95% CI: 0.36-0.58), 
HR: 0.68, (95% CI: 0.58-0.80), HR: 0.72 (95% CI: 
0.61-0.84), HR: 0.80 (95% CI: 0.69-0.94)) (Table 4).  
Calcium channel blockers, diuretics, nitrates, coumarins 
and digoxin, however, were not significantly and 
independently associated with long-term mortality. In 
patients using β-blockers, no difference was observed 
between selective and non-selective β-blockers on the 
long-term outcome (selective β-blockers: HR of 1.31 
(95% CI: 0.87-1.72)). 
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Table 2. The number of patients (%) receiving cardiac medication. 
 
Medications Total population 
(n=2420) 
Statin  457 (19%) 
β -Blocker  602 (25%) 
     Selective β-blockers 468 (19%) 
     Non-selective β-blockers 134 (6%) 
Aspirin 542 (22%) 
ACE-inhibitors 626 (26%) 
Calcium channel blockers 677 (28%) 
    Dihydropyridines 460 (19%) 
    Non-dihydropyridines 217 (9%) 
Coumarin  597 (25%) 
Nitrates 568 (23%) 
Diuretics  365 (15%) 
Digoxin  159 (7%) 
ACE-inhibitor = angiotensin-converting enzyme inhibitor;  
Values are expressed as number (%) or mean +/-SD. 
 
 
DISCUSSION 
 
In this cohort study of consecutive patients referred to 
our center for the evaluation of PAD, we found that 
statins, β-blockers, aspirins and ACE-inhibitors were 
significantly associated with a reduction of all-cause 
mortality, independent of baseline clinical variables and 
independent of PAD severity.  
HMC-Co-A reductase inhibitor drugs (statins) have 
been shown to reduce cardiovascular morbidity and 
mortality in high-risk patients [18-22]. The beneficial 
effect of statins may not only be due to its lipid-
lowering effect, but also to the inhibition of the 
inflammatory processes of atherosclerosis [23]. It has 
been shown that a reduction in the inflammatory 
component through the use of statins improved the 
clinical outcome in patients with coronary artery 
disease, regardless of the reduction in cholesterol levels 
[24,25]. In patients with PAD, statin use has been 
demonstrated to favorably influence leg functioning, 
walking performance, ABI values and symptoms of 
claudication [26-28]. The association of statin use and 
superior leg functioning was also demonstrated in 
patients with an ABI of 0.90 to 1.49, which may reflect 
the favorable influence of statins on subclinical PAD 
[26]. A recent study by Schillinger et al showed that 
statin therapy was associated with an improved survival 
of patients with severe PAD with elevated high-
sensitivity C-reactive protein levels (>0.42 mg/dL) [29]. 
The observation that patients with low inflammatory 
activity had no survival benefit supports the view that 
statins may exert beneficial effect though anti-
inflammatory properties.  
 
 
Table 3. Univariate and multivariate associations of clinical variables and overall mortality. 
 
Characteristic Univariate analysis  P-value Multivariate analysis  P-value 
 HR and 95% CI  HR and 95% CI  
Age >70 years 1.75 (1.55-1.97) <0.001 1.68 (1.48-1.91) <0.001 
Male gender  1.08 (0.94-1.24) 0.3 1.05 (0.91-1.22) 0.5 
Coronary artery disease 1.59 (1.41-1.80) <0.001 1.39 (1.19-1.62) <0.001 
History of heart failure  2.69 (2.26-3.19) <0.001 1.73 (1.42-2.11) <0.001 
History of cerebrovascular accident 1.55 (1.26-1.90) <0.001 1.28 (1.04-1.57) 0.02 
Diabetes Mellitus  1.42 (1.22-1.66) <0.001 1.35 (1.15-1.60) <0.001 
Hypercholesterolemia  1.54 (1.29-1.84) <0.001 1.77 (1.44-2.18) <0.001 
Hypertension  1.22 (1.08-1.38) 0.002 1.26 (1.10-1.45) <0.001 
Current smoking  1.25 (1.11-1.42) <0.001 1.27 (1.12-1.44) <0.001 
Renal failure  3.81 (3.09-4.69) <0.001 3.34 (2.68-4.16) <0.001 
Chronic pulmonary disease 1.52 (1.29-1.80) <0.001 1.37 (1.15-1.65) <0.001 
Severe PAD (ABI ≤0.70) 1.40 (1.20-1.62) <0.001 1.21 (1.05-1.41) 0.01 
Abnormal electrocardiogram 1.71 (1.52-1.93) <0.001 1.36 (1.17-1.59) <0.001 
Statin  0.65 (0.54-0.78) <0.001 0.42 (0.34-0.53) <0.001 
Beta-blocker  0.76 (0.65-0.88) <0.001 0.64 (0.55-0.75) <0.001 
Aspirin 0.87 (0.77-1.01) 0.08 0.78 (0.67-0.91) 0.002 
ACE-inhibitors 1.13 (0.98-1.30) 0.08 0.80 (0.69-0.93) 0.004 
Calcium channel blockers 1.14 (1.01-1.30) 0.04 1.04 (0.91-1.19) 0.6 
Coumarins 1.15 (1.01-1.32) 0.03 1.13 (0.98-1.29) 0.08 
Diuretics 1.22 (1.03-1.43) 0.02 0.82 (0.68-0.98) 0.03 
Nitrates 1.36 (1.19-1.56) <0.001 1.00 (0.86-1.16) 1.0 
Digoxin. 1.91 (1.57-2.33) <0.001 1.2 (1.01-1.57) 0.04 
ABI = ankle brachial index;  
ACE-inhibitor = angiotensin-converting enzyme inhibitor  
PAD = peripheral arterial disease; 
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Table 4. Cox regression models, adjusted for baseline variables and 
propensity scores. 
Medication HR and 95% CI for overall 
death 
P-value 
 Adjusted for baseline variables 
and propensity scores 
 
Statin  0.46 (0.36-0.58) <0.001 
β-Blocker  0.68 (0.58-0.80) <0.001 
Aspirin 0.72 (0.61-0.84) <0.001 
ACE-inhibitors 0.80 (0.69-0.94) 0.005 
Diuretics 0.85 (0.71-1.02) 0.09 
Calcium-blockers 1.03 (0.90-1.18) 0.7 
Nitrates 1.00 (1.86-1.16) 1.0 
Coumarins 1.13 (0.98-1.29) 0.08 
Digoxin. 1.21 (1.95-1.53) 0.1 
ACE-inhibitor = angiotensin-converting enzyme inhibitor 
 
Although β-blockers were considered relatively 
contraindicated in patients with PAD, several studies 
showed that β-blockers do not adversely affect walking 
capacity, symptoms of intermittent claudication and 
peripheral skin microcirculation [14-16]. β-Blockers are 
effective anti-hypertensive agents and improve 
prognosis in patients with ischemic heart disease and 
congestive heart failure and are thus indicated in a 
majority of patients with PAD. However, it seems that 
β-blockers have been underused by vascular surgeons 
and primary care providers, perhaps because of 
concerns that β-blockers will aggravate symptoms of 
intermittent claudication [30,31]. Patients with PAD are 
at increased risk for cardiovascular morbidity and 
mortality, and recent studies have demonstrated the 
beneficial effect of β -blockers in these patients. In a 
study cohort of 575 patients with symptomatic PAD and 
with a previous myocardial infarction, Aronow et al 
demonstrated that β-blocker therapy was associated with 
a 53% significant reduction in new coronary events, 
independent of other confounding variables [32]. This 
was confirmed in a more recently published study, 
which demonstrated a 3-fold reduction in cumulative 
cardiac mortality in 78 post-infarction patients with 
intermittent claudication who were treated with β-
blocker therapy, compared to patients not treated with 
β-blocker therapy [33]. It has been shown that 
hemodynamic forces (blood pressure and heart rate) are 
associated with the development of disruption of the 
vulnerable plaque, which consists of an atheromatous 
plaque core covered by a thin fibrous cap with ongoing 
inflammation [34]. Β-blockers may prevent plaque 
disruption by reducing heart rate and blood pressure. In 
addition, it can be hypothesized that anti-inflammatory 
properties of β-blockers may limit the phased 
progression of cardiovascular disease [35]. 
Antiplatelet drugs are now established agents for 
preventing cardiovascular and cerebrovascular ischemic 
events. However, a randomized controlled trial in 
patients with PAD demonstrating the effect of aspirin in 
reducing cardiovascular events still has to be awaited. 
The meta-analysis of the anti-thrombotic trialists 
collaboration showed a proportional reduction of 23% 
in serious vascular events among 9214 patients with 
PAD using antiplatelet therapy (primarily aspirin), 
compared to those using no antiplatelet therapy (5.8 vs. 
7.1%, p<0.004) [36]. Limited information is available 
regarding the optimal antiplatelet treatment choice in 
patients with PAD. Potential adverse effects, including 
diarrhea, neutropenia and thrombotic thrombocytopenic 
purpura, may limit the use of ticlopidine. Based on 
current evidence, aspirin or clopidogrel seem to be the 
first-line oral antiplatelet drugs of choice. 
ACE-inhibitors have been shown to inhibit the 
atherosclerotic process and to improve peripheral blood 
pressure and blood flow in patients with PAD [37]. The 
HOPE study investigators showed that ramipril 
significantly reduced the rate of mortality, myocardial 
infarction and stroke in 9297 high-risk patients without 
a low ejection fraction or heart failure [38]. A recent 
randomized placebo-controlled study demonstrated the 
effect of ramipril in patients with clinical or subclinical 
PAD for preventing major cardiovascular events [39]. 
Activation of the renin-angiotensin system seems to be 
associated with an increased risk of cardiovascular 
events. Growing evidence suggest that ACE-inhibitors 
directly inhibit the atherosclerotic process and improve 
vascular endothelial function [40, 41]. In addition, the 
benefit of ACE-inhibitors seems to be independent of 
the antihypertensive properties of these agents [42].  
The results of our study are in accordance with 
previously published studies demonstrating the effect of 
statins, β-blockers, aspirin and ACE-inhibitors for 
reducing complications in patients with PAD. Several 
limitations of our study should be addressed. The major 
limitation of this study is that the use of cardiac 
medication was not randomly assigned to patients with 
PAD. However, properly conducted observational 
studies might not produce misleading or biased results 
[43]. Moreover, we used propensity analysis to adjust 
for selection bias and in multivariate analysis we 
adjusted for known possible confounding factors.  
PAD is a highly prevalent disease and its presence 
should be a marker for atherosclerosis in other vascular 
beds. Although patients are at increased risk for 
cardiovascular morbidity and mortality, PAD seems to 
be undertreated and underdiagnosed. Therefore, the 
identification of patients with clinical or subclinical 
PAD is important for disease control and selection of 
appropriate treatment strategies. Conventional treatment 
strategies have focused on risk factor modification and 
antiplatelet therapy. Our study, as well as several other 
previously published studies, has proven the beneficial 
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effect of statins, β-blockers, aspirin and ACE-inhibitors. 
It might be hypothesized that its beneficial effects are 
exerted not only through their conventional therapeutic 
effects, but also through their plaque-stabilizing and 
anti-inflammatory properties. Based on current 
evidence, we suggest aggressive risk factor modification 
and pharmacological treatment in patients with PAD 
who are at increased risk of future cardiovascular 
events. 
 
Conclusion 
Based on this observational longitudinal study, statin, β-
blocker, aspirin and ACE-inhibitor therapy are 
associated with a reduction in long-term mortality risk 
in patients with PAD, independent of clinical risk 
factors and adjusted for propensity scores. The use of 
cardiac medications as therapeutic and preventive 
agents in patients with PAD seems to be promising in 
reducing long-term mortality and could be incorporated 
among other management strategies, including walking 
exercise and risk factor modification. Future studies 
should be conducted to determine which patients with 
PAD would mostly benefit from statins, β-blockers, 
aspirin and ACE-inhibitor therapy. 
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The effect of intensified lipid lowering therapy on 
long-term prognosis in patients with peripheral 
arterial disease 
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Schouten, MDc, Jeroen J. Bax, MDd, Don Poldermans, MDb 
 
 
Context: HMG-CoA reductase inhibitors (statins) are 
associated with improved outcome in patients with 
peripheral arterial disease. Statins may also have 
beneficial properties beyond its lipid lowering effect. 
Objective: To examine whether higher doses of statins 
and lower LDL-cholesterol levels are both 
independently associated with improved outcome in 
peripheral arterial disease. 
Design, setting, participants: A prospective 
observational cohort study, conducted at a university 
hospital from 1990 to 2005. A total of 1374 consecutive 
patients (age: 61 ± 10 years, 73% male) with peripheral 
arterial disease (ankle-brachial index ≤0.90) were 
enrolled and screened for clinical risk factors, statin 
therapy and LDL-cholesterol levels. Serial LDL-
cholesterol levels were measured at 6 months and every 
1 year after enrollment. The mean follow-up time was 
6.4 ± 3.6 years and no patients were lost to follow-up. 
Main Outcome Measure(s): The primary endpoints of 
the study were all-cause and cardiac mortality. 
Secondary endpoint was the progression to kidney 
failure. 
Results: Overall mortality, cardiac death and 
progression to kidney failure occurred in 29%, 20% and 
5% of patients, respectively. Multivariate analysis 
revealed that higher doses of statins (per 10% increase) 
and lower 6-month LDL-cholesterol levels (per 10 
mg/dL decrease) were both independently associated 
with lower all-cause mortality (HR: 0.71, 95% CI: 0.62-
0.80 and HR: 0.96, 95% CI: 0.93-0.98, respectively) and 
cardiac death (HR: 0.76, 95% CI: 0.67-0.86 and HR 
0.95, 95% CI: 0.92-0.98, respectively). Higher HDL-
cholesterol levels also correlated significantly with 
lower all-cause and cardiac mortality. Higher doses of 
statins (per 10% increase) were associated with less 
progression to kidney failure (HR: 0.69, 95% CI: 0.54-
0.89).  
Conclusions: This study showed that higher doses of 
statins and lower LDL-cholesterol levels are both 
independently associated with improved outcome in 
patients with peripheral arterial disease. These results 
support the view that statins have beneficial effects 
beyond its lipid lowering properties and should be 
considered in all patients with PAD, irrespective of 
LDL-cholesterol levels.  
_____________________________________________________________________________________________
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THE BENEFICIAL PROPERTIES of 3-hydroxy-3-
methylglutaryl coenzyme A reductase inhibitors 
(statins) beyond the lipid-lowering effect include 
atherosclerotic plaque stabilization, oxidative stress 
reduction and decrease in vascular inflammation [1]. It 
has been shown that a reduction in the inflammatory 
component through the use of statins improved the 
clinical outcome in patients with coronary artery disease  
[2,3].  
Peripheral arterial disease (PAD) is a 
manifestation of systemic atherosclerosis and has been 
recognized as a growing health burden worldwide [4]. 
Prevalence rates up to 29% have been reported for PAD 
in the United States, depending on the age of the study 
cohort, the underlying atherosclerosis risk factor profile, 
and the presence of cardiovascular co-morbidities [5]. In 
patients with PAD, statin use has been demonstrated to 
favorably influence leg functioning, walking 
performance, ABI values, symptoms of claudication, 
and mortality [6-8]. The guidelines of the American 
College of Cardiology/American Heart Association on 
the management of patients with PAD recommend 
statin treatment in all patients with PAD to achieve a 
target low-density lipoprotein cholesterol level less than 
100 mg per dL [4]. Despite the use of statin therapy, 
mortality and morbidity among patients with PAD 
remain high [5]. In addition, patients with low ankle-
brachial index values are at risk of progressive renal 
dysfunction which may be due to the underlying 
atherosclerotic risk profile [9]. In these patients, statins 
may also exert a renoprotective effect.   
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We hypothesized that intensive statin treatment 
improves outcome in patients with PAD and may have a 
beneficial effect on long-term outcome due to properties 
other than reducing cholesterol levels. In a large 
observational cohort study, we therefore sought to 
determine the independent effect of high-dose statin 
therapy and low target LDL-cholesterol levels on all-
cause mortality, cardiac death and progression to kidney 
dysfunction during a long-term follow-up period in 
patients with PAD. In this observational study, we used 
propensity analysis to adjust for selection bias in the 
comparison of treatments. 
 
Figure 1. Mean LDL-cholesterol level (standard error of the mean) at 
different times of measurement. 
 
METHODS 
 
Study design and participants 
This was a single-center observational cohort study of 
1374 consecutive patients with PAD who were referred 
to our university clinic for ankle-brachial index 
measurement, clinical evaluation and therapeutic 
management between January 1990 and January 2005. 
Patients presented with typical symptoms of PAD 
including typical intermittent claudication or other 
symptoms of chronic arterial insufficiency, such as 
ulceration of the foot, hair loss, or reduced capillary 
refill. Patients eligible for the study had to be older than 
18 years of age and only patients with an ankle-brachial 
index (ABI) of 0.90 or less were included. Patients were 
excluded from the study if they had a myocardial 
infarction or coronary revascularization procedure 
within the previous 6 months, or if they presented with 
chronic liver disease (cirrhosis or hepatitis). All patients 
agreed on participation in the study after given informed 
consent and the study was conducted according to the 
declaration of Helsinki. The Institutional Review Board 
approved the protocol. During the first visit, patients 
were screened for clinical risk factors, ankle-brachial 
index values, 12-lead electrocardiographic 
abnormalities, serum cholesterol levels and medication 
use. Diabetes mellitus was recorded if patients presented 
with a fasting glucose level of ≥7.0 mmol/L, or in those 
who required treatment. Hypertension was recorded if 
patients presented with a blood pressure ≥140/90 mmHg 
or if patients were medically treated for hypertension. 
Renal dysfunction was recorded if patients presented 
with a serum creatinine level ≥ 2.0 mg/dL (177 μmol/L) 
or in those who required dialysis. Smoking included 
only current smoking. Clinical data were prospectively 
collected and stored into a computerized registry. Risk 
factor reduction, life style modification and a lipid-
lowering diet were encouraged in all patients presenting 
with clinical risk factors. 
 
Ankle-brachial index measurement 
Systolic blood pressures in the right and left brachial 
artery, right and left dorsalis pedis artery and right and 
left posterior tibial artery were measured by trained 
technicians, using a Doppler ultrasonic instrument with 
an 8 MHz vascular probe (Imexdop CT+ Vascular 
Doppler, Miami Medical, USA). The ankle-brachial 
index in the right and left leg was calculated by dividing 
the right and the left ankle pressure by the brachial 
pressure. The higher of the two brachial blood pressures 
was used if a discrepancy in systolic blood pressure was 
present. Again, the higher of the dorsalis pedis and 
posterior tibial artery pressure was used when a 
discrepancy in systolic blood pressure between the two 
arteries was measured. If no pressure in the dorsalis 
pedis artery was obtained due to a congenitally absent 
or occluded dorsalis pedis artery, the pressure in the 
posterior tibial artery was used. The ankle-brachial 
index was measured after the participants had been 
resting in the supine position for at least 10 minutes. Of 
the ankle-brachial index values obtained in each leg, the 
lower was used in all analyses. Inter- and intra-observer 
agreement for the ankle-brachial index was 97% and 
98%, respectively.  
 
Statin therapy and cholesterol measurements  
During the initial visit, patients were screened for statin 
use. The duration of statin treatment prior to enrollment 
was recorded in patients who were already being treated 
with statins (chronic statin users). In non-statin users 
presenting with indications for cholesterol reduction, 
statins were prescribed according to standard guidelines 
of the Erasmus Medical Center (first-time statin users). 
According to these guidelines, statin treatment was 
indicated in patients with hypercholesterolemia (LDL-
cholesterol >200 mg/dL). After 2003, LDL-cholesterol 
level was targeted to levels less than 100 mg/dL. During 
the initial visit, the daily dosage of statin therapy was 
recorded and converted to a percentage value of the 
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maximum recommended therapeutic dose (MRTD) 
according to the FDA’s Center for Drug Evaluation and 
Research database [10]. During follow-up, patients were 
monitored for medication adherence and for the 
occurrence of side effects, which included myopathy, 
elevated serum transaminases, rhabdomyolysis, 
proteinuria and diarrhea or nausea. Serial cholesterol 
levels were measured at 6 months and every year after 
the initial visit. Measurements were obtained with an 
automated enzymatic method and included low-density 
lipoprotein (LDL)-cholesterol, high-density lipoprotein 
(HDL)-cholesterol, triglycerides and total cholesterol. 
Cholesterol measurements at 6-months were obtained in 
all patients and these values were used for survival 
analysis. Cholesterol measurements at 1 year , 2 year 
and 3 year were obtained in 1281 patients (93%), 1219 
patients (89%), and 1110 patients (81%), respectively.  
 
Definition of study endpoints 
Primary endpoints of the study were all-cause mortality 
and cardiac death. Information about the patient’s vital 
status was obtained at the Office of Civil Registry. For 
patients who died at our hospital during follow-up, 
hospital records and autopsy results were reviewed. For 
patients who died outside our hospital, death certificates 
were reviewed and  general practitioners were 
approached to ascertain the cause of death. A cardiac 
cause of death was defined as death caused by cardiac 
arrhythmias, congestive heart failure or acute 
myocardial infarction (post-mortem evidence of acute 
myocardial infarction or the presence of at least two of 
the following within the 4 weeks prior to death: elevated 
cardiac enzyme levels (CK level > 190 U/L and CK-MB 
>14 U/L, or CK-MB fraction >10% of total CK, or 
cardiac troponin T >0.1 ng/mL), development of typical 
electrocardiographic changes (new Q waves >1 mm or > 
30 ms), and typical symptoms of angina pectoris). 
Sudden unexpected death in a previously stable patient 
was also considered cardiac death if pathology did not 
reveal a conclusive cause of death. 
Secondary endpoint was progression to kidney 
failure. Serum creatinine measurements were regularly 
obtained during follow-up visits and the estimated 
glomerular filtration rate (eGFR) was calculated using 
the following equation: glomerular filtration rate 
(ml/min/1.73 m2) = 186 x (serum creatinine level)-1.154 x 
(age)-0.203 x (0.742 if female) x (1.210 if of African 
descent) [11]. Kidney failure was defined as eGFR less 
than 15 ml/min per 1.73 m2 or a need to start kidney 
replacement therapy, which included dialysis or renal 
transplantation.   
 
Data analysis 
Continuous data were compared using the Student t test 
or the Mann-Whitney U test, when appropriate. 
Categorical data were compared using the Chi square 
test. Group comparisons were performed with analysis 
of variance (ANOVA) techniques. Univariate and 
multivariate Cox proportional hazard regression 
analysis was used to evaluate the effect of statin therapy 
and cholesterol levels on the study endpoints. All 
clinical risk factors were entered in multivariate 
analysis, irrespective of the significance level in 
univariate analysis. Statin therapy was not randomly 
assigned in these patients and the impact of selection 
bias may distort the results of our study. Propensity 
analyses are reliable tools to correct for selection bias 
and the rationale for using propensity scores has been 
described previously [12]. Therefore, propensity scores 
for statin therapy were calculated, which were 
constructed by using multiple logistic regression 
analysis. Variables as listed in Table I that were 
independently associated with the decision to prescribe 
statins (p<0.25) were included in the multivariate 
propensity score. In propensity analysis, important  
 
 
 
Figure 2. Kaplan-Meier curves for all-cause mortality (a) and cardiac 
death (b) stratified according to the duration of statin therapy. 
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Table I. Baseline characteristics of the patients. 
 
Characteristic Total 
population 
(n=1374) 
Age (years), mean ± SD 61 ± 10 
Male gender, no (%)  1001 (72.9) 
Angina pectoris, no (%)  345 (25.1) 
Previous myocardial infarction, no (%)  484 (35.2) 
History of congestive heart failure, no (%) 102 (7.4) 
Previous coronary artery bypass grafting, no (%)  264 (19.2) 
Previous percutaneous coronary intervention, no (%) 84 (6.1) 
History of stroke or transient ischemic attack, no (%)  105 (7.6) 
Diabetes mellitus, no (%)  232 (16.9) 
Hypertension, no (%)  602 (43.8) 
Current smoking, no (%)   385 (28.0) 
Renal failure, no (%)  83 (6.0) 
Chronic obstructive pulmonary disease, no (%)  139 (10.1) 
Q waves, no (%) 348 (25.3) 
ST segment changes 250 (18.2) 
Left bundle branch block, no (%)  62 (4.5) 
Right bundle branch block, no (%)  30 (2.2) 
Ankle-brachial index at rest, mean ± SD 0.60 ± 18 
Aspirin, no (%)  353 (25.7) 
Angiotensin-converting enzyme inhibitor, no (%) 397 (28.9) 
Beta-blocker, no (%) 443 (32.2) 
Calcium channel blocker, no (%) 453 (32.9) 
Statins, no (%) 481 (35.0) 
LDL-cholesterol level (mg/dL), mean ± SD 144 ± 51 
HDL-cholesterol level (mg/dL), mean ± SD 44 ± 19 
Triglyceride level (mg/dL), mean ± SD 194 ± 158 
Total cholesterol level (mg/dL), mean ± SD 215 ± 55 
Ratio of LDL-cholesterol to HDL-cholesterol 3.2 ± 1.5 
Ratio of total cholesterol to HDL-cholesterol 5.3 ± 2.6 
 
 
 
 
variables (p<0.001) associated with the prescription of 
statin therapy were high baseline LDL-cholesterol 
levels, coronary artery disease, smoking, male gender, 
diabetes mellitus and previous coronary intervention. 
The propensity score ranged from 0.03 to 0.93. The 
Kaplan-Meier method with the log-rank test was used to 
assess differences in survival between different groups 
of patients. For all tests, a P value <0.05 (two-sided) 
was considered significant. All analyses were performed 
using SPSS-11.0 statistical software (SPSS Inc., 
Chicago, Illinois). 
 
RESULTS 
 
Baseline characteristics 
Baseline characteristics of the 1374 study participants 
are presented in Table I. The mean age was 61 ± 10 
years and 1001 patients (73%) were male. The mean 
ABI was 0.60 ± 0.18 and ranged from 0.05 to 0.90. ABI 
of 0.70 or less was identified in 1070 patients (78%). 
During the initial visit, 285 patients (21%) presented 
with chronic statin therapy and statin therapy was 
started in 196 patients (14%). The following statins 
were used in our study cohort: simvastatin in 293 
patients, pravastatin in 55, fluvastatin in 15 patients, 
atorvastatin in 88 patients, and rosuvastatin in 30 
patients. In patients with chronic statin therapy, median 
duration of statin therapy prior to enrollment was 3.1 
years (interquartile range: 1.3-5.0 years). The mean 
percentage (±SD) of maximum recommended dose was 
37 ± 27% in first-time statin users and 34 ± 27% in 
chronic statin users (p=0.30). 
 
 
Figure 3. Kaplan-Meier curves for all-cause mortality (a) and cardiac 
death (b) stratified according to the dose of statin therapy, expressed 
as percentage of maximum recommended therapeutic dose (MRTD). 
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Figure 1 demonstrates mean LDL-cholesterol levels at 
baseline and during follow-up stratified according to no, 
chronic or first-time statin use. A reduction of LDL-
cholesterol at 6 months from baseline values was 
observed in 900 patients (66%). A total of 257 patients 
(19%) had a LDL-cholesterol reduction of more than 
35%. Higher statin doses were significantly associated 
with larger reductions in LDL-cholesterol (β-
coefficient: -0.24, p<0.0001). Six months after 
enrollment, 423 patients (30.8%) had a LDL-cholesterol 
level less than 100 mg/dL and 133 patients (9.7%) had a 
LDL-cholesterol less than 70 mg/dL.  
 
Follow-up 
During a mean follow-up time of 6.4 ± 3.6 years, death 
was recorded in 404 patients (29%) and cardiac death in 
278 patients (20%). Non-cardiac causes of death were 
renal disease in 23 patients (2%), respiratory failure in 
32 patients (2%), cancer in 23 patients (2%), stroke in 
21 patients (2%), sepsis in 12 patients (1%) and other or 
unknown causes in 15 patients (1%). During follow-up, 
68 patients (5%) progressed to kidney failure. Statin 
therapy during follow-up was discontinued in 6 patients 
(1%) due to myopathy and in 3 patients (1%) due to 
nausea and/or diarrhea. Kaplan-Meier survival curves 
demonstrate that first-time and chronic statin users were 
at significantly lower risk for all-cause mortality 
(p<0.001) and cardiac death (p<0.001), compared to 
patients who were not using statins (Figure 2). An 
improved survival (p<0.001) and freedom from cardiac 
death (p<0.001) was also observed in patients who were 
using higher doses of statin therapy (Figure 3). Figure 4 
demonstrates that all-cause mortality (15%) and cardiac 
death (10%) were lowest in patients with the largest 
percentage LDL-cholesterol reduction (reduction >35%) 
(p<0.001 and p<0.001, respectively). Figure 5 
demonstrates the incidence of overall and cardiac 
mortality stratified according to different LDL-
cholesterol levels at 6 months. The lowest all-cause 
mortality rate (18%) and cardiac death rate (13%) was 
observed in the group of patients with LDL-cholesterol 
levels less than 70 mg/dL (p<0.001 and p<0.001, 
respectively). Overall and cardiac mortality rates were 
gradually increasing in patients with higher 6-month 
LDL-cholesterol levels (p<0.001 and p<0.001, 
respectively).  
 
Multivariate analysis 
Cox hazard regression analysis with adjustment for 
clinical variables, ABI values, electrocardiography and 
propensity scores demonstrated that chronic statin 
therapy, higher doses of statin therapy, larger reductions 
in LDL-cholesterol during the first 6 months and lower 
LDL-cholesterol levels at 6-month were significantly 
 
Figure 4. The estimated incidence of overall mortality and cardiac 
death at 10 years of follow-up in patients with no, low (1-35%) and 
high (>35%) 6-months LDL-cholesterol reduction from baseline 
values.  
 
Figure 5. The estimated incidence of overall mortality and cardiac 
death at 10 years of follow-up in patients with varying LDL-
cholesterol levels after 6 months of study enrollment. 
 
associated with a lower risk of overall and cardiac 
mortality (Table II and III). Higher triglyceride 
concentrations, higher total cholesterol levels, a higher 
LDL/HDL-cholesterol ratio and a higher total/HDL-
cholesterol ratio at 6 months also proved to be 
significantly correlated with higher all-cause and 
cardiac mortality rate (Table II and III). Higher mean 
cholesterol levels during follow-up were also 
significantly associated with adverse outcome (Table II 
and III). A final multivariate model including statin 
dose, baseline and 6-month cholesterol levels supported 
our hypothesis that higher statin doses (per 10% 
increase) and lower 6-month LDL-cholesterol levels 
(per 10 mg/dL decrease) were both independently 
associated with lower all-cause mortality (HR: 0.71, 
95% CI: 0.62-0.80 and HR: 0.96, 95% CI: 0.93-0.98, 
respectively) and cardiac death (HR: 0.76, 95% CI:0.67-
0.86 and HR 0.95, 95% CI: 0.92-0.98, respectively). 
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Table II. Univariate and multivariate Cox proportional hazards models to predict overall mortality. 
 Univariate  
HR (95% CI)  
 
P value 
Multivariate*  
HR (95% CI)  
 
P value 
Statin therapy at enrollment     
  No statins (reference group) 1.0  1.0  
  First-time statin therapy 0.42 (0.30-0.59) <.001 0.37 (0.25-0.54) <.001 
  Chronic statin therapy 0.27 (0.18-0.39) <.001 0.24 (0.16-0.37) <.001 
Statin dose (per 10% increase)** 0.70 (0.63-0.77) <.001 0.69 (0.61-0.77) <.001 
LDL-cholesterol reduction (per 10%)*** 0.94 (0.91-0.97) <.001 0.93 (0.90-0.96) <.001 
Cholesterol levels at 6 months     
  LDL-cholesterol (per 10 mg/dL decrease) 0.96 (0.93-0.98) <.001 0.97 (0.94-0.99) .009 
  HDL-cholesterol (per 10 mg/dL increase) 0.94 (0.87-1.01) .09 0.94 (0.86-1.03) .17 
  Triglycerides (per 10 mg/dL decrease) 0.99 (0.98-1.00) .02 0.99 (0.98-1.00) .01 
  Total cholesterol (per 10 mg/dL decrease) 0.94 (0.92-0.97) <.001 0.94 (0.90-0.97) <.001 
  LDL/HDL-cholesterol 1.16 (1.08-1.24) <.001 1.13 (1.05-1.22) <.001 
  Total/HDL-cholesterol 1.12 (1.06-1.17) <.001 1.13 (1.07-1.19) <.001 
Mean cholesterol levels during follow-up     
  LDL-cholesterol (per 10 mg/dL decrease) 0.94 (0.92-0.96) <.001 0.95 (0.92-0.97) <.001 
  HDL-cholesterol (per 10 mg/dL increase) 0.89 (0.82-0.97) .004 0.90 (0.82-0.98) .02 
  Triglycerides (per 10 mg/dL decrease) 0.99 (0.98-1.00) .1 0.99 (0.98-1.00) .04 
  Total cholesterol (per 10 mg/dL decrease) 0.94 (0.91-0.97) <.001 0.95 (0.91-0.98) <.001 
  LDL/HDL-cholesterol 1.26 (1.17-1.35) <.001 1.24 (1.15-1.34) <.001 
  Total/HDL-cholesterol 1.16 (1.08-1.25) <.001 1.17 (1.07-1.27) <.001 
*Adjusted for clinical risk factors, ankle-brachial index values, electrocardiography and propensity scores. **Expressed as percentage of 
maximum recommended therapeutic dose. ***The relative reduction (%) in LDL-cholesterol at 6-months from baseline measurements. 
 
 
 
Table III. Univariate and multivariate Cox proportional hazards models to predict cardiac mortality. 
 Univariate  
HR (95% CI)  
 
P value 
Multivariate* HR 
(95% CI)  
 
P value 
Statin therapy at enrollment     
  No statins (reference group) 1.0  1.0  
  First-time statin therapy 0.53 (0.36-0.78) .001 0.44 (0.29-0.68) <.001 
  Chronic statin therapy 0.34 (0.22-0.52) <.001 0.28 (0.17-0.46) <.001 
Statin dose (per 10% increase)** 0.74 (0.67-0.82) <.001 0.71 (0.63-0.80) <.001 
LDL-cholesterol reduction (per 10%)*** 0.95 (0.91-0.99) .01 0.94 (0.90-0.98) .004 
Cholesterol levels at 6 months     
  LDL-cholesterol (per 10 mg/dL decrease) 0.95 (0.92-0.98) <.001 0.95 (0.93-0.98) <.001 
  HDL-cholesterol (per 10 mg/dL increase) 0.91 (0.88-0.99) .04 0.90 (0.82-0.98) .01 
  Triglycerides (per 10 mg/dL decrease) 0.98 (0.98-0.99) <.001 0.99 (0.98-0.99) <.001 
  Total cholesterol (per 10 mg/dL decrease) 0.93 (0.90-0.96) <.001 0.92 (0.89-0.96) <.001 
  LDL/HDL-cholesterol 1.16 (1.07-1.26) <.001 1.15 (1.06-1.25) <.001 
  Total/HDL-cholesterol 1.15 (1.09-1.20) <.001 1.16 (1.10-1.23) <.001 
Mean cholesterol levels during follow-up     
  LDL-cholesterol (per 10 mg/dL decrease) 0.93 (0.90-0.96) <.001 0.94 (0.91-0.96) <.001 
  HDL-cholesterol (per 10 mg/dL increase) 0.88 (0.80-0.97) .008 0.87 (0.78-0.96) .008 
  Triglycerides (per 10 mg/dL decrease) 0.99 (0.98-1.00) .01 0.98 (0.97-0.99) .004 
  Total cholesterol (per 10 mg/dL decrease) 0.92 (0.89-0.96) <.001 0.93 (0.89-0.97) <.001 
  LDL/HDL-cholesterol 1.23 (1.13-1.35) <.001 1.22 (1.12-1.34) <.001 
  Total/HDL-cholesterol 1.19 (1.10-1.29) <.001 1.21 (1.10-1.33) <.001 
*Adjusted for clinical risk factors, ankle-brachial index values, electrocardiography and propensity scores. **Expressed as percentage of 
maximum recommended therapeutic dose. ***The relative reduction (%) in LDL-cholesterol at 6-months from baseline measurements. 
 
 
 
 
Secondary endpoint outcome 
Multivariate analysis demonstrated that first time statin 
users and chronic statin users were at lower risk of 
progression to kidney failure, compared to patients not 
using statins (HR: 0.16, 95% CI: 0.04-0.65 and HR: 
0.29, 95% CI: 0.12-0.71, respectively). In addition, 
higher doses of statin therapy were associated with a 
lower occurrence of the secondary endpoint of kidney 
failure (HR per 10% increase: 0.69, 95% CI: 0.54-0.89), 
independent of baseline characteristics and cholesterol 
levels. In the same model, a non-significant association 
was observed between lower 6-month LDL-cholesterol 
levels (per 10 mg/dL decrease) and a lower rate of 
kidney failure (HR: 0.97, 95% CI: 0.91-1.03). 
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DISCUSSION 
 
The present study shows that intensified statin therapy 
and lower target LDL-cholesterol levels are 
significantly associated with improved survival in 
patients with PAD. The beneficial effects of higher 
statin doses and lower target LDL-cholesterol levels 
were independent of each other and independent of the 
presence of clinical risk factors, ABI values, 
electrocardiography and propensity scores for statin 
therapy. These findings suggest the importance of 
achieving low target LDL-cholesterol levels in patients 
with PAD. Secondly, they suggest that statins have 
beneficial long-term effects, due to properties other than 
reducing cholesterol levels. 
  
Statins in peripheral arterial disease 
The Heart Protection Study provided convincing 
evidence that 40 mg of daily simvastatin significantly 
lowered the risk of vascular events in 6748 patients with 
PAD, when compared to placebo [13]. During 5 years 
of follow-up, first major vascular events were observed 
in 26% of statin users versus 33% in placebo-allocated 
patients [13]. Schillinger and colleagues also 
demonstrated that statin therapy was associated with 
improved survival in patients with severe PAD with 
elevated high-sensitivity C-reactive protein levels [14]. 
Several earlier studies have confirmed the beneficial 
effects of statins on symptoms of claudication, walking 
performance, ABI values and leg functioning [6-8]. 
 
LDL-cholesterol threshold in coronary artery 
disease 
The National Cholesterol Education Program (NCEP) 
Adult Treatment Panel III guidelines and the European 
guidelines on cardiovascular disease prevention in 
clinical practice recommend a target LDL-cholesterol 
level less than 100 mg/dL in persons with (risk 
equivalents of) coronary artery disease [15,16]. Recent 
clinical trials have shown the beneficial effect of LDL-
cholesterol levels below 100 mg/dL on cardiovascular 
outcome. The Treating to New Targets trial showed that 
intensive lipid-lowering therapy with 80 mg of daily 
atorvastatin significantly reduced first major 
cardiovascular event rate during a median follow-up of 
5 years, compared to 10 mg of daily atorvastatin (8.7% 
vs. 10.9%, respectively) [17]. Mean LDL cholesterol 
levels were 77 mg/dL during 80 mg atorvastatin 
treatment and 101 mg/dL during 10 mg atorvastatin 
treatment [17]. Cannon and colleagues enrolled patients 
after acute coronary syndromes and compared 40 mg of 
pravastatin to 80 mg of atorvastatin [18]. Median LDL-
cholesterol levels during treatment were 95 mg/dL and 
62 mg/dL, respectively. After 2 years of follow-up, a 
16% reduction in the hazard ratio was found in favor of 
atorvastatin. Nissen and colleagues demonstrated that 
intensive treatment with 80 mg of atorvastatin (mean 
LDL-cholesterol level: 79 mg/dL) reduced the 
percentage change in atheroma volume, compared to 40 
mg of pravastatin (mean LDL-cholesterol level: 110 
mg/dL) [19]. Moreover, it has been demonstrated that 
intensive 40 mg rosuvastatin therapy with mean LDL-
cholesterol reduction of 53.2% to a mean LDL-
cholesterol of 61 mg/dL resulted in significant 
regression of atherosclerosis during serial intravascular 
ultrasound examinations [20].  
 
Recommendations in PAD 
After the revision of the NCEP Adult Treatment Panel 
III guidelines in July 2004 [21], the American College 
of Cardiology/American Heart Association has 
recommended in “very high” risk patients with PAD a 
LDL-cholesterol level <70 mg/dL [4]. Very high risk 
patients included those with established PAD plus 
multiple major risk factors, severe and poorly controlled 
risk factors or multiple risk factors of the metabolic 
syndrome. These recommendations have mainly been 
extrapolated from studies including patients with 
coronary artery disease or from post hoc analysis of 
patients with PAD [13]. The current study suggests that 
all patients with ankle-brachial index values less than 
0.90 may benefit from LDL-cholesterol levels less than 
70 mg/dL. Although much attention has given to LDL-
cholesterol as measure of risk, our study demonstrated 
that higher HDL-cholesterol, lower triglyceride, lower 
total cholesterol, lower LDL/HDL-cholesterol and 
total/HDL-cholesterol ratio were also significant 
correlates of improved survival. 
 
Pleiotropic effects of statins 
In the current study, higher statin doses were associated 
with improved outcome independent of LDL-
cholesterol levels, suggesting that other than lipid-
lowering properties of statins are beneficial in PAD 
patients. The cholesterol-independent effects of statins 
have been suggested in previous studies. In human 
carotid plaques, statins decrease lipids, lipid oxidation, 
inflammation, matrix metalloproteinase 2 and cell death 
and increase tissue inhibitor of metalloproteinase 1 and 
collagen, suggesting a plaque-stabilizing effect [22]. 
Studies also demonstrated that statins lower the 
concentration of C-reactive protein and improve the 
outcome in patients with coronary artery disease, 
independent of the effect on LDL-cholesterol levels 
[2,3,23]. Therefore, long-term intensive statin therapy 
should be considered in all patients with PAD.  
 
Statins and renal outcome  
Atherosclerosis is now becoming a recognized cause of 
renal deterioration. Experimental studies have suggested 
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a preventive effect of statins on nephropathy by halting 
extracellular matrix accumulation, overexpression of 
connective growth factors [24], and tubular-interstitial 
fibrosis [25]. A meta-analysis showed that statins can 
reduce proteinuria or albuminuria, especially in patients 
with cardiovascular disease [26]. Finally, a recent study 
demonstrated in 103 consecutive patients with 
hyperlipidemia and PAD that creatinine levels 
decreased after 3-4 months of treatment with 
simvastatin, independent of the degree of low-density 
lipoprotein cholesterol reduction [27]. In the current 
study, every 10% increase in statin dose was associated 
with a 31% lower risk of progression to kidney failure, 
irrespective of cholesterol levels. However, these results 
should be interpreted in the context of the study design 
in which the occurrence of kidney failure was relatively 
low (5%). 
 
Study limitations 
The findings apply to patients with PAD referred to a 
university hospital. Adverse outcome rates may 
therefore be higher than in the general population. The 
study population consisted mostly of Caucasian men 
with a high prevalence of cardiovascular risk factors. 
The study was observational in nature and the major 
limitation which should be addressed is that statins were 
not assigned in a random fashion. However, in 
multivariate analysis we have adjusted for known 
possible confounding factors and for the propensity to 
prescribe statin therapy to reduce a possible selection 
bias [28]. This study did not systematically recorded the 
number of patients who became eligible for statin 
therapy during follow-up. Since analysis was based on 
treatment at enrolment, the results for statin therapy 
may have been underestimated, assuming that all 
patients with statin treatment continued their 
medication. Before recommending low LDL-cholesterol 
levels and high statin doses in all patients with PAD, it 
should be noted that concerns about the safety of very 
low cholesterol levels have been raised, as cholesterol 
plays an important role in cell membrane composition 
and in neuronal and optic development. In addition, 
higher statin doses may result in higher rates of side 
effects, such as treatment-related myalgia and liver 
toxicity [29]. Future studies should further evaluate the 
safety of high-dose statin therapy and very-low LDL-
cholesterol concentrations in patients with PAD. 
 
Conclusion 
In conclusion, the current prospective observational 
cohort study of 1374 patients with peripheral arterial 
disease demonstrated that intensified statin therapy and 
lower target LDL cholesterol levels are independently 
associated with improved outcome. Target LDL-
cholesterol levels below 70 mg/dL were associated with 
the lowest overall and cardiac mortality rate during a 
mean follow-up of 6 years. Higher statin doses were 
also associated with a lower occurrence of progression 
to kidney failure. The current results support the view 
that statins have beneficial effects beyond its lipid 
lowering properties and should be considered in all 
patients with PAD, irrespective of LDL-cholesterol 
levels. 
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Harm H.H. Feringa, MDa, Stefanos E. Karagiannis, MDa, Michel Chonchol, MDb, Radosav Vidakovic, MDa, Peter 
G. Noordzij, MDc, Abdou Elhendy, MDd, Ron T. van Domburg, MDa, Gijs Welten, MDe, Olaf Schouten, MDe, Jeroen 
J. Bax, MDf, Tomas Berl, MDb, Don Poldermans, MDc 
 
 
Background. Patients with peripheral atherosclerotic 
disease (PAD) are at increased risk of end-stage renal 
disease and cardiovascular events. 
Aim. Primary objective was to assess the association 
between ankle-brachial index values and renal outcome. 
Secondary objective was to evaluate whether statins and 
angiotensin-converting enzyme (ACE-)inhibitors are 
associated with improved renal and cardiovascular 
outcome in patients with PAD 
Methods. In a prospective observational cohort study of 
1,940 consecutive patients with PAD, ankle-brachial 
index was measured and chronic statin and ACE-
inhibitor therapy was noted at baseline. Serial creatinine 
concentrations were obtained at baseline, 6 months and 
every year after enrolment. Endpoints were end-stage 
renal disease, all-cause mortality and cardiac events 
during a median follow-up period of 8 years.  
Results: Baseline eGFR <60 ml/min/1.73 m2 was 
assessed in 27% of patients. End-stage renal disease, all-
cause mortality and cardiac events occurred in 10%, 
46% and 31% of patients, respectively. In multivariate 
analysis, a lower baseline ankle-brachial index was 
significantly associated with a higher progression rate of 
end-stage renal disease (HR per 0.10 decrease: 1.34, 
95% CI: 1.21-1.49). Chronic use of statins and ACE-
inhibitors were significantly associated with lower end-
stage renal disease (HR [95% CI]: 0.41 [0,28-0.63] and 
0.74 [0.54-0.98], respectively), mortality (HR [95% CI]: 
0.66 [0.55-0.82] and 0.84 [78-0.95], respectively) and 
cardiac events (HR [95% CI]: 0.71 [0.56-0.91] and 0.81 
[0.68-0.96], respectively). 
Conclusion. In patients with PAD, low ankle-brachial 
index values independently predict the onset of end-
stage renal disease. Less progression towards end-stage 
renal disease and improved cardiovascular outcome was 
observed among patients with chronic statins and ACE-
inhibitors.  
_____________________________________________________________________________________________
 
LOWER EXTREMITY peripheral arterial disease 
(PAD) is a manifestation of systemic atherosclerosis 
and has been recognized as a growing health burden 
worldwide [1]. In the United states, prevalence rates for 
PAD have been reported ranging from 4% in patients 40 
years and older to 29% in patients older than 70 years or 
aged 50 to 59 years with a history of smoking or 
diabetes mellitus [2-6]. 
The prevalence and incidence of PAD is high 
among patients with renal insufficiency [7-9]. Little 
information is available about the prognostic value of 
renal insufficiency in patients with peripheral arterial 
disease, although this may be useful to identify high risk 
patients who may benefit from subsequent medical 
therapy. [10]. Due to atherosclerotic lesions in the renal 
artery or renal microvascular system, patients with PAD 
may be at increased risk of developing end-stage renal 
disease. The association between the extent of 
atherosclerosis, as defined by ankle-brachial index 
(ABI) values, and the onset of end-stage renal disease 
remains ill-defined.  
Several studies have suggested that statins and 
angiotensin-converting enzyme (ACE) inhibitors can 
slow or halt the progression of chronic kidney disease 
[11]. Given the fact that statins and ACE-inhibitors can 
inhibit the atherosclerotic process and reduce 
cardiovascular events [12-15], a beneficial effect of 
statins and ACE-inhibitors on renal outcome may be 
anticipated in patients who present with lower extremity 
PAD  
In this observational cohort study, our primary 
aim was to determine the association between baseline 
ABI values and renal outcome in patients with PAD. 
Our secondary objective was to evaluate whether 
chronic use of statins and ACE-inhibitors was 
associated with a lower progression rate of end-stage 
renal disease, mortality and cardiovascular events 
during long-term follow-up. 
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METHODS 
 
Study participants 
This was a single-center observational cohort study of 
consecutive patients with PAD who were referred to the 
Erasmus Medical Center between January 1988 and 
January 2006. The Erasmus MC serves a population of 
approximately 3 million people and acts as a tertiary 
referral enter for approximately 30 affiliated hospitals. 
Patients were referred for ABI measurement, clinical 
evaluation and therapeutic management. These patients 
presented with symptoms of PAD, which included 
typical intermittent claudication or other symptoms of 
chronic arterial insufficiency, such as ulceration of the 
foot, hair loss, or reduced capillary refill. Patients 
eligible for the study had to be older than 18 years of 
age and only patients with an ABI of 0.90 or less were 
included. Patients with one or more episodes of dialysis 
during the 6 months prior to enrolment were excluded. 
All patients agreed on participation in the study and the 
study was conducted according to the declaration of 
Helsinki. During the first visit, patients were screened 
for clinical risk factors, ABI values and 12-lead 
electrocardiographic abnormalities. The chronic use of 
statins and ACE-inhibitors was ascertained if patients 
were taking these medications for at least 1 year after 
the first visit. According to the hospital’s protocol, 
ACE-inhibitors were not prescribed in patients 
presenting with significant bilateral renal artery stenosis 
(>70% or >50% with post-stenotic dilatation), stenosis 
to a solitary kidney or to patients with decompensated 
congestive heart failure in a sodium-depleted state. 
Diabetes mellitus was recorded if patients presented 
with a fasting glucose level of ≥126 mg/dL (7.0 
mmol/L), or in those who required treatment. 
Hypertension was recorded if patients presented with a 
blood pressure ≥140/90 mmHg or if patients were 
medically treated for hypertension. Smoking included 
only current smoking. A baseline electrocardiogram was 
obtained in all patients and was considered abnormal in 
the presence of one or more of the following: Q waves, 
left ventricular hypertrophy, left bundle branch block, 
right bundle branch block or atrial fibrillation. Clinical 
data were prospectively collected and stored into a 
computerized database. Risk factor reduction and life 
style modifications were encouraged in all patients 
presenting with clinical risk factors. During follow-up 
visits, blood pressure was monitored to achieve levels 
less than 140/90 mmHg or less than 130/80 mmHg for 
those with diabetes or kidney disease. 
  
Ankle-brachial index measurement 
Systolic blood pressures in the right and left brachial 
artery, right and left dorsalis pedis artery and right and 
left posterior tibial artery were measured by trained 
technicians, using a Doppler ultrasonic instrument with 
an 8 MHz vascular probe (Imexdop CT+ Vascular 
Doppler, Miami Medical, USA). The ABI in the right 
and left leg was calculated by dividing the right and the 
left ankle pressure by the brachial pressure. The higher 
of the two brachial blood pressures was used if a 
discrepancy in systolic blood pressure was present. 
Again, the higher of the dorsalis pedis and posterior 
tibial artery pressure was used when a discrepancy in 
systolic blood pressure between the two arteries was 
measured. If no pressure in the dorsalis pedis artery was 
obtained due to an absent dorsalis pedis artery, the 
pressure in the posterior tibial artery was used. The ABI 
was measured after the participants had been resting in 
the supine position for at least 10 minutes. Of the ABI 
values obtained in each leg, the lower was used in all 
analyses. Inter- and intra-observer agreement for  the 
ABI was 97% and 98%, respectively. 
 
Renal function 
In all patients, a baseline serum creatinine level was 
obtained during the first visit from a central laboratory. 
Using serum creatinine, age, gender and race, the eGFR 
was calculated by the following equation: glomerular 
filtration rate (ml/min/1.73 m2) = 186 x (serum 
creatinine level)-1.154 x (age)-0.203 x (0.742 if female) x 
(1.210 if of African descent) [16,17]. Patients were 
classified according to the level of renal function as 
recommended by the Kidney Disease Outcomes Quality 
Initiative of the National Kidney Foundation: normal 
renal function (eGFR ≥90 ml/min per 1.73 m2), mildly 
reduced renal function (eGFR 60-89 ml/min per 1.73 
m2), moderately reduced renal function (eGFR 30-59 
ml/min per 1.73 m2), severely reduced renal function 
(eGFR 15-29 ml/min per 1.73 m2) and kidney failure 
(eGFR <15 ml/min per 1.73 m2). During regularly 
scheduled follow-up visits, serial creatinine levels were 
measured at 6 months, 1 year and every year after the 
initial visit to determine deterioration in renal function, 
compared to baseline renal function. Baseline serum 
creatinine measurements were obtained in all patients 
and creatinine measurements at 1-year were obtained in 
99% of the patients. Progression to end-stage renal 
disease was defined as the need for kidney replacement 
therapy (treatment with dialysis or kidney 
transplantation). 
 
All-cause mortality and cardiac events 
During follow-up, primary study endpoints were all-
cause mortality and cardiac events, which included 
cardiac death or non-fatal myocardial infarction.  
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Table 1. Baseline characteristics of the study population, divided by level of renal function. 
Characteristic Normal renal 
function 
(n=603) 
Mildly 
reduced renal 
function 
(n=812) 
Moderately 
reduced renal 
function 
(n=423) 
Severely 
reduced  renal 
function 
(n=56) 
Kidney failure 
(n=46) 
P-value 
Age (years) (± SD) 60 ± 12 65 ± 10 68 ± 9 66 ± 10 58 ± 13 <0.001 
Male gender  77.1% 70.2% 68.1% 62.5% 58.7% 0.001 
Current stable or unstable AP 19.4% 17. 2% 19.4% 30.4% 23.9% 0.13 
Previous myocardial infarction  21.7% 27.7% 33.1% 46.4% 39.1% <0.001 
Previous CABG  9.5% 15.0% 12.8% 16.1% 4.3% 0.01 
CAD (summary variable) 33.3% 38.4% 44.7% 60.7% 45.7% <0.001 
History of heart failure 3.5% 5.9% 9.7% 25.0% 10.9% <0.001 
Diabetes mellitus  11.9% 11.5% 13.5% 19.6% 28.3% 0.007 
Hypertension  23.2% 34.1% 40.7% 46.4% 45.7% <0.001 
Cigarette smoking   24.9% 25.5% 23.2% 19.6% 21.7% 0.78 
COPD 15.1% 14.0% 11.3% 3.6% 6.5% 0.042 
Electrocardiography       
   Q waves  22.6% 26.8% 24.1% 35.7% 37.0% 0.051 
   Left ventricular hypertrophy  5.6% 4.8% 10.5% 6.7% 6.7% 0.077 
   Left bundle branch block  2.5% 2.7% 4.3% 7.1% 2.2% 0.18 
   Right bundle branch block  0.5% 1.2% 2.1% 1.8% 0% 0.17 
Medication       
   Aspirin  23.7% 21.8% 22.5% 16.1% 6.5% 0.07 
   ACE-inhibitors 17.9% 26.0% 37.4% 41.1% 32.6% <0.001 
   Beta-blocker 21.6% 26.2% 22.9% 23.2% 43.5% 0.008 
   Calcium channel blocker 19.4% 22.5% 29.6% 28.6% 41.3% <0.001 
   Digoxin 4.1% 3.7% 5.7% 10.7% 4.3% 0.10 
   Diuretic  6.8% 12.4% 22.2% 41.1% 4.3% <0.001 
   Nitrate 14.3% 16.1% 21.5% 42.9% 32.6% <0.001 
   Statin  27.5% 29.6% 27.4% 30.4% 26.1% 0.88 
Ankle-brachial index 61 ± 17 59 ± 17 58 ± 19 54 ± 13 47 ± 22 <0.001 
Estimated Glomerular Filtration Rate 
(mL/min/1.73 m2) 
112 ± 20 76 ± 8 48 ± 8 23 ± 4 7 ± 3 <0.001 
AP = angina pectoris; CABG = coronary artery bypass grafting; PTCA =  percutaneous transluminal coronary angioplasty; CAD = coronary 
artery disease; TIA = transient ischemic attack; COPD = chronic obstructive pulmonary disease; ACE-= angiotensin converting enzyme. Values 
are expressed in number (%) or mean (± SD).  
 
 
Information on all-cause mortality and cardiac events 
was obtained during out-patient follow-up visits, by 
mailed questionnaires, by telephone interviews, by 
reviewing hospital records, by contacting the referring 
physician or by approaching the municipal civil registry 
to determine survival status. In patients who died during 
follow-up, death certificates and autopsy reports were 
reviewed and general practitioners were approached to 
ascertain the cause of death. Cardiac death was defined 
as death caused by acute myocardial infarction, cardiac 
arrhythmias, or congestive heart failure. Sudden 
unexpected death in a previously stable patients was 
considered as cardiac death. Non-fatal myocardial 
infarction was diagnosed when at least two of the 
following were present: elevated cardiac enzyme levels 
(CK level > 190 U/L and CK-MB >14 U/L, or CK-MB 
fraction >10% of total CK, or cardiac troponin T >0.1 
ng/mL), development of typical electrocardiographic 
changes (new Q waves >1 mm or > 30 ms), and typical 
symptoms of angina pectoris.  
 
Statistical analysis 
Continuous data were compared using the Student t test 
or ANOVA techniques when appropriate. Categorical 
data were compared using the Chi square test. The 
Kaplan-Meier method with the log-rank test was used to 
assess differences in survival between patients with 
different levels of renal function. Statins and ACE-
inhibitors were not randomly assigned in these patients, 
and the impact of selection bias may profoundly distort 
the results of our study. Propensity analyses are reliable 
tools to correct for selection bias and the rationale for 
using propensity scores has been described previously 
[18]. Therefore, we calculated separate propensity 
scores for statins and ACE-inhibitors. Variables that 
were independently associated with the decision to 
prescribe statins and ACE-inhibitors (p<0.25) were 
included in the multivariate propensity score, which was 
constructed using multiple logistic regression analysis. 
Multivariate Cox proportional hazard regression 
analysis was used to evaluate whether statins and ACE-
inhibitors were associated with lower progression 
towards end-stage renal disease, all-cause mortality and 
cardiac events during long-term follow-up. Multivariate 
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Cox proportional hazard regression analysis with 
stepwise backward deletion of the least significant 
variable was used to determine independent predictors 
of all-cause mortality and cardiac events. Propensity 
scores were added to all multivariate regression models. 
However, results were comparable in multivariate 
analysis with or without adjusting for weighted 
propensity scores. Tests for heterogeneity were used to 
evaluate the effect of statins and ACE-inhibitors on 
outcome between patients with different levels of 
baseline renal function and between patients with or 
without diabetes mellitus. For all tests, a p value <0.05 
(two-sided) was considered significant. All analyses 
were performed using SPSS-11.0 statistical software 
(SPSS Inc., Chicago, Illinois). 
 
 
 
 
 
Figure 1. Kaplan-Meier curves for survival and freedom from hard 
cardiac events in patients with peripheral arterial disease stratified 
according to the level of renal function. 
 
 
 
 
RESULTS 
 
Baseline characteristics 
A total of 1,940 patients were available for analysis. 
The mean age was 64 ± 11 years and 1385 patients 
(71%) were male. The mean ABI was 0.61 ± 0.19. 
Severe PAD (ABI was ≤0.70) was identified in 1397 
patients (72%). An abnormal electrocardiogram was 
observed in 911 patients (47%). A total of 551 patients 
(28%) were using chronic statins and 515 patients 
(27%) were using chronic ACE-inhibitors. The mean 
eGFR at baseline was 78 ± 31 ml/min per 1.73 m2. 
Normal renal function, mildly reduced renal function, 
moderately reduced renal function, severely reduced 
renal function and kidney failure was assessed in 31%, 
42%, 22%, 3% and 2% of patients, respectively. A 
history of coronary artery disease, history of heart 
failure, diabetes and hypertension were significantly 
associated with declining baseline renal function (Table 
1).  
 
Follow-up 
Mean time from baseline to last follow-up visit was 8 
years (interquartile range 4-11 years). At 1-year follow-
up, a reduction in eGFR of >25% was assessed in 211 
patients (11%). Assessment of renal function at the last 
follow-up visit revealed a reduction in eGFR of >25% 
in 443 patients (23%) and progression to end-stage renal 
disease in 198 patients (10%). Improvement in eGFR of 
>25% was assessed in 293 patients (15%). All-cause 
mortality occurred in 889 patients (46%), cardiac death 
in 474 patients (24%) and non-fatal myocardial 
infarction in 127 patients (7%). Kaplan Meier curves 
demonstrate that higher decreases in baseline estimated 
glomerular filtration rate were associated with higher 
rates in all-cause mortality (p<0.001) and cardiac events 
(p<0.001) during follow-up (Figure 1). 
 
ABI and outcome  
Patients with lower baseline ABI values were more 
likely to present with a lower baseline eGFR, compared 
to patients with higher ABI values (Figure 2) (p<0.001). 
In multivariate analysis, lower ABI values were 
significantly associated with a higher progression rate of 
end-stage renal disease (Table 2). Multivariate analysis 
also demonstrated that lower ABI values significantly 
correlated with higher all-cause mortality and cardiac 
event rate (Table 2).  
 
Independent predictors of mortality and cardiac 
events 
Significant predictors for adverse long-term outcome 
were determined by stepwise multivariate analysis and 
are presented in Figure 3. Lower baseline eGFR (per 10  
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ml/min per 1.73 m2) and reduction in eGFR (per 25%) 
during the first year of follow-up were both significantly 
associated with higher all-cause mortality rate (HR: 
1.09, 95% CI: 1.06-1,12 and HR: 1.05, 95% CI: 1.01-
1.09, respectively) and cardiac event rate (HR: 1.07, 
95% CI: 1.02-1.11 and HR: 1.04, 95% CI: 1.00-1.08, 
respectively). Lower ABI (per 0.10 decrease) was also 
an independent predictor of mortality (HR: 1.08, 95% 
CI: 1.03-1.12) and cardiac events (HR: 1.08, 95% CI: 
1.02-1.14). Importantly, chronic statin and ACE-
inhibitor use was associated with a lower all-cause 
mortality rate (HR: 0.66, 95% CI: 0.55-0.80 and HR: 
0.85, 95% CI: 0.77-0.96, respectively) and lower 
cardiac event rate (HR: 0.70, 95% CI: 0.56-0.90 and 
HR: 0.82, 95% CI: 0.69-0.97, respectively). Although in 
multivariate analysis the combined treatment of statins 
and ACE-inhibitors was associated with a decreased 
risk of all-cause mortality (HR: 0.79, 95% CI: 0.65-
0.97) and cardiac events (HR: 0.74, 95% CI: 0.57-0.98), 
it was not independently associated with improved 
outcome in a multivariate model which included the 
single treatment of statin and ACE-inhibitor therapy. 
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Figure 2. Baseline ankle-brachial index values in relation to baseline 
estimated glomerular filtration rate (eGFR) (p<0.001) 
 
Statin and ACE-inhibitor therapy across different 
levels of renal function 
Multivariate analysis demonstrated that chronic statin 
therapy was associated with a significantly lower risk of 
end-stage renal disease, mortality and cardiac events 
during follow-up across all categories of renal function 
(Table 3). Tests for heterogeneity revealed non-
significant p-values for interaction (Table 3). ACE 
inhibitors were significantly associated with lower 
progression rate of end-stage renal disease, all-cause 
mortality and cardiac events in patients with moderately 
reduced renal function, severely reduced renal function 
and kidney failure, but not in patients with preserved or 
mildly reduced renal function (Table 3). Tests for 
heterogeneity further revealed that statins and ACE-
inhibitors were associated with improved outcome 
among both patients with and without diabetes (non-
significant p-values for interaction) 
 
 
 
Figure 3. Multivariate model demonstrating significant predictors of 
all-cause mortality and cardiac events in patients with peripheral 
arterial disease.  
 
DISCUSSION 
 
The present study shows that renal dysfunction is highly 
prevalent among patients presenting with PAD, Mildly 
reduced, moderately reduced, severely reduced renal 
function and kidney failure were assessed in 42%, 22%, 
3% and 2% of patients, respectively, perhaps reflecting 
the significance of generalized atherosclerosis as 
potential cause of renal dysfunction in patients with 
PAD. The mean baseline eGFR in this Dutch population 
of PAD patients was 78 ml/min per 1.73 m2, which was 
almost similar to the results of the National Health and 
Nutrition Examination Survey, which found a mean 
eGFR of 77 ml/min per 1.73 m2 in a United States 
population of PAD patients, aged 40 years and older. 
Many patients with PAD may present with undiagnosed  
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Table 2. The association between baseline ankle-brachial index values and renal and cardiovascular outcome in multivariate analysis. 
 Progression to end-stage 
renal disease 
All-cause mortality Cardiac events 
Ankle brachial index per 0.10 ↓ 1.34 (1.21-1.49) 1.08 (1.03-1.12) 1.08 (1.02-1.14) 
Ankle brachial index 0.71-0.90 (reference category) 1.00 1.00 1.00 
Ankle brachial index 0.51-0.70 1.20 (0.73-2.00) 1.34 (0.96-1.85) 1.15 (0.95-1.40) 
Ankle brachial index 0.31-0.50 1.66 (1.03-2.81) 1.62 (1.14-2.30) 1.41 (1.13-1.74) 
Ankle brachial index 0.00-0.30 5.81 (3.21-9.49) 2.79 (1.75-4.44) 2.64 (2.01-3.45) 
* Adjusted for age, gender, clinical risk factors, blood pressure, LDL-cholesterol, hemoglobin A1c in patients with diabetes, baseline estimated 
glomerular filtration rate, propensity scores for statin and angiotensin converting enzyme inhibitors, and medication including beta-blockers, 
calcium channel blockers, aspirin and diuretics.  
 
Table 3. The association between medication and renal and cardiovascular outcome in patients presenting with different levels of renal function. 
 Progression to end-stage 
renal disease 
All-cause mortality Cardiac events 
Statins (all patients)  
 
0.41 (0.28-0.63) 0.66 (0.55-0.82) 0.71 (0.56-0.91) 
• Normal renal function 
        (eGFR ≥90 ml/min per 1.73 m2) 
0.35 (0.15-0.81) 0.66 (0.48-0.91) 0.46 (0.28-0.81) 
• Mildly reduced renal function  
        (eGFR 60-89 ml/min per 1.73 m2) 
0.39 (0.16-0.94) 0.76 (0.61-0.96) 0.74 (0.60-0.93) 
• Moderately reduced renal function 
        (eGFR 30-59 ml/min per 1.73 m2) 
0.47 (0.25-0.89) 0.60 (0.45-0.79) 0.57 (0.34-0.97) 
• Severely reduced renal function 
        (eGFR 15-30 ml/min per 1.73 m2) 
0.22 (0.08-0.59) 0.42 (0.21-0.84) 0.25 (0.08-0.76) 
• Kidney failure 
        ( eGFR <15 ml/min per 1.73 m2) 
0.13 (0.03-0.54) 0.03 (0.01-0.70) 0.02 (0.01-1.94) 
P value for interaction 
 
0.9 0.07 0.3 
ACE-inhibitors (all patients)  
 
0.74 (0.54-0.98) 0.84 (0.78-0.95) 0.81 (0.68-0.96) 
• Normal renal function 
        (eGFR ≥90 ml/min per 1.73 m2) 
0.96 (0.72-1.32) 1.02 (0.81-1.28) 0.80 (0.55-1.15) 
• Mildly reduced renal function  
        (eGFR 60-89 ml/min per 1.73 m2) 
1.18 (0.58-2.41) 0.95 (0.68-1.36) 0.94 (0.62-1.40) 
• Moderately reduced renal function 
       (eGFR 30-59 ml/min per 1.73 m2) 
0.67 (0.47-0.98) 0.80 (0.62-0.98) 0.76 (0.51-0.96) 
• Severely reduced renal function 
        (eGFR 15-30 ml/min per 1.73 m2) 
0.20 (0.06-0.67) 0.64 (0.39-0.95) 0.62 (0.34-0.97) 
• Kidney failure 
        ( eGFR <15 ml/min per 1.73 m2) 
0.27 (0.12-0.63) 0.44 (0.18-0.94) 0.14 (0.01-0.91) 
P value for interaction 
 
0.02 0.04 0.03 
Adjusted for age. gender. clinical risk factors. blood pressure. LDL-cholesterol. hemoglobin A1c in patients with diabetes. baseline estimated 
glomerular filtration rate. propensity scores for statin and angiotensin converting enzyme inhibitors. and medication including beta-blockers. 
calcium channel blockers. aspirin and diuretics.  eGFR = estimated glomerular filtration rate. ACE-inhibitors = angiotensin-converting enzyme 
inhibitors.  
 
 
renal dysfunction, which may eventually progress to 
chronic kidney disease or end-stage renal disease. In our 
population, 4% progressed to end-stage renal disease at 
1-year of follow-up and 10% progressed to end-stage 
renal disease as assessed during the last follow-up visit. 
 
ABI and renal outcome 
Baseline characteristics demonstrated that a lower ABI 
value, a measure of atherosclerotic disease severity, was 
associated with more severe baseline renal dysfunction. 
The Atherosclerosis Risk in Communities Study showed 
that patients with an ABI of 0.90-0.99 and <0.90 were at 
increased risk of serum creatinine increases over a 3-
year time period, compared to patients with ABI values 
above 1.00 [19]. The current study showed that even in 
patients with ABI levels ≤0.90, lower ABI values can 
independently predict reductions in eGFR during 
follow-up and can identify patients at greatest risk of 
renal deterioration. Another strength is the use of end-
stage renal disease as clinically significant endpoint in 
addition to declines in eGFR. This finding supports the 
notion that atherosclerosis has indirect effects on the 
kidney because of atherosclerotic lesions in the renal 
artery and that atherosclerosis or atherogenic factors 
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induce directly intrarenal microvascular disease and 
renal injury [20]. Low ABI values should therefore be 
regarded as risk factor for developing end-stage renal 
disease. These high-risk patients may benefit from close 
renal monitoring and appropriate treatment strategies.   
 
Statins and renal outcome 
A major finding in our study was that chronic use of 
statins was significantly associated with a lower rate of 
end-stage renal disease progression across all patients 
with different levels of baseline renal function. The 
beneficial properties of statins beyond the lipid-
lowering effect include atherosclerotic plaque 
stabilization, oxidative stress reduction and decrease in 
vascular inflammation [21,22]. Intensive statin therapy 
may even results in significant regression of 
atherosclerosis, as demonstrated in a recent study [23]. 
Given the fact that atherosclerosis is now becoming a 
recognized cause of renal deterioration, it seems 
plausible that statins can prevent renal deterioration in 
PAD patients, due to its pleiotropic effects. 
Experimental studies have suggested a preventive effect 
of statins on nephropathy [24,25]. A meta-analysis 
showed that statins can reduce proteinuria or 
albuminuria, especially in patients with cardiovascular 
disease [26]. Finally, a recent study demonstrated in 103 
consecutive patients with hyperlipidemia and PAD that 
creatinine levels decreased after 3-4 months of 
treatment with simvastatin, independent of the degree of 
low-density lipoprotein cholesterol reduction [27]. 
 
ACE-inhibitors and renal outcome 
The current study also showed that chronic ACE-
inhibitor therapy was associated with a lower rate of 
renal deterioration, especially in patients with decreased 
baseline renal function. ACE-inhibitors have been 
shown to inhibit the atherosclerotic process and improve 
vascular endothelial function, peripheral blood pressure 
and blood flow [28-30]. Many studies have suggested 
that ACE-inhibitors slow or halt the progression of 
chronic nephropathies [31]. Patients with PAD may 
have a high rate of renal artery stenosis, in whom 
activation of the renin-angiotensin-aldosteron system 
serves to preserve renal blood flow and filtration rate. It 
should be noted that in our study population ACE-
inhibitors were not prescribed to patients with bilateral 
renal artery stenosis, stenosis to a solitary kidney, or to 
patients with decompensated congestive heart failure in 
a sodium-depleted state, in order to minimize the risk of 
acute renal failure. 
 
Combined use of statins and ACE-inhibitors 
Our study failed to demonstrate an independent effect of 
the combined treatment of statins and ACE-inhibitors. 
However, animal studies have demonstrated that 
combining statins and ACE-inhibitors resulted in 
improved renal function, remarkable antiproteinuric 
effect and less glomerulosclerosis, tubular damage, 
interstitial inflammation and podocyte damage [32,33]. 
These results are also supported by a previous clinical 
study which suggested that atorvastatin in addition to 
ACE-inhibitors or angiotensin AT1 receptor antagonists 
reduce proteinuria and the rate of progression of kidney 
disease in patients with chronic kidney disease, 
proteinuria, and hypercholesterolemia [34].  
 
Cardiovascular outcome 
The prognosis of patients with PAD is characterized by 
a high cardiovascular event rate, due to the high 
prevalence of concomitant coronary artery disease. 
Based on previous reports in literature, patients with 
PAD are at 2 to 4 times increased risk of cardiovascular 
events, compared to patients with no PAD [35-39]. Our 
study showed that across the whole range of renal 
function, statins were associated with a lower risk of 
mortality and cardiac events. The beneficial effect of 
ACE inhibitors was noted especially in patients with 
decreased renal function. The Heart Protection Study 
provided convincing evidence that 40 mg of daily 
simvastatin significantly lowered the risk of vascular 
events in 6748 patients with PAD, when compared to 
placebo [11]. The HOPE study investigators showed in 
a subgroup of 4051 patients with PAD that ramipril 
significantly reduced the rate of major cardiovascular 
events [40]. In our study, baseline eGFR and reduction 
in eGFR during the first year were both independent 
predictors for late mortality and cardiac events. In 
addition to ABI values, these variables may be useful to 
identify patients at increased risk who may benefit from 
statin and ACE-inhibitor therapy. 
 
Limitations 
The main limitation of this study is that the findings 
must be interpreted in the context of the study design. 
To minimize selection bias, propensity scores were 
added to multivariate analysis. The causal relationship 
between statins and ACE-inhibitors and improved renal 
outcome could not be established in this observational 
cohort study. Randomized controlled trials would be 
required to establish this. Secondly, the results apply to 
patients referred to a university hospital which acts as a 
tertiary referral center for 30 affiliated hospitals. 
Patients admitted to our hospital may have a higher risk 
profile compared to patients with suspected or known 
PAD in the general population. Extrapolation of our 
results to PAD patients in the general population should 
therefore be done with caution. Furthermore, we used 
the Modification of Diet in Renal Disease equation to 
estimate renal function and our study may be limited by 
the absence of data on albuminuria and proteinuria, 
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which is recommended for the detection of early kidney 
disease. However, this equation is now widely used in 
clinical practice and has been recommended by the 
National Kidney Foundation practice guidelines as 
useful estimate of renal function [16,17]. Another 
limitation which should be mentioned is that it was not 
known whether patients with low ABI values may have 
been exposed to more intravenous contrast material 
during follow-up, leading to temporary or permanent 
renal dysfunction. However, imaging was performed 
with low-dose contrast material and the hospital 
protocol required cautious use of IV contrast material in 
patients with severe ABI. Finally, before implementing 
routine use of ACE-inhibitors in clinical practice in 
PAD patients with or without renal dysfunction, future 
studies should confirm its safety.  
 
Conclusion 
In conclusion, the current long-term prospective cohort 
study showed that renal dysfunction is highly prevalent 
among patients with PAD. Lower ABI values proved to 
be correlated with renal deterioration and may be used 
to identify patients at increased risk of end-stage renal 
disease. Baseline eGFR and reductions in 1-year eGFR 
could also identify patients at increased risk of mortality 
and cardiac events, in addition to ABI values. These 
patients may benefit from chronic statins and ACE-
inhibitor therapy which was demonstrated to be 
associated with a lower progression rate of end-stage 
renal disease. In patients with PAD, statins and ACE-
inhibitors were significantly associated with improved 
survival and freedom from cardiac events. Tests for 
heterogeneity revealed that the beneficial effect of 
statins existed across the whole range of renal function 
and among both patients with and without diabetes. 
ACE inhibitors were associated with improved renal 
and cardiovascular outcome, especially in patients with 
reduced baseline renal function. 
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Glycemic control, lipid lowering treatment and 
prognosis in diabetic patients with peripheral 
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Glycemic control may be an underestimated risk factor 
in diabetic patients with peripheral arterial disease. 
Chronic statin therapy may improve glycemic control 
and outcome in these patients. In an observational 
cohort study of 425 consecutive diabetic patients with 
PAD, chronic statin therapy was noted, the ankle-
brachial index was measured and serial glycemic 
hemoglobin (HbA1c) measurements were obtained. 
During follow-up (median 7 years), all-cause mortality 
and cardiac death occurred in 37% and 22%, 
respectively. Decreases in HbA1c and HbA1c variability 
independently predicted outcome in addition to baseline 
ankle-brachial index values. Patients with chronic statin 
therapy were more likely to have decreasing HbA1c 
values (adjusted HR: 1.86, 95% CI: 1.27-2.74) and 
HbA1c values less than 7% (adjusted HR 2.58, 95% CI: 
1.49-4.48) during follow-up. Statins were also 
significantly associated with lower all-cause mortality 
(adjusted HR: 0.39, 95% CI: 0.26-0.61) and cardiac 
death rate (adjusted HR: 0.40, 95% CI: 0.24-76). Based 
on the results of the current observational study, we 
conclude that serial HbA1c measurements can improve 
risk stratification in diabetic patients with PAD. In 
addition, statin therapy is associated with desirable 
glycemic control and improved long-term outcome. 
_____________________________________________________________________________________ 
 
INDIVIDUALS WITH lower extremity peripheral 
arterial disease (PAD) are at increased risk of all-cause 
and cardiovascular mortality [1-4]. Concomitant 
diabetes with chronic hyperglycemia may further cause 
significant morbidity which may require surgical 
intervention. PAD has therefore been recognized as a 
growing health burden worldwide, especially in the 
presence of diabetes mellitus [5,6].  
 Intensive blood glucose control with insulin or 
oral hypoglycemic medication has been demonstrated to 
attenuate many of the complications associated with 
dysglycemia. The identification of patients who fail to 
maintain strict glucose control is important for 
clinicians so that measures can be applied to prevent 
adverse consequences. The ankle-brachial index (ABI) 
is a simple and effective measurement to identify 
patients with PAD who are at increased risk of adverse 
outcome [7,8]. Repeated glycosylated hemoglobin 
(HbA1c) measurements may improve risk stratification 
in addition to clinical risk factors and ABI values. 
The current medical treatment of patients with 
PAD and diabetes is aimed at risk factor reduction, life 
style modifications and antiplatelet therapy [6]. Statin 
therapy has also been recommended by the American 
College of Cardiology/American Heart Association to 
achieve low serum low-density lipoprotein cholesterol 
levels [6]. Although recent studies have suggested that 
statins may improve insulin sensitivity in patients with 
the metabolic syndrome [9-14], it remains a matter of 
debate whether statins can improve glycemic control in 
patients with PAD and diabetes in order to reduce 
complications associated with dysglycemia and 
systemic atherosclerosis. 
In an observational cohort study of patients 
with lower extremity PAD and diabetes, we sought to 
determine the prognostic value of repeated HbA1c 
measurements in addition to ABI values, and we 
evaluated whether chronic use of statins was associated 
with improved glycemic control and outcome during 
long-term follow-up. 
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METHODS 
 
Study participants 
This was a single-center observational cohort study of 
consecutive patients with PAD who were referred to our 
university clinic for ABI measurement, clinical 
evaluation and therapeutic management between 
January 1990 and September 2005. A total of 425 
consecutive patients with diabetes were included in the 
current study. Patients eligible for the study were >18 
years of age and only patients with an ABI ≤0.90 were 
included. Patients with a myocardial infarction in the 
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previous 6 months, patients with kidney failure (dialysis 
or estimated glomerular filtration rate (eGFR) < 15 
ml/min/1.73 m2) and patients with ketonuria (>3 
mmol/L) were excluded. During the first visit, patients 
were screened for clinical risk factors, ABI values and 
12-lead electrocardiographic abnormalities. All patients 
had a history of diabetes which was diagnosed 
according to fasting plasma glucose concentrations of 
≥7.0 mmol/l or according to an impaired glucose 
tolerance test (2 hour glucose concentration of ≥11.1 
mmol/l). All patients received insulin or oral 
antidiabetic treatment at presentation. Insulin regimen 
and the dose of oral antidiabetic therapy was prescribed 
at the discretion of the treating physician with the aim to 
reduce HbA1c values to less than 7% [15]. In general, 
insulin was prescribed when glucose levels could not be 
regulated by oral anti-diabetic therapy alone. The 
management of diabetes was primarily directed by 
family physicians in collaboration with internists. 
Chronic use of statins was recorded if patients were 
taking these medications for at least 1 year after the first 
visit. Clinical data were prospectively collected and 
stored into a computerized database. Risk factor 
reduction and life style modifications were encouraged 
in all patients presenting with clinical risk factors and 
all patients received dietary advice from a dietician.  
 
ABI measurement 
Systolic blood pressures in the right and left brachial 
artery, right and left dorsalis pedis artery and right and 
left posterior tibial artery were measured by trained 
technicians, using a Doppler ultrasonic instrument with 
an 8 MHz vascular probe (Imexdop CT+ Vascular 
Doppler, Miami Medical, USA). The ABI in the right 
and left leg was calculated by dividing the right and the 
left ankle pressure by the brachial pressure. The higher 
of the two brachial blood pressures was used if a 
discrepancy in systolic blood pressure was present. 
Again, the higher of the dorsalis pedis and posterior 
tibial artery pressure was used when a discrepancy in 
systolic blood pressure between the two arteries was 
measured. If no pressure in the dorsalis pedis artery was 
obtained due to an absent dorsalis pedis artery, the 
pressure in the posterior tibial artery was used. The ABI 
was measured after the participants had been resting in 
the supine position for at least 10 minutes. Of the ABI 
values obtained in each leg, the lower was used in all 
analyses. Inter- and intra-observer agreement for  the 
ABI was 97% and 98%, respectively. 
 
Serial HbA1c measurements 
Baseline serum HbA1c level was obtained during the 
first visit at a central laboratory using an enzyme 
immunoassay based on microtiter plate technology [16]. 
During regularly scheduled follow-up visits at 3, 6 and 9 
months and every year after the initial visit, serial HbA1c 
levels were measured to determine glycemic control 
over time. Absolute HbA1c values and percentage 
changes in HbA1c during follow-up were regarded as a 
measure of glycemic control over time. In addition, the 
standard deviation of the serial HbA1c measurements 
and the absolute difference between minimum and 
maximum HbA1c values was used as a measure of 
HbA1c variability. Baseline HbA1c measurements were 
obtained in all patients. In 13 patients (3%) in whom 1-
year HbA1c measurements were not available, 9- or 6-
month HbA1c measurement was used for analysis.  
 
Study endpoints 
During follow-up, primary endpoints were all-cause and 
cardiac mortality. Secondary endpoints were non-fatal 
myocardial infarction, congestive heart failure, stroke, 
progression to end-stage renal disease (ESRD) and 
ocular complications including retinopathy requiring 
photocoagulation, cataract extraction or blindness 
according to the WHO criteria [17]. Information on 
mortality was obtained by contacting the referring 
physician or by approaching the municipal civil registry. 
In patients who died, death certificates and autopsy 
reports were reviewed and general practitioners were 
approached to ascertain the cause of death. Cardiac 
death was defined as death caused by acute myocardial 
infarction, cardiac arrhythmias or congestive heart 
failure. Sudden unexpected death was also considered 
cardiac death. Information on secondary endpoints were 
obtained by follow-up visits, mailed questionnaires, 
telephone interviews and by reviewing the hospital 
records. Non-fatal myocardial infarction was diagnosed 
when at least two of the following were present: 
elevated cardiac enzyme levels (CK level > 190 U/L 
and CK-MB >14 U/L, or CK-MB fraction >10% of total 
CK, or cardiac troponin T >0.1 ng/mL), typical 
electrocardiographic changes (new Q waves >1 mm or > 
30 ms), and typical symptoms of angina. Heart failure 
was defined as hospitalization for cardiac 
decompensation with an ejection fraction ≤35%. Stroke 
was diagnosed when patients presented with typical 
symptoms for at least 1 month. ESRD was defined as an 
eGFR less than 15 ml/min per 1.73 m2 or a need to start 
kidney replacement therapy (dialysis or renal 
transplantation) [18]. Ophthalmologists independent of 
the study made the clinical decision for 
photocoagulation or cataract extraction. 
 
Statistical analysis 
Continuous data (expressed as mean ± standard error of 
mean) were compared using the Student-t test or 
ANOVA techniques when appropriate. Categorical data  
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Table 1. Baseline characteristics of the study participants. 
 
Values are expressed as mean ± standard error of the mean or number with percentage 
 
were compared using the Chi-square test. The Kaplan-
Meier method with the log-rank test was used to assess 
differences in survival between patients with and 
without statins. Statins were not randomly assigned in 
these patients, and the impact of selection bias may 
profoundly distort the results of our study. Propensity 
analyses are reliable tools to correct for selection bias 
and the rationale for using propensity scores has been 
described previously [19]. Therefore, we calculated 
separate propensity scores for statins. Variables 
independently associated with the decision to prescribe 
statins and ACE inhibitors (p<0.25) were included in 
the multivariate propensity score, which was 
constructed using multiple logistic regression analysis. 
Multivariate logistic regression analysis and Cox 
proportional hazard regression analysis were used to 
evaluate whether statins were associated with improved 
glycemic control and a lower rate of primary and 
secondary endpoints. Age, clinical risk factors, ABI 
values, electrocardiography, baseline cholesterol levels, 
cardiovascular medication and propensity scores were 
added to all multivariate regression models. Glycemic 
control was assessed at 1-year of follow-up and at the 
last follow-up visit to assess the sustained effect of 
statins. Tests for heterogeneity were used to evaluate 
differences in the effect of statins between patients with 
insulin treatment and oral medication. For all tests, a p 
value <0.05 (two-sided) was considered significant. All 
analyses were performed using SPSS-11.0 statistical 
software (SPSS Inc., Chicago, Illinois). 
 
RESULTS 
 
Baseline characteristics 
Baseline characteristics of the 425 study participants are 
presented in Table 1. The mean age was 61 ± 0.6 years 
and 291 patients (68%) were male.  Mean body mass 
index at baseline was 25 ± 5 kg⋅m-2. The mean ABI was 
0.61 ± 0.01. Severe PAD (ABI ≤0.70) was identified in 
268 patients (63%). During the initial visit, 208 patients 
(49%) presented with insulin therapy and oral anti-
diabetic medication was used in 217 patients (51%). A 
total of 158 patients (37%) received chronic statin  
Characteristic All patients 
(n=425) 
No statins 
(n=267) 
Statins 
(n=158) p-value 
Age (years) 61 ± 0.61 60 ± 0.85 62 ± 0.95 0.10 
Male gender  291 (68%) 181 (68%) 110 (70%) 0.70 
Angina pectoris  102 (24%) 55 (21%) 47 (30%) 0.033 
Previous myocardial infarction 132 (31%) 74 (28%) 58 (37%) 0.053 
Previous coronary artery bypass surgery 66 (16%) 36 (14%) 30 (19%) 0.13 
Coronary artery disease (summary variable) 198 (47%) 115 (43%) 83 (53%) 0.059 
History of congestive heart failure  45 (11%) 26 (10%) 19 (12%) 0.46 
History of stroke or transient ischemic attack 49 (12%) 25 (9%) 24 (15%) 0.069 
Hypercholesterolemia  104 (24%) 18 (7%) 86 (54%) <0.001 
Hypertension  195 (46%) 108 (40%) 87 (55%) 0.003 
Cigarette smoking  127 (30%) 85 (32%) 42 (27%) 0.25 
Chronic obstructive pulmonary disease 31 (7%) 21 (8%) 10 (6%) 0.56 
Q waves  103 (24%) 60 (23%) 43 (27%) 0.27 
Left bundle branch block 23 (5%) 17 (6%) 6 (4%) 0.26 
Right bundle branch block  6 (1%) 4 (2%) 2 (1%) 0.84 
Atrial fibrillation 26 (6%) 18 (7%) 8 (5%) 0.49 
Aspirin 127 (30%) 53 (20%) 74 (47%) <0.001 
Angiotensin converting enzyme-inhibitor 161 (38%) 80 (30%) 81 (51%) <0.001 
Beta-blocker  135 (32%) 60 (23%) 75 (48%) <0.001 
Calcium channel blocker  123 (29%) 75 (28%) 48 (30%) 0.62 
Coumarin  82 (19%) 46 (17%) 36 (23%) 0.16 
Digoxin  25 (6%) 18 (7%) 7 (4%) 0.33 
Diuretic  82 (19%) 45 (17%) 37 (23%) 0.13 
Oral antidiabetic treatment  215 (51%) 136 (51%) 79 (50%) 0.85 
Insulin treatment 210 (49%) 131 (49%) 79 (50%) 0.85 
Ankle brachial index at rest 0.61 ± 0.01 0.60 ± 0.01 0.62 ± 0.02 0.44 
Blood total cholesterol  (mg/dL) 206 ± 6.2 198 ± 7.0 221 ± 10.7 0.057 
Blood LDL-cholesterol (mg/dL) 129 ± 3.3 137 ± 4.1 116 ± 4.9 <0.001 
Blood HDL-cholesterol (mg/dL) 40 ± 1.0 38 ± 1.1 43 ± 2.0 0.010 
Blood triglyceride (mg/dL) 226 ± 26.5 272 ± 46 171 ± 13.5 0.009 
Blood glycosylated hemoglobin (%) 8.1 ± 0.1 8.2 ± 0.2 8.1 ± 0.1 0.20 
Blood glycosylated hemoglobin <7% 119 (28%) 72 (27%) 47 (30%) 0.60 
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Table 2. Glycemic control and outcome during follow-up in patients using statins or no statins  
 No statins (n=267) Statins (n=158) p-value 
Glycemic control during 1 year of follow-up    
HbA1c value at 1 year  8.7 ± 0.16 7.6 ± 0.16 <0.001 
Change (%) in HbA1c from baseline values + 4.2 ± 1.5 - 6.4 ± 1.6 <0.001 
Patients with decreasing HbA1c 89 (33%) 120 (76%) <0.001 
Patients with HbA1c <7% at 1-year 37 (14%) 71 (45%) <0.001 
Mean HbA1c during  first year of follow-up 8.2 ± 0.13 7.8 ± 0.15 0.15 
Standard deviation of mean  HbA1c  0.8 ± 0.05 0.6 ± 0.04 <0.001 
Minimum HbA1c level  7.3 ± 0.12 7.3 ± 0.14 0.87 
Maximum HbA1c level  9.1 ± 0.17 8.6 ± 0.18 0.033 
Difference between minimum and maximum  HbA1c level 1.8 ± 0.12 1.3 ± 0.10 0.002 
Glycemic control up to last follow-up visit    
HbA1c value at last visit 8.2 ± 0.12 7.3 ± 0.12 <0.001 
Change (%) in HbA1c from baseline values 3.5 ± 1.9 -9.2 ± 1.4 <0.001 
Patients with decreasing HbA1c 86 (32%) 99 (63%) <0.001 
HbA1c of less than 7% at last visit 40 (15%) 80 (51%) <0.001 
Mean HbA1c during follow-up 8.2 ± 0.13 7.7 ± 0.14 0.023 
Standard deviation of mean  HbA1c 0.9 ± 0.05 0.7 ± 0.05 <0.001 
Minimum HbA1c level  7.0 ± 0.11 6.9 ± 0.12 0.45 
Maximum HbA1c level  9.5 ± 0.19 8.7 ± 0.19 0.004 
Difference between minimum and maximum  HbA1c level 2.5 ± 0.16 1.8 ± 0.14 0.002 
Events during follow-up    
All-cause mortality 135 (51%) 21 (13%) <0.001 
Cardiac death 81 (30%) 13 (8%) <0.001 
Non-fatal myocardial infarction 34 (13%) 17 (11%) 0.54 
Hospitalization for heart failure 25 (9%) 4 (3%) 0.007 
Coronary artery bypass grafting 19 (7%) 13 (8%) 0.68 
Cerebrovascular event 42 (16%) 15 (10%) 0.068 
Progression towards end-stage renal disease 43 (16%) 9 (6%) 0.002 
Photocoagulation for retinopathy 29 (11%) 5 (3%) 0.005 
Cataract extraction 23 (9%) 9 (6%) 0.27 
Blindness 1 (0.4%) 0 (0%) 0.44 
Composite of end-stage renal disease and ocular complications 84 (32%) 26 (17%) 0.001 
Composite of all non-fatal events 162 (61%) 71 (45%) 0.002 
Values are expressed as mean ± standard error of the mean or number and percentage 
 
 
therapy. In propensity analysis, important variables 
(p<0.001) associated with the prescription of statins 
were high baseline LDL-cholesterol levels and 
hypertension. Aspirin, angiotensin-converting enzyme 
inhibitors and beta-blockers were also more commonly 
prescribed in patients with chronic statin therapy. Mean 
LDL-cholesterol levels at 1-year of follow-up were 
lower in patients using statins, compared to patients 
using no statins (102 ±4.3 mg/dL vs. 130 ±6.1 mg/dL, 
p<0.001).The mean HbA1c at baseline was 8.1 ±0.1%. A 
total of 119 patients (28%) presented with a baseline 
HbA1c value of less than 7%.  
 
Glycemic control during follow-up 
At 1-year of follow-up, an elevation in HbA1c was 
assessed in 216 patients (51%) and a lowering in 209 
(49%). Figure 1 demonstrates changes in HbA1c from 
baseline values during the first year of follow-up. HbA1c 
decreased with 6.4% in patients using statins and 
increased with 4.2% in patients using no statins 
(p<0.001). During follow-up, 12 patients (3%) switched 
to a less intensive diabetic treatment strategy (6 patients 
switched from insulin therapy to oral medication and 6 
patients discontinued oral medication due to adequate 
glycemic control). In statin users, a higher percentage of 
patients (7%) switched to less intensified treatment 
compared to no statin users (0.4%) (p<0.001) (Figure 
1). Table 2 summarizes differences in glycemic control 
between patients using statins and no statins during the 
first year of follow-up and during overall follow-up. 
Absolute HbA1c values at 1-year and at the last follow-
up were lower in patients using statins (Table 2). The 
proportion of patients with decreasing HbA1c values and 
HbA1c values less than 7% during follow-up was also 
higher in patients using statins (Table 2). In addition, 
the standard deviation of the mean and the absolute 
difference between minimum and maximum HbA1c 
values during follow-up was smaller in statin users, 
compared to non-statin users (Table 2). In multivariate 
analysis, patients with chronic statin therapy were more 
like to have decreasing HbA1c values (HR: 3.48, 95% 
CI: 2.03-5.98) and HbA1c values less than 7% (HR 4.96, 
95% CI: 2.71-9.38) during the first year of follow-up. 
The association between statins and decreasing HbA1c 
values (HR: 1.86, 95% CI: 1.27-2.74) and HbA1c values 
less than 7% (HR 2.58, 95% CI: 1.49-4.48) was also  
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Figure 1. Change in HbA1c and diabetic treatment during follow-up in 
diabetic patients with peripheral arterial disease according to statin use 
or no statin therapy. 
 
sustained after 1-year of follow-up.  During follow-up, 
203 patients underwent lower extremity 
revascularization surgery for progressive PAD. Patients 
using statins were less likely to have surgery, compared 
to patients with no statins (41% vs. 60% respectively, 
p=0.021).  
 
Study endpoints 
During a median follow-up period of 6.9 ±0.2 years, all-
cause mortality occurred in 156 patients (37%), cardiac 
death in 94 patients (22%), non-fatal cardiovascular 
complications in 150 patients (35%), progression to 
ESRD in 52 patients (12%), ocular complications in 67 
patients (16%) and the composite of ESRD and ocular 
complications in 110 patients (26%). In Table 2, a 
univariate comparison between the number of events in 
patients with statins and no statins is presented. All-
cause mortality, cardiac death, congestive heart failure, 
progression towards ESRD and photocoagulation for 
retinopathy during follow-up was significantly lower in 
chronic statin users, compared to no statin users. 
Kaplan-Meier curves also showed a significantly 
improved survival, freedom from cardiac death and 
freedom from the composite of ESRD and ocular 
complications in patients using statins (Figure 2). 
Multivariate analysis showed that statins remained 
significantly associated with improved outcome (Table 
3). Other significant correlates of improved outcome 
included higher ABI values, lower HbA1c values during 
follow-up, decreasing HbA1c values during follow-up 
and a lower variability in HbA1c during follow up 
(lower standard deviation of the mean HbA1c). Tests for 
heterogeneity revealed that statins were associated with 
improved outcome both among patients with insulin 
therapy and among patients with oral anti-diabetic 
treatment (non-significant p-values for interaction ).  
 
DISCUSSION 
 
The current observational study demonstrated that 
diabetic patients with PAD who were receiving chronic 
statin therapy had improved glycemic control compared 
to patients not using statins. Statins were also associated 
with lower all-cause and cardiac mortality rate and non-
fatal diabetic complications, even after adjustment for 
clinical risk factors, baseline cholesterol levels, ABI 
values, cardiovascular medication and propensity 
scores. This study further demonstrated that patients 
with increasing HbA1c values and higher HbA1c 
variability over time were at increased risk of adverse 
outcome and that serial HbA1c measurements may be 
useful for risk stratification in addition to clinical risk 
factors and baseline ABI values.  
Different prevalence rates of diabetes in 
patients with lower extremity PAD have been reported, 
ranging from 8% to 18% [2,20,21]. Patients with PAD 
are at increased risk of developing diabetes which may 
partly be explained by underlying lipid abnormalities 
[22]. Conversely, diabetes itself may also increase the 
risk of developing PAD. Results from the Framingham 
study demonstrated that men and women with diabetes 
were at 4- and 9-fold increased risk, respectively, of 
developing PAD [23]. Moreover, the severity and 
duration of diabetes has also been related proportionally 
to the risk of developing PAD [24,25]. The coexistence 
of PAD and diabetes may reflect an advanced state of 
health impairment in which the prognosis is poor. 
Indeed, in the current study cohort, more than 1 out of 3 
patients (37%) died during a median follow-up of 7 
years. Non-fatal complications related to diabetes were 
also frequently observed. Cardiovascular events 
occurred in 35%, progression to ESRD in 12% and 
ocular complications in 16% of patients. Therefore, the 
identification of patients who are at highest risk is 
necessary for selection of appropriate treatment 
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Figure 2. Kaplan-Meier curve for mortality, cardiac death and non-
fatal diabetic complications (end-stage renal disease, photocoagulation 
for retinopathy, cataract extraction or blindness), stratified according 
to statin therapy. 
 
 
strategies and for control of disease related 
complications.  
Poor glycemic control and elevated HbA1c 
values are important determinants of micro- and 
macrovascular complications in patients with diabetes 
[28]. The American College of Cardiology/American 
Heart Association has therefore recommended in their 
guidelines that all diabetic patients with PAD should be 
treated in order to achieve HbA1c levels of less than 7% 
[6]. Despite the use of strict insulin treatment or oral 
antidiabetic medication, physicians may still be 
challenged to achieve these goals. In the current study 
population, only 28% of the patients presented with 
HbA1c values of less than 7% at study enrolment. In 
most of the patients, a HbA1c value of less than 7% was 
not achieved during follow-up. These results reflect the 
high rate of poor glycemic control in diabetic patients 
with PAD. Different factors have been associated with 
poor glycemic control, including diabetes disease 
duration, poor self-care, failure to receive diet 
recommendations, non-insurance and high cholesterol 
levels [29,30]. Especially in patients presenting with 
these characteristics, much benefit can be derived from 
appropriate patient counseling and intensive medical 
treatment.     
Several reports in literature have suggested the 
beneficial properties of statins regarding insulin 
sensitivity, insulin secretion and insulin-mediated 
glucose uptake in non-diabetic and diabetic patients [10-
13]. Moreover, a post-hoc analysis of the West of 
Scotland Coronary Prevention Study showed that 
patients receiving statins had a 30% reduction in the 
hazard of becoming diabetic [9]. Four different known 
effects of statins may possibly explain its effect on 
glucose metabolism. Firstly, dyslipidemia has been 
associated with the development of diabetes and statins 
may have effects on glucose metabolism through lipid-
lowering effects [22]. Secondly, the anti-inflammatory 
properties of statins may reduce circulating levels of 
pro-inflammatory cytokines which can negatively 
influence the insulin receptor leading to insulin 
insensitivity [31]. Thirdly, it may be speculated that 
statins restore endothelial function and may therefore 
improve tissue perfusion and glucose and insulin 
transport [32]. Finally, the anti-oxidative properties of 
statins may prevent the development of endothelial 
dysfunction, since  oxidative stress during 
hyperglycemia is a key element in the pathogenesis of 
endothelial dysfunction and diabetic complications [33].  
Large studies have demonstrated that statins 
improve cardiovascular outcome in patients with PAD 
[34] and with diabetes [35]. Statin therapy has therefore 
been recommended in all patients with PAD [6] and 
diabetes [15] to achieve LDL-cholesterol levels of less 
than 100 mg/dL. The current results not only confirm  
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Table 3. Prognostic value of ankle-brachial index values, HbA1c values and chronic statin therapy in diabetic patients with peripheral arterial 
disease, adjusted for baseline clinical variables 
ESRD = end-stage renal disease; HbA1c = glycosylated hemoglobin. *Adjusted for age, baseline clinical variables, electrocardiography, baseline 
cholesterol levels, cardiovascular medication and propensity scores **Adjusted for age, baseline clinical variables, ankle-brachial index values, 
electrocardiography, baseline cholesterol levels, cardiovascular medication and propensity scores. *** Ocular complications include 
photocoagulation for retinopathy, cataract extraction and blindness.  
 
 
that statins significantly lower all-cause mortality and 
cardiac death rate, but they also showed that it 
significantly lowers the rate of diabetes-related 
complications, including ESRD and ocular 
complications. It may be hypothesized that an 
improvement in glucose metabolism due to chronic 
statin therapy may partially explain the lower rate of 
mortality and non-fatal diabetic complications. Lower 
absolute HbA1c values, decreasing HbA1c values and 
lower variability in HbA1c during follow up were all 
independently associated with lower mortality and non-
fatal diabetic complications. In addition, the severity of 
atherosclerosis as measured by the ABI remained an 
important determinant of adverse outcome. In clinical 
practice, serial HbA1c measurements may not only be 
valuable to guide medical treatment, but may also allow 
refinement of risk stratification in addition to clinical 
risk factors and ABI values in order to identify patients 
at highest risk of adverse outcome who may benefit 
from aggressive lipid-lowering treatment. 
Several limitations should be addressed. The 
main limitation of this study is that the findings must be 
interpreted in the context of the observational study 
design in which statins were not randomly assigned to 
the study participants. Although we have used 
propensity scores, it may not have compensated for all 
bias in the decision to prescribe statins. Secondly, 
potentially confounding variables such as poor health 
behaviors and poor adherence to a strict diabetic 
regimen were not obtained in this study and may have 
influenced the results. However, patients with statins 
were more likely to switch from insulin treatment to 
oral medication or from oral medication to only a 
diabetic diet, suggesting that a strict regimen of insulin 
therapy itself does not fully account for the 
improvement in HbA 1c. Finally, the use of HbA1c as 
measure of glycemic control may be debated. HbA1c has 
been proven to be a reliable measure of long-term 
glycemic control in patients with diabetes, however, 
fasting glucose and 2-hour post-glucose-load 
concentrations in addition to HbA1c may have 
represented a more reliable measure of glycemic 
control.  
 
Conclusion 
Based on the current results, we conclude that in 
diabetic patients with PAD chronic statin therapy is 
associated with desirable glycemic control, improved 
survival and lower non-fatal diabetic complication rate. 
In addition, serial HbA1c measurements may allow 
refinement in risk stratification in addition to clinical 
risk factors and ABI values to identify patients at 
increased risk. Despite the limitations of an 
observational study, the current findings suggest new 
clinical possibilities, which should be explored in 
further studies. 
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Aims. Prophylactic preoperative treatment of the culprit 
coronary artery lesion is not associated with improved 
postoperative outcome in vascular surgery patients. This 
study evaluates the incidence and location of 
perioperative ST-depression and ST-elevation as related 
to the culprit coronary lesion.  
Methods and Results: In a prospective study of 401 
consecutive vascular surgery patients, high-sensitivity 
C-reactive protein (HS-CRP) and white blood cell count 
(WBCC) were measured preoperatively. Stress 
echocardiography was performed to locate the culprit 
coronary lesion. Prolonged ST-depression and ST-
elevation was recorded by 12-lead Holter monitoring 
starting 1 day before to 2 days after surgery. Cardiac 
death or Q-wave myocardial infarction were noted 
during follow-up (mean 2.5 years). Perioperative ST-
depression occurred in 16.2% and ST-elevation in 7.5% 
of patients. Culprit coronary lesion-related ST-
depression occurred in 89% and ST-elevation in 53% 
(p<0.001). Both ST-depression and ST-elevation were 
associated with long-term cardiac events (OR, 18.7 [CI, 
5.2-66] and OR, 8.4 [CI, 4.6-15], respectively). Elevated 
HS-CRP (OR, 3.8 [CI, 2.2-6.5]) and WBCC (OR, 1.5 
[CI, 1.1-2.2]) were associated with a higher incidence of 
ST-elevation, but not with ST-depression. 
Conclusion: In contrast to perioperative ST-depression, 
perioperative ST-elevation often occurs in non-culprit 
related coronary artery territories.  
_____________________________________________________________________________________________ 
 
THE INCIDENCE OF myocardial infarction and 
cardiac death in patients undergoing major vascular 
surgery is high with estimates ranging from 2% to 19% 
[1]. A perioperative myocardial infarction is the major 
cause of postoperative mortality in this population [2]. 
A perioperative myocardial infarction can be caused by 
prolonged subendocardial ischemia in the presence of a 
culprit coronary lesion and/or by acute coronary 
occlusion resulting in transmural ischemia [3-5]. 
Perioperative myocardial ischemia has been described 
in up to 41% of patients undergoing major vascular 
surgery and has been associated with increased 
postoperative cardiac morbidity and mortality [6]. 
Differences between perioperative ST-elevation 
ischemia and ST-depression ischemia in terms of 
incidence, location and prognosis are not well known.  
The prediction of mortality and acute coronary 
events remains a challenge, due to the vulnerability of 
atherosclerotic plaques. According to the American 
College of Cardiology/ American Heart Association 
guidelines, clinical evaluation and non-invasive testing 
are the recommended risk assessment strategies [7]. 
Cardiac evens, however, still occur in the presence of 
negative stress-test results. We hypothesized that 
perioperative ST-depression and ST-elevation can occur 
at sites other than the preoperatively identified culprit 
coronary lesion. A disagreement in pre- and 
perioperatively assessed ischemia may explain why 
preoperative localized treatment of the coronary lesion 
fails to prevent perioperative ischemic events [8,9].  
 In this study, we defined the location of ST-
depression and ST-elevation ischemia and assessed its 
relation to the culprit coronary lesion as identified by 
dobutamine stress echocardiography. We also evaluated 
whether both ST-depression and ST-elevation are 
associated with early and late cardiac events.  
 
METHODS 
 
Study population 
The study population consisted of 401 consecutive 
patients undergoing elective abdominal aortic aneurysm 
repair (n=200), peripheral artery bypass surgery (n=128) 
or carotid artery surgery (n=73) at the Erasmus Medical 
Center in Rotterdam, the Netherlands, during the period 
2002 to 2006. The study was approved by the hospital’s 
ethical committee and complied with the Declaration of 
Helsinki. All patients gave informed consent. Patients 
were enrolled up to 3 months prior to surgery at the 
outpatient clinic. Patients with a cardiac pacemaker, left 
ventricular hypertrophy, left or right bundle branch 
block and atrial fibrillation were excluded. Patients who 
participated in clinical intervention trials at or outside 
the Erasmus MC were also excluded. In all patients, β-
blockers were considered prior to surgery to obtain 
perioperative heart rates of 60-65 beats per minute. All 
patients were screened for hypertension (blood pressure 
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³140/90 mmHg), diabetes mellitus (fasting glucose level 
³7.0 mmol/L or use of insulin or oral glucose lowering 
medication), hypercholesterolemia (plasma cholesterol 
level ≥5.5 mmol/L or use of cholesterol-lowering 
medication) and renal failure (serum creatinine level ≥ 
2.0 mg/dL (177 μmol/L)). Body mass index was 
calculated using the formula weight/height2. The ankle-
brachial index was calculated by dividing the right and 
the left ankle blood pressure by the higher of the two 
brachial blood pressures. Prior to surgery, blood was 
drawn from all patients and high-sensitivity C-reactive 
protein (HS-CRP) level and white blood cell count were 
used as markers of inflammation activity. Other 
laboratory tests included hemoglobin, hematocrit, 
glucose, glycosylated hemoglobin, urea, creatinine, 
cholesterol, uric acid and N-terminal pro-B-type 
natriuretic peptide (NT-proBNP), which were measured 
by commercially available tools. 
 
Dobutamine stress echocardiography 
During preoperative stress echocardiography, 
dobutamine hydrochloride was administered 
intravenously by infusion pump, starting at 10 
mcg/kg/min for 3 minutes (5 mcg/kg/min for 5 minutes, 
followed by 10 mcg/kg/min for 5 minutes in patients 
with resting wall motion abnormalities), and increased 
by 10 mcg/kg/min every 3 minutes to a maximum of 40 
mcg/kg/min. The dobutamine infusion was stopped if a 
target heart rate (85% of a theoretic maximal heart rate) 
was achieved. Two experienced investigators, blinded to 
the clinical data, performed off-line assessment of 
echocardiographic images, using the 17-segment 5-point 
scoring model. Ischemia was defined as new or 
worsening wall-motion abnormalities (compared to 
resting images of the same test) as indicated by an 
increase of regional wall motion score ≥1 grade(s) with 
stress. Myocardial segments were assigned to a 
coronary artery territory as follows: the anterior, 
anteroseptal, apical septal, apical anterior, apical lateral, 
and midinferoseptal segments were assigned to the left 
anterior descending (LAD) coronary artery; the lateral 
and posterior segments were assigned to the left 
circumflex artery (LCX); and the apical, inferior, 
midinferior, basal inferior, and basal inferoseptal 
segments were assigned to the right coronary artery 
(RCA).  
 
Continuous ECG monitoring 
Patients were continuously monitored with a 10-
electrode, 12-lead digital ECG recorder (DR180+ 
Digital Recorder, NorthEast Monitoring Inc. 
Massachusetts), starting 1 day before surgery up to 2 
days after. Recordings were performed in the 
continuous 12-lead mode with a recording length of 10 
seconds every minute. The frequency response was 0.05 
– 150Hz. Electrocardiographic data were initially 
processed by a technician and analyzed by 2 
experienced cardiologists who were blinded to the 
patient’s clinical data. After excluding all abnormal 
QRS complexes, the ambulatory electrocardiography 
recordings were analyzed for ST-segment deviations. A 
continuous ST segment trend was generated and all 
potential ischemic episodes were identified. Episodes of 
ischemia were defined as ST-depression or ST-
elevation, lasting more than 10 minutes and shifting 
from baseline to more than 0.1 mV (1 mm). The 
baseline ST segment level was defined as the average 
ST segment during a stable period (duration of 20 
minutes) preceding each ischemic episode. ST segment 
change was measured 60 ms after the J point. If the J 
point fell within the T-wave, the ST segment change 
was measured 40 ms after that point. Ischemic burden 
was defined as ST-deviation times duration (mm*min). 
ST-segment changes in the precordial leads were 
assigned to the LAD territory, in the lateral leads (I, 
aVL, V5, V6) to the LCX territory and in the inferior 
leads (II, III, aVF) to the RCA territory. Mean heart rate 
prior to, during and after surgery was calculated for 
each patient. Heart rate variability (SDNN) was 
computed using time-domain analysis of short-term 5-
minute recordings during the first 24-hour recording. 
This 24-hour recording started at the evening prior to 
surgery and included night and surgical period. 
 
Troponin T release 
Troponin T levels were measured on postoperative day 
1, 3, 7, before discharge and whenever clinically 
indicated by ECG changes, consistent with myocardial 
ischemia or infarction. Troponin T level was measured 
by an electrochemiluminescence immunoassay on the 
Elecsys 2010 (Roche Diagnostics, Mannheim, 
Germany). The lower limit of 0.03 ng/ml was used to 
define positive troponin T levels since lower levels do 
not meet the imprecision criteria of <10%. 
 
Major cardiac events 
Study endpoints were major cardiac events (cardiac 
death and non-fatal Q-wave myocardial infarction) 
during the perioperative period (30-day period after 
surgery) and during follow-up (mean: 2.5 years). During 
follow-up, outpatient visits were scheduled every 3 
months after discharge. Cardiac death was defined as 
death caused by acute myocardial infarction, cardiac 
arrhythmias, congestive heart failure or sudden death. 
Q-wave myocardial infarction was diagnosed when at 
least the following were present: elevated cardiac 
enzyme levels, development of new Q waves (>1 mm or 
> 30 ms), and typical symptoms of angina pectoris. No 
patients were lost to follow-up. 
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Table 1.  Baseline characteristics of the study population according to perioperative ST-segment changes.
Values are expressed as number (%), mean standard deviation, SD) or median (interquartile range, IQR). 
* P<0.05 ST depression myocardial ischemia versus no ST changes 
† P<0.05 ST elevation myocardial ischemia versus no ST change 
‡ P<0.05 ST elevation myocardial ischemia versus ST depression myocardial ischemia 
 
Data analysis 
Clinical, laboratory and electrocardiographic 
characteristics between patients with ST-segment 
depression and ST-elevation were compared using one-
way analyses of variance for continuous characteristics 
and chi-square analyses for dichotomous characteristics. 
Non-parametric tests were used if distributions were 
skewed. The three patients who had both ST-elevation 
and ST-depression during the same recording were 
classified according to the ST-change with the largest 
ischemic burden. Multivariate logistic regression 
analysis was used to evaluate the association between 
laboratory measurements and ST-depression or ST-
elevation. Multivariate logistic and Cox regression 
analysis was also used to evaluate the prognostic value 
of ST-segment changes with perioperative and long-
term outcome. In multivariate analysis, adjustments 
were made for age, gender, smoking, hypertension and 
the risk factors according to the Lee risk index 
(coronary artery disease, congestive heart failure, 
cerebrovascular disease, diabetes and renal 
dysfunction). Odds and hazard ratios are given with 
95% confidence intervals. For all tests, a p value <0.05 
(two-sided) was considered significant. All analysis was 
performed using SPSS 13.0 statistical software (SPSS 
Inc., Chicago, Illinois). 
 
RESULTS 
 
Mean age of the study population was 66.8 ± 10.1 years 
and 77.6% was male. During continuous Holter 
monitoring, ST-segment changes occurred in 23.7% of  
Characteristic No ST-changes 
(n=306) 
ST-depression (n=65) ST-elevation (n=30) 
Age, years (SD) 166 ± 10 71± 8* 67 ± 11 
Gender, male 227 (74.2%) 57 (87.7%)* 27 (90.0%) 
Angina pectoris 47 (15.4%) 17 (26.2%)* 7 (23.3%) 
Myocardial infarction 94 (30.7%) 32 (49.2%)* 21 (70.0%) † 
Previous percutaneous coronary angioplasty 23 (7.8%) 1 (1.5%) 6 (20%) † ‡ 
Previous coronary artery bypass grafting 41 (13.4%) 14 (21.5%) 4 (13.3%) 
Congestive heart failure 9 (2.9%) 5 (7.7%) 4 (13.3%) † 
Diabetes 48 (15.7%) 8 (12.3%) 9 (30.0%) † ‡ 
Hypertension 124 (40.5%) 30 (46.2%) 12 (40.0%) 
Stroke 48 (15.7%) 6 (9.2%) 3 (10.0%) 
Smoking 171 (55.9%) 41 (63.1%) 16 (53.3%) 
Ankle-brachial index (SD) 0.77 ± 0.28 0.72 ± 0.29 0.64 ± 0.24 
High sensitivity C-reactive protein, mg/L (median, IQR) 8 (2-23) 19 (7-105)* 49 (22-198) † ‡ 
White blood cell count, x109/L (SD) 8.5 ±2.9 8.5 ± 2.6 10.0 ± 3.4† ‡ 
Ureum level, mmol/L (SD) 6.76 ± 3.21 8.27 ± 4.05 8.91 ± 6.46† 
Creatinine level, umol/L (SD) 95 ± 74 101 ± 42 142 ± 157† ‡ 
Estimated glomerular filtration rate ml/min/1.73m3 (SD) 85 ± 26) 74 ± 22* 74 ± 28 † 
Hemoglobin, gl/L (SD) 13.9 ± 1.7 13.7  ± 1.9 13.7 ± 1.8 
Hematocrit, L/L (SD) 0.41 ± 0.05 0.41 ± 0.05 0.41 ± 0.05 
Glucose level, mmol/L (SD) 6.1 ± 2.1 7.2 ± 3.2* 6.6 ± 2.4 
Glycosylated hemoglobin level, % (SD) 6.15 ± 1.34 6.35 ± 0.73 7.06 ± 1.71† 
Low-density lipoprotein cholesterol, mmol/L (SD) 3.0 ± 1.0 3.6 ± 1.4*  3.2 ± 1.4 
High-density lipoprotein cholesterol, mmol/L (SD) 1.3 ± 0.5 1.3 ± 0.9 1.0 ± 0.5 
Triglycerides, mmol/L (SD) 1.9 ± 1.0 2.1 ± 0.8 2.6 ± 1.6‡ 
Total cholesterol, mmol/L (SD) 4.8 ± 1.2 5.6 ± 1.5* 5.3 ± 1.5 
N-terminal proBNP, pmol/L (median, IQR) 20 (9-46) 82 (18-140)* 84  (15-180) † 
Uric acid, mmol/L (SD) 0.34 ± 0.10 0.38 ± 0.09 0.37 ± 0.09 
Angiotensin-converting enzyme inhibitor 73 (23.9%) 23 (35.4%) 5 (16.7%) 
Aspirin 168 (54.9%) 33 (50.8%) 15 (50.0%) 
Nitroglycerin 38 (12.4%) 14 (21.5%) 8 (26.7%) † 
Statin 181 (59.2%) 20 (30.8%)* 7 (23.3%) † 
Calcium channel blocker 68 (22.2%) 21 (32.3%) 12 (40.0%) † 
β-Blocker 242 (79.1%) 28 (43.1%)* 16 (53.3%) † 
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Table 2. Significant laboratory predictors of perioperative ST-segment changes in multivariate regression analysis. 
Baseline predictors ST-deviation 
(n=95) 
OR¶ (95% CI) 
ST-depression 
(n=65) 
OR¶ (95% CI) 
ST-elevation 
(n=30) 
OR¶ (95% CI) 
*HS-CRP, per LN increase in mg/L 2.3 (1.2-4.3) NS** 3.8 (2.2-6.5) 
White blood cell count per 109/L increase NS** NS** 1.5 (1.1-2.2) 
†NT-pro-BNP, per LN increase in pmol/L 2.3 (1.2-4.2) 1.4 (1.0-2.0) 3.2 (1.2-9.2) 
Hemoglobin, per mmol/L decrease 1.7 (1.2-2.6) NS** 3.3 (1.3-8.3) 
Glucose level, per mmol/L increase 1.6 (1.1-2.5) NS** NS** 
Glycosylated hemoglobin, per % increase 1.8 (1.0-3.2) NS** NS** 
‡LDL-cholesterol, per mmol/L increase 3.8 (1.1-14.2) 1.9 (1.0-3.9) NS** 
§HDL-cholesterol, per mmol/L decrease 0.2 (0.02-0.7) NS** NS** 
║EGFR, per ml/min/1.73m3 decrease NS** NS** 0.9 (0.8-1.0) 
 
*High-sensitivity C-reactive protein; †N-terminal pro-B-type natriuretic peptide; ‡Low-density lipoprotein cholesterol; §High-
density lipoprotein cholesterol; ║Estimated glomerular filtration rate. Associations were adjusted for age, gender, smoking, 
hypertension, coronary artery disease, congestive heart failure, cerebrovascular disease, diabetes and renal dysfunction; **Non-
significant. 
 
patients. Mean duration of ST-segment change was 62.8 
min (range: 10-1020 minutes), mean (SD) ST-deviation 
was 2.0 1.2) mm and mean ischemic burden was 432.9 
(range: 15-5632 mm*min). ST-segment change in the 
LAD, LCX and RCA territory was observed in 12.5%, 
9.5%, and 8.5% of patients. ST-depression occurred in 
16.2% and ST-elevation in 7.5% of patients. Troponin T 
release occurred in 90 patients (22.4%). 
 
Perioperative ischemia in relation to the culprit 
coronary lesion 
Non-invasive testing revealed rest wall motion 
abnormalities in 21.7% and stress-induced wall motion 
abnormalities in 20.7% of patients. Stress-induced 
ischemia in the LAD, LCX and RCA territory was 
observed in 12.7%, 8.5% and 15.2% of patients. In 
patients with both stress-induced and perioperative 
ischemia, location agreement was 89% for ST-
depression in contrast to 53% for ST-elevation 
(p<0.001) (Figure 1). This agreement in location for ST-
depression and ST-elevation was smallest in the LCX 
territory (Figure 1). Prior to surgery, a percutaneous 
coronary angioplasty intervention was performed in 30 
patients (7.5%). None of the 30 patients developed ST-
depression in the stented coronary territory, while 5/30 
(16.7%) developed ST-elevation in the same stented 
territory (p=0.02). 
 
ST-elevation versus ST-depression 
Baseline characteristics of patients with no ST changes, 
ST-depression and ST-elevation are presented in Table 
1. Patients with ST-elevation had significantly higher 
levels of HS-CRP and white blood cell count, compared 
to patients with ST-depression (Table 1). In multivariate 
analysis, increased levels of HS-CRP and white blood 
cell count remained independently associated with ST-
elevation, together with advanced age, previous 
myocardial infarction, history of heart failure, decreased 
hemoglobin levels and increased NT-proBNP levels 
(Table 2). Risk factors associated with ST-depression 
did not include inflammation activity but did include 
previous myocardial infarction, decreased ankle-
brachial index and increased LDL-cholesterol and NT-
proBNP levels (Table 2). Patients with ST-depression 
and ST-elevation had significantly higher heart rates 
before, during and after surgery, compared to patients 
with no ST changes. The highest ischemic burden, 
amount of troponin T release, incidence of ventricular 
arrhythmias and lowest variability in heart rate was 
observed in patients with ST-elevation (Table 3). 
 
 
Figure 1. Myocardial ischemia during preoperative stress 
echocardiography in relation to perioperative myocardial ischemia 
during Holter electrocardiography. 
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Table 3.  ST-depression and ST-elevation myocardial ischemia in relation to electrocardiographic variables. 
Characteristic No ST-changes 
(n=306) 
ST-depression 
(n=65) 
ST-elevation (n=30) 
Heart rate before operation, bpm (SD) 67 ± 12 75 ± 15* 75 ± 11† 
Heart rate during operation, bpm (SD) 68 ± 12 79 ± 12* 81 ± 15† 
Heart rate after operation, bpm (SD) 72 ± 13  85 ± 14* 88 ± 15† 
Heart rate at onset of ischemia, bpm (SD) - 85 ± 12 92 ± 13 
Peak heart rate during ischemia, bpm (SD) - 100 ± 16 104 ± 15 
Number of ischemic episodes per registration (SD)  1.9 ± 1.0 1.0 ± 1.2 
Mean duration, minutes - 143 ± 232 203 ± 258‡ 
Mean ST-segment deviation, mm - 1.9 ± 0.9 2.2 ± 1.6‡ 
Ischemic burden, mm*min - 512 ± 877 951 ± 1764‡ 
Ischemia before surgery - 17 (26.2%) 7 (23.3%) 
Ischemia during surgery - 47 (72.3%) 18 (60.0%) 
Ischemia after surgery - 35 (53.8%) 21 (70.0%) 
Non-sustained ventricular tachycardia 43 (14.1%) 21 (32.3%)* 13 (43.3)% † 
Sustained ventricular tachycardia 6 (2.0%) 3 (4.6%) 7 (23.3%) † ‡ 
Ventricular fibrillation 0 (0%) 5 (7.7%) 4 (13.3%) † 
Heart rate variability, 24 hour SDNN, ms (SD) 135 ± 45 119 ± 40 93 ± 36† 
Troponin T positive 21 (6.9%) 45 (69.2%)* 24 (80.0%) † 
Troponin T value, ug/L (median IQR) 0.15 (0.05-0.75)  0.19 (0.06-0.45)  0.67 (0.23-4.49) † ‡ 
Values are expressed as number (%), mean standard deviation, SD) or median (interquartile range, IQR) 
* P<0.05 ST depression myocardial ischemia versus no ST changes 
† P<0.05 ST elevation myocardial ischemia versus no ST change 
‡ P<0.05 ST elevation myocardial ischemia versus ST depression myocardial ischemia 
 
Table 4. Association between electrocardiographic variables and cardiac events. 
Characteristics  Perioperative cardiac events 
(n=23) 
OR* (95% CI) 
Long-term cardiac events 
(n=69) 
HR* (95% CI) 
No ST-deviation (reference) 1.0 1.0 
- ST-segment depression 6.9 (2.1-22.4) 4.1 (2.3-7.2) 
- ST-segment elevation 18.7 (5.2-66.2) 8.4 (4.6-15.4) 
Heart rate before operation, per 10 bpm ↑ 1.2 (0.9-1.7) 1.1 (1.0-1.4) 
Heart rate during operation, per 10 bpm ↑ 1.4 (1.0-1.9) 1.2 (1.0-1.5) 
Heart rate after operation, per 10 bmp ↑ 1.3 (1.1-1.7) 1.3 (1.1-1.5) 
Number of ischemic episodes per registration 2.1 (1.6-2.8) 1.7 (1.5-2.0) 
Ischemia duration, per hour ↑ 1.3 (1.1-1.4) 1.2 (1.1-1.2) 
ST-segment deviation, per mm ↑ 2.3 (1.6-3.3) 1.6 (1.4-2.0) 
Ischemic burden, per 1000 mm*min ↑ 2.5 (1.5-4.1) 1.8 (1.4-2.4) 
Ischemia before surgery 6.4 (2.1-19.3) 4.8 (2.8-8.4) 
Ischemia during surgery 5.9 (2.4-14.9) 2.7 (1.6-4.3) 
Ischemia after surgery 4.6 (1.8-11.8) 2.8 (1.7-4.7) 
Stress echocardiography location disagreement 1.1 (0.3-3.3) 1.9 (1.1-2.9) 
Heart rate variability, 24 hour SDNN, per 10 ms ↑ 0.9 (0.7-1.1) 0.9 (0.7-1.0) 
*Adjusted for age, gender, smoking, hypertension, coronary artery disease, congestive heart failure, cerebrovascular disease, 
diabetes and renal dysfunction. 
 
Prognostic value of ST-depression and ST-elevation 
In the 30-day period, major cardiac events occurred in 
23 patients (6.0%). During follow-up, cardiac events 
occurred in 69 patients (17.2%). ST-depression during 
continuous ECG monitoring was associated with a 7-
fold and 4-fold increased risk of perioperative and long-
term cardiac events, respectively (Table 4). ST-
elevation was associated with a 19-fold and 8-fold 
increased risk, respectively (Table 4). Higher intra- and 
postoperative heart rates and increased ischemic burden 
were also important correlates of adverse perioperative 
and long-term cardiac outcome (Table 4). This study 
confirmed that both higher doses of statins and β-
blockers were associated with a lower rate of 
perioperative ischemia and cardiac evens (Table 5).  
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Table 5.The association of β-blockers and statins with perioperative ST-depression, ST-elevation and cardiac events in 
multivariate analysis.  
Model Perioperative  
ST-depression 
(n=65) 
Perioperative  
ST-elevation (n=30) 
Perioperative cardiac 
death or Q-wave 
myocardial infarction 
(n=23) 
Long-term cardiac 
death or Q-wave 
myocardial infarction 
(n=69) 
Statin dose per 10% 
increase of MRTD 
0.85  (0.78-0.94) 0.72  (0.62-0.86) 0.60  (0.39-0.95) 0.75  (0.64-0.89) 
β-Blocker dose per 
10% increase of 
MRTD 
0.67  (0.57-0.81) 0.83 (0.69-0.98) 0.72 (0.59-0.84) 0.73 (0.62-0.86) 
The dose of statins and β-blocker therapy was converted to the percentage of maximum recommended therapeutic dose (MRTD) 
according to the FDA's Center for Drug Evaluation and Research database. The MRTD for simvastatin, pravastatin and 
fluvastatin was 0.67 mg/kg/day. A MRTD of 0.33 mg/kg/day was used for atorvastatin and rosuvastatin. The MRTD for atenolol 
and bisoprolol was 3.33 mg/kg/day, for metoprolol 6.67 mg/kg/day, for carvedilol 0.42 mg/kg/day, for propranolol 10.7 
mg/kg/day, and for labetolol 40.7 mg/kg/day. Associations were adjusted for age, gender, smoking, hypertension, coronary artery 
disease, congestive heart failure, cerebrovascular disease, diabetes and renal dysfunction. 
 
 
DISCUSSION 
 
This study demonstrates that perioperative ST-
depression occurs in 16% and ST-elevation in 8% of 
patients undergoing major vascular surgery. 
Importantly, there is a poor agreement between 
perioperative ST-elevation and the culprit coronary 
artery lesion as identified by preoperative stress testing. 
In addition, patients with ST-elevation were 
characterized by elevated inflammation activity, 
ischemic burden, troponin T amount, incidence of 
ventricular arrhythmias and the lowest heart rate 
variability compared to patients with ST-depression. 
 
Perioperative ST-depression myocardial ischemia 
occurs mostly within the first two days after surgery and 
is often silent and presents without Q waves in the 
majority of cases [10]. ST-elevation-type ischemia has 
been considered relatively uncommon [10], although a 
high incidence of 12% of perioperative ST-elevation 
was observed in a study by London and colleagues [11]. 
This study found a high incidence of both prolonged 
ST-segment depression (16%) and ST-elevation 
ischemia (8%) in patients undergoing major vascular 
surgery, which were both significantly associated with 
early and late cardiac events. Prolonged myocardial ST-
depression preceding postoperative cardiac 
complications has been observed in up to 85% of events 
[4,12]. Autopsy studies demonstrated that up to 55% of 
patients with fatal perioperative myocardial infarction 
has evidence of unstable plaques with disruption [5,13]  
 
Several studies have investigated whether prophylactic 
revascularization of coronary artery lesions could 
prevent postoperative events. In the CARP (Coronary 
Artery Revascuarization Prophylaxis) randomized trial, 
the incidence of perioperative myocardial infarction was 
similar in patients allocated to prophylactic 
revasculization versus those allocated to optimal 
medical therapy (12% vs. 15% events) [8]. There was 
also no beneficial effect observed during long-term 
follow-up. The DECREASE (Dutch Echocardiographic 
Cardiac Risk Evaluation Applying Stress Echo Study 
Group)-V study confirmed these results in vascular 
surgery patients with extensive stress-induced ischemia 
[14]. In the current study, perioperative ST-elevation 
ischemia was poorly related to the coronary artery 
territory revealing wall motion abnormalities during 
stress testing. ST-depression ischemia, on the other 
hand, showed a much better agreement in location. If 
we assume that ST-elevation myocardial ischemia is the 
result of a vulnerable plaque, than this observation 
supports the hypothesis that vulnerable plaques can 
rupture at different sites in the absence of a critically 
narrowed coronary artery lumen. This may explain why 
preoperative revascularization of a coronary lesion fails 
to prevent perioperative cardiac events.  
 
The positive association between HS-CRP and white 
blood cell count with ST-elevation supports the 
hypothesis that inflammation is a critical process in the 
development and progression of atherosclerotic 
vulnerable plaques in the perioperative setting. HS-CRP 
can directly influence vascular vulnerability by a variety 
of mechanisms, which include up-regulation of 
adhesion molecules [15,16], decreased nitric oxide 
production [17], increased LDL uptake by macrophages 
[18] and enhanced intravascular thrombosis in arterial 
injury [19]. Leukocytes have also been shown to play a 
major role in inflammatory processes and to be 
 94
pathogenic within unstable coronary plaques [20]. We 
also observed that decreased hemoglobin and increased 
NT-proBNP levels were associated with an increased 
risk of ST-elevation. Decreased hemoglobin levels have 
been recognized as an independent risk factor for major 
adverse cardiovascular events in community cohorts, 
heart failure and acute coronary syndromes [21-23]. 
NT-proBNP has prognostic value in patients with acute 
coronary syndromes and stable coronary artery disease 
[24,25]. Although the magnitude of NT-proBNP rises 
with the severity of ischemia during exercise testing 
[26], data linking NT-proBNP to the pathogenesis of 
ST-elevation are limited. More studies are needed to 
confirm the association between laboratory markers and 
the onset of ST-elevation myocardial ischemia. 
 
It has been suggested that ST depression ischemia has a 
more unfavorable outcome compared to ST elevation 
[10]. The current study suggests the contrary. Not only 
was ischemic burden and amount of troponin T release 
higher, ventricular arrhythmias were more common and 
heart rate variability was lower in patients with 
perioperative ST-elevation. Monitoring for both ST-
elevation and depression may significantly improve risk 
stratification in addition to clinical risk variables, 
laboratory markers and stress test results. Therefore, 
vascular surgery patients may benefit from routine 
ischemia screening with 12-lead electrocardiographic 
monitoring. This non-invasive and readily applicable 
procedure identifies high-risk patients who can benefit 
from medical risk reduction strategies, such as β-
blockers and statins [7].  
 
A limitation of this study is the high preponderance of 
male and Caucasian patients. In addition, the risk profile 
of this study population may be higher than average, 
since the study was performed in a University hospital 
which acts as tertiary referral center. The lack of 
coronary angiography is a limitation in the current 
study. However, we used stress echocardiography to 
identify the culprit coronary lesion, since this is the 
recommended method for preoperative risk stratification 
according to ACC/AHA guidelines. ECG monitoring 
was performed during a 72-hour perioperative period. 
Although longer than in most previous studies in this 
setting, a more precise estimation of the results may 
have been obtained by longer ECG recordings. Lastly, 
co-morbidities associated with perioperative 
cardiovascular events may have influenced our results, 
since statins and β-blockers were not randomized. 
However, we conducted multivariate analysis to adjust 
for known confounding factors. 
 
In conclusion, both perioperative ST-depression and 
ST-elevation are common in patients undergoing major 
vascular surgery. The highest inflammation activity, 
ischemic burden, troponin T amount, incidence of 
ventricular arrhythmias and the lowest heart rate 
variability were observed in patients with ST-elevation. 
In contrast to perioperative ST-depression, a poor 
agreement was observed between perioperative ST-
elevation and the culprit coronary artery lesion as 
identified by preoperative stress testing.  
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The prevalence and prognosis of unrecognized 
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Objective(s): The aim of this study is to determine the 
prevalence and prognosis of unrecognized myocardial 
infarction (MI) and silent myocardial ischemia in 
vascular surgery patients. 
Methods: In a cohort of 1,092 patients undergoing 
preoperative dobutamine stress echocardiography and 
non-cardiac vascular surgery, unrecognized MI was 
determined by rest wall motion abnormalities in the 
absence of a history of MI. Silent myocardial ischemia 
was determined by stress-induced wall motion 
abnormalities in the absence of angina pectoris. β-
Blockers and statins were noted at baseline. During 
follow-up (mean: 6 ± 4 years), all-cause mortality and 
major cardiac events (cardiac death or non-fatal MI) 
were noted. 
Results: The prevalence of unrecognized MI and silent 
myocardial ischemia was 23% and 28%, respectively. 
Both diabetes and heart failure were important 
predictors of unrecognized MI and silent myocardial 
ischemia. During follow-up, all-cause mortality 
occurred in 45% and major cardiac events in 23% of 
patients. In multivariate analysis, unrecognized MI and 
silent myocardial ischemia were significantly associated 
with increased risk of mortality (HR: 1.86, 95% CI: 
1.53-2.25 and HR: 1.74, 95% CI: 1.46-2.06, 
respectively) and major cardiac events (HR: 2.15, 95% 
CI: 1.59-2.92, HR: 1.86, 95% CI: 1.43-2.41, 
respectively). In patients with unrecognized MI, β-
blockers and statins were significantly associated with 
improved survival. Statins improved survival in patients 
with silent myocardial ischemia. 
Conclusions: In patients undergoing major vascular 
surgery, unrecognized MI and silent myocardial 
ischemia are highly prevalent (23% and 28%) and 
associated with increased long-term mortality and major 
cardiac events. 
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SINCE 1919, cardiovascular disease has been the 
single leading cause of death in the United States and is 
the underlying or contributing cause of death in about 
58% of all cases [1]. Cardiac complications also remain 
the leading cause of morbidity and mortality in patients 
undergoing major vascular surgery. Perioperative 
cardiac complication rate in vascular surgery patients 
have been reported to range from 2.2% to 19.0% [2]. 
The high frequency of perioperative cardiac 
complications reflects the high prevalence of underlying 
coronary artery disease. Indeed, coronary angiographic 
abnormalities have been reported in up to 92% of 
patients [3]. Patients with coronary artery disease, 
however, may not always present with a history of 
myocardial infarction (MI) or with symptoms of angina 
pectoris [4,5]. Unfortunately, the prevalence and 
prognosis of these patients with asymptomatic coronary 
artery disease is not well known. In view of the many 
major vascular surgery procedures performed annually, 
routine screening for asymptomatic coronary artery 
disease may be recommended to identify high-risk 
patients who may benefit from medical treatment. 
Dobutamine stress echocardiography is  a 
widely used non-invasive technique for the detection of 
coronary artery disease. Regional wall motion 
abnormalities during rest signify infarcted myocardial 
tissue and wall motion abnormalities during stress 
testing signify myocardial ischemia. The current study 
reports the prevalence and long-term prognosis of 
unrecognized MI and silent myocardial ischemia in 
1,092 patients who underwent preoperative dobutamine 
stress echocardiography and major vascular surgery. In 
addition, the effect of chronic β-blocker and statin 
therapy on survival in patients with asymptomatic 
coronary artery disease was evaluated. 
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METHODS 
 
Patient population 
A total of 1,092 patients who underwent major non-
emergent non-cardiac vascular surgery at the Erasmus 
Medical Centre in Rotterdam, the Netherlands, were 
enrolled in this study from April 1990 to January 2004. 
In all patients, a preoperative dobutamine stress 
echocardiography was performed to detect the presence 
and extent of coronary artery disease. The study 
protocol was approved by the Hospital’s Ethics 
Committee and all patients gave informed consent. Prior 
to surgery, patients were screened for the following 
cardiac risk factors: age over 70 years, angina pectoris, 
prior MI on the basis of history or a finding of 
pathologic Q waves on electrocardiography, 
compensated congestive heart failure or a history of 
congestive heart failure, drug therapy for diabetes 
mellitus, renal dysfunction and prior stroke or transient 
ischemic attack. The use of cardiac medication was 
recorded and chronic use was ascertained if medication 
was documented at least one month prior to surgery and 
at hospital discharge. 
 
Dobutamine stress echocardiography 
Patients underwent a resting two-dimensional precordial 
echocardiographic examination and standard apical and 
parasternal views were recorded on videotaped. 
Dobutamine hydrochloride was administered 
intravenously with an infusion pump with incremental 
doses of 10 μg/kg/min every 3 minutes to a maximum 
of 40 μg/kg/min (stage 4) and continued for 6 minutes. 
The dobutamine infusion was stopped if a target heart 
rate was achieved (85% of a theoretic maximal heart 
rate; men: [220 – age] x 85%; women: [200 – age] x 
85%). If the target heart rate was not achieved and 
patients had no symptoms or signs of ischemia, atropine 
sulphate (starting with 0.25 mg and increased to a 
cumulative maximum of 2.0 mg) was given 
intravenously at the end of stage 4 while the dobutamine 
administration was continued. During the test, a 12-lead 
ECG was recorded at baseline and every minute. Blood 
pressure was measured by sphygmomanometry every 3 
minutes. Metoprolol was administered (1,0 to 5,0 mg 
intravenously) to reverse the side effects of the 
administration of dobutamine or the dobutamine-
atropine combination if the side effects did not revert 
spontaneously and quickly. Atropine was administered 
as an antidote if bradycardia and hypotension occurred. 
The criteria for stopping the test were: (1) severe new 
echocardiographic wall motion abnormalities in 
multiple locations, (2) horizontal or downsloping 
electrocardiographic ST depression of ≥0.2 mV 
measured 80 ms after the J point, or ST-segment 
elevation of ≥0.2 mV in the absence of Q waves, (3) 
symptomatic decline in systolic blood pressure of more 
than 40 mmHg from the resting value, or a systolic 
blood pressure of less than 100 mmHg, (4) hypertension 
(blood pressure >240/140 mmHg), (5) the occurrence of 
cardiac arrhythmias, (6) severe angina pectoris, and (7) 
intolerable adverse side effects. considered to be the 
result of dobutamine or atropine.  
 
Assessment of echocardiographic images 
Off-line assessment of echocardiographic images was 
performed by two experienced investigators without 
knowledge of the patient’s clinical data but with 
knowledge of the doses of dobutamine and atropine 
used. From 1990 to 1993, the left ventricle was divided 
into 14 segments and wall motion was scored on a 4-
point ordinal scale [6]. After 1993 a 16-segment 5-point 
score was used [7]. MI was considered in the presence 
of rest wall abnormalities. Myocardial ischemia was 
considered if new wall motion abnormalities occurred 
(i.e., if wall motion in any segment worsened by ≥1 
grade(s) during the test, with the exception of akinesis 
becoming dyskinesis). For each patient, a wall motion 
score index (total score divided by the number of 
assessable segments) was calculated at rest and during 
peak stress. The extent of ischemia was defined as the 
number of segments exhibiting deteriorating wall 
motion during stress. When there was disagreement 
between the two assessors, a third investigator viewed 
the images without knowledge of the previous 
assessments and a majority decision was reached. 
Unrecognized MI was defined as rest wall motion 
abnormalities in the absence of a history of MI. Silent 
myocardial ischemia was defined as stress-induced wall 
motion abnormalities in the absence of a history of 
angina pectoris or complaints during stress test.  
 
Follow-up 
Study endpoints were death and cardiac events 
(composite of cardiac death and non-fatal MI) during 
long-term follow-up after successful vascular surgery. 
Information on mortality and cause was obtained by 
contacting the referring physician or by approaching the 
municipal civil registry to determine survival status. In 
patients who died, death certificates and autopsy reports 
were reviewed and general practitioners were 
approached to ascertain the cause of death. Cardiac 
death was defined as death caused by acute MI, cardiac 
arrhythmias, congestive heart failure, or sudden death. 
Non-fatal MI was diagnosed when at least the following 
were present: elevated cardiac enzyme levels, 
development of new Q waves (>1 mm or > 30 ms), and 
typical symptoms of angina pectoris. No patients were 
lost to follow-up. 
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Data analysis 
Continuous data were expressed as mean (± SD) and 
compared using the Student t test. Categorical data were 
compared using the Chi square test. A final set of 
independent and significant predictors of asymptomatic 
coronary artery disease was obtained by multivariate 
logistic regression analysis with stepwise deletion of the 
least significant variable. Only variables with a p-value 
≤0.10 were retained in the model. The Kaplan-Meier 
method with the log-rank test was used to assess 
differences in survival between patient groups. Cox 
proportional hazard regression analysis was used to 
evaluate the long-term prognostic value of 
asymptomatic coronary artery disease. In multivariate 
analysis, adjustments were made for age, gender, 
diabetes, heart failure, cerebrovascular disease, 
hypertension and cardiovascular medication. The risk 
associated with a given variable was expressed by a 
hazard ratio (HR) with corresponding 95% confidence 
interval (CI). For all tests, a p-value <0.05 (two-sided) 
was considered significant. All analysis were performed 
using SPSS statistical software.  
 
RESULTS 
 
Baseline characteristics of the study population are 
presented in Table 1. A total of 371 patients (34%) 
presented with a history of MI, 178 patients (16%) had 
angina pectoris and 446 patients (41%) presented with 
symptomatic coronary artery disease. During stress 
echocardiography, the maximum dobutamine dose was 
36 μg/kg/min and atropine was administered in 30%. 
The test was terminated for the following reasons: 
achievement of the target heart rate in 89%, maximal 
dobutamine/atropine dose in 3%, ST-segment changes 
in 3%, abnormal blood pressure in 1%, arrhythmias in 
1%, severe angina in 1% and for other symptoms in 2%. 
There were no fatal complications. Rest wall motion 
abnormalities were observed in 533 patients (49%) and 
new wall motion abnormalities in 399 (37%).  
 
Prevalence and predictors of asymptomatic coronary 
artery disease 
Unrecognized MI and silent myocardial ischemia was 
detected in 255 (23%), and 309 (28%) patients, 
respectively. The incidence of unrecognized MI and 
silent myocardial ischemia was significantly higher in 
patients with diabetes (34% and 41%, respectively) 
(Figure 1). The rest wall motion score index in patients 
with unrecognized MI was comparable to the rest wall 
motion score index in patients with a recognized MI 
(1.52 vs. 1.48, respectively, p=0.4). The wall motion 
score index at peak stress between patients with silent 
and symptomatic myocardial ischemia was comparable  
 
 
Table 1. Baseline characteristics of patients undergoing major 
vascular surgery. 
 n=1,092 
Age (years) 64 ± 15 
Gender (male) 848 (78%) 
Length (cm) 171 ± 9 
Body mass index (kg/m2) 25 ± 4 
History of angina pectoris 178 (16%) 
History of myocardial infarction  371 (34%) 
Coronary artery disease 446 (41%) 
History of congestive heart failure  65 (6%) 
Hypertension 491 (45%) 
Smoking  331 (30%) 
Hypercholesterolemia  205 (19%) 
Diabetes Mellitus 124 (11%) 
Chronic obstructive pulmonary disease 202 (18%) 
Renal insufficiency 73 (7%) 
Angiotensin converting enzyme inhibitor   296 (27%) 
Aspirin 270 (25%) 
β-blockers 289 (35%) 
Calcium antagonist  296 (36%) 
Coumarin 212 (19%) 
Digitalis 41 (4%) 
Diuretic 169 (15%) 
Nitrates 241 (22%) 
Statins 286 (26%) 
Values are expressed as mean ± SD or number and percentage.  
 
 
(1.52 vs. 1.61, respectively, p=0.1). The extent of 
ischemia between patients with silent and symptomatic 
myocardial ischemia was also comparable (4.9 vs. 4.8 
segments, respectively, p=0.7). As demonstrated in 
Table 2, a history of heart failure and diabetes were 
strong predictors of unrecognized MI and silent 
myocardial ischemia. 
 
Prognosis of asymptomatic coronary artery disease 
During a mean follow-up of 6 ± 4 years, all-cause 
mortality and cardiac events occurred in 491 patients 
(45%) and 253 patients (23%), respectively. Kaplan-
Meier analysis showed that patients with unrecognized 
MI (p<0.001) and silent myocardial ischemia  (p<0.001) 
had a worse survival compared to patients with no 
symptoms or signs of coronary artery disease. In 
multivariate analysis, unrecognized MI and silent 
myocardial ischemia  remained significantly associated 
with increased all-cause mortality and cardiac events 
(Table 3). 
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Table 2. Independent predictors of unrecognized myocardial infarction (a) and silent myocardial ischemia (b) in patients undergoing major 
vascular surgery.  
 
a. Unrecognized myocardial infarction (n=255) 
 Odds ratio 95% confidence interval p-value 
History of heart failure 7.88 2.16-28.74 0.002 
Diabetes mellitus 2.28 1.34-3.88 0.002 
C-index   <0.001 
 
b. Silent myocardial ischemia (n=397) 
 Odds ratio 95% confidence interval p-value 
Renal failure 1.88 1.09-3.23 0.02 
History of heart failure 4.40 2.18-8.87 <0.001 
Diabetes mellitus 1.83 1.20-2.79 0.005 
C-index   <0.001 
 
 
 
 
 
 
 
Figure 1. The prevalence of unrecognized myocardial infarction and 
silent myocardial ischemia in patients with and without diabetes. 
 
 
Prognostic value of stress echocardiography in 
symptomatic coronary artery disease 
Multivariate analysis revealed that rest wall motion 
abnormalities were associated with increased all-cause 
mortality (HR: 1.52, 95% CI: 1.16-1.99) and cardiac 
events (HR: 1.56, 95% CI: 1.09-2.23) in patients with a 
history of MI. Stress-induced wall motion abnormalities 
were associated with increased all-cause mortality (HR: 
1.83, 95% CI: 1.35-2.49) and cardiac events (HR: 1.90, 
95% CI: 1.27-2.83) in patients with a history of angina 
pectoris. Either rest or new wall motion abnormalities 
were associated with increased all-cause mortality (HR: 
1.43, 95% CI: 1.16-1.76) and cardiac events (HR: 1.44, 
95% CI: 1.08-1.88) in patients with a history of MI or 
angina pectoris. 
 
Chronic β-blocker and statin therapy 
Multivariate analysis showed that β-blockers were 
significantly associated with a lower mortality rate in 
subgroups of patients with unrecognized MI, compared 
to patients with no β-blockers (Table 4). Statins were 
associated with a lower mortality rate in subgroups of 
patients with unrecognized MI and silent myocardial 
ischemia, compared to patients with no statins (Table 4). 
 
DISCUSSION 
 
Prevalence 
We found that vascular surgery patients with 
asymptomatic coronary artery disease are an 
underestimated risk group. Unrecognized MI and silent 
myocardial ischemia was detected in 23% and 28% of 
patients, respectively. The prevalence of unrecognized 
MI and silent myocardial ischemia was considerably 
higher in patients with diabetes (34% and 41%, 
respectively). This suggests a later clinical 
manifestation of coronary artery disease in patients with 
diabetes, compared to patients with no diabetes. 
Interestingly, abnormalities during cardiac testing were  
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Table 3. The prognostic value of unrecognized myocardial infarction 
and silent myocardial ischemia in patients undergoing major vascular 
surgery. 
 Long-term 
mortality (n=491) 
Long-term cardiac 
events 
(n=253) 
No myocardial infarction 
(reference)  
1.0 1.0 
Unrecognized myocardial 
infarction  
1.86 (1.53-2.25) 2.15 (1.59-2.92) 
Recognized myocardial 
infarction  
1.99 (1.70-2.33) 3.08 (2.42-3.92) 
   
No myocardial ischemia 
(reference)  
1.0 1.0 
Silent myocardial 
ischemia  
1.74 (1.46-2.06) 1.86 (1.43-2.41) 
Symptomatic myocardial 
ischemia  
1.42 (1.17-1.75) 1.80 (1.35-2.40) 
   
Values are expressed as hazard ratio with 95% confidence interval. All 
associations were entered in multivariate analysis with adjustment for 
baseline clinical risk factors and chronic medication use. 
 
comparable between patients with and without 
symptomatic disease. Thus, the absence of symptoms 
does not imply less coronary artery disease severity. A 
high prevalence of asymptomatic coronary artery 
disease is not uncommon in the general population. 
Among participants in the Framingham Study with MIs, 
around 25% presented with electrocardiographic 
abnormalities suggestive of MI without recollection of 
any relevant discomfort or symptoms compatible with 
infarction [8]. Among asymptomatic type 2 diabetic 
patients, 22% presented with silent myocardial ischemia 
as detected by cardiac stress testing [9]. 
 
 
 
Prognosis 
Unrecognized MI and silent myocardial ischemia have 
now been recognized as clinical syndromes within the 
spectrum of coronary artery disease. Our results showed 
that the prognosis of asymptomatic coronary artery 
disease was as poor as the prognosis of patients with 
symptomatic coronary artery disease. The ultimate goal 
of surgery in patients with vascular disease is to 
improve symptoms and prognosis. Many studies have 
focused on the reduction of mortality and morbidity 
during hospital stay and their findings have resulted in 
helpful recommendations on perioperative care [10]. 
Unfortunately, guidelines on clinical management after 
successful hospital discharge are limited, although many 
patients remain at increased risk of adverse late events. 
Screening for asymptomatic coronary artery disease is 
still controversial.  Stress testing may influence patient 
management and long-term outcome. However, when 
optimal medical therapy is provided routine non-
invasive testing may not influence patient management 
[10]. The COURAGE trial, for example, demonstrated 
that in patients with stable coronary artery disease, 
percutaneous coronary intervention did not reduce the 
risk of death, myocardial infarction, or other major 
cardiovascular events when added to optimal medical 
therapy [11]. 
 
Stress echocardiography in symptomatic coronary 
artery disease 
Stress echocardiography has been demonstrated to be a 
useful method for prognostic risk assessment in patients 
undergoing major vascular surgery. Patients with 
symptomatic coronary artery disease have a high pre-
test probability of coronary artery disease. According to 
the Bayes theorem, a normal stress test result in these 
patients only modestly reduces the  post-test probability 
of coronary artery disease [12]. In this study, 
dobutamine stress echocardiography added independent 
prognostic information in patients with a history of 
angina or MI and with a high pre-test probability of 
coronary artery disease. Symptomatic patients with 
stress induced myocardial ischemia had a higher risk of 
death and hard cardiac events, whereas in patients with 
a normal dobutamine stress echocardiography the 
incidence of events was substantially lower. These 
findings indicate that symptomatic patients with 
negative dobutamine stress echocardiography findings 
can be exempted from further (invasive) evaluation 
unless a change in clinical status occurs. Those with 
positive findings may benefit from further cardiac 
evaluation with appropriate management. 
 
Medical treatment 
Since patients with asymptomatic coronary artery 
disease are at similar mortality risk as symptomatic 
patients, cardioprotective strategies should be 
considered in all asymptomatic patients who 
successfully underwent major vascular surgery. 
Previous studies have demonstrated that statins reduce 
cardiovascular events during perioperative and long-
term follow-up [13,14]. β-Blockers have been 
demonstrated to effectively protect against the life-
threatening complications of coronary artery disease in 
post-infarct patients [15] and in those with heart failure 
[16]. In the current study, a protective effect of statins 
was observed in both symptomatic and asymptomatic 
disease patients. Beta-blockers were significantly 
protective in patients with unrecognized or recognized 
MI, and non-significantly in patients with silent 
myocardial ischemia. It should be noted that no decisive 
evidence has been published in literature which 
demonstrates that β-blockers improve survival in 
patients with angina, except for its effect on 
symptomatic relief and blood-pressure reduction [17]. 
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Table 4. Association between beta-blockers and long-term mortality among patients with unrecognized myocardial infarction and silent 
myocardial ischemia.  
 Chronic β-
blocker 
therapy 
β-blockers and 
 long-term mortality 
(n=491) 
Chronic statin 
therapy 
Statins and  
long-term mortality  
(n=491) 
No myocardial infarction (reference)  22% 0.80 (0.45-1.41) 23% 0.43 (0.26-0.71) 
Unrecognized myocardial infarction  43% 0.46 (0.27-0.81) 28% 0.44 (0.23-0.85) 
Recognized myocardial infarction  47% 0.59 (0.39-0.91) 28% 0.26 (0.16-0.45) 
     
No myocardial ischemia (reference)  22% 0.70 (0.47-1.06) 24% 0.42 (0.27-0.64) 
Silent myocardial ischemia  52% 0.59 (0.33-1.05) 29% 0.32 (0.19-0.54) 
Symptomatic myocardial ischemia  43% 0.52 (0.24-1.09) 28% 0.30 (0.11-0.86) 
Values are expressed as hazard ratio with 95% confidence interval. All associations were entered in multivariate analysis with adjustment for 
baseline clinical risk factors 
 
.
Study limitations 
No angiography was performed in this study. Therefore, 
the prevalence and prognosis of asymptomatic 
angiographic coronary artery stenosis cannot be 
described. Secondly, although physicians can be 
confident about the interpretation of the 
echocardiographic images, misinterpretation of wall 
motion abnormalities can still occur. However, excellent 
technical performance and diagnostic accuracy of 
dobutamine stress echocardiography for coronary artery 
disease have been reported previously [18]. Lastly, the 
data apply to patients referred to a tertiary referral 
center in Western Europe. These patients may have a 
different cardiovascular risk profile compared to 
patients referred to primary or secondary referral 
centers.  
 
Summary 
The prevalence of unrecognized MI and silent 
myocardial ischemia in patients undergoing major 
vascular surgery was 23% and 28%, respectively. Both 
diabetes and heart failure were important predictors of 
asymptomatic coronary artery disease. Abnormalities 
during cardiac testing were comparable between 
symptomatic and asymptomatic patients. The prognosis 
of patients with asymptomatic disease was similar to the 
prognosis of patients with symptomatic disease and was 
distinctively worse than that of patients without 
coronary artery disease. Not only symptomatic patients, 
but also patients with asymptomatic coronary artery 
disease may benefit from cardiovascular medication. 
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Aims: Cardiac morbidity and mortality is high in 
patients undergoing high-risk surgery. This study 
evaluates whether impaired glucose and elevated 
glycosylated hemoglobin (HbA1c) levels are associated 
with increased cardiac ischemic events in vascular 
surgery patients. 
Methods: Baseline glucose and HbA1c were measured 
in 401 vascular surgery patients. Glucose <5.6 mmol/L 
was normal. Fasting glucose between 5.6-7.0 mmol/L or 
random glucose between 5.6-11.1 mmol/L was 
impaired. Fasting glucose ≥7.0 or random glucose ≥11.1 
mmol/L was diabetes. Perioperative ischemia was 
identified by 72-hour Holter monitoring. Troponin T 
was measured on day 1, 3, 7 and before discharge. 
Cardiac death or Q-wave myocardial infarction were 
noted at 30-day and follow-up (mean 2.5 years).  
Results: Mean glucose and HbA1c was 6.3 ± 2.3 
mmol/L and 6.2 ± 1.3%, respectively. Ischemia, 
troponin release, 30-day and long-term cardiac events 
occurred in 27%, 22%, 6% and 17%, respectively. 
Multivariate analysis revealed that patients with 
respectively impaired glucose and diabetes were at 2.2- 
and 2.6-fold increased risk for ischemia, 3.8- and 3.9-
fold for troponin release, 4.3- and 4.8-fold for 30-day 
cardiac events and 1.9- and 3.1-fold for long-term 
cardiac events. Patients with HbA1c values >7% (n=63, 
16%) were at 2.8-fold, 2.1-fold, 5.3-fold and 5.6-fold 
increased risk for ischemia, troponin release, 30-day and 
long-term cardiac events, respectively.  
Conclusions: Impaired glucose and elevated HbA1c 
levels are risk factors for cardiac ischemic events in 
vascular surgery patients. This finding suggests the need 
for aggressive glucose management in this setting and 
supports a vigorous screening strategy for early 
recognition of diabetes. 
_________________________________________________________________________________ 
 
 
ANNUALLY, AROUND 0.2% of the Dutch 
population is scheduled for major non-cardiac vascular 
surgery [1]. Among diabetic patients undergoing major 
vascular surgery, cardiac complications are the leading 
cause of morbidity and mortality. The incidence of 
perioperative cardiac events in these patients ranges 
from 6% to 21% [2-5]. Cardiac complications in 
diabetes are likely the result of impaired glucose 
metabolism leading to endothelial dysfunction, 
myocardial ischemia and myocardial tissue damage [6]. 
Pre-diabetes represents  a metabolic stage intermediate 
between normal glucose homeostasis and diabetes [7]. 
These patients exhibit a long asymptomatic period of 
increased glucose dysregulation and are at risk of 
developing type 2 diabetes [7]. Although diabetes has 
been recognized as an independent predictor of 
postoperative outcome, the prognosis of non-diabetic 
patients with impaired glucose levels is not well known. 
In addition, poor glycemic control in diabetic and non-
diabetic patients may be associated with adverse cardiac 
outcome. 
This study was conducted to elucidate the 
association between impaired glucose and elevated 
glycosylated hemoglobin (HbA1c) levels with 
perioperative and long-term cardiac ischemic events in 
patients undergoing major vascular surgery. 
 
PATIENTS AND METHODS 
 
The study population consisted of 401 patients 
undergoing elective abdominal aortic aneurysm repair, 
peripheral artery bypass surgery or carotid artery 
surgery at the Erasmus Medical Center in Rotterdam, 
the Netherlands, during the period 2002 to 2006. The 
study was approved by the hospital’s ethical committee 
and performed with informed consent of all patients. 
Patients with a cardiac pacemaker, left ventricular 
hypertrophy, left or right bundle branch block and atrial 
fibrillation were excluded. Patients who participated in 
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clinical intervention trials at or outside the Erasmus 
Medical Center were also excluded. Patients were 
enrolled up to 3 months prior to surgery at the outpatient 
clinic. In all patients, β-blockers were considered prior 
to surgery to obtain perioperative heart rates of 60-65 
beats per minute. Baseline characteristics were obtained 
and included demographic, historical, laboratory and 
electrocardiographic information. Body mass index was 
calculated using the formula weight/height2. Renal 
dysfunction was defined as serum creatinine level ≥177 
μmol/L (2.0 mg/dL) or if renal dialysis was required. 
 
Baseline glucose and HbA1c measurements. Baseline 
glucose and HbA1c measurements were obtained during 
preoperative evaluation at a central laboratory. Blood 
samples were obtained using venipuncture with minimal 
stasis. Glucose was enzymatically determined using the 
Hexokinase method (Boehringer Mannheim). HbA1c 
was determined by using an enzyme immunoassay 
based on microtiter plate technology. Information was 
obtained on history of diabetes and use of blood glucose 
lowering treatment. Patients were classified into three 
categories: glucose levels <5.6 mmol/L were normal. 
Fasting glucose of 5.6-7.0 mmol/L or random glucose of 
5.6-11.1 mmol/L was impaired. Fasting glucose ≥ 7.0 or 
random glucose ≥ 11.1 mmol/L, or the use of blood 
glucose–lowering medication was diabetes [7].  
 
 
Figure 1. Histogram demonstrating baseline glucose levels in the 
study population. 
 
Perioperative myocardial ischemia.  
Patients were continuously monitored with a 10-
electrode, 12-lead digital ECG recorder (DR180+ 
Digital Recorder, NorthEast Monitoring Inc. 
Massachusetts), starting 1 day before surgery up to 2 
days after. Recordings were performed in the 
continuous 12-lead mode with a recording length of 10 
seconds every minute. The frequency response was 0.05 
– 150Hz. Electrocardiographic data were initially 
processed by a technician and analyzed by 2 
experienced cardiologists who were blinded to the 
patient’s clinical data. After excluding all abnormal 
QRS complexes, the ambulatory electrocardiography 
recordings were analyzed for ST-segment deviations. A 
continuous ST segment trend was generated and all 
potential ischemic episodes were identified. Episodes of 
ischemia were defined as reversible ST-segment 
changes, lasting at least one minute and shifting from 
baseline to more than 0.1 mV (1 mm). The baseline ST 
segment level was defined as the average ST segment 
during a stable period (duration of 20 minutes) 
preceding each ischemic episode. ST segment change 
was measured 60 ms after the J point. If the J point fell 
within the T-wave, the ST segment change was 
measured 40 ms after that point.  
 
Perioperative troponin T release.  
Troponin T levels were measured on postoperative day 
1, 3, 7, before discharge and whenever clinically 
indicated by ECG changes, consistent with myocardial 
ischemia or infarction. Troponin T level was measured 
by an electrochemiluminescence immunoassay on the 
Elecsys 2010 (Roche Diagnostics, Mannheim, 
Germany). The lower limit of 0.03 ng/ml was used to 
define positive troponin T levels since lower levels do 
not meet the imprecision criteria of <10%. 
 
Clinical cardiac outcome.  
Study endpoints were major cardiac events (cardiac 
death and non-fatal Q-wave myocardial infarction) 
during the perioperative period (30-day period after 
surgery) and during follow-up (mean: 2.5 years). During 
follow-up, outpatient visits were scheduled every 3 
months after discharge. Cardiac death was defined as 
death caused by acute myocardial infarction, cardiac 
arrhythmias, congestive heart failure, or sudden death. 
Non-fatal myocardial infarction was diagnosed when at 
least the following were present: elevated cardiac 
enzyme levels, development of new Q waves (>1 mm or 
> 30 ms), and typical symptoms of angina pectoris. No 
patients were lost to follow-up. 
 
Data analysis.  
Characteristics of patients with normal glucose, 
impaired glucose and diabetes were calculated and 
tested for differences between groups using one-way 
analysis of variance for continuous characteristics and 
chi-square for dichotomous characteristics. Binary 
logistic regression analysis was used to evaluate the 
association of glucose and HbA1c status with 
perioperative myocardial ischemia, troponin T release 
and 30-day cardiac events. Cox proportional hazard 
analysis was used to assess the association of glucose  
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Table 1. Characteristics of the study population (n=401) by glucose status. 
No diabetes 
(n=332) 
Characteristic 
Normal glucose  
(n =220) 
Impaired glucose 
(n =112) 
Diabetes 
(n = 69) 
Age, years 66 ± 11 68 ± 9 66 ± 11 
Gender, male 77.3% 80.4% 72.5% 
Angina pectoris 14.5% 24.1%* 20.3% 
Myocardial infarction 28.2% 47.3%* 44.9%† 
Previous percutaneous coronary angioplasty 5.9% 10.7% 10.1% 
Previous coronary artery bypass grafting 9.5% 26.8%* 17.4% 
History of congestive heart failure 0.9% 9.3%* 4.3% 
Rest wall motion abnormalities 29.5% 33.0% 27.5% 
Stress-induced wall motion abnormalities 25.0% 29.5% 27.5% 
Hypertension 40.0% 36.6% 49.3% 
Stroke 13.1% 16.1% 13.0% 
Past smoking 60.9% 58.0% 43.5%† 
Current smoking 31.4% 28.6% 20.3% 
Renal dysfunction 1.8% 8.9% 4.3% 
Body mass index (kg/m2) 24.9 ± 3.5 25.3 ± 4.0 26.8 ± 3.6† 
Ankle-brachial index 0.88 ± 0.26 0.80 ± 0.32 0.80 ± 0.28 
Forced expiratory volume in 1 second, liter 2.5 ± 0.8 2.4 ± 0.8 2.4 ± 0.8 
Urea level, mmol/L 6.6 ± 3.7 8.3 ± 3.9* 7.5 ± 3.6 
Creatinine level, μmol/L 97 ± 83 101 ± 68 100 ± 69 
Low density lipoprotein cholesterol, mmol/L 3.1 ±  1.1 3.1 ±  1.1  2.8 ±  1.0 
High density lipoprotein cholesterol, mmol/L 1.3 ±  0.6 1.3 ±  0.5 1.2 ±  0.4 
Total cholesterol, mmol/L 4.9 ±  1.2 5.1 ± 1.3 4.8 ±  1.3 
Hemoglobin, mmol/L 8.7 ± 0.9 8.4 ± 1.2*  8.4 ± 1.3† 
Hematocrit, L/L 0.42 ± 0.04 0.39 ± 0.05* 0.40 ± 0.06 
High sensitivity C-reactive protein, mg/L 9.9 ± 13.8 46 ± 77* 24 ± 40‡ 
Uric acid, mmol/L 0.34 ± 0.09 0.35 ± 0.1 0.38 ± 0.12 
N-terminal proBNP level, pmol/L, median 101 124 111 
Glycosylated hemoglobin, % 5.6 ± 0.4 6.0 ± 0.8 7.9 ± 1.8 †‡ 
Values are presented as percentage or as mean ± standard deviation, unless otherwise notified. 
* P<0.05 impaired glucose versus normal glucose 
† P<0.05 diabetics versus normal glucose 
‡ P<0.05 diabetics versus impaired glucose 
 
and HbA1c status with late cardiac events. In 
multivariate analysis, adjustments were made for age, 
gender, angina pectoris, myocardial infarction, 
congestive heart failure, hypertension, stroke, smoking, 
renal dysfunction and laboratory measures. Only 
laboratory measures of which the values were 
significantly different among the three groups were 
included (Table 1). Patients with impaired glucose 
levels and diabetes were compared to patients with 
normal glucose levels. In addition, absolute glucose and 
HbA1c values were assessed as continuous variables. 
Odds and hazard ratios are given with 95% confidence 
intervals. For all tests, a p value <0.05 (two-sided) was 
considered significant. All analysis was performed 
using SPSS 12.0 statistical software (SPSS Inc., 
Chicago, Illinois).  
 
RESULTS 
 
Mean glucose level in the study population was 6.3 ± 
2.3 mmol/L (Figure 1). Mean HbA1c level was 6.2 ± 
1.3%. The characteristics of the patients with normal 
glucose levels (n=220, 55%), impaired glucose (n=112, 
28%) and diabetes (n=69, 17%) are presented in Table 
1. Patients with impaired glucose levels had a higher 
prevalence of angina pectoris, myocardial infarction, 
coronary bypass surgery and congestive heart failure, 
compared to patients with normal glucose levels. 
Laboratory testing revealed that urea and high-
sensitivity C-reactive protein were significantly higher 
in patients with impaired glucose levels, compared to 
patients with normal glucose levels (Table 1). 
Hemoglobin and hematocrit were significantly lower in 
patients with impaired glucose levels (Table 1).  
 
Events  
Perioperative myocardial ischemia during 72-hour 12-
lead electrocardiographic monitoring occurred in 108 
patients (27%). Perioperative troponin T release 
occurred in 90 patients (22%) and 30-day major cardiac 
events in 23 patients (6%). A total of 131 patients (33%) 
experienced either an episode of myocardial ischemia, 
troponin T release or a major cardiac event in the 
perioperative period. During follow-up, 85 patients 
  108
(21%) died. Cardiac death or non-fatal myocardial 
infarction during follow-up occurred in 69 patients 
(17%). 
 
 
Figure 2. The incidence of myocardial ischemia (p<0.001), troponin T 
(p<0.001) release and 30-day cardiac events (p<0.001) in patients with 
different baseline glucose and glycosylated hemoglobin status. 
 
 
 
Glucose and  HbA1c status in relation to events  
As demonstrated in Figure 2, the lowest incidence of 
myocardial ischemia, troponin T release and 30-day 
cardiac events occurred in patients with normal glucose 
levels. Patients with normal baseline glucose levels had 
the best survival, in comparison to patients with 
impaired glucose or diabetes (p<0.001) (Figure 3). 
Multivariate analysis revealed that patients with 
respectively impaired glucose and diabetes, were at 2.2 
and 2.6-fold increased risk for myocardial ischemia, 
3.8- and 3.9-fold increased risk for troponin T release, 
4.3- and 4.8-fold increased risk for 30-day cardiac 
events, 2.0- and 2.7-fold increased risk for long-term 
mortality and 1.9- and 3.1-fold increased risk for long-
term cardiac events (Table 2). Patients with HbA1c 
values above 7% (n=63, 16%) were at 2.8-fold, 2.1-fold, 
5.3-fold, 3.6-fold and 5.6-fold increased risk for 
myocardial ischemia, troponin T release, 30-day cardiac 
events, long-term mortality and long-term cardiac 
events, respectively (Table 2). When using absolute 
values, higher glucose and HbA1c values remained 
significantly associated with increased perioperative and 
long-term events (Table 2). 
 
 
Figure 3. Kaplan-Meier curves demonstrating survival in patients with 
different baseline glucose and glycosylated hemoglobin status 
(p<0.001). 
 
DISCUSSION 
 
The results of this study indicate that impaired glucose 
is highly prevalent in vascular surgery patients (28%). 
Moreover, poor glycosylated hemoglobin status (HbA1c 
>7%) was assessed in 16% of patients. Importantly, 
both impaired glucose and elevated HbA1c levels were 
associated with an increased incidence of perioperative 
myocardial ischemia, perioperative troponin T release, 
and 30-day and long-term cardiac events, independent 
of age, gender and clinical risk factors. 
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Table 2. Multivariate association between glucose and glycosylated hemoglobin status at baseline with perioperative and long-term cardiac 
events. 
Characteristic Myocardial 
ischemia 
 
 
(n=108) 
OR (95%CI) 
Troponin T 
release 
 
 
(n=90) 
OR (95%CI) 
30-day 
cardiac events 
 
 
(n=23) 
OR (95%CI) 
Composite 
of 
perioperative 
events 
(n=131) 
OR (95%CI) 
Mortality 
during follow-
up 
 
(n=85) 
HR (95% CI) 
Cardiac 
events during 
follow-up 
(n=69) 
HR (95% CI) 
Normal glucose levels (reference) 
(n=220) 
1.0 1.0 1.0 1.0 1.0 1.0 
- Impaired glucose (n=112) 2.2 (1.3-3.9) 3.8 (2.1-7.0) 4.3 (1.4-13.5) 2.4 (1.4-4.1) 2.0 (1.1-3.8) 1.9 (1.0-3.7) 
- Diabetes (n=69) 2.6 (1.4-4.9) 3.9 (2.0-7.7) 4.8 (1.4-16.6) 3.9 (2.1-7.3) 2.7 (1.2-5.6) 3.1 (1.5-6.4) 
Absolute glucose levels, per mmol/L ↑ 1.3 (1.1-1.4) 1.4 (1.2-1.5) 1.2 (1.0-1.3) 1.4 (1.2-1.5) 1.2 (1.1-1.3) 1.1 (1.0-1.2) 
HbA1c >7% (n=63) 2.8 (1.3-6.0) 2.1 (1.1-6.5) 5.3 (1.7-16.6) 3.0 (1.4-6.5) 3.6 (1.2-11.1) 5.6 (2.1-14.6) 
Absolute HbA1c levels, per % ↑ 1.5 (1.2-2.0) 1.3 (1.0-1.7) 1.5 (1.1-3.8) 1.5 (1.1-1.9) 1.5 (1.0-2.1) 1.4 (1.1-1.8) 
Adjusted for age, gender, angina pectoris, myocardial infarction, congestive heart failure, hypertension, stroke, smoking, renal dysfunction and 
the laboratory variables which showed significant differences among the three groups as in Table 1. HbA1c = glycosylated hemoglobin 
 
 
Insulin resistance with hyperglycemia is believed to be 
the major underlying pathologic mechanism for the 
associated susceptibility to premature cardiovascular 
disease in pre-diabetic patients. Adipose tissue plays a 
crucial role in the pathogenesis of insulin resistance and 
is the main causative mechanism of type 2 diabetes. 
Metabolic disturbances associated with insulin 
resistance beyond hyperglycemia include dyslipidemia, 
hypercoagulability and inflammation. In the current 
study, the highest level of the inflammation marker 
high-sensitivity C-reactive protein was found in patients 
with impaired glucose levels. Inflammation probably 
links the metabolic and vascular pathologies [8]. 
Hyperglycemia also exerts direct effects on the 
progression of atherosclerosis by the formation of 
reactive advanced glycation end products that mediate 
vascular damage [8]. In addition, hyperglycaemia can 
be deleterious for the heart due to hypovolaemia, 
modulation of nitric oxide metabolism and oxidative 
stress and down regulation of ischemic preconditioning 
[9]. 
 
Cardiac event rate in vascular surgery patients is high 
[10]. The high incidence of cardiac events reflects the 
high prevalence of underlying coronary artery disease. 
Indeed, coronary angiographic abnormalities have been 
reported in up to 92% of patients [11]. In our 
contemporary study cohort, a relatively high incidence 
of perioperative cardiac complications was observed 
(6%). It should be noted that this study was conduced at 
a university hospital which acts as a tertiary referral 
center for approximately 30 affiliated hospitals. The 
high incidence may be related to the admission and 
treatment of high-risk patients, who would have been 
denied in other hospitals. The rate of myocardial 
ischemia as assessed by continuous 12-lead 
electrocardiographic monitoring was more than three 
times higher (27%) than the incidence of perioperative 
cardiac events. The recognition of silent perioperative 
ischemic episodes is important, since these directly 
relate to myocardial damage, infarction and cardiac 
death [6]. The incidence of myocardial ischemia was 
significantly higher in patients with impaired glucose 
levels (35%) and patients with diabetes (41%), 
compared to patients with normal glucose levels (19%).  
 
This study demonstrated the value of glucose and HbA1c 
levels in defining perioperative and long-term risk in 
vascular surgery patients. However, the management of 
these patients remains a challenge. Patients with 
impaired glucose levels do not meet the criteria for 
diabetes, but have impaired glucose metabolism which 
places them at risk for developing diabetes or 
cardiovascular disease. We observed that survival in 
patients with impaired glucose metabolism was 
comparable to survival in patients with diabetes. 
Although loss of body weight, exercise, and certain 
pharmacological agents can prevent the development of 
diabetes in patients with impaired glucose levels, the 
impact on cardiovascular risk has not yet been examined 
to date. Randomized trials have demonstrated the 
benefit of β-blockers and statins in the reduction of 
perioperative cardiac events in vascular surgery patients 
[12,13]. In diabetic patients, however, randomization to 
either metoprolol or placebo failed to demonstrate a 
differential effect in outcome [5]. The relatively short-
term use of metoprolol in this study (from the day 
before surgery to a maximum of eight days after) may 
explain this finding, since long-term β-blocker treatment 
with tight heart rate are important factors in ischemic 
event reduction. In addition to cardiovascular 
medication,  aggressive glucose management in these 
patients should improve outcome. Intensive insulin 
treatment to achieve normoglycemic levels (<6.1 
mmol/L) reduced mortality in critically-ill patients [14] 
and diabetic patients undergoing cardiac surgery [15]. 
However, randomized trials in major vascular surgery  
  110
patients should definitely determine the role of 
intensified insulin therapy on cardiovascular outcome. 
  
In conclusion, the results of this study show that 
impaired glucose and elevated HbA1c levels are risk 
factors for cardiac ischemic events in vascular surgery 
patients. This finding suggests the need for aggressive 
glucose management in this setting and supports a 
vigorous screening strategy for early recognition of 
diabetes. 
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Association of Plasma N-terminal Pro-B-type 
Natriuretic Peptide with Postoperative Cardiac Events 
in Patients Undergoing Surgery for Abdominal Aortic 
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Postoperative cardiac events are related to myocardial 
ischemia and reduced left ventricular function. The 
utility of N-terminal Pro-B-type natriuretic peptide  for 
preoperative cardiac risk evaluation has not been 
evaluated. Objective of this study was to assess whether 
plasma N-terminal Pro-B-type natriuretic peptide  
predicts postoperative cardiac events in patients 
undergoing major vascular surgery additional to clinical 
and dobutamine stress echocardiography data. We 
prospectively evaluated 170 consecutive patients 
scheduled for major non-cardiac vascular surgery by 
dobutamine stress echocardiography and N-terminal 
Pro-B-type natriuretic peptide measurements. 
Multivariable logistic regression analysis was 
performed to evaluate the predictors of cardiac death 
and non-fatal myocardial infarction during a follow-up 
of 30-days. Receiver Operating Characteristic analysis 
was performed to determine the optimal cut-off value of 
N-terminal Pro-B-type natriuretic peptide  values that 
predicts outcome. Mean age was 59 +/- 13 years and 
71% was male. The median N-terminal Pro-B-type 
natriuretic peptide  level was 110 pg/ml (interquartile 
range: 42-389 pg/ml). Cardiac events occurred in 2/144 
(1.4%) patients with N-terminal Pro-B-type natriuretic 
peptide  <533 pg/ml (i.e. the optimal cut-off value to 
predict cardiac events), and in 11/26 (42%) of patients 
with N-terminal Pro-B-type natriuretic peptide ≥533 
pg/ml (unadjusted odds ratio 52, 95% CI: 11-256, 
p<0.0001). After adjustment for cardiac risk factors and 
dobutamine stress echocardiography results, N-terminal 
Pro-B-type natriuretic peptide  remained significantly 
associated with cardiac events (adjusted odds ratio 
(OR): 17, 95% CI: 3-106, p=0.002). In conclusion, in 
patients scheduled for major vascular surgery, elevated 
plasma N-terminal Pro-B-type natriuretic peptide  levels 
are independently associated with an increased risk of 
postoperative cardiac events. Further studies in a larger 
number of patients are required to confirm these 
findings.  
_____________________________________________________________________________________________ 
 
 
PATIENTS UNDERGOING major vascular surgery 
are at increased risk for postoperative cardiac 
complications, due to coronary heart disease (1,2). To 
identify high-risk patients prior to surgery, cardiac risk 
scores such as the revised cardiac risk index according 
to Lee is commonly used (3). In patients with multiple 
risk factors undergoing high-risk surgery, additional 
non-invasive stress testing is recommended according to 
the guidelines of the American Heart 
Association/American College of Cardiology (4). 
Stress-induced myocardial ischemia and reduced left 
ventricular function are major determinants of cardiac 
events in these patients. The aim of this study was to 
assess the value of NT-proBNP for predicting 
postoperative cardiac events, additional to clinical data 
and dobutamine stress echocardiography (DSE) results. 
 
*Vascular Surgery, Erasmus MC, University Medical Center, 
Rotterdam, the Netherlands.  †Cardiology, Leiden University Medical 
Center, Leiden, the Netherlands.  ‡Internal Medicine, Section of 
Cardiology, University of Nebraska, Omaha, NE. §Clinical Chemistry, 
Erasmus MC, University Medical Center, Rotterdam, the Netherlands.  
װInternal medicine, Erasmus MC, University Medical Center, 
Rotterdam, the Netherlands. ¶Cardiology, Erasmus MC, University 
Medical Center, Rotterdam, the Netherlands.  #Anesthesiology, 
Erasmus MC, University Medical Center, Rotterdam, the Netherlands. 
 
METHODS 
 
Study population 
Patients scheduled for major non-cardiac vascular 
surgery at the Erasmus University Medical Center in 
Rotterdam, the Netherlands were prospectively included 
in the study from October 2003 to December 2004 after 
giving informed consent. The study protocol was 
approved by the hospital’s Medical Ethics Committee. 
Clinical data were collected by structured interview 
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with patients and by reviewing medical records. Based 
on the revised cardiac risk index by Lee et al, a 
preoperative cardiac risk score was calculated by 
assigning one point to each of the following cardiac risk 
factors: high-risk type of surgery, coronary artery 
disease (angina pectoris or previous myocardial 
infarction), a history of congestive heart failure (mean 
time of heart failure prior to surgery: 3.5 +/-2 years), a 
history of cerebrovascular disease, insulin therapy for 
diabetes mellitus and renal dysfunction, defined by a 
preoperative serum creatinine level >2.0 mg/dL (177 
μmol/L) (3). 
 
Dobutamine stress echocardiography 
Patients underwent a resting two-dimensional precordial 
echocardiographic examination and standard apical and 
parasternal views were recorded on videotape and a 12-
lead ECG was recorded. Dobutamine hydrochloride was 
then administered intravenously by infusion pump, 
starting at 10 μg/kg/min for 3 minutes (5 μg/kg/min for 
5 minutes, followed by 10 μg/kg/min for 5 minutes in 
patients with resting wall motion abnormalities), 
increasing by 10 μg/kg/min every 3 minutes to a 
maximum of 40 μg/kg/min. The dobutamine infusion 
was stopped if a target heart rate (85% of a theoretic 
maximal heart rate) was achieved. If the target heart rate 
was not achieved and patients had no symptoms or signs 
of ischemia, atropine sulfate (starting with 0.25 mg, 
increased to a maximum of 2.0 mg) was given 
intravenously while the administration of dobutamine 
was continued. Metoprolol was administered (1.0 to 5.0 
mg intravenously) to reverse the side effects of the 
administration of dobutamine or the dobutamine-
atropine combination if the side effects did not revert 
spontaneously and quickly. Two experienced 
investigators, blinded to the clinical data, performed off-
line assessment of echocardiographic images. The left 
ventricle was divided into 17 segments, and wall motion 
was scored on a 5-point scale (1 = normal, 2 = mild 
hypokinesis, 3 = severe hypokinesis, 4 = akinesis, and 5 
= dyskinesis). Ischemia was defined as new or 
worsening wall-motion abnormalities (compared to 
resting images of the same test) as indicated by an 
increase of regional wall motion score ≥ 1 grade(s) with 
stress. Akinesis becoming dyskinesis was not 
considered an ischemic response.  
 
Measurement of plasma N-terminal pro-B-type 
natriuretic peptide 
The mean time of venous blood sampling prior to 
surgery was 21 +/-11 days and all samples were 
collected before DSE. The samples were centrifuged 
and plasma was frozen at -80°C until assay. NT-
proBNP was measured with an 
electrochemiluminescence immunoassay kit (Elecsys 
2010, Roche GmbH, Mannheim, Germany). The 
method is a ‘sandwich’-type quantitative immunoassay 
based on polyclonal antibodies against epitopes in the 
N-terminal part of proBNP. The lower detection limit 
was 5 pg/ml. Intra-assay coefficients of variance at 271 
pg/ml and 6436 pg/ml were 1.9% and 0.9%, 
respectively. Essays were performed by a laboratory 
technician blinded to the patient’s clinical data (5).   
 
Outcomes 
Patients were monitored for cardiac events for 30 days 
after surgery. Twelve-lead electrocardiography, serum 
creatine kinase (CK) measurements (with the MB 
fraction), and troponin T measurements were performed 
immediately prior to surgery and one, three and seven 
days after surgery and before discharge. Serum CK and 
CK-MB activity were measured and troponin T was 
measured in heparinized plasma using a 
chemiluminescence immunoassay. Cardiac death was 
defined as death caused by acute myocardial infarction, 
cardiac arrhythmias, or congestive heart failure. Non-
fatal myocardial infarction was diagnosed when at least 
two of the following were present: elevated cardiac 
enzyme levels (CK level > 190 U/L and CK-MB >14 
U/L, or CK-MB fraction >10% of total CK, or cardiac 
troponin T >0.1 ng/mL), development of typical 
electrocardiographic changes (new Q waves >1 mm or > 
30 ms), and typical symptoms of angina pectoris. 
 
Statistical analysis 
Continuous data with a normal distribution were 
expressed as mean and compared using the Student t 
test. Continuous data with a significant skewed 
distribution were expressed as median and compared 
using the Mann-Whitney U test. Categorical data are 
presented as percent frequencies and differences 
between proportions were compared using the chi-
square test with Yates’ correction. NT-proBNP levels in 
patients with different DSE results and different cardiac 
risk scores were compared for trend across ordered 
groups using analysis of variance (ANOVA) techniques. 
Receiver operating characteristic (ROC) curve analysis 
was performed to calculate sensitivity, specificity and 
area under the curve values and to select an optimal cut-
off value for predicting postoperative cardiac events. 
Univariable logistic regression analysis was used to 
evaluate the association of baseline characteristics, DSE 
results and NT-proBNP-values with postoperative 
outcome. NT-proBNP level (dichotomized according to 
the optimal cut-off value), new wall motion 
abnormalities (a marker for ischemic heart disease), rest 
wall motion abnormalities (a marker for left ventricular  
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Table 1. Overall characteristics of patients with plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels higher and those with 
equal or lower levels than the median.  
N-terminal pro-B-type natriuretic 
peptide (pg/ml) 
P-value Characteristic 
<533 (n=144) ≥533 (n=26)  
Age (years) (mean +/-SD) 59 +/-13 64 +/-11 0.03 
Men 98 (68%) 22 (85%) 0.1 
Angina pectoris 28 (19%) 17 (65%) <0.001 
Previous myocardial infarction 48 (33%) 21 (81%) <0.001 
Congestive heart failure 25 (17%) 14 (54%) <0.001 
Previous cerebrovascular event 10 (7%) 5 (19%) 0.1 
Previous coronary revascularization  14 (10%) 2 (8%) 1.0 
Hypertension 35 (24%) 11 (42%) 0.1 
Diabetes Mellitus  20 (14%) 11 (42%) 0.001 
Hypercholesterolemia   57 (40%) 13 (50%) 0.4 
Current smoking  25 (17%) 7 (27%) 0.4 
Renal failure  0  6 (23%) <0.001 
Aspirin  46 (32%) 10 (38%) 0.7 
Angiotensin converting enzyme inhibitor 48 (33%) 15 (58%) 0.03 
Beta-blocker  86 (60%) 23 (88%) 0.01 
Calcium channel blocker   19 (13%) 9 (35%) 0.02 
Warfarin  23 (16%) 13 (50%) <0.001 
Digoxin  9 (6%) 6 (23%) 0.02 
Diuretic  33 (23%) 16 (62%) <0.001 
Nitrate  9 (6%) 7 (27%) 0.003 
Statin  71 (49%) 16 (62%) 0.3 
Left ventricular hypertrophy  1 (1%) 0 0.3 
Q waves  32 (22%) 13 (50%) 0.007 
ST-segment changes  4 (3%) 5 (19%) 0.003 
Rest wall motion abnormalities  51 (35%) 22 (85%) <0.001 
New wall motion abnormalities 15 (10%) 13 (50%) <0.001 
Abdominal aortic repair  58 (40%) 9 (35%) 0.7 
Lower extremity revascularization  86 (60%) 17 (65%) 0.7 
 
 
dysfunction), renal failure, and diabetes mellitus, were 
analyzed in a final multivariable logistic model. Odds 
ratios are given with 95% confidence intervals. For all 
tests, a p value <0.05 (two-sided) was considered 
significant. All analyses were performed using SPSS-
11.0 statistical software (SPSS Inc., Chicago, Illinois). 
 
RESULTS 
 
Patient characteristics 
The study population consisted of 170 consecutive 
patients (71% men). Mean age was 59 +/-13 years. 
Abdominal aortic repair was performed in 67 patients 
(39%), lower extremity revascularization in 103 patients 
(61%). Sixteen patients (9%) had a history of previous 
coronary artery revascularization. No patient underwent 
myocardial revascularization prior to surgery as a 
consequence of DSE stress results. The median 
concentration of NT-proBNP was 110 pg/ml 
(interquartile range: 42-389 pg/ml). The baseline 
characteristics of the patients, subdivided according to a 
NT-proBNP level of 533 pg/ml, are listed in Table 1. 
Patients with NT-proBNP levels equal or above 533 
pg/ml were older, had a higher incidence of angina 
pectoris, previous myocardial infarction, congestive 
heart failure, diabetes mellitus and renal failure, 
compared to patients with NT-proBNP levels below 533 
pg/ml. Q-wave and ST-segment changes were also more 
common in patients with NT-proBNP levels equal or 
above 533 pg/ml.  
 
DSE results 
Heart rate increased from 73 +/-14 beats per minute at 
rest to 133 +/-17 beats per minute at peak stress. The 
maximum dose of dobutamine infusion was 36.8 +/-7 
μg/kg/min. Atropine was administered in 52% of 
patients to achieve target heart rate. Stress induced 
myocardial ischemia occurred in 28 patients (16%). The 
mean number of ischemic segments in patients with 
stress induced myocardial ischemia was 3.2 +/-1.2. No 
fatal complications occurred during or immediately after 
the stress test. 
 
NT-proBNP levels in relation to dobutamine stress 
echocardiography results  
The distribution of NT-proBNP was positively skewed 
and the Mann-Whitney U test was used to compare NT-
proBNP values in different groups. Median NT-proBNP 
level was higher in patients with rest wall motion 
abnormalities during DSE (397 pg/ml, interquartile 
range: 178-710 pg/ml), compared to those without (59 
pg/ml, interquartile range: 34-118 pg/ml) (p<0.001). In 
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the 39 patients with a history of congestive heart failure, 
mean ejection fraction was 41% +/-15. NT-proBNP 
level was higher in patients with a history of CHF 
(median 338 pg/ml, interquartile range 85-846 pg/ml) 
compared to patients without a history of CHF (median 
93 pg/ml, interquartile range 42-296 pg/ml ) (p=0.007). 
In the 39 patients with a history of congestive heart 
failure, the mean left ventricular ejection fraction was 
41% +/-15 and was inversely correlated with the level 
of NT-proBNP (Pearson’s R correlation -0.59). 
 
 
Figure 1. Correlation between median plasma N-terminal pro-B-type 
natriuretic peptide levels in patients with (p = 0.002) and without 
(0.001)  new wall motion abnormalities, divided in subgroups 
according to the Lee risk score (high-risk type of surgery, coronary 
artery disease, a history of congestive heart failure, a history of 
cerebrovascular disease, diabetes mellitus and renal dysfunction (7).  
The Box-Whisker plot shows the median, upper and lower quartiles 
and the range of the data. 
 
A higher median NT-proBNP level was observed in 
patients with new wall motion abnormalities (NWMA) 
during DSE (440 pg/ml, interquartile range: 195-1336 
pg/ml), compared to those without (93 pg/ml, 
interquartile range: 42-279 pg/ml) (p=0.001). A direct 
relation was observed between the extent of stress 
induced myocardial ischemia and NT-proBNP levels, 
with median levels of NT-proBNP of 364, 710 and 2376 
pg/ml in patients with 1-2, 3-4 and >4 ischemic 
segments, respectively (p for trend <0.001). 
 
Figure 1 presents median NT-proBNP levels in patients 
with and without NWMA during DSE, divided in 
subgroups according to the cardiac risk score. In the 
group of patients with no NWMA during DSE, median 
NT-proBNP level increased from 51 pg/ml in patients 
with a risk score of 1 to a level of 609 pg/ml in patients 
with a risk score of ≥4 (p for trend: 0.001). In the group 
of patients with NWMA during DSE, median NT-
proBNP level increased from 321 pg/ml in patients with 
a risk score of 1 to a level of 2148 pg/ml in patients with 
a risk score of ≥4 (p for trend: 0.002). 
 
Postoperative outcome 
Postoperative cardiac events occurred in 13 patients 
(8%) (cardiac death in 4 patients, non-fatal myocardial 
infarction in 9 patients). Median NT-proBNP level was 
higher in patients with cardiac events (939 pg/ml, 
interquartile range: 634-2469 pg/ml), compared to 
patients with no cardiac events (101 pg/ml, interquartile 
range: 42-304 pg/ml) (p<0.0001). Using ROC curve 
analysis for predicting postoperative cardiac events, a 
cut-off value of 533 pg/ml was identified as optimal 
predictor of postoperative cardiac events (area under the 
curve: 0.91) (Figure 2). Using this cut-off value, NT-
proBNP had a sensitivity of 85% and specificity of 
91%. Cardiac events were observed in 2/144 (1.4%) 
patients with NT-proBNP <533 pg/ml and in 11/26 
(42%) patients with NT-proBNP ≥533 pg/ml 
(p<0.0001). Of the two patients who experienced 
cardiac events despite a low NT-proBNP level (533 
pg/ml), one patient had a preoperative risk score of 1 
and NWMA in 1 segment with no rest wall motion 
abnormalities during DSE; the other patient had a 
preoperative risk-score of 2 and only rest wall motion 
abnormalities with no NWMA during DSE. 
 
 
 
Figure 2. Receiver operating characteristic curve of plasma N-terminal 
pro-B-type natriuretic peptide levels to predict postoperative cardiac 
events.  Sensitivity and 1-specificity are plotted for various NT-
proBNP levels. The ideal cutoff value is indicated by the arrow. 
 
Postoperative cardiac event rate was 1/65 (2%) in 
patients with a risk-score of 0-1 was, and 12/105 (11%) 
in patients with a risk-score greater than 1 (p=0.04). 
Univariable predictors of cardiac events are listed in 
Table 2. Each point increase on the cardiac risk score 
was associated with an estimated risk of 3.6 (95% CI: 
2.0-6.6, p<0.0001) to develop postoperative cardiac  
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Table 2. Univariable association of clinical characteristics, dobutamine stress echocardiography results and plasma N-terminal pro-B-type 
natriuretic peptide (NT-proBNP) levels and the composite endpoint of cardiac death or non-fatal myocardial infarction. 
 OR 95% CI P-value 
Age > 70 years 1.1 0.3-4.3 0.9 
Men 0.9 0.3-3.2 0.9 
Angina pectoris 5.3 1.6-17.3 0.005 
Previous myocardial infarction 3.7 1.1-12.5 0.04 
Congestive heart failure 4.5 1.4-14.4 0.01 
Previous cerebrovascular event 1.8 0.4-9.2 0.5 
Previous coronary revascularization 0.8 0.1-6.5 0.8 
Hypertension 2.5 0.8-7.8 0.1 
Diabetes mellitus 4.7 1.5-15.3 0.01 
Hypercholesterolemia 0.6 0.2-2.0 0.4 
Current smoking 0.8 0.2-3.6 0.7 
Renal failure 34.2 5.5-212.4 <0.0001 
Abnormal electrocardiography 2.5 0.8-7.9 0.1 
Q waves 3.4 1.1-10.6 0.03 
ST-segment changes  4.4 1.1-18.5 0.04 
Rest wall motion abnormalities 19.2 2.4-151.4 0.005 
New wall motion abnormalities 25.6 6.4-101.6 <0.0001 
Abdominal aortic repair 1.0 0.3-3.4 1.0 
Lower extremity revascularization 1.1 0.4-3.4 0.9 
NT-proBNP level per 100 pg/ml increase 1.20 1.1-1.3 <0.0001 
NT-proBNP level ≥ 533 pg/ml 51.7 10.5-255.6 <0.0001 
 
  
Table 3. Multivariable model to predict cardiac events in patients undergoing major vascular surgery. 
 OR 95% CI P-value 
N-terminal pro-B-type natriuretic peptide ≥533 pg/ml 17.2 2.8-106.4 0.002 
New wall motion abnormalities 13.0 2.0-86.9 0.009 
Diabetes mellitus 4.6 0.7-30.7 0.1 
Renal failure 2.0 0.1-33.8 0.6 
Rest wall motion abnormalities 2.0 0.2-25.4 0.6 
 
 
 
events. In multivariable analysis, independent predictors 
of cardiac events were NT-proBNP levels ≥533 pg/ml 
and NWMA during DSE (Table 3). 
 
 
 
Figure 3.  Postoperative cardiac events as observed in patients with 
and without new wall motion abnormalities (NWMA), divided in 
subgroups according to the risk score. The figure presents only 
patients with plasma N-terminal pro-B-type natriuretic peptide (NT-
proBNP) concentration ≥63 pmol/L.  
 
 
DISCUSSION 
 
Our study showed that elevated levels of NT-proBNP 
are significantly associated with increased risk of 
postoperative cardiac events (cardiac death or non-fatal 
myocardial infarction) in patients undergoing major 
vascular surgery. The increased level of NT-proBNP 
was especially substantial for those with extensive stress 
induced myocardial ischemia during DSE. Using ROC 
curve analysis, NT-proBNP value of ≥533 pg/ml had 
the best prognostic value for postoperative cardiac 
events. This association between NT-proBNP and 
postoperative outcome was independent of clinical data, 
rest wall motion abnormalities, and stress-induced 
myocardial ischemia.  
In this study, NT-proBNP levels were 
measured and not B-type natriuretic peptide (BNP). The 
half-life time of NT-proBNP is considered to be 60-120 
minutes, while the half-life time of BNP is around 20 
minutes (6,7). Considering the longer half-life time of 
NT-proBNP compared to BNP, NT-proBNP may be a 
superior screening marker in patients attending the out-
patient preoperative clinic. 
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Prior to surgery, patients are screened for 
coronary artery disease by vascular surgeons. Initial 
screening is performed by using the revised cardiac risk 
index according to Lee (3). High-risk patients are 
referred to a cardiologist for additional stress testing to 
assess the presence and extent of coronary artery 
disease. As shown in this study, patients with a higher 
risk score have elevated NT-proBNP levels. 
Importantly, those patients with stress-induced ischemia 
also have elevated NT-proBNP levels, and the rise of 
NT-proBNP level is related to the magnitude of stress-
induced ischemia. Therefore we speculate that NT-
proBNP measurements can be used for an initial 
screening in patients undergoing major vascular 
surgery. Those patients without risk factors and a low 
level of NT-proBNP represent a low-risk population, in 
which additional testing is not warranted. Patients with 
elevated NT-proBNP should be referred for additional 
stress testing to assess the presence and extent of 
coronary artery disease. Postoperative cardiac events 
may still occur in patients without stress-induced 
myocardial ischemia during preoperative DSE. Elevated 
NT-proBNP levels may identify some patients at high 
risk despite absence of inducible ischemia. The reason 
for the independent association of NT-proBNP levels 
with cardiac events after controlling for DSE results is 
not clear. Possible explanations include the higher 
sensitivity for detecting ischemia, the ability to reflect 
the occurrence of spontaneous ischemic episodes and 
the objective nature of measurements as compared to 
DSE interpretation.  
In our study, the number of patients as well as 
events was small. However, our results are supported by 
a recently published paper by Yeh et al, who also found 
a significant association between NT-proBNP levels and 
cardiac complications in patients undergoing non-
cardiac surgery (8).Further studies are needed to 
confirm our findings in a larger population prior to 
recommending the use of NT-proBNP as a routine 
clinical investigation. Although the study has shown an 
additional value of NT-proBNP levels in defining risk, 
the management of these patients remains a challenge, 
since the Coronary Artery Revascularization 
Prophylaxic trial showed that coronary artery 
revascularization before elective vascular surgery does 
not significantly alter the long-term outcome (9). 
However, several studies have demonstrated the 
beneficial effect of perioperative beta-blocker therapy 
and minimal invasive surgery in reducing postoperative 
adverse events in high-risk patients undergoing major 
non-cardiac surgery (2,10,11). Patients with elevated 
NT-proBNP levels, with or without stress induced 
myocardial ischemia, are at increased risk for adverse 
postoperative events and may therefore benefit from 
these management strategies. 
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Plasma N-terminal pro-B-type natriuretic peptide as 
long-term prognostic marker after major vascular 
surgery 
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Objective: To assess the long-term prognostic value of 
plasma N-terminal pro-B-type natriuretic peptide (NT-
proBNP) after major vascular surgery.   
Design: A single-centre prospective cohort study 
Patients: 306 patients who underwent successful 
abdominal aortic aneurysm repair or lower extremity 
bypass surgery. 
Interventions: Prior to surgery, baseline NT-proBNP 
level was measured. Patients were also evaluated for 
cardiac risk factors according to the Revised Cardiac 
Risk Index. Dobutamine stress echocardiography (DSE) 
was performed to detect stress-induced myocardial 
ischemia. 
Main outcome measures: The prognostic value of NT-
proBNP was evaluated for the endpoints all-cause 
mortality and major adverse cardiac events (MACE) 
during long-term follow-up. 
Results: In this patient cohort (mean age: 63 years, 77% 
male), median NT-proBNP level was 158 ng/l 
(interquartile range: 58-400 ng/l). During a mean 
follow-up of 15 ± 6 months, 33 patients (11%) died and 
30 (10%) experienced a MACE. Using receiver 
operating characteristic curve analysis for 6-month 
mortality and MACE, NT-proBNP had the greatest area 
under the curve, compared to cardiac risk score and 
DSE. In addition, a NT-proBNP level of 315 ng/l was 
identified as optimal cut-off value to predict 6-month 
mortality and MACE. After adjustment for age, cardiac 
risk score, DSE results and cardioprotective medication, 
NT-proBNP ≥315 ng/l was associated with a hazard 
ratio of 3.37 for all-cause mortality (95% CI: 1.28-8.87) 
and with a hazard ratio of 8.64 for MACE (95% CI: 
2.69-27.75).  
Conclusion: Preoperative NT-proBNP level is a strong 
predictor of late mortality and major adverse cardiac 
events after successful major non-cardiac vascular 
surgery.
_____________________________________________________________________________________________ 
 
ASSESSMENT OF SHORT- and long-term risk in 
patients undergoing major vascular surgery is regarded 
by the American College of Cardiology/American Heart 
Association as one of the most important initial steps in 
the evaluation and treatment of these patients [1]. Risk 
stratification is especially important given the 
substantial risk of perioperative and long-term 
morbidity and mortality [2-5]. To identify high-risk 
patients prior to surgery, several risk stratification 
scores have been developed and adjusted, using the 
patient’s history and type of surgery to predict 
postoperative outcome [6-9]. In patients with multiple 
risk factors undergoing high-risk surgery, preoperative 
non-invasive stress testing provides additional 
prognostic information [10].  
The natriuretic peptides are endogenous cardiac 
hormones that include atrial natriuretic peptide (A-
type), brain natriuretic peptide (B-type or BNP), and its 
amino-terminal portion N-terminal pro-B-type 
natriuretic peptide (NT-proBNP) [11,12]. NT-proBNP 
is synthesized in the ventricular myocardium and 
released in response to ventricular wall stress [13,14]. 
NT-proBNP has been demonstrated to be an important 
diagnostic and prognostic marker in patients with heart 
failure [15,16]. The diagnostic and prognostic value of 
elevated levels of NT-proBNP has more recently been 
shown in patients with acute coronary syndromes and 
stable coronary artery disease [17,18]. It has also 
recently been demonstrated that elevated NT-proBNP 
levels predict short-term adverse cardiovascular events 
in patients undergoing elective non-cardiac surgical 
procedures [19]. Unfortunately, the long-term 
prognostic value of elevated baseline NT-proBNP levels 
along with clinical risk factors and dobutamine stress 
echocardiography results is not yet known.    
The present prospective study was conducted 
to determine whether preoperative plasma NT-proBNP 
levels have significant long-term prognostic value in 
addition to conventional cardiac risk factors and 
dobutamine stress echocardiography in patients who 
underwent successful elective abdominal aortic 
aneurysm repair or lower extremity revascularization 
procedures.  
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METHODS 
 
Study population 
Patients scheduled for elective abdominal aortic 
aneurysm repair or lower extremity bypass surgery at 
the Erasmus University Medical Center in Rotterdam, 
the Netherlands, were prospectively included in the 
study from October 2003 to August 2005 after giving 
informed consent. Patients who died (n=16), and who 
suffered a non-fatal myocardial infarction (n=13) during 
the perioperative period were excluded. Patients who 
underwent preoperative coronary artery 
revascularization were also excluded. Prior to surgery, 
baseline clinical data was collected by structured 
interviews with the patients and by reviewing the 
medical records. Based on the Revised Cardiac Risk 
Index by Lee et al [8], each of the following cardiac risk 
factors was obtained: history of coronary artery disease, 
a history of congestive heart failure, a history of 
cerebrovascular accident or transient ischemic attack, 
diabetes mellitus type I (fasting glucose level ≥7.0 
mmol/l or treatment with insulin) and renal dysfunction 
(preoperative serum creatinine level >2.0 mg/dL (177 
μmol/L) or treatment with renal dialysis). A cardiac risk 
score was calculated by assigning 1 point to each of 
these risk factors when present in the patient. Coronary 
artery disease was indicated if patients presented with 
current stable or unstable angina pectoris or if patients 
had a history of myocardial infarction. A preoperative 
electrocardiogram was obtained and evaluated. Patients 
were also screened for hypertension (blood pressure 
≥140/90 mmHg or antihypertensive drugs), 
hypercholesterolemia (plasma cholesterol level ≥5.5 
mmol/L or treatment with cholesterol lowering drugs), 
smoking, and cardiac medication use, including statins, 
β-blockers, aspirin, angiotensin-converting enzyme 
inhibitors and calcium channel blocking agents.  
 
Measurement of plasma N-terminal pro-B-type 
natriuretic peptide 
The mean time of venous blood sampling prior to 
surgery was 23 ± 12 days and all samples were collected 
before DSE. The samples were centrifuged and plasma 
was frozen at -80°C until assay. NT-proBNP was 
measured with an electrochemiluminescence 
immunoassay kit (Elecsys 2010, Roche GmbH, 
Mannheim, Germany). This ‘sandwich’-type 
quantitative immunoassay is based on polyclonal 
antibodies against epitopes in the N-terminal part of 
proBNP. The lower detection limit was 5 ng/l. Intra-
assay coefficients of variance at 271 ng/l and 6436 ng/l 
were 1.9% and 0.9%, respectively. Assays were 
performed by a laboratory technician blinded to the 
patient’s baseline clinical data.   
 
Dobutamine stress echocardiography 
Patients underwent a resting two-dimensional precordial 
echocardiographic examination and standard apical and 
parasternal views were recorded on videotape. 
Dobutamine hydrochloride was then administered 
intravenously by infusion pump, starting at 10 
μg/kg/min for 3 minutes (5 μg/kg/min for 5 minutes, 
followed by 10 μg/kg/min for 5 minutes in patients with 
resting wall motion abnormalities), and increased by 10 
μg/kg/min every 3 minutes to a maximum of 40 
μg/kg/min. The dobutamine infusion was stopped if a 
target heart rate (85% of a theoretic maximal heart rate) 
was achieved. If the target heart rate was not achieved 
and patients had no symptoms or signs of ischemia, 
atropine sulphate (starting with 0.25 mg, increased to a 
maximum of 2.0 mg) was given intravenously while the 
administration of dobutamine was continued. 
Metoprolol was administered (1.0 to 5.0 mg 
intravenously) to reverse the side effects of the 
administration of dobutamine or the dobutamine-
atropine combination if the side effects did not revert 
spontaneously and quickly. Two experienced 
investigators, blinded to the clinical data, performed off-
line assessment of echocardiographic images. The left 
ventricle was divided into 17 segments, and wall motion 
was scored on a 5-point scale (1 = normal, 2 = mild 
hypokinesis, 3 = severe hypokinesis, 4 = akinesis, and 5 
= dyskinesis). Ischemia was defined as new or 
worsening wall-motion abnormalities (compared to 
resting images of the same test) as indicated by an 
increase of regional wall motion score ≥ 1 grade(s) with 
stress. Akinesis becoming dyskinesis was not 
considered an ischemic response.  
 
Outcomes 
Patients were monitored for all-cause mortality and 
major adverse cardiac events (MACE) (cardiac death or 
non-fatal myocardial infarction) during long-term 
follow-up after their vascular surgical procedure. 
Cardiac death was defined as death caused by acute 
myocardial infarction, cardiac arrhythmias, or 
congestive heart failure. Non-fatal myocardial infarction 
was diagnosed when at least two of the following were 
present: 1. elevated cardiac enzyme levels (creatine 
kinase (CK) level > 190 U/L and CK-MB >14 U/L, or 
CK-MB fraction >10% of total CK, or cardiac troponin  
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Table 1. Baseline clinical characteristics according to the median of N-terminal pro-B-type natriuretic peptide 
Characteristic  NT-proBNP (ng/l) P-value 
  <158 ng/l (n=153) ≥158 ng/l (n=153)  
Age (years) (mean +/-SD) 63.0 ± 12.3 58.7 ± 12.0 67.3 ± 11.1 <0.001 
Male gender 236 (77.1) 111 (72.5) 125 (81.7) 0.057 
Medical history     
   Current stable or unstable angina pectoris 75 (24.5) 21 (13.7) 54 (35.3) <0.001 
   Previous myocardial infarction 119 (38.9) 37 (24.2) 82 (53.6) <0.001 
   Coronary artery disease (summary variable) 145 (47.4) 48 (31.4) 97 (63.4) <0.001 
   Previous coronary artery revascularization 37 (12.1) 10 (6.5) 27 (17.6) 0.003 
   History of congestive heart failure 47 (15.4) 17 (11.1) 30 (19.6) 0.076 
   Previous cerebrovascular event 54 (17.6) 15 (9.8) 39 (25.5) <0.001 
   Diabetes mellitus type 1 55 (18.0) 23 (15.0) 32 (20.9) 0.18 
   Renal dysfunction   12 (3.9) 1 (0.7) 11 (7.2) 0.003 
   Hypertension 106 (34.6) 41 (26.8) 65 (42.5) 0.004 
   Hypercholesterolemia 124 (40.5) 67 (43.8) 57 (37.3) 0.24 
   Current smoking 105 (34.3) 46 (30.1) 59 (38.6) 0.12 
Cardiac risk score 1.0 ± 0.9 0.6 ± 0.8 1.3 ± 1.0 <0.001 
Electrocardiography     
   Q waves 79 (25.8) 27 (17.6) 52 (34.0) 0.001 
   ST-segment changes  31 (10.1) 7 (4.6) 24 (15.7) 0.001 
Medication     
   Aspirin  129 (42.2) 56 (36.6) 73 (47.7) 0.049 
   Angiotensin converting enzyme inhibitor 102 (33.3) 41 (26.8) 61 (39.9) 0.015 
   Beta-blocker  223 (72.9) 101 (66.0) 122 (79.7) 0.007 
   Calcium channel blocker   54 (17.6) 20 (13.1) 34 (22.2) 0.036 
   Digoxin  16 (5.2) 1 (0.7) 15 (9.8) <0.001 
   Statin  175 (57.2) 80 (52.3) 95 (62.1) 0.083 
Abdominal aortic aneurysm repair  142 (46.4) 70 (47.1) 70 (45.8) 0.82 
Lower extremity revascularization 164 (53.6) 81 (52.9) 83 (54.2) 0.82 
Values are expressed in number (%) or in mean ± SD 
 
 
T >0.1 ng/mL); 2. development of typical 
electrocardiographic changes (new Q waves >1 mm or > 
30 ms); and 3. typical symptoms of angina pectoris. All 
patients had at least 6 months of follow-up. 
 
Statistical analysis 
Normally distributed, continuous data were expressed as 
mean (±SD) and compared using the Student t test. 
Non-normally distributed continuous data were 
expressed as median (25th and 75th percentile) and 
compared using the Mann-Whitney U test. Categorical 
data were presented as percent frequencies and 
differences between proportions were compared using 
the chi-square test with Yates’ correction. To compare 
the predictive value of NT-proBNP, cardiac risk score 
and DSE results for 6-month outcome, receiver 
operating characteristic (ROC) curve analysis was 
performed and the area under the curve was calculated. 
The 6-month outcome was used, since all patients had a 
complete follow-up at this time. The optimal cut-off 
value of NT-proBNP for mortality and MACE at 6 
months was determined and was defined as the NT-
proBNP value providing the maximal sum of sensitivity 
and specificity. Age, cardiac risk score, DSE results, 
NT-proBNP values (dichotomized according to the 
optimal cut-off value for 6-month outcome) and 
cardioprotective medication (statins and β-blockers) 
were then entered in a multivariable Cox hazard 
regression model to identify independent predictors of 
long-term mortality and MACE. Hazard ratios are given 
with 95% confidence intervals. For all tests, a p value 
less than 0.05 (two-sided) was considered significant. 
All analysis was performed using SPSS-11.0 statistical 
software (SPSS Inc., Chicago, Illinois). 
 
RESULTS 
 
Baseline characteristics 
The study population consisted of 306 patients (77.1% 
male) with a mean age of 63.0 ± 12.3 years. Abdominal 
aortic aneurysm repair was performed in 142 patients 
(46.4%) and lower extremity revascularization in 164 
patients (53.6%). The NT-proBNP level ranged from 4 
to 8257 ng/l, with a mean (±SD) of 417 ± 838 ng/l, a 
median of 158 ng/l, and 25th and 75th percentile values 
of 58 ng/l and 400 ng/l, respectively. Baseline clinical 
characteristics of the patients, divided according to the 
median level of NT-proBNP, are presented in Table 1. 
Patients with NT-proBNP levels above the median were 
more likely to be older and to present with coronary 
artery disease, history of cerebrovascular events, renal 
dysfunction, hypertension, Q-waves and ST segment 
changes on electrocardiography than patients with NT-
proBNP levels below the median. These patients were 
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also more likely to be treated with aspirin, angiotensin-
converting enzyme inhibitors, β-blockers, calcium 
channel blockers and digoxin.  
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Figure 1.  Histogram demonstrating the distribution of N-terminal pro-
B-type natriuretic peptide level according to its natural logarithm in 
the study population 
 
DSE results  
The mean maximal dobutamine dose used during stress 
echocardiography was 36.3 ± 8 μg/kg/min. Atropine 
was used in 125 patients (41%). Stress induced 
myocardial ischemia occurred in 58 patients (19%) and 
the mean number of ischemic segments in patients with 
stress induced myocardial ischemia was 3.4 ± 1.5. No 
fatal complications occurred during or immediately after 
the stress test. The median NT-proBNP level was 
significantly higher in patients with a positive test (426 
ng/l, IQ range: 163-1391 ng/l) compared to those with a 
negative stress test (120 ng/l, IQ range: 46-307 
ng/l)(p<0.001). 
 
Outcome and ROC curve analysis 
During a mean follow-up of 15 ± 6 months, all-cause 
mortality occurred in 33 patients (11%) and MACE in 
30 (10%). NT-proBNP had a greater area under the  
 
 
 
Figure 2. Receiver operating characteristic curves of plasma N-
terminal pro-B-type natriuretic peptide against 6-month mortality and 
major adverse cardiac events, respectively, in 306 patients who 
underwent major vascular surgery. 
 
 
 
 
Table 2. Optimal cut-off values of N-terminal pro-B-type natriuretic peptide to predict mortality and major adverse cardiac events at 6, 12 and 18 
months of follow-up. 
Endpoint Mortality 
number 
ROC area 
under the 
curve 
Optimal cutoff value of N-
terminal pro-B-type 
natriuretic peptide (ng/l)  
Sensitivity Specificity 
Mortality within 6 months 16 0.72 315 69% 70% 
Mortality within 12 months 24 0.72 303 67% 70% 
Mortality within 18 months 26 0.74 228 73% 67% 
Cardiac events within 6 months 12 0.81 315 83% 70% 
Cardiac events within 12 months 20 0.80 205 90% 60% 
Cardiac events within 18 months 24 0.80 206 88% 66% 
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ROC curve for the endpoint 6-month mortality 
(AUC=0.72), compared to the cardiac risk score 
(AUC=0.64) and DSE (AUC=0.66). (Figure 1). Also for 
MACE, the area under the curve was greater for NT-
proBNP (AUC=0.81) compared to cardiac risk score 
(AUC=0.65) and DSE (AUC=0.66). (Figure 2). A NT-
proBNP level of 315 ng/l was identified as the optimal 
cut-off value to predict both mortality and cardiac 
events at 6 months follow-up. Using this cut-off value, 
the sensitivity and specificity for 6-month mortality was 
69% and 70%, respectively. Sensitivity and specificity 
for 6-month MACE was 83% and 70%, respectively. 
 
 
 
Figure 3. Kaplan-Meier curves showing the cumulative incidence of 
death and major adverse cardiac events during follow-up, according to 
N-terminal pro-B-type natriuretic peptide level. 
 
 
 
 
 
 
 
 
 
Prognostic value of NT-proBNP 
Kaplan-Meier survival curves demonstrate that patients 
with NT-proBNP level ≥315 ng/l had a lower survival 
and freedom of MACE compared to patients with NT-
proBNP levels <315 ng/l (Figure 2). Independent 
predictors of all-cause mortality and MACE were 
identified by Cox hazard regression analysis, which 
demonstrated that NT-proBNP was the strongest 
predictor for all-cause mortality and for MACE (Figure 
3). The adjusted hazard ratio for all-cause mortality in 
patients with baseline NT-proBNP levels ≥315 ng/l was 
3.37 (95% CI: 1.28-8.87, p=0.014). The adjusted hazard 
ratio for MACE in patients with baseline NT-proBNP 
levels ≥315ng/ml was 8.64 (95% CI; 2.69-27.75, 
p<0.001). Notably, β-blockers and statin therapy were  
 
significantly associated with an improved long-term 
outcome (Figure 3). 
 
DISCUSSION 
 
This study demonstrates that a single measurement of 
NT-proBNP, obtained prior to surgery, provides 
powerful information for use in risk stratification in 
patients undergoing abdominal aortic aneurysm repair 
or lower extremity bypass surgery. Patients with higher 
NT-proBNP levels were more likely to present with 
older age, coronary artery disease, previous coronary 
artery bypass grafting, history of cerebrovascular 
events, renal dysfunction, hypertension and Q-waves 
and ST segment changes on electrocardiography, 
compared to those with lower NT-proBNP levels. This 
finding suggests that high baseline NT-proBNP levels 
due to activation of the cardiac neurohormonal system 
may be a unifying feature in patients at high risk for late 
mortality or major adverse cardiac events. 
 
NT-proBNP as a prognostic marker in non-surgical 
patients 
NT proBNP is the physiologically inactive 1-76 amino 
acid fragment that is secreted along with the 32 amino 
acid brain natriuretic peptide after cleavage from the 
pro-hormone pro-BNP [11-14]. Considering the longer 
half life and better in vitro stability, NT-proBNP may be 
a superior target for assay in comparison to BNP [11-
14]. The long-term prognostic value of NT-proBNP has 
been evaluated in non-surgical patients with congestive 
heart failure, demonstrating that higher levels of NT-
proBNP were associated with adverse outcome [20-22]. 
In our study cohort, only 15% of the study cohort 
presented with a history of congestive heart failure, 
however, a history of coronary artery disease was much 
more frequently observed (47%). Recent studies have 
demonstrated the prognostic value of NT-proBNP in 
non-surgical patients with acute and stable coronary  
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Figure 4. Multivariate Cox regression model showing independent 
predictors of all-cause mortality and major adverse cardiac events. 
 
 
 
 
 
artery disease. In a  sub-study of the Global Utilization 
of Strategies To Open occluded arteries (GUSTO)-IV 
trial with 6,809 patients with non-ST-segment elevation 
acute coronary syndromes, NT-proBNP was the 
strongest predictor of death at 1-year, among other 
biochemical and clinical markers [23]. The prognostic 
value of NT-proBNP was also proved in a group of 
patients presenting with a full range of severities of 
acute coronary syndromes (from unstable angina 
pectoris, through non-ST segment elevation myocardial 
infarction, to ST-segment elevation myocardial 
infarction [24]. In 755 patients with symptoms 
suggestive of an acute coronary syndrome and no ST-
segment elevation, Jernberg and colleagues 
demonstrated that NT-proBNP levels were 
independently associated with long-term prognosis [25]. 
Finally, NT-proBNP has been proven to provide long-
term prognostic information above and beyond that 
provided by conventional cardiac risk factors and the 
degree of left ventricular systolic dysfunction in1034 
patients referred for angiography because of symptoms 
or signs of coronary heart disease [26]. 
 
NT-proBNP as promising prognostic marker in 
major vascular surgery 
The substantial postoperative mortality rate in patients 
undergoing major vascular surgery has led researchers 
and physicians to find strategies that identify high risk 
patients [2-5]. In the investigated study cohort, more 
than 1 out of 10 patients died from all causes during a 
mean follow-up of 15 months, with the exclusion of 
patients who died in the perioperative period. The 
Revised Cardiac Risk Index has currently been 
considered as the best available cardiac risk index in 
non-cardiac surgery [8]. This index uses the patient’s 
history to predict major cardiac complications. Stress 
induced myocardial ischemia during DSE has also been 
shown to be a strong predictor of early and late cardiac 
events [27,28]. The American College of 
Cardiology/American Heart Association guidelines on 
perioperative cardiovascular evaluation for non-cardiac 
surgery recommends preoperative clinical evaluation to 
identify high risk patients and recommends further 
cardiac stress testing in selected patients [1].  
Few data are available whether NT-proBNP 
levels provide additional prognostic information in 
vascular surgery patients. A recently published study 
including 190 patients undergoing elective non-cardiac 
surgery demonstrated that a NT-proBNP level greater 
than 450 ng/l was predictive of perioperative cardiac 
complications [19]. Although there is no consensus of 
what normal NT-proBNP values are, we have identified 
315 ng/l as optimal cut-off values to predict 6-month 
mortality and MACE, using ROC curve analysis. Our 
study extends currently available information about the 
value of NT-proBNP as risk marker and suggests that 
NT-proBNP may be a superior long-term prognostic 
marker compared to conventional cardiac risk scores 
and DSE. Measurement of plasma NT-proBNP 
concentration is an objective, convenient and 
inexpensive test. For the purpose of optimal risk 
stratification and for the targeting of treatment 
strategies, our results suggest that NT-proBNP should 
be incorporated in the management of major vascular 
surgery patients.    
 
Conclusion 
Patients undergoing major vascular surgery are at 
increased risk of late cardiac morbidity and mortality. 
The present study demonstrates that elevated 
preoperative plasma NT-proBNP level is associated 
with an increased risk of late all-cause mortality and 
MACE after successful major vascular surgery, 
independent of cardiac risk factors and DSE results. 
Using ROC curve analysis, a level of 315 ng/ml of NT-
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proBNP was identified as optimal cut-off values to 
predict 6-month mortality and MACE. NT-proBNP 
levels above these cut-off values may be a promising 
marker of long-term prognosis and should be 
incorporated in preoperative risk stratification.   
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Baseline plasma N-terminal pro-B-type natriuretic 
peptide is associated with the extent of stress induced 
myocardial ischemia during dobutamine stress 
echocardiography 
Harm H. H. Feringa, M.D.a, Abdou Elhendy, M.D., Ph.D.b, Jeroen J. Bax, M.D., Ph.D.c, Eric Boersma, Ph.D.d, 
Robert de Jonge, Ph.D.e, Olaf Schouten, M.D.f, Stefanos E. Karagiannis, M.D.g, Arend F.L. Schinkel, M.D., Ph.D.d, 
Jan Lindemans, M.D., Ph.D.e, Don Poldermans, M.D., Ph.D.a 
 
 
Objective: To determine the relation between baseline 
plasma N-terminal pro-B-type natriuretic peptide (NT-
proBNP) levels and the presence and extent of 
myocardial ischemia during dobutamine stress 
echocardiography (DSE). 
Methods: NT-proBNP was measured in 170 
consecutive patients prior to DSE. Rest wall motion 
abnormalities (RWMAs) and new wall motion 
abnormalities (NWMAs) were scored using a 5-point, 
17-segment model. Kruskal-Wallis tests were applied to 
study differences in NT-proBNP levels between patients 
with normal DSE, RWMAs but no NWMAs, and 
NWMAs, and (in patients with NWMAs) between those 
with 1-2, 3-4 and >4 ischemic segments. Univariate and 
multivariate regression analyses were used to determine 
the value of NT-proBNP in predicting NWMAs. 
Results: The median NT-proBNP level was 13 pmol/L 
(interquartile range: 5-46 pmol/L). Median NT-proBNP 
was 7, 38 and 52 pmol/L in patients with normal DSE, 
with RWMAs but no NWMAs, and with NWMAs, 
respectively (p<0001). Among patients with NWMAs, 
median NT-proBNP was associated with the number of 
ischemic segments: 43, 84 and 281 pmol/L in patients 
with 1-2, 3-4 and >4 ischemic segments, respectively 
(p<0.001). Elevated NT-proBNP levels were 
significantly associated with NWMAs (OR per 10 
pmol/L: 1.13, 95% CI: 1.1-1.2) in a multivariate 
analysis of clinical baseline variables and RWMAs.  
Conclusion: Elevated baseline levels of NT-proBNP 
are associated with the presence and extent of 
myocardial ischemia during DSE, independent of the 
presence of RWMAs. 
___________________________________________________________________________________________ 
 
 
PLASMA N-TERMINAL PRO-TYPE natriuretic 
peptide (NT-proBNP) is a neurohormone, synthesized 
in the ventricular myocardium and released in response 
to ventricular wall stress [1-3]. NT-proBNP is produced 
as a prohormone that is enzymatically cleaved into 
brain-type natriuretic peptide and NT-proBNP [4]. NT-
proBNP is a strong marker for the diagnosis, severity 
and prognosis of patients with heart failure [5,6]. More 
recently, NT-proBNP was shown to have prognostic 
value in patients with acute coronary syndromes [7-11]. 
Limited information is available on the association 
between NT-proBNP levels and the presence and extent 
of stress induced myocardial ischemia. Dobutamine 
stress echocardiography (DSE) is a widely used non-
invasive technique for the diagnosis and prognosis of 
coronary artery disease [12]. Patients who experience 
transient new wall motion abnormalities (NWMAs) 
during DSE, a specific marker of myocardial ischemia, 
may also experience transient ischemic episodes during 
daily life.  
We conducted a prospective study to assess the relation 
between pre-test NT-proBNP levels and the presence 
and extent of stress induced myocardial ischemia in 
patients undergoing DSE.  
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METHODS 
 
Study population  
The study included consecutive patients with suspected 
or known coronary artery disease who were referred for 
DSE at the Thorax-center, Rotterdam, the Netherlands 
between October 2003 and December 2004. Patients 
with severe valvular heart disease or hypertrophic or 
dilated cardiomyopathy were excluded. The hospital’s 
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Medical Ethical Committee approved the study 
protocol. Based on hospital records and personal 
interviews at the time of stress testing, a medical history 
was recorded, including clinical risk factors, 
medications, prior history of myocardial infarction, 
angina pectoris, congestive heart failure, coronary artery 
revascularization, stroke and transient ischemic attacks, 
and a baseline 12-leaed electrocardiogram was obtained. 
We have chosen to include the 6 patients with renal 
failure into our analysis in multivariate analysis, we 
have adjusted for renal failure.  Patients were 
characterized as having diabetes mellitus if they were 
treated with insulin or if  they had a pre-test fasting 
plasma glucose level ≥126 mg/dL (≥7.0 mmol/L). 
Hypercholesterolemia was recorded if patients 
presented with a plasma cholesterol level of ≥212 
mg/dL (≥5.5 mmol/L) or if patients were taking lipid-
lowering agents. Hypertension was recorded if patients 
presented with a blood pressure of 140/90 mmHg or 
higher or if patients received antihypertensive 
medication. Smoking included only current smoking. 
Renal failure was recorded if patients presented with a 
serum creatinine level ≥2.0 mg/dL (≥177 μmol/L) or in 
those who required dialysis 
 
Measurement of plasma N-terminal pro-B-type 
natriuretic peptide 
Immediately before the performance of DSE, a 
heparinized venous blood sample was collected for 
measurement of NT-proBNP level. Venous blood 
samples were centrifuged and plasma was frozen at -
80°C until assay. NT-proBNP was measured with an 
electrochemiluminescence immunoassay kit (Elecsys 
2010, Roche GmbH, Mannheim, Germany). The 
method is a ‘sandwich’-type quantitative immunoassay 
based on polyclonal antibodies against epitopes in the 
N-terminal part of proBNP. The lower detection limit 
was 0.6 pmol/l. Intra-assay coefficients of variance at 32 
pmol/L and 761 pmol/L were 1.9% and 0.9%, 
respectively. A reference value of NT-proBNP was 
determined in 100 control patients prior to the start of 
the study. In these patients the median (IQ-range) NT-
proBNP level was 2.3 (1.4-4.4) pmol/L in males and 4.4 
(3.2-6.1) pmol/L in females.  Essays were performed by 
a laboratory technician blinded to the patient’s clinical 
and stress test data [13]. 
 
Dobutamine stress echocardiography 
Patients underwent a resting two-dimensional 
echocardiographic examination from the standard apical 
and parasternal views. Images were digitally stored and 
were also recorded on videotape. A 12-lead ECG was 
recorded. Dobutamine hydrochloride was then 
administered intravenously by infusion pump, starting at 
5 μg/kg/min for 3 minutes, followed by 10 μg/kg/min  
Table 1. Baseline characteristics of 170 patients. 
Characteristic Number (%), or 
Mean (+/- SD) 
Demographics  
     Age (years) 59 +/-13 
     Male gender  120 (71%) 
Cardiovascular history   
      Angina pectoris  45 (26%) 
      Previous myocardial infarction 69 (41%) 
      History of congestive heart failure  39 (23%) 
      Previous coronary artery revascularization 16 (9%) 
      History of cerebrovascular accident 15 (9%) 
Clinical risk factors  
      Diabetes Mellitus  31 (18%) 
      Hypercholesterolemia  70 (41%) 
      Hypertension  46 (27%) 
      Smoking  32 (19%) 
      Renal failure  6 (4%) 
Abnormal baseline electrocardiogram* 70 (41%) 
Cardiac medication use  
      Aspirin 56 (33%) 
      ACE-inhibitor 63 (37%) 
      Beta-blocker  109 (64%) 
      Calcium channel blocker  28 (16%) 
      Diuretic  49 (29%) 
      Nitrate 16 (9%) 
      Statin  87 (51%) 
 
* Abnormal ECG = electrocardiography with one or more of the 
following: Q-waves consistent with a previous myocardial infarction, 
ST segment changes, left bundle branch block and right bundle branch 
block. ACE-inhibitor = Angiotensin converting enzyme-inhibitor 
 
for 3 minutes and increasing by 10 μg/kg/min every 3 
minutes to a maximum of 40 μg/kg/min (stage 5). The 
dobutamine infusion was stopped if a target heart rate 
(85% of a theoretic maximal heart rate (men: (220 – 
age) x 85%; women: (200 – age) x 85%) was achieved. 
If the target heart rate was not achieved and patients had 
no symptoms or signs of ischemia, atropine sulphate 
(starting with 0.25 mg, increased to a cumulative 
maximum of 2.0 mg) was given intravenously at the end 
of stage 5 while the dobutamine administration was 
continued. During the test, a 12-lead ECG was recorded 
every minute. Blood pressure was measured by 
sphygmomanometry every 3 minutes. Metoprolol was 
administered to reverse the side effects of the 
administration of dobutamine or the dobutamine-
atropine combination if the side effects did not revert 
spontaneously and quickly. The criteria for stopping the 
test were: (1) severe new echocardiographic wall 
motion abnormalities in multiple locations, (2) 
horizontal or down-sloping electrocardiographic ST 
depression of ≥0.2 mV measured 80 ms after the J point, 
or ST-segment elevation of ≥0.2 mV in the absence of 
Q waves, (3) symptomatic decline in systolic blood 
pressure of more than 40 mmHg from the resting value, 
or a systolic blood pressure of less than 100 mmHg, (4) 
hypertension (blood pressure >240/140 mmHg), (5) 
severe angina pectoris, and (6) intolerable adverse  
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Table 2. Median plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels in relation to patient characteristics 
 
 Median NT-proBNP level 
(Interquartile range) 
p-value 
Characteristic + -  
Age > 70 years 12 (4-40) 25 (11-59) 0.04 
Male gender 17 (5-51) 11 (4-29) 0.1 
Angina pectoris 52 (23-84) 10 (4-26) <0.001 
Previous myocardial infarction 39 (13-81) 10 (4-22) <0.001 
History of congestive heart failure 40 (10-100) 11 (5-36) 0.007 
History of cerebrovascular accident 33 (15-67) 12 (5-43) 0.08 
Diabetes Mellitus 38 (8-81) 12 (5-37) 0.2 
Hypertension 29 (10-62) 11 (4-38) 0.03 
Smoking 23 (4-49) 12 (5-46) 0.5 
Hypercholesterolemia 13 (5-51) 13 (5-40) 0.9 
Renal failure 172 (64-254) 12 (5-49) 0.04 
Electrocardiography    
    ST segment changes 53 (30-92) 12 (5-38) 0.004 
    Q-waves  37 (10-80) 11 (5-33) <0.001 
    Left bundle branch block 51 (11-59) 12 (5-40) 0.2 
    Right bundle branch block 27 (7-46) 13 (5-46) 0.5 
 
effects considered to be the result of dobutamine or 
atropine.  
Wall motion analysis 
Off-line assessment of echocardiographic images was 
performed by two experienced investigators without 
knowledge of the patient’s clinical data (D.P., J.J.B., 
and S.E.K.). The left ventricle was divided into 17 
segments and wall motion was scored on a 5-point scale 
(a score of 1 indicating normal, 2 mild hypokinesis, 3 
severe hypokinesis, 4 akinesis, and 5 dyskinesis). For 
each patient, a wall motion score index (total score 
divided by the number of segments scored) was 
calculated at rest and at peak heart rate. NWMA during 
the stress test were considered diagnostic for ischemia. 
When there was disagreement between the two 
assessors, a third investigator viewed the images 
without knowledge of the previous assessments, and a 
majority decision was reached. 
 
Statistical analysis 
Continuous data were expressed as mean (+/- SD) or 
median (+/- interquartile range) (in skewed 
distributions), and compared using the Student t test or 
the Mann-Whitney U test, when appropriate. Patients 
were divided into three groups according to DSE 
results: group 1 normal DSE, group 2 RWMAs but no 
NWMAs, and group 3 NWMAs. Patients with NWMA 
were further divided into patients with 1-2 ischemic 
segments, 3-4 ischemic segments and >4 ischemic 
segments. NT-proBNP values in patients with a normal 
DSE, with RWMAs but no NWMAs, and with NWMAs 
were compared using the Kruskal-Wallis test. Kruskal-
Wallis test was also used to compare NT-proBNP 
values in patients with 1-2, 3-4 and >4 ischemic 
segments. Receiver Operating Curve analysis was used 
to determine the optimal cutoff value of NT-proBNP to 
predict NWMAs. Univariable logistic regression 
analysis was used to evaluate the crude value of NT-
proBNP in predicting stress induced myocardial 
ischemia. NT-proBNP level and clinical risk factors 
identified as confounders (significant univariate 
predictors of stress induced myocardial ischemia) were 
included in a final multivariable logistic model. Odds 
ratios are given with 95% confidence intervals. For all 
tests, a p value <0.05 (two-sided) was considered 
significant. All analyses were performed using SPSS-
11.0 statistical software (SPSS Inc., Chicago, Illinois). 
 
RESULTS 
 
Patient characteristics 
Inclusion criteria were fulfilled in 170 patients. Baseline 
characteristics are presented in Table 1. The median 
NT-proBNP level for all patients was 13 pmol/L 
(interquartile range: 5-46 pmol/L). The following 
clinical parameters were associated with increased 
levels of NT-proBNP: age above 70 years, angina 
pectoris, previous myocardial infarction, congestive 
heart failure, hypertension, renal failure, ST segment 
changes, and Q-waves on baseline electrocardiogram 
(Table 2). 
 
DSE results 
Heart rate increased from 73 +/-14 beats per minute at 
rest to 133 +/-17 beats per minute at peak stress. The 
maximum dose of dobutamine infusion was 36.8 +/-7 
μg/kg/min. Atropine was administered in 52% of 
patients to achieve target heart rate. No fatal 
complications occurred during or immediately after the 
stress test.  DSE was normal in 97 patients (57%). 
RWMAs but no NWMAs were detected in 45 patients 
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(26%). NWMAs occurred in 28 patients (16%). The 
mean number of ischemic segments in patients with 
stress induced myocardial ischemia was 3.2 +/-1.2.  
 
p<0.001
11
43
84
281
0
50
100
150
200
250
300
0 1-2 3-4 >4
Number of ischemic segments
 Figure 1. Median plasma N-terminal pro-B-type natriuretic peptide 
levels (NT-proBNP) in relation to the number of ischemic segments 
during dobutamine stress echocardiography.  
 
NT-proBNP levels and DSE results 
The median NT-proBNP level was 7 pmol/L 
(interquartile range: 4-14) in patients with a normal 
DSE, 38 pmol/L (interquartile range: 19-61) in patients 
with RWMAs but no NWMAs, and 52 pmol/L 
(interquartile range: 23-157) in patients with NWMAs 
(p<0.001). In the group of patients with NWMA, NT-
proBNP levels correlated with the extent (number of 
segments) of stress induced myocardial ischemia 
(Figure 1): the median level of NT-proBNP was 43 
pmol/L (interquartile range: 11-52), 84 pmol/L 
(interquartile range 20-185) and 281 pmol/L 
(interquartile range: 114-302), in patients with 1-2 
(n=10), 3-4 (n=14) and >4 (n=4) ischemic segments, 
respectively (p<0.001).  
The optimal cut-off value of NT-proBNP to predict 
stress induced myocardial ischemia was 36 pmol/L, 
using Receiver Operating Curve analysis (area under the 
curve 0.80) (Figure 2). A cutoff value of 36 pmol/L was 
associated with a sensitivity and specificity of 76%. 
Univariate associations of clinical parameters and NT-
proBNP levels with stress induced myocardial ischemia 
are presented in Table 3. After adjusting for RWMA 
and clinical risk factors, elevated NT-proBNP levels 
were independently associated with stress induced 
myocardial ischemia (OR for every 10 pmol/L increase 
of NT-proBNP level: 1.13, 95% CI: 1.09-1.17) (Table 
4).  
 
DISCUSSION 
 
The present study was conducted to evaluate the relation 
between baseline levels of NT-proBNP and the extent of 
stress induced myocardial ischemia during DSE. The 
level of NT-proBNP was related to the presence and 
extent of myocardial ischemia, manifested as NWMAs. 
An elevated baseline NT-proBNP level was  
 
Figure 2. ROC curve analysis demonstrates that the optimal cutoff 
value of plasma N-terminal pro-B-type natriuretic peptide levels (NT-
proBNP) for predicting new wall motion abnormalities was 36 pmol/L 
(dashed line crossing at intersection of sensitivity and specificity) (A). 
The area under the curve (AUC) was 0.80 (B). The x-axis (NT-
proBNP values) presents individual values and does not represent a 
linear or logarithmic scale.  
 
 
 
 
 
 
independently associated with stress induced 
myocardial ischemia after adjustment for clinical data 
and RWMA. To our knowledge, this is the first study to 
demonstrate an independent association between 
baseline NT-proBNP levels and dobutamine stress 
induced myocardial ischemia.  
The human brain natriuretic peptide (BNP) gene, 
located on chromosome 1, encodes the prohormone 
proBNP, which is split into the 32 amino-acid BNP and 
the 76 amino-acid NT-proBNP [4]. NT-proBNP is 
synthesized predominantly in the left ventricular 
myocardium and released in response to ventricular wall 
stress, i.e. ventricular dilatation and pressure overload 
[3,4]. The synthesis and release of natriuretic peptides in 
patients with coronary artery disease may be triggered  
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Table 3. Univariate predictors of stress induced myocardial ischemia. 
 
 OR  95% CI p-value 
NT-proBNP level per 10 pmol/L increase 1.15 1.1-1.2 <0.001 
Age >70 years  2.0 0.8-.4.9 0.1 
Male gender 2.9 0.9-8.9 0.06 
Angina pectoris  2.6 1.1-5.9 0.03 
History of myocardial infarction  2.7 1.2-6.2 0.02 
History of congestive heart failure 2.6 0.9-7.8 0.07 
History of cerebrovascular accident 1.8 0.5-6.0 0.4 
Hypertension 1.3 0.6-3.2 0.5 
Smoking 1.2 0.5-3.2 0.7 
Hypercholesterolemia 0.6 0.3-1.5 0.3 
Diabetes Mellitus 1.3 0.5-3.6 0.6 
Renal failure 11.6 2.0-66.8 0.006 
Abnormal ECG* 3.7 1.5-8.7 0.003 
 
* Abnormal ECG = electrocardiography with one or more of the following: Q-waves consistent with a previous myocardial infarction, ST 
segment changes, left bundle branch block and right bundle branch block 
 
Table 4. Multivariate model to predict stress induced myocardial ischemia. 
 
 OR  95% CI p-value 
NT-proBNP level per 10 pmol/L increase 1.13 1.1-1.2 0.02 
Age >70 years  2.2 0.8-6.3 0.1 
Male gender 2.0 0.5-7.5 0.3 
Angina pectoris  1.1 0.3-3.3 0.9 
History of myocardial infarction  0.8 0.2-2.8 0.7 
History of congestive heart failure 1.1 0.3-4.5 0.9 
Renal failure 1.0 0.1-12.0 1.0 
Abnormal baseline ECG* 1.5 0.4-5.3 0.5 
Rest wall motion abnormalities 2.4 0.8-7.4 0.1 
 
Abnormal ECG = electrocardiography with one or more of the following: Q-waves consistent with a previous myocardial infarction, ST segment 
changes, left bundle branch block and right bundle branch block. NT-proBNP = plasma N-terminal pro-B-type natriuretic peptide. 
 
 
 
by the effects of ventricular wall stress secondary to 
chronic or repetitive ischemia or by ischemia itself. It 
has been demonstrated in an experimental rat model of 
acute myocardial infarction, that ventricular BNP 
mRNA expression and tissue concentrations of BNP 
were increased in the non-infarcted region as well as in 
the infarcted region [14]. Another published study, 
using myocardial biopsies from patients with coronary 
artery disease, has demonstrated an association between 
BNP mRNA expression in ischemic myocardium and 
plasma BNP levels, even in the absence of left 
ventricular dysfunction as evaluated by 
ventriculography [15]. 
Ndrepepa et al. studied patients with angina pectoris and 
acute myocardial infarction, and found a positive 
association between the level of NT-proBNP and the 
severity of angiographic coronary artery disease [16]. 
Sabatine et al. measured NT-proBNP levels before and 
after exercise testing with nuclear perfusion imaging, 
and it showed that NT-proBNP levels rose immediately 
in patients with exercise induced transient myocardial 
ischemia and that the magnitude of NT-proBNP rise 
was associated with the severity of ischemia [17]. It was 
unclear from their study whether baseline levels were 
independently associated with myocardial ischemia.  
DSE is an established method for diagnosis of coronary 
artery disease [12,18,19]. Elevated NT-proBNP levels 
before stress testing suggest that patients with inducible 
ischemia during DSE often sustain spontaneous 
ischemic episodes prior to stress testing. A low level of 
NT-proBNP was associated with a low incidence of 
ischemia. On the contrary, a high level was associated 
with a high incidence of ischemia. NT-proBNP levels 
may potentially be useful in determining the probability 
of an abnormal test and perhaps exempting patients with 
low or high probability of myocardial ischemia from 
stress testing. Considering the longer half-life time of 
NT-proBNP compared to BNP, NT-proBNP may be a 
superior screening marker in patients scheduled for 
stress testing. Nevertheless, more studies are needed to 
confirm this conclusion prior to recommending this 
approach in clinical practice. 
In conclusion, patients with stress induced myocardial 
ischemia during DSE had higher baseline levels of NT-
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proBNP than patients without ischemia. NT-proBNP 
level was a significant predictor of stress induced 
myocardial ischemia, independent of clinical risk 
factors and RWMA. In addition, the extent of stress 
induced myocardial ischemia was positively correlated 
to the level of NT-proBNP. Levels of NT-proBNP could 
stratify patients with regard to the probability of having 
inducible ischemia. 
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Baseline natriuretic peptide levels in relation to 
myocardial ischemia, troponin T release and heart 
rate variability in patients undergoing major vascular 
surgery 
Harm H.H. Feringa, M.D.a, Radosav Vidakovic, M.D.a, Stefanos E. Karagiannis, M.D.a, Robert de Jonge, Ph.D.b, 
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Background: This study was conducted to determine 
the association between baseline N-terminal pro-B-type 
natriuretic peptide (NT-proBNP) and myocardial 
ischemia, troponin T release and heart rate variability 
(HRV) in patients undergoing major vascular surgery.  
Methods: In a prospective study, 182 vascular surgery 
patients were evaluated by clinical risk factors, 
dobutamine stress echocardiography and baseline NT-
proBNP levels. Myocardial ischemia was detected by 
continuous 12-lead electrocardiographic monitoring 
starting 1 day before to 2 days after surgery. Troponin T 
(>0.03 ng/ml) was measured on day 1, 3, and 
7 postoperatively and before discharge. HRV was 
measured at the day prior to surgery.  
Results: The median NT-proBNP level was 184 ng/L 
(interquartile range: 79-483 ng/L). Myocardial ischemia 
was detected in 21% and troponin T release in 17% of 
patients. After adjustment for clinical risk factors and 
stress echocardiography results, higher NT-proBNP 
levels (per 1 ng/L increase in the natural logarithm of 
NT-proBNP) were associated with a higher incidence of 
myocardial ischemia (OR: 1.59, 95% CI: 1.21-2.08, 
p<0.001) and troponin T release (OR: 1.76, 95% CI: 
1.33-2.34, p<0.001). The optimal cut-off value of NT-
proBNP to predict ischemia and/or troponin T release 
was 270 ng/L (area under the curve: 0.70). Higher 
baseline NT-proBNP levels were also associated with 
a larger ischemic burden at electrocardiographic 
monitoring (r=0.22, p=0.03). However, no significant 
correlation was found between NT-proBNP and 
preoperative HRV (r=-0.024, p=0.78).  
Conclusion: Elevated baseline NT-proBNP levels are 
significantly associated with perioperative myocardial 
ischemia and troponin T release, but not with 
preoperative HRV in patients undergoing major 
vascular surgery.  
___________________________________________________________________________________________ 
 
 
NATRIURETIC PEPTIDES are endogenous cardiac 
hormones that include atrial natriuretic peptide (A-
type), brain natriuretic peptide (B-type or BNP), and its 
amino-terminal portion N-terminal pro-B-type 
natriuretic peptide (NT-proBNP) [1,2]. NT-proBNP is 
synthesized in the ventricular myocardium and released 
in response to ventricular wall stress [3,4]. NT-proBNP 
has been demonstrated to be an important diagnostic 
and prognostic marker in patients with heart failure 
[5,6]. The diagnostic and prognostic value of elevated 
levels of NT-proBNP has more recently been shown in 
patients with acute coronary syndromes and stable 
coronary artery disease [7,8]. In the search for safe, 
inexpensive and accurate preoperative screening, 
natriuretic peptides have emerged as promising 
preoperative risk measures. Three studies published last 
year have consistently demonstrated that elevated 
natriuretic peptide levels predict short-term adverse 
cardiovascular events in patients undergoing elective 
non-cardiac surgery [9,10,11]. The prognostic value of 
preoperative natriuretic peptides was also sustained for 
long-term events, as demonstrated in a study involving 
335 patients who were followed for a mean duration of 
14 months [12]. 
Patients who experience perioperative myocardial 
ischemia detected during continuous 12-lead 
electrocardiographic monitoring or who have troponin T 
release are considered to be at increased risk for adverse 
postoperative cardiac events [13,14]. In addition, 
reduced heart rate variability has also been associated 
with a worse prognosis in patients with myocardial 
infarction, congestive heart failure, or in patients 
undergoing major surgery [15,16]. A positive 
association of elevated baseline natriuretic peptides with 
increased perioperative myocardial ischemia and 
decreased preoperative heart rate variability may 
strengthen the evidence that natriuretic peptides can be 
used as a preoperative risk marker. The primary 
objective of this study was to determine whether 
baseline NT-proBNP levels are associated with 
myocardial ischemia as assessed by continuous 12-lead 
electrocardiographic monitoring and troponin T release 
in patients undergoing major vascular surgery. The 
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secondary objective was to assess the association 
between baseline NT-proBNP levels and preoperative 
heart rate variability. 
 
aDepartment of Cardiology, Erasmus MC, Rotterdam, the 
Netherlands. bDepartment of Clinical Chemistry, Erasmus MC, 
Rotterdam, the Netherlands. cDepartment of Vascular Surgery, 
Erasmus MC, Rotterdam, the Netherlands. dDepartment of Cardiology, 
Leiden University Medical Center, Leiden, the Netherlands. 
eDepartment of Anesthesiology, Erasmus MC, Rotterdam, the 
Netherlands. 
 
METHODS 
 
Study population 
Patients scheduled for elective abdominal aortic 
aneurysm repair, lower extremity bypass surgery or 
carotid artery surgery at the Erasmus University 
Medical Center in Rotterdam, the Netherlands, were 
prospectively included in the study from January 2004 
to December 2006 after giving informed consent. 
Patients with severe valvular heart disease or 
hypertrophic or dilated cardiomyopathy were excluded. 
Patients who participated in clinical intervention trials at 
or outside the Erasmus Medical Center were also 
excluded (i.e. the DECREASE III trial). All patients 
agreed on participation in the study after given informed 
consent and the Institutional Review Board approved 
the protocol.  Baseline clinical data were collected by 
structured interviews with the patients and by reviewing 
the medical records. Based on the Revised Cardiac Risk 
Index by Lee et al [17], patients were screened for each 
of the following cardiac risk factors: history of coronary 
artery disease, congestive heart failure, cerebrovascular 
accident or transient ischemic attack, diabetes mellitus 
(fasting glucose level ≥7.0 mmol/l or treatment with 
insulin) and renal dysfunction (preoperative serum 
creatinine level >2.0 mg/dL (177 μmol/L) or treatment 
with renal dialysis). Coronary artery disease was 
defined as patients presented with current stable or 
unstable angina pectoris or if patients had a history of 
myocardial infarction. A preoperative electrocardiogram 
was obtained and evaluated. Patients were also screened 
for hypertension (blood pressure ≥140/90 mmHg or 
antihypertensive drugs), hypercholesterolemia (plasma 
cholesterol level ≥5.5 mmol/L or treatment with 
cholesterol lowering drugs), smoking, and cardiac 
medication use, including statins, β-blockers, aspirin, 
angiotensin-converting enzyme inhibitors and calcium 
channel blocking agents.  
 
Measurement of baseline N-terminal pro-B-type 
natriuretic peptide 
The mean time of venous blood sampling prior to 
surgery was 22 ± 11 days and all samples were collected 
before dobutamine stress echocardiography. The 
samples were centrifuged and plasma was frozen at -
80°C until assay. NT-proBNP was measured with an 
electrochemiluminescence immunoassay kit (Elecsys 
2010, Roche GmbH, Mannheim, Germany). This 
‘sandwich’-type quantitative immunoassay is based on 
polyclonal antibodies against epitopes in the N-terminal 
part of proBNP. The lower detection limit was 5 ng/l. 
Intra-assay coefficients of variance at 271 ng/l and 6436 
ng/l were 1.9% and 0.9%, respectively.  
 
Dobutamine stress echocardiography 
Dobutamine stress echocardiography was performed 
prior to surgery. Patients underwent a resting two-
dimensional precordial echocardiographic examination 
and standard apical and parasternal views were recorded 
on videotape. Dobutamine hydrochloride was then 
administered intravenously by infusion pump, starting at 
10 μg/kg/min for 3 minutes (5 μg/kg/min for 5 minutes, 
followed by 10 μg/kg/min for 5 minutes in patients with 
resting wall motion abnormalities), and increased by 10 
μg/kg/min every 3 minutes to a maximum of 40 
μg/kg/min. The dobutamine infusion was stopped if a 
target heart rate (85% of a theoretic maximal heart rate) 
was achieved. If the target heart rate was not achieved 
and patients had no symptoms or signs of ischemia, 
atropine sulfate (starting with 0.25 mg, increased to a 
maximum of 2.0 mg) was given intravenously while the 
administration of dobutamine was continued. 
Metoprolol was administered (1.0 to 5.0 mg 
intravenously) to reverse the side effects of the 
administration of dobutamine or the dobutamine-
atropine combination if the side effects did not revert 
spontaneously and quickly. Two experienced 
investigators performed off-line assessment of 
echocardiographic images. The left ventricle was 
divided into 17 segments, and wall motion was scored 
on a 5-point scale (1=normal, 2=mild hypokinesis, 
3=severe hypokinesis, 4=akinesis and 5=dyskinesis). 
Ischemia was defined as new or worsening wall-motion 
abnormalities (compared to resting images of the same 
test) as indicated by an increase of regional wall motion 
score ≥ 1 grade(s) with stress. Akinesis becoming 
dyskinesis was not considered an ischemic response.  
 
Myocardial ischemia during 12-lead 
electrocardiography 
Patients were continuously monitored with a 10-
electrode, 12-lead digital ECG recorder (DR180+ 
Digital Recorder, NorthEast Monitoring Inc. 
Massachusetts), starting 1 day before surgery up to 2 
days after. Recordings were performed in the 
continuous 12-lead mode with a recording length of 10 
seconds every minute. The frequency response was 0.05 
– 150Hz. Electrocardiographic data were initially 
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processed by a technician and analyzed by two 
experienced investigators, who were blinded to the 
patient’s clinical data. After excluding all abnormal 
QRS complexes, the ambulatory ECG recordings were 
analyzed for ST-segment deviations. A continuous ST 
segment trend was generated and all potential ischemic 
episodes were identified. Episodes of ischemia were 
defined as reversible ST-segment changes, lasting at 
least one minute and shifting from baseline to more than 
0.1 mV (1 mm). The baseline ST segment level was 
defined as the average ST segment during a stable 
period (duration of 20 minutes) preceding each ischemic 
episode. ST segment change was measured 60 ms after 
the J point. If the J point fell within the T-wave, the ST 
segment change was measured 40 ms after that point. 
The ischemic burden (mm*min) was defined as 
maximum ST segment deviation multiplied by ischemia 
duration.  
 
Troponin T measurement 
In all patients, troponine T levels were measured on 
postoperative day 1, 3, 7, before hospital discharge and 
whenever clinically indicated by ECG changes, 
consistent with myocardial ischemia or infarction. 
Troponin T level was measured using a whole blood 
rapid test (TropT version 2, Roche Diagnostics, 
Mannheim, Germany). A value of >0.03 ng/ml was used 
to define positive troponin T levels. 
 
 
 
Table 1. Baseline characteristics of the study population. 
 n=182 
Age (years) 66 ± 11 
Male gender 147 (81%) 
Current stable angina pectoris 34 (19%) 
History of myocardial infarction 52 (29%) 
Previous coronary artery revascularization 23 (13%) 
History of congestive heart failure 11 (65) 
History of cerebrovascular event 50 (28%) 
Renal failure 9 (5%) 
Diabetes mellitus 28 (15%) 
Hypertension 76 (42%) 
Hypercholesterolemia 70 (39%) 
Current or past smoking 91 (50%) 
Aspirin  101 (56%) 
Angiotensin-converting enzyme inhibitors 46 (25%) 
Beta-blockers 152 (84%) 
Calcium channel blockers 37 (20%) 
Digoxin 2 (1%) 
Statins 109 (60%) 
Preoperative heart rate 67 ± 10 
Rest wall motion abnormalities 45 (25%) 
Stress induced new wall motion abnormalities 31 (17%) 
Abdominal aortic aneurysm repair  91 (50%) 
Lower extremity revascularization 57 (31%) 
Carotid artery surgery 34 (19%) 
Values are given in number (%), or in mean ±  standard deviation 
 
 
Heart rate variability 
Heart rate variability was computed for each subject 
using time-domain analysis of short-term 5-minute 
recordings in the preoperative period. Consecutive 5-
minute recordings of 2-hour periods were standardly 
obtained at the evening before surgery. The average 
heart rate variability of the 5-minute recordings during 
the 2-hour period was calculated. We used standard 
time domain measures including the standard deviation 
of the normal-to-normal (NN) intervals (SDNN) and the 
square root of the mean squared differences of 
successive NN intervals (rMSSD).  
 
Perioperative management 
Prior to surgery, patients with beta-blockers were asked 
about medication adherence. Beta-blockers were 
withheld if patients presented with a systolic blood 
pressure <100 mmHg or with a heart rate <50 bpm. 
Beta-blockers were administered orally. In patients not 
able to take their medication orally, beta-blockers were 
administered by naso-gastric tube or by intravenous 
line. All patients received standard perioperative pain 
management. Surgical procedures were classified as 
abdominal aortic aneurysm repair (91 patients, 50%), 
lower extremity revascularization (57 patients, 31%) 
and carotid artery surgery (34 patients, 19%). 
 
Follow-up 
Study endpoints were hard cardiac events (cardiac death 
and non-fatal myocardial infarction) during follow-up. 
Outpatient visits were scheduled every 3 months after 
discharge. Cardiac death was defined as any death with 
a cardiovascular cause, including those deaths following 
a cardiac procedure, cardiac arrest, myocardial 
infarction, pulmonary embolus, stroke, hemorrhage, or 
sudden deaths due to unknown causes. Non-fatal 
myocardial infarction was diagnosed when at least two 
of the following were present: elevated cardiac enzyme 
levels (troponin T >0.1 ng/ml), development of typical 
electrocardiographic changes (new Q waves >1 mm or > 
30 ms), and typical symptoms of angina pectoris. No 
patients were lost to follow-up. 
 
Statistical analysis 
Continuous data are expressed as mean (± SD) and 
compared by using the Student t test. Categorical data 
are presented as percentages and analyzed using the chi-
square test with Yates’ correction. Baseline natriuretic 
peptide levels were abnormally distributed and 
converted to its natural logarithm. Binary logistic 
regression analysis was used to study the association 
between natriuretic peptides and myocardial ischemia 
and troponin T release. Receiver operating curve 
characteristic analysis was used to assess the optimal 
cutoff value of NT-proBNP in predicting the composite  
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Table 2. Univariate and multivariate analysis of the association between baseline N-terminal pro-B-type natriuretic peptide and perioperative 
myocardial ischemia as detected by continuous 12-lead electrocardiographic monitoring, troponin T release and early and late hard cardiac 
events. 
Odds/Hazard Ratio per 1 ng/l increase in the natural logarithm of 
baseline NT-proBNP (95% CI) 
 Number of 
events 
Univariate Multivariate* 
Perioperative myocardial ischemia 38 (21%) 1.59 (1.21-2.08) 1.49 (1.12-1.98) 
Troponin T release 31 (17%) 1.76 (1.33-2.34) 1.63 (1.22-2.19) 
Hard cardiac events during follow-up 11 (6%) 1.68 (1.10-2.55) 1.59 (1.03-2.50) 
Adjusted for age, gender, coronary artery disease, history of congestive heart failure, history of cerebrovascular events, diabetes mellitus, renal 
failure, hypertension, dobutamine stress echocardiography results and cardiovascular medication.  
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Figure 1. A histogram showing the distribution of N-terminal pro-B-
type natriuretic peptide levels and its natural logarithm in the study 
population 
 
 
 
 
of myocardial ischemia and troponin T release. Cox 
regression analysis was use to study the association 
between natriuretic peptides and long-term events. The 
Pearson coefficient was used to estimate the correlation 
between baseline natriuretic peptides and preoperative 
heart rate variability. In multivariate analysis, 
adjustments were made for age, gender, cardiac risk 
factors according to the Revised Cardiac Risk Index 
(coronary artery disease, history of congestive heart 
failure, cerebrovascular disease, diabetes mellitus and 
renal failure), dobutamine stress test results, 
hypertension and cardiovascular medication. Odds and 
hazard ratios are given with 95% confidence intervals. 
For all tests, a p value <0.05 (two-sided) was considered 
significant. All analysis was performed using SPSS 12.0 
statistical software (SPSS Inc., Chicago, Illinois). 
 
RESULTS 
 
Baseline characteristics 
Inclusion criteria were fulfilled in 182 patients. Baseline 
characteristics are presented in Table 1. The mean age 
of the study population was 66 ± 11 years and 81% was 
male. The distribution of baseline NT-proBNP levels 
and its natural logarithm are presented in Figure 1. The 
median NT-proBNP level was 184 ng/L (interquartile 
range: 79-483 ng/L). Dobutamine stress 
echocardiography revealed rest wall motion 
abnormalities in 25% and stress induced wall motion 
abnormalities in 17% of the patients. No fatal 
complications occurred during or immediately after the 
stress test. 
 
NT-proBNP in relation to myocardial ischemia and 
troponin T release 
Myocardial ischemia during continuous 12-lead 
electrocardiographic registration was assessed in 38 
participants (21%). A total of 77 periods of myocardial 
ischemia were detected. The number of ischemic events 
per patient ranged from 1 to 5. The median duration of 
ischemic events was 43 minutes (range 5-1130 minutes)  
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Figure 2. The incidence of myocardial ischemia, troponin T release 
and late hard cardiac events and the median N-terminal pro-B-type 
natriuretic peptide level. 
 
and the median ST-segment deviation was 1.5 mm 
(range 1.0-5.6 mm). In patients with ischemia, median 
ischemic burden was 72 mm*min (range: 7-5508 
mm*min). Troponin T levels >0.03 ng/ml were 
measured in 31 patients (17%). Troponin T values 
ranged from 0.03 to 8.2 ng/ml. Figure 2 demonstrates 
the median NT-proBNP level in patients with 
myocardial ischemia, troponin T release and late cardiac 
events.  
As demonstrated in Figure 3, higher baseline 
NT-proBNP levels were associated with an increased 
incidence of myocardial ischemia and troponin T 
release. The optimal cut-off value to predict the 
composite of myocardial ischemia and troponin T 
release as determined by receiver operating 
characteristic analysis was 270 ng/L (area under the 
curve: 0.70) (Figure 4).  
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Figure 3. The proportion of patients with perioperative myocardial 
ischemia detected by continuous 12-lead electrocardiographic 
monitoring and troponin T release in relation to baseline N-terminal 
pro-B-type natriuretic peptide levels, according to the quartiles.  
 
Interestingly, in the 38 patients with myocardial 
ischemia, higher NT-proBNP levels correlated 
significantly with a larger ischemic burden at 12-lead 
ECG monitoring (r=0.22, p=0.03). In multivariate 
analysis, higher baseline NT-proBNP levels remained 
significantly associated with a higher incidence of 
myocardial ischemia and troponin T release (Table 2). 
During follow-up, hard cardiac events occurred 
in 11 patients (6%). Higher baseline NT-proBNP levels 
were significantly associated with a higher incidence of 
hard cardiac events, irrespective of clinical variables 
and dobutamine stress echocardiography results (Table 
2). 
 
NT-proBNP and preoperative heart rate variability 
Mean SDNN and rMSSD prior to surgery was 47 ± 26 
and 37 ± 34 ms respectively. No correlation was found 
between baseline NT-proBNP levels and preoperative 
SDNN (r=-0.024, p=0.78) and rMSSD (r=0.14, p=0.1) 
(Figure 5). Also in a subgroup of patients without rest 
wall motion abnormalities and new wall motion 
abnormalities (n=130), no correlation was found 
between baseline NT-proBNP levels and preoperative 
SDNN (r=-0.009, p=0.9) and rMSSD (r=0.12, p=0.08). 
 
DISCUSSION 
 
In this study of patients undergoing major vascular 
surgery, we found that increased levels of preoperative 
NT-proBNP significantly correlated with an increased 
incidence of perioperative myocardial ischemia during 
continuous 12-lead electrocardiographic monitoring and 
with increased troponin T release. This association was 
independent of baseline clinical variables and 
independent of preoperative dobutamine stress 
echocardiography results. No association was observed 
between baseline NT-proBNP levels and preoperative 
heart rate variability.  
 
NT-proBNP and perioperative myocardial ischemia 
Natriuretic peptides are released from the ventricle and 
play a valuable role in the regulation of body fluid and 
blood pressure. Ventricular wall stress causes synthesis 
and release of natriuretic peptides and explains the 
elevated levels in patients with left ventricular 
dysfunction. The reason of elevated natriuretic peptides 
in patients with ischemic heart disease has not been 
completely understood. In an experimental rat model of 
acute myocardial infarction, ventricular BNP mRNA 
expression and tissue concentrations of BNP were 
increased both in the non-infarcted as well as in the 
infarcted region [188]. Another study obtained 
myocardial biopsies from patients with coronary artery 
disease and demonstrated an association between BNP 
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Figure 4. Receiver operating curve analysis demonstrating the optimal 
cutoff value of plasma N-terminal pro-B-type natriuretic peptide 
levels for predicting the composite of perioperative myocardial 
ischemia and troponin T release.  
 
 
 
Figure 5. A scatter plot demonstrating the correlation between the 
natural logarithm of baseline plasma N-terminal pro-B-type natriuretic 
peptide level and preoperative heart rate variability (SDNN). 
 
mRNA expression in ischemic myocardium and plasma 
BNP levels, even in the absence of left ventricular 
dysfunction as evaluated by ventriculography [19]. 
Ndrepepa and colleagues found a positive association 
between the level of NT-proBNP and the severity of 
angiographic coronary artery disease in patients with 
angina pectoris and acute myocardial infarction [20]. It 
has been hypothesized that ventricular wall stress 
secondary to chronic or repetitive ischemia triggers the 
synthesis and release of natriuretic peptides. Sabatine 
and colleagues measured NT-proBNP levels before and 
after exercise testing with nuclear perfusion imaging, 
and showed that NT-proBNP levels rose immediately in 
patients with exercise induced transient myocardial 
ischemia and that the magnitude of NT-proBNP rise 
was associated with the severity of ischemia [21]. The 
current study supports the notion that natriuretic peptide 
levels are associated with myocardial ischemia, 
irrespective of baseline rest wall motion abnormalities, 
and that elevations in natriuretic peptides may reflect 
early silent or symptomatic ischemic heart disease. 
 
NT-proBNP and heart rate variability 
Heart rate variability, a commonly used measure of 
cardiac autonomic dysfunction, mostly reflects vagal 
tone. Reduced heart rate variability in patients following 
a myocardial infarction or congestive heart failure has 
consistently been shown to be predictive of sudden, 
arrhythmic, cardiovascular and non-cardiovascular 
mortality. Also in patients undergoing major non-
cardiac surgery at high risk of coronary artery disease, 
depressed heart rate variability before induction of 
anesthesia has been found to be an independent 
predictor of one-year mortality [16]. It has been 
hypothesized that natriuretic peptides are released as an 
early response to cardiac autonomic dysfunction, before 
the onset of clinically detectable cardiac dysfunction. In 
an histological study of a dissected bovine heart, BNP 
and ANP immunoreactivities frequently occur in the 
atrioventricular bundle and are co-localized in Purkinje 
fibres, suggesting that natriuretic peptides may act in an 
autocrine and/or paracrine way in the conduction system 
[22]. It also has been reported that exogenous 
administration of BNP in a rat model can modulate 
autonomic nervous activity [23].  However, the relation 
between NT-proBNP and the severity of autonomic 
dysfunction remains poorly understood. A previously 
published study found in 32 consecutive patients with 
type 2 diabetes that increased levels of plasma BNP 
correlated with cardiac reflex parasympathetic 
dysfunction [24]. A significant association between 
BNP and heart rate variability could not be established, 
which may have been due to the small sample size. In 
the current study involving 182 patients, an association 
between NT-proBNP and heart rate variability could 
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also not be established in the total population as well as 
in the population of patients without resting and stress 
induced echocardiographic abnormalities. Therefore, in 
our opinion, it seems not likely that decreased heart rate 
variability contributes significantly to the synthesis and 
release of NT-proBNP.     
 
Clinical implications 
Risk stratification identifies patients at risk for 
perioperative and long-term mortality who benefit from 
primary and secondary prevention strategies, such as 
risk factor reduction, life-style modification and optimal 
medical treatment with β-blockers and statins. 
Natriuretic peptides are promising markers for risk 
assessment in patients undergoing major vascular 
surgery. Currently, preoperative risk stratification is 
based on a set of clinical risk factors that allows an 
estimate of the weighted risk of perioperative cardiac 
complications. According to the American College of 
Cardiology/American Heart Association guidelines, 
preoperative cardiac exercise or pharmacological stress 
testing is recommended in all patients at increased 
cardiac risk based on clinical risk profile, functional 
capacity and type of surgery [25]. Extensive screening 
increases costs and delays surgery. The optimal 
algorithm that includes NT-proBNP for preoperative 
risk stratification still has to be developed. Although the 
current study was not designed to elucidate the 
biological mechanism between elevated NT-proBNP 
levels and cardiovascular events, the results showed that 
NT-proBNP levels are associated with important 
correlates of adverse cardiovascular outcome. 
Ultimately, the utility of NT-proBNP lies in its ability to 
guide and improve perioperative medical management.  
 
Study limitations 
Several limitations should be noted when interpreting 
the results of the study. The results apply to patients 
undergoing major vascular surgery, and our findings 
may not be generalized to patients undergoing general 
or low-risk surgery. For troponin T release, we used a 
lower cut-off level of 0.03 ng/ml to define positive 
troponin T levels. Lower troponin T levels were not 
used, since they do not meet the imprecision criteria 
(coefficient of variation) of <10%. Therefore, the results 
may have been biased to the detection of higher 
troponin T release.  
 
Conclusion 
On the basis of this observational study, increased 
preoperative NT-proBNP levels in patients scheduled 
for major vascular surgery are associated with an 
increased incidence of perioperative myocardial 
ischemia during 12-lead electrocardiographic 
monitoring and increased troponin T release, 
independent of clinical risk factors and dobutamine 
stress echocardiography results. These findings support 
the evidence that natriuretic peptides can be used as 
prognostic marker in patients undergoing major vascular 
surgery. Although it has been hypothesized that NT-
proBNP may be elevated in patients with cardiac 
autonomic dysfunction, this study could not establish an 
association between baseline NT-proBNP levels and 
preoperative heart rate variability.  
 
REFERENCES 
 
1. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N 
Engl J Med. 1998;339:321-328. 
2. Hall C. Essential biochemistry and physiology of (NT-pro)BNP. 
Eur J Heart Fail. 2004;6:257-260. 
3. Yoshimura M, Yasue H, Okumura K, Ogawa H, Jougasaki M, 
Mukoyama M, et al. Different secretion patterns of atrial 
natriuretic peptide and brain natriuretic peptide in patients with 
congestive heart failure. Circulation. 1993;87:464-469. 
4. Yasue H, Yoshimura M, Sumida H, Kikuta K, Kugiyama K, 
Jougasaki M, et al. Localization and mechanism of secretion of 
B-type natriuretic peptide in comparison with those of A-type 
natriuretic peptide in normal subjects and patients with heart 
failure. Circulation. 1994;90:195-203. 
5. Lainchbury JG, Campbell E, Frampton CM, Yandle TG, 
Nicholls MG, Richards AM. Brain natriuretic peptide and n-
terminal brain natriuretic peptide in the diagnosis of heart failure 
in patients with acute shortness of breath. J Am Coll Cardiol. 
2003;42:728-735. 
6. Bettencourt P, Azevedo A, Pimenta J, Frioes F, Ferreira S, 
Ferreira A. N-terminal-pro-brain natriuretic peptide predicts 
outcome after hospital discharge in heart failure patients. 
Circulation. 2004;110:2168-2174.  
7. AtheroGene Investigators. Analysis of N-terminal-pro-brain 
natriuretic peptide and C-reactive protein for risk stratification in 
stable and unstable coronary artery disease: results from the 
AtheroGene study. Eur Heart J. 2005;26:241-249. 
8. Kragelund C, Gronning B, Kober L, Hildebrandt P, Steffensen 
R. N-terminal pro-B-type natriuretic peptide and long-term 
mortality in stable coronary heart disease. N Engl J Med 
2005;352:666-675. 
9. Yeh HM, Lau HP, Lin JM, Sun WZ, Wang MJ, Lai LP. 
Preoperative plasma N-terminal pro-brain natriuretic peptide as a 
marker of cardiac risk in patients undergoing elective non-
cardiac surgery. Br J Surg. 2005;92:1041-1045. 
10. Feringa HH, Bax JJ, Elhendy A, de Jonge R, Lindemans J, 
Schouten O, et al. Association of plasma N-terminal pro-B-type 
natriuretic peptide with postoperative cardiac events in patients 
undergoing surgery for abdominal aortic aneurysm or leg 
bypass. Am J Cardiol. 2006;98:111-115. 
11. Dernellis J, Panaretou M. Assessment of cardiac risk before non-
cardiac surgery: brain natriuretic peptide in 1590 patients. Heart. 
2006;92:1645-1650. 
12. Feringa HH, Schouten O, Dunkelgrun M, Bax JJ, Boersma E, 
Elhendy A, et al. Plasma N-terminal pro-B-type natriuretic 
peptide as long-term prognostic marker after major vascular 
surgery. Heart. 2007;93:226-231. 
13. The Study of Perioperative Ischemia Research Group. 
Association of perioperative myocardial ischemia with cardiac 
morbidity and mortality in men undergoing non-cardiac surgery. 
N Engl J Med 1990;323:1781-1788. 
14. Lopez-Jimenez F, Goldman L, Sacks DB, Thomas EJ, Johnson 
PA, Cook EF et al. Prognostic value of cardiac troponin T after 
  142
noncardiac surgery: 6-month follow-up data. J Am Coll Cardiol. 
1997;29:1241-1245 
15. Bilchick KC, Berger RD. Heart rate variability. J Cardiovasc 
Electrophysiol. 2006;17:691-694. 
16. Filipovic M, Jeger R, Probst C, Girard T, Pfisterer M, Gurke L, 
et al. Heart rate variability and cardiac troponin I are incremental 
and independent predictors of one-year all-cause mortality after 
major noncardiac surgery in patients at risk of coronary artery 
disease. J Am Coll Cardiol. 2003;42:1767-1776 
17. Lee TH, Marcantonio ER, Mangione CM, Thomas EJ, 
Polanczyk CA, Cook EF, et al. Derivation and prospective 
validation of a simple index for prediction of cardiac risk of 
major noncardiac surgery. Circulation. 1999;100:1043-1049. 
18. Hama N, Itoh H, Shirakami G, Nakagawa O, Suga S, Ogawa Y, 
et al. Rapid ventricular induction of brain natriuretic peptide 
gene expression in experimental acute myocardial infarction. 
Circulation 1995;92:1558-1564. 
19. Goetze JP, Christoffersen C, Perko M, Arendrup H, Rehfeld JF, 
Kastrup J, et al. Increased cardiac BNP expression associated 
with myocardial ischemia. FASEB J 2003;17:1105-1107.  
20. Ndrepepa G, Braun S, Mehilli J, von Beckerath N, Vogt W, 
Schomig A, et al. Plasma levels of N-terminal pro-brain 
natriuretic peptide in patients with coronary artery disease and 
relation to clinical presentation, angiographic severity, and left 
ventricular ejection fraction. Am J Cardiol 2005;95:553-557. 
21. Sabatine MS, Morrow DA, de Lemos JA, Omland T, Desai MY, 
Tanasijevic M, et al. Acute changes in circulating natriuretic 
peptide levels in relation to myocardial ischemia. J Am Coll 
Cardiol 2004;44:1988-1995. 
22. Hansson M, Forsgren S. Immunoreactive atrial and brain 
natriuretic peptides are co-localized in Purkinje fibres but not in 
the innervation of the bovine heart conduction system. 
Histochem J. 1995;27:222-230. 
23. Thomas CJ, Head GA, Woods RL. Similar baroreflex 
bradycardic actions of atrial natriuretic peptide and B and C 
types of natriuretic peptides in conscious rats. J Hypertens. 
1999;17:801-806. 
24. Yufu K, Takahashi N, Nakagawa M, Hara M, Saikawa T, 
Yoshimatsu H. Brain natriuretic peptide and cardiac autonomic 
function in type 2 diabetic patients. Diabetes Res Clin Pract. 
2006;72:12-19. 
25. Eagle KA, Berger PB, Calkins H, Chaitman BR, Ewy GA, 
Fleischmann KE, et al. ACC/AHA guideline update for 
perioperative cardiovascular evaluation for noncardiac surgery---
executive summary a report of the American College of 
Cardiology/American Heart  
26. Association Task Force on Practice Guidelines (Committee to 
Update the 1996 Guidelines on Perioperative Cardiovascular 
Evaluation for Noncardiac Surgery). Circulation. 
2002;105:1257-1267. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  143
Chapter 17 
 
Plasma natriuretic peptides reflect left ventricular function and 
functional status after mitral valve repair 
 
International Journal of Cardiovascular Imaging. 2007;23:159-165 
 
Harm H.H. Feringa  
Don Poldermans  
Patrick Klein  
Jerry Braun 
Robert J. Klautz 
Ron T. van Domburg  
Arnoud van der Laarse 
Ernst E. van der Wall 
Robert A. Dion  
Jeroen J. Bax 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  144
Plasma natriuretic peptide levels reflect changes in 
heart failure symptoms, left ventricular size and 
function after surgical mitral valve repair 
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M.D.*, Ron T. van Domburg, Ph.D.‡, Arnoud van der Laarse, Ph.D.*, Ernst E. van der Wall, M.D.*, Robert A.E. 
Dion, M.D.* &  Jeroen J. Bax, M.D.* 
 
 
Background and aim: N-terminal pro-B-type 
natriuretic peptide (NT-proBNP) has diagnostic and 
prognostic value in patients with heart failure. The 
present prospective study was designed to assess 
whether changes in NT-proBNP levels after surgical 
mitral valve repair reflect changes in heart failure 
symptoms and changes in left atrial size, left ventricular 
size and left ventricular function. 
Methods: The study population consisted of 22 patients 
(mean age: 62.8 ± 14.2 years, 68% male) undergoing 
surgical mitral valve repair. Serial NT-proBNP 
measurements, transthoracic echocardiography and New 
York Heart Association (NYHA) class assessment were 
performed before and 6 months after surgery. 
Results: All patients underwent successful mitral valve 
repair and no patients died during follow-up. The 
decrease in NT-proBNP level was associated with the 
reduction in left atrial dimension (r=0.72, p<0.001), left 
ventricular end-systolic dimension (r=0.63, p=0.002), 
left ventricular end-diastolic dimension (r=0.46, 
p=0.031), and the increase in fractional shortening (r=-
0.63, p=0.002). Finally, patients with decreasing NT-
proBNP levels revealed a significant improvement in 
heart failure symptoms (NYHA class). 
Conclusion: Changes in NT-proBNP after surgical 
mitral valve repair reflect changes in heart failure 
symptoms and changes in left atrial and ventricular 
dimensions and function. 
______________________________________________________________________________ 
 
 
THE NATRIURETIC PEPTIDES are endogenous 
cardiac hormones that include atrial natriuretic peptide 
(ANP), brain natriuretic peptide (BNP), and its amino-
terminal portion N-terminal pro-B-type natriuretic 
peptide (NT-proBNP) [1,2]. The BNP peptides are 
synthesized in the ventricular myocardium and released 
in response to ventricular wall stress [3,4]. In the 
clinical setting, both BNP and NT-proBNP have been 
demonstrated to provide important diagnostic and 
prognostic information in patients with heart failure [5-
8]. 
Recently, elevated plasma BNP levels have been 
demonstrated in patients with chronic valvular disease 
[9-11]. In patients with chronic mitral regurgitation, the 
severity of regurgitation was directly related to the BNP 
levels [9-11]. The effect of mitral valve repair on BNP 
levels however, has not been studied. Accordingly, the 
topic of the current study was to evaluate the change in 
BNP levels after surgical correction of severe mitral 
regurgitation and to relate the findings to left ventricular 
reverse remodeling and improvement in clinical status 
after surgery. 
 
*Cardiothoracic Surgery / Cardiology, Leiden University Medical 
Center, Leiden, the Netherlands. ‡Cardiology, Erasmus Medical 
Center, Rotterdam, the Netherlands 
 
MATERIALS AND METHODS 
 
Study population 
Between July 2005 and September 2005, 22 consecutive 
patients undergoing mitral valve repair for severe mitral 
regurgitation were prospectively enrolled. All patients 
gave informed consent to participate in the study and 
the study was conducted in accordance with the 
Declaration of Helsinki. Patients with mitral valve 
stenosis (mitral valve area <1.5 cm2) or aortic valve 
disease (severe aortic stenosis or regurgitation) were not 
included. 
Mitral regurgitation was related to cardiomyopathy in 
11 patients, and to degenerative disease in 11 patients. 
  
Assessment of symptoms and follow-up 
Clinical evaluation and assessment of symptoms using 
NYHA class was conducted by the patient’s referring 
cardiologist and was confirmed by an independent 
cardiothoracic surgeon at the time of hospital admission. 
A clinical follow-up was performed at 6 months after 
mitral valve repair to evaluate the change in NYHA 
class. During the 6-month follow-up period, adverse 
events including non-fatal myocardial infarction, repeat 
mitral valve surgery, cerebrovascular events, renal 
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dysfunction and hospitalization for heart failure were 
noted. 
 
Echocardiography 
Prior to surgery, transthoracic echocardiography was 
performed in all patients. The patients were imaged in 
the left lateral decubitus position by using a 
commercially available system (Vingmed Vivid Seven, 
General Electric – Vingmed, Milwaukee, WI, USA). 
Using a 3.5 MHz transducer, images were obtained at a 
depth of 16 cm in the parasternal (long- and short-axis 
images) and apical views (2- and 4-chamber images). 
From parasternal M-mode acquisitions, the left atrial 
diameter and left ventricular dimensions (end-systolic and 
end-diastolic diameter) were determined and the fractional 
shortening was calculated. The severity of mitral 
regurgitation was graded semi-quantitatively from 
color-flow Doppler in the conventional parasternal long-
axis and apical 4-chamber images. Mitral regurgitation 
was characterized as mild = 1+ (jet area/left atrial area 
<10%), moderate = 2+ (jet area/left atrial area 10-20%), 
moderately severe = 3+ (jet area/left atrial area 20-
45%), and severe = 4+ (jet area/left atrial area >45%) 
[12]. Immediately after surgery, transesophageal 
echocardiography was performed to assess residual 
mitral valve regurgitation. A transthoracic 
echocardiogram was repeated at 6 months follow-up to 
assess left atrial and ventricular dimensions, fractional 
shortening, the presence of residual mitral valve 
regurgitation, the transmitral diastolic gradient, the 
length of leaflet coaptation and the mitral valve area. 
Two experienced cardiologists who were blinded to the 
BNP levels and clinical data analyzed the 
echocardiographic data.  
 
NT-proBNP measurement 
Venous blood samples were collected on the day before 
and 6 months after surgery with the patient at rest and in 
semi-supine position. The samples were collected in 
chilled ethylene-diamine-tetra-acetic acid vacutainers 
and were immediately placed on ice. After 
centrifugation, the plasma samples were stored at -80°C 
until assay. Plasma NT-proBNP concentrations was 
measured with an electrochemiluminescence 
immunoassay kit (Elecsys 2010, Roche GmbH, 
Mannheim, Germany). The method is a ‘sandwich’-type 
quantitative immunoassay based on polyclonal 
antibodies against epitopes in the N-terminal part of 
pro-BNP [13]. Assays were performed by a laboratory 
technician blinded to the patient’s clinical data. 
 
 
 
 
Table 1. Baseline clinical characteristics of the study population divided into patients with increasing and decreasing N-terminal pro-B-type 
natriuretic peptide levels. 
 Overall (n=22) Decreasing NT-proBNP 
levels  (n=10) 
Increasing NT-
proBNP levels (n=12) 
p value 
Clinical variables     
    Age (yrs) 62.8 ± 14.2 63.3 ± 13.5 62.4 ± 15.3 0.89 
    Male gender 15 (68.2) 7 (70.0) 8 (66.7) 1.00 
    Hypertension 4 (18.2) 3 (30.0) 1 (8.3) 0.29 
    Diabetes mellitus 3 (13.6) 2 (20.0) 1 (8.3) 0.57 
    Chronic obstructive pulmonary disease 4 (18.2) 1 (10.0) 3 (25.0) 0.59 
    Peripheral arterial disease 3 (13.6) 3 (30.0) 0 (0) 0.078 
    History of stroke 0 (0) 0 (0) 0 (0) - 
    New York Heart Association class 2.9 ± 1.0 3.3 ± 0.9 2.8 ± 0.8 0.23 
Medication     
    Angiotensin-converting enzyme inhibitors 10 (45.5) 6 (60.0) 4 (33.3) 0.39 
    Beta-blockers 8 (36.4) 5 (50.0) 3 (25.0) 0.38 
    Diuretics 9 (40.9) 4 (40.0) 5 (41.7) 1.00 
Reason of mitral regurgitation     
    Degenerative disease 11 (50.0) 5 (50.0) 6 (50.0) 1.00 
    Cardiomyopathy 11 (50.0) 5 (50.0) 6 (50.0) 0.17 
Echocardiographic measurements     
    Mitral regurgitation, grade 3.6 ± 0.5 3.7 ± 0.5 3.6 ± 0.5 0.54 
    Left atrial dimension (cm) 4.9 ± 0.7 5.2 ±0.6 4.7 ± 0.7 0.040 
    Left ventricular end-systolic dimension (cm) 4.5 ± 0.8 4.7 ± 1.0 4.3 ± 0.6 0.21 
    Left ventricular end-diastolic dimension (cm) 6.1 ± 0.8 6.3 ± 0.7 5.9 ± 0.9 0.27 
    Fractional shortening (%) 26.8 ± 7.3 25.4 ± 8.3 28.0 ± 6.6 0.42 
Baseline LN NT-proBNP level (ng/l) 6.2 ± 1.5 6.6  ± 1.4 5.8 ± 1.5 0.18 
Values are expressed in mean ± standard deviation or in number (%). NT-proBNP denotes N-terminal pro-B-type natriuretic peptide 
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Statistical analysis 
The change in NT-proBNP levels from baseline to 6 
months follow-up was calculated and expressed as 
percentage values. Changes in left atrial dimension, left 
ventricular end-systolic and end-diastolic dimensions 
and fractional shortening were also calculated and 
expressed as percentage values. Continuous data were 
expressed as mean (± SD) or median (interquartile 
range) when the distributions were skewed and 
compared using the Student t-test or the Mann-Whitney 
U-test when appropriate. Categorical data were 
compared using the Fisher’s exact test. Group 
comparisons were performed with analysis of variance 
(ANOVA) techniques. The Pearson correlation 
coefficient was used to assess the association between 
changes in NT-proBNP levels and changes in 
echocardiographic variables. For all tests, a p value 
<0.05 was considered significant. All analysis was 
performed using SPSS-11.0 statistical software (SPSS 
Inc., Chicago, Illinois). 
 
RESULTS 
 
Baseline characteristics 
The baseline characteristics of the 22 patients (mean age 
62.8 ± 14.2 years, 68% male) are summarized in Table 
1. Eight patients (36%) were in NYHA class II, 5 (23%) 
in class III and 9 (41%) in class IV (mean NYHA class 
3.1 ± 0.9). Prior to surgery, all patients presented with 
severe mitral valve regurgitation (grade 3 to 4+), with a 
mean regurgitation grade of 3.6 ± 0.5. Mean left atrial 
dimension was 4.9 ± 0.7 cm, mean left ventricular end-
systolic dimension 4.5 ± 0.8 cm, mean left ventricular 
end-diastolic dimension 6.1 ± 0.8 cm and mean 
fractional shortening 26.8 ± 7.3%. Median NT-proBNP 
level at baseline was 418 ng/l (interquartile range: 204-
1258 ng/l). 
 
Surgical results and follow-up 
Mean length of hospital stay was 9.8 ± 4.3 days. 
Transesophageal echocardiography immediately after 
surgery demonstrated competent valves with minimal 
residual mitral valve regurgitation in all patients (mitral 
regurgitation grade 0 in 13 patients, 59% and grade 1 in 
9 patients, 41%). All patients survived the 6-month 
follow-up period and no patients were lost to follow-up. 
During hospital stay and follow-up, none of the patients 
required repeat mitral valve surgery. Adverse events, 
including nonfatal myocardial infarction, 
cerebrovascular events, hospitalization for heart failure 
or endocarditis were not observed. Two patients (9%) 
developed renal dysfunction in the postoperative period 
which was successfully treated with a short period of 
renal dialysis. None of the patients presented with renal 
dysfunction at 6 months follow-up. Median NT-proBNP 
level at 6 months follow-up was 426 ng/l (interquartile 
range 196-1172 ng/l). In 10 patients (45%), NT-proBNP 
levels decreased >10% and in 12 patients (55%) NT-
proBNP level remained unchanged or increased >10% 
as compared to baseline values. 
The patient population was subsequently divided into 
patients with a decrease in plasma NT-proBNP level 
versus patients with unchanged/increased NT-proBNP 
plasma levels (Table 1). Baseline characteristics were 
comparable between the 2 groups, including baseline 
NT-proBNP levels. Only left atrial dimension was 
somewhat larger in patients with decreasing NT-
proBNP levels after surgery as compared to those with 
increasing NT-proBNP levels (p=0.04).  
 
Changes in NT-proBNP levels and symptoms 
NYHA class deteriorated in 3 patients (14%), remained 
unchanged in 5 (23%) and improved in 14 (64%). The 
10 patients with decreased NT-proBNP levels exhibited 
a mean improvement in NYHA class of 2.0 ± 1.1, 
whereas the 12 patients with unchanged/increased NT-
proBNP levels revealed a small but significant 
worsening in NYHA class (0.3 ± 0.9, p<0.001 versus 
baseline).  
 
Changes in NT-proBNP levels and 
echocardiographic variables 
The transthoracic echocardiogram at 6 months follow-
up revealed a mean mitral regurgitation grade of 0.5 ± 
0.7, mean length of leaflet coaptation of 0.9 ± 0.2 cm, 
mean mitral valve area of 2.6 ± 0.9 cm2, and mean 
transmitral diastolic gradient of 3.3 ± 1.2 mmHg. At 
follow-up, mean left atrial dimension was 4.4 ± 0.5 cm, 
mean left ventricular end-systolic dimension 4.2 ± 0.9 
cm, mean left ventricular end-diastolic dimension 5.8 ± 
0.6 cm, and mean fractional shortening 28.0 ± 10.7%. 
The 10 patients with decreased NT-proBNP levels 
demonstrated significant reverse left ventricular 
remodeling, with a reduction in left ventricular end-
systolic dimension from 4.7 ± 1.0 cm to 3.8 ± 0.9 cm 
(p=0.042), a reduction in left ventricular end-diastolic 
dimension from 6.5 ± 0.8 cm to 5.7 ± 0.6 cm (p=0.036) 
and a reduction in left atrial dimension from 5.3 ± 0.6 
cm to 4.3 ± 0.5 cm (p=0.001). Conversely, reverse left 
ventricular remodeling was not observed in the 12 
patients with unchanged/increased NT-proBNP levels. 
Mean left ventricular end-systolic dimension was 4.3 ± 
0.6 cm at baseline versus 4.5 ± 0.7 cm (p=0.43) at 
follow-up, and mean left ventricular end-diastolic 
dimension was 5.9 ± 0.9 cm at baseline versus 5.8 ± 0.6 
cm at follow-up (p=0.66). Mean left atrial dimension 
did also not change (4.7 ± 0.7 cm versus 4.5 ± 0.6 cm, 
p=0.67). Scatter plots demonstrating the correlation 
between changes in NT-proBNP level and changes in 
echocardiographic variables during the 6-month follow- 
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Figure 1. Scatter plots demonstrating the correlation between changes in plasma N-terminal pro-B-type natriuretic peptide level (NT-proBNP) 
and changes in echocardiographic variables (A. left atrial dimension; B. left ventricular end-systolic dimension; C. left ventricular end-diastolic 
dimension; D. fractional shortening) during the 6-month follow-up period after mitral valve surgery. Of note, negative changes in left atrial 
dimension, left ventricular end-systolic dimension and left ventricular end-diastolic dimension indicate reductions in dimensions (reverse 
remodeling), whereas positive changes indicate ongoing dilatation. A positive change in fractional shortening indicates an increase in systolic 
function, whereas a negative change in fractional shortening indicates a decrease in systolic function. Negative changes in NT-proBNP indicate a 
reduction in plasma levels after surgery, whereas positive changes indicate an increase in plasma levels after surgery.  
 
up period after mitral valve surgery are presented in 
Figure 1. Decreases in NT-proBNP levels at follow-up 
were significantly correlated with reductions in left 
atrial dimension (r=0.72, p<0.001), left ventricular end-
systolic dimension (r=0.63, p=0.002), and left 
ventricular end-diastolic dimension (r=0.46, p=0.031), 
indicating reverse remodeling; conversely, increases in 
NT-proBNP levels were related to increases in the 
different dimensions, indicating ongoing dilatation. 
Moreover, decreases in NT-proBNP levels at follow-up 
were significantly correlated with improved fractional 
shorting (r=-0.63, p=0.002), indicating improved 
systolic function. 
 
COMMENTS 
 
BNP has been used extensively in the diagnosis and 
prognosis of patients with heart failure [5-8]. More 
recently, Sutton and colleagues demonstrated in 49 
patients with mitral regurgitation and preserved left 
ventricular ejection fraction that plasma levels of BNP 
and NT-proBNP levels were directly related to the 
severity of mitral valve regurgitation [11]. In addition, 
Detaint et al evaluated 124 patients with chronic mitral 
regurgitation and demonstrated that BNP levels were 
correlated with long-term outcome [14]. In particular, 
higher BNP levels independently predicted mortality 
and the combined endpoint of mortality and heart 
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failure. Moreover, the authors demonstrated that BNP 
levels in chronic mitral regurgitation were related to left 
atrial volumes, left ventricular end-systolic volume 
index, atrial fibrillation and heart failure symptoms. 
These findings indicate that the BNP plasma level 
reflects the hemodynamic, ventricular and atrial 
consequences of mitral regurgitation and that it may be 
a useful parameter to predict outcome in patients treated 
conservatively. 
In the present study, NT-proBNP was assessed in 
patients with severe mitral regurgitation and re-assessed 
after surgical correction of regurgitation. The patient 
population consisted of patients with severe mitral valve 
regurgitation (grade 3 to 4+), left ventricular dilatation 
(left ventricular end-diastolic dimension 6.1± 0.8 cm) 
and reduced left ventricular function (fractional 
shortening 26.8 ± 7.3%), with a mean NYHA class of 
3.1 ± 0.9. 
All patients underwent successful surgical correction 
and demonstrated competent mitral valves without or 
minimal regurgitation on echocardiography at 6-months 
follow-up.  
The current study is the first to report the association 
between NT-proBNP changes and echocardiographic 
outcome after surgical repair for mitral regurgitation. 
The changes in NT-proBNP levels were directly related 
to changes in left atrial dimension, left ventricular 
dimensions and systolic function (as indicated by the 
fractional shortening, see Figure 1). 
In particular, the patients with a decrease in NT-proBNP 
levels exhibited a reduction in left atrial size, with 
reverse left ventricular remodeling. On the contrary, the 
patients with an increase in NT-proBNP levels did not 
exhibit this reverse remodeling and left atrial size did 
also not decrease after surgery. In addition, the patients 
with a reduction in NT-proBNP levels demonstrated an 
improvement in symptoms (reduction in NYHA class), 
whereas patients with an increase in NT-proBNP did not 
show a change in symptoms. 
The findings confirm the use of NT-proBNP to assess 
clinical status. In addition to the heart failure 
population, NT-proBNP may be of use to reflect clinical 
status after mitral valve surgery, with a decrease in NT-
proBNP indicating an improvement in symptoms and 
reverse left ventricular remodeling; conversely, an 
increase in NT-proBNP should alert the clinician, since 
it was associated with absence of reverse remodeling 
and absence of improvement in symptoms. 
The main limitations of the current study are the small 
sample size and the relatively short follow-up; 
accordingly, larger studies with longer follow-up are 
needed to confirm the present results. In addition, 
patients with mitral regurgitation with different 
etiologies were included, and findings need 
confirmation in homogenous populations. Also, the 
patients in the current study had moderate left 
ventricular dysfunction, and additional studies in 
patients with severe left ventricular dysfunction are 
needed.  
 
Conclusion 
In conclusion, changes in NT-proBNP after surgical 
mitral valve repair reflect changes in heart failure 
symptoms and changes in left ventricular dimensions. 
Changes in NT-proBNP levels may guide therapy after 
mitral valve surgery. 
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IN PATIENTS WITH END-STAGE renal failure, 
coronary artery disease is the leading cause of morbidity 
and mortality. It has been shown in a prospective 
randomized study that prophylactic coronary artery 
revascularization in renal transplant candidates with 
diabetes and without symptoms of coronary artery 
disease reduces the incidence of cardiac events. 1 The 
detection of coronary artery disease prior to renal 
transplantation has therefore been an important goal in 
transplant programs. The American Society of 
Transplantation reported guidelines for the pre-
transplant evaluation of renal transplant candidates. 2 
They included the use of non-invasive cardiac stress 
testing, however, it remained unclear which test to use 
due to the lack of firm support for a single test. 
In this issue of the European Journal of 
Echocardiography, Sharma et al evaluated the 
diagnostic accuracy and prognostic value of dobutamine 
stress echocardiography (DSE) and elevated baseline 
plasma cardiac troponin T levels in a study population 
of 118 consecutive patients with end-stage renal disease. 
They used coronary angiography for stress test 
validation and found DSE to be an accurate technique 
for detecting coronary artery disease (sensitivity of 
88%, specificity of 94%). Also, elevated troponin T 
levels in addition to an abnormal stress test could not 
improve the sensitivity of the test, however, this was an 
important marker for the prognosis in renal transplant 
candidates (cardiac troponin T level >0.08 ng/mL for 
predicting mortality: sensitivity 75%, specificity of 
76%). 
Previously published studies evaluating the 
diagnostic accuracy of DSE for detecting coronary 
artery disease reported sensitivities of 52-95% and 
specificities of 71-86%.3,4 In addition, the result of the 
DSE has been shown to be an independent predictor of 
prognosis in patients with end-stage renal disease. 5-7 
The accuracy of these studies may have been limited by 
small sample sizes, low event rates and the lack of 
adjustment for clinical risk factors, but a meta-analysis 
of 12 studies assessed the prognostic utility of DSE and 
thallium scintigraphy in patients with end-stage renal 
disease and confirmed that abnormal test results were 
associated with a higher risk for cardiac events.8 
Inducible ischemia was associated with a six-fold 
increased risk of myocardial infarction and an almost 
four-fold increased risk of cardiac death. Fixed defects 
(rest wall motion abnormalities) were also significantly 
associated with an increased risk of cardiac death. 
Cardiac isoforms of troponin I and troponin T 
are sensitive and specific markers of myocardial injury, 
have been accepted as a standard biomarker for the 
diagnosis of acute myocardial infarction and unstable 
angina pectoris, and identify patients at increased risk 
for subsequent cardiac events.  Elevated troponin levels 
in asymptomatic patients with renal disease have been 
well-documented 9 and there is substantial evidence that 
cardiac troponins predict cardiac complications in 
patients with end-stage renal disease. 10-12 Dierkes et al 
studied 102 patients with end-stage renal disease on 
haemodialysis without clinical evidence of acute 
coronary artery disease and they found a strong 
association of elevated troponin T levels and all-cause 
mortality (cardiac troponin T level >0.10 ng/mL: 
sensitivity 83%).10 In a large study cohort of 244 
haemodialysis patients, Ooi et al found that higher 
plasma cardiac troponin T levels and increasing cardiac 
troponin T concentrations over time predicted all-cause 
mortality. 11 The association between increases in 
cardiac troponin T concentrations and mortality was 
confirmed in a large study cohort of 733 patients with 
end-stage renal disease, conducted by Apple et al. 12  
Although the underlying pathophysiological 
mechanism is still not clearly elucidated, elevated 
troponin levels may be a marker of subclinical myocyte 
damage secondary to clinically silent myocardial 
necrosis. 13 The sensitivity of troponin T to predict 
angiographic coronary artery disease in patients has 
been demonstrated in patients with a normal renal 
function; however, future studies are still needed to 
confirm this in patients with end-stage renal failure. 14 It 
may be difficult to detect elevated plasma cardiac 
troponin T levels in asymptomatic patients with 
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coronary artery disease, not only because of the 
transient release of cardiac troponin T during transient 
myocardial ischemia, but also because cardiac troponins 
are susceptible to various biochemical modifications, 
including phosphorylation, oxidation and proteolysis. 13 
In addition, dialysis may affect serum levels of cardiac 
troponins. 15 Serial troponin measurements may enhance 
the detection rate of plasma cardiac troponin levels and 
the value of cardiac troponins to predict coronary artery 
disease. 
 Coronary angiography is an effective method 
for detecting CAD and essential for the performance of 
percutaneous transluminal coronary angiography and 
revascularization surgery, however, it is invasive, 
expensive and potentially nephrotoxic. Dissimilarities in 
sensitivity and specificity for DSE and myocardial 
scintigraphy to detect anatomic evidence of coronary 
artery disease have been reported in patients with end-
stage renal failure, and the use of invasive coronary 
angiography might still be necessary to rule out 
significant coronary artery disease. 16 Coronary 
angiography in comparison to non-invasive stress 
testing might have stronger prognostic value in patients 
with end-stage renal disease. 16 However, the good 
negative predictive value of non-invasive stress testing 
suggests that patients with no stress-induced myocardial 
ischemia do not need further coronary angiography. In 
addition, the risk of contrast-associated nephropathy is 
an important concern in these patients. Coronary 
angiography should only be performed in patients with 
end-stage renal disease, when coronary artery 
revascularization is considered a reasonable option. 
 Recently, interest has focused on coronary CT 
scanning as non-invasive method for diagnosing 
coronary artery disease.  Coronary calcification detected 
by coronary CT scanning has been shown to be 
associated with silent myocardial ischemia as assessed 
with myocardial perfusion studies and to detect 
coronary artery disease in symptomatic patients. 17 
Coronary calcification is frequently observed in patients 
with end-stage renal failure and coronary CT may be a 
promising tool to improve cardiac risk stratification in 
these population.  
Traditionally, coronary artery disease in 
patients with end-stage renal disease has been treated 
conservatively, but these patients may gain from an 
aggressive treatment strategy, including mechanical 
coronary revascularization for clinically significant 
coronary artery disease. Manske et al randomly assigned 
26 asymptomatic diabetic renal transplant candidates to 
medical treatment or coronary revascularization and 
demonstrated that revascularization significantly 
decreased the frequency of cardiac events during 
follow-up. 1 Retrospective studies also suggest that 
mechanical coronary revascularization is associated 
with improved outcomes, compared to medical therapy 
alone in patients with end-stage renal disease. 18 
Prophylactic mechanical coronary artery 
revascularization before surgery may only be 
recommended in patients with advanced left main 
coronary artery disease or unstable cardiac symptoms. 
However, many physicians are reluctant to perform 
mechanical coronary revascularization procedures in 
patients with end-stage renal disease because of the poor 
outcomes compared to patients with normal renal 
function. The Coronary Artery Revascularization 
Prophylaxis trial showed that long-term outcome after 
elective major vascular surgery was not significantly 
altered by coronary artery revascularization before 
surgery in 510 patients with stable coronary artery 
disease randomly assigned to either revascularization of 
no revascularization. 19 Large, prospective, randomized, 
controlled trials are needed to prove a survival benefit 
of preoperative coronary artery revascularization in 
renal transplant candidates with stable coronary artery 
disease. Besides surgical strategies, attention should 
also be focused on medical treatment strategies for 
cardiovascular disease, which may be under-utilized in 
patients with severe chronic kidney disease.  
Appropriate preoperative evaluation of renal 
transplant candidates is not only mandated to identify 
those at increased cardiac risk, but also because the 
number of available organs is limited and early death of 
a recipient can be prevented by pre-transplant coronary 
intervention. Dobutamine stress echocardiography is 
widely recognized as an accurate diagnostic method for 
use in the general population and several studies have 
proved its diagnostic and prognostic value in patients 
with end-stage renal disease. Dobutamine stress testing 
has substituted exercise stress testing, because a 
substantial number of patients do not reach 85% of their 
maximum heart rate during exercise stress testing. It 
furthermore avoids the potentially nephrotoxic influence 
of contrast material as observed during nuclear imaging 
techniques. The ideal algorithm, incorporating risk 
factors, laboratory results, non-invasive stress testing, 
coronary angiography and preoperative coronary 
revascularization for the work-up of renal transplant 
patients still has to be validated.  
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Debate surrounds the impact of renal function on the 
prognostic value of minor troponin T release in vascular 
surgery patients. Objective of this study was to assess 
the long-term prognostic value of minor degrees of 
troponin T release in patients undergoing major vascular 
surgery, especially in those with concomitant renal 
dysfunction. Survivors of major non-cardiac vascular 
surgery (n=558) were preoperatively screened for 
cardiac risk factors and renal function. Serial troponin T 
was measured on day 1, 3, and 7 after surgery, using a 
threshold of 0.03 ng/ml. All-cause mortality and major 
adverse cardiac events (MACE) were noted during 
follow-up (mean: 3.5 ± 2.0 years). Minor (0.03-0.09 
ng/ml) and major (≥0.1 ng/ml) release of troponin T was 
observed in 5% and 8%, respectively. During follow-up, 
21% of the patients died and 15% experienced 
MACE. After adjustment for estimated glomerular 
filtration rate, patients with minor and major troponin T 
release were both at comparable increased risk for late 
mortality (HR: 3.43, 95% CI: 1.79-6.58, HR: 3.72, 95% 
CI: 2.37-5.85, respectively), and MACE (HR: 5.47, 
95% CI: 2.60-11.48, HR: 6.32, 95% CI: 3.82-10.48, 
respectively), compared to patients with troponin T 
release <0.03 ng/ml. Tests for heterogeneity revealed 
that both minor and major troponin T release have 
prognostic value across the entire spectrum of renal 
function. In conclusion, marginal elevations of troponin 
T strongly predict late mortality and MACE after major 
vascular surgery, irrespective of renal function. A 
currently underestimated high-risk subgroup of patients 
may be identified by using a lower troponin T threshold 
level.   
_____________________________________________________________________________________________ 
 
 
THE PRESENT STUDY was conducted to investigate 
whether minor (0.03-0.09 ng/ml) and major (≥0.1 
ng/ml) elevations of perioperative troponin T level have 
significant prognostic value in patients undergoing 
successful elective abdominal aortic aneurysm repair or 
lower extremity revascularization procedures. The 
impact of renal function on the prognostic value of 
minor troponin T release was also evaluated. 
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METHODS 
 
The study population consisted of consecutive adult 
patients undergoing and surviving elective abdominal 
aortic aneurysm repair or lower extremity bypass 
surgery at the Erasmus Medical Centre in Rotterdam, 
the Netherlands between January 2000 and January 
2006. For the assessment of long-term prognosis, we 
have excluded patients who died during surgery or 
before hospital discharge. All patients gave informed 
consent. Preoperative evaluation was performed 
according to the ACC/AHA guidelines on perioperative 
cardiovascular evaluation for non-cardiac surgery [1]. 
Prior to surgery, patients were screened for cardiac risk 
factors, including hypertension (blood pressure ≥140/90 
mmHg or treatment with antihypertensive drugs), 
diabetes mellitus (fasting glucose level ≥126 mg/dl 
(≥7.0 mmol/l) or treatment with antidiabetic drugs) and 
hypercholesterolemia (plasma cholesterol level ≥5.5 
mmol/L or treatment with cholesterol lowering drugs). 
A detailed cardiac history was obtained and coronary 
artery disease was indicated by a previous myocardial 
infarction, by a previous coronary intervention, or by 
the presence of angina pectoris. Patients were also 
screened for a history of stroke, congestive heart failure 
and chronic obstructive pulmonary disease. Preoperative 
serum creatinine levels were obtained and the last single 
serum creatinine measurement was used when multiple 
measurements were performed before surgery. The 
Modification of Diet in Renal Disease study has 
  155
provided  a useful estimate of the glomerular filtration 
rate (eGFR) in adults, which has been recommended by 
the National Kidney Foundation practice guidelines for 
chronic kidney disease [2,3]. eGFR was calculated by 
the following equation: glomerular filtration rate 
(ml/min/1.73 m2) = 186 x (serum creatinine level)-1.154 x 
(age)-0.203 x (0.742 if female) x (1.210 if African-
American) [2,3]. A total of 275 patients (49%) 
underwent elective abdominal aortic aneurysm repair 
and 283 patients (51%) underwent lower extremity 
bypass surgery. 
Serial cardiac troponin T levels measurements 
were obtained in all patients on postoperative day 1, 3 
and 7 and before discharge by an 
electrochemiluminescence immunoassay on the Elecsys 
2010 immunoanalyzer (Roche Diagnostics, Mannheim, 
Germany). If one of these measurements was elevated, 
measurements were repeated on every day until the 
level returned to normal values. Absolute troponin T 
levels were noted and the highest of the serial troponin 
T measurements was used for analysis. We used the 
recommended lower limit of 0.03 ng/ml, since lower 
troponin T levels do not meet the imprecision criteria 
(coefficient of variation) of <10% [4].  
During follow-up, the end-points of the study 
were mortality from all causes and major adverse 
cardiac events (cardiac death or non-fatal myocardial 
infarction, MACE). Survival status was obtained by 
approaching the municipal civil registries. The cause of 
death was determined by reviewing autopsy reports, 
death certificates and by approaching the referring 
physician. Cardiac death was defined as death caused by 
acute myocardial infarction, cardiac arrhythmias, or 
congestive heart failure. Sudden unexpected death was 
included as cardiac death. Clinical information was 
obtained by regularly scheduled outpatient visits, by 
telephone interviews, by reviewing hospital records and 
by approaching the referring physician. Non-fatal 
myocardial infarction was diagnosed when at least two 
of the following were present: elevated cardiac enzyme 
levels (creatine kinase (CK) level > 190 U/L and CK-
MB fraction >14 U/L, or CK-MB fraction >10% of total 
CK, or cardiac troponin T >0.1 ng/ml), development of 
typical electrocardiographic changes (new Q waves >1 
mm or > 30 ms), and typical symptoms of angina 
pectoris.  
Continuous data were expressed as mean (± 
SD) and compared using the Student t test or using 
analysis of variance techniques. Categorical data were 
compared using the Chi-square test. Troponin T release 
was divided in minor release (between 0.03-0.09 ng/ml) 
and major release (≥0.10 ng/ml). Renal function was 
classified according to non-standard cut-off values: 
normal renal function (eGFR ≥75.0 ml/min per 1.73 
m2), mild dysfunction (eGFR 60.0-74.9 ml/min per 1.73 
m2), moderate dysfunction (eGFR 45.0-59.9 ml/min per 
1.73 m2) and severe dysfunction (eGFR <45.0 ml/min 
per 1.73 m2). The Kaplan-Meier method with the log-
rank test was used to compare survival between 
different groups of patients. Multivariate Cox 
proportional hazard regression analysis was used to 
evaluate the long-term prognostic value of perioperative 
troponin T elevations, independent of eGFR, 
demographics, cardiac risk factors according to the 
Revised Cardiac Risk Index (coronary artery disease, 
history of congestive heart failure, history of 
cerebrovascular disease, and diabetes mellitus) [5] and 
cardioprotective medication. Tests for heterogeneity 
were used to reveal a possible interaction between 
troponin T release and eGFR. For all tests, a p value 
<0.05 (2-sided) was considered significant. All analyses 
were performed using SPSS-11.0 statistical software 
(SPSS Inc., Chicago, Illinois). 
 
 
Table 1. Clinical characteristics of the study cohort according to different troponin T elevations 
Characteristic All Troponin T levels P-value 
 n=558 <0.03 ng/ml 
n=487 
0.03-0.09 ng/ml 
n=25 
≥0.10 ng/ml 
n=46 
 
Age (years) (mean +/-SD) 66.6 ± 10.7 66.1 ± 10.9 68.6 ± 10.2 70.7 ± 7.8 0.014 
Male gender 428 (76.7) 373 (76.6) 19 (76.0) 36 (78.3) 0.96 
Angina pectoris 100 (17.9) 81 (16.6) 6 (24.0) 13 (28.3) 0.10 
Previous myocardial infarction 192 (34.4) 157 (32.2) 11 (44.0) 24 (52.2) 0.014 
Previous CABGa 89 (15.9) 72 (14.8) 4 (16.0) 13 (28.3) 0.058 
Coronary artery disease (summary) 239 (42.8) 197 (40.5) 15 (60.0) 27 (58.7) 0.012 
History of congestive heart failure 22 (3.9) 18 (3.7) 3 (12.0) 1 (2.2) 0.093 
Previous cerebrovascular event 70 (12.5) 61 (12.5) 4 (16.0) 5 (10.9) 0.82 
Diabetes mellitus type 1 78 (14.0) 65 (13.3) 5 (20) 8 (17.4) 0.51 
Hypertension 232 (41.6) 198 (40.7) 11 (44.0) 23 (50.0) 0.46 
Hypercholesterolemia 172 (30.8) 150 (30.8) 6 (24.0) 16 (34.8) 0.64 
Current smoking 326 (58.4) 293 (60.2) 13 (52.0) 20 (43.5) 0.072 
Abdominal aortic aneurysm repair  275 (49.3) 229 (47.0) 20 (80.0) 26 (56.5) <0.001 
Lower extremity revascularization 283 (50.7) 258 (53.0) 5 (20.0) 20 (43.5) 0.003 
Serum creatinine (mg/dl) 1.21 ± 1.08 1.13 ± 0.89 1.58 ± 1.58 1.93 ± 2.00 <0.001 
eGFRb (ml/min per 1.73 m2) 80 ± 31 82 ± 31 67 ± 33 61 ± 32 <0.001 
acoronary artery bypass grafting; bestimated glomerular filtration rate. Values are expressed in mean ± SD or number (%).  
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RESULTS 
 
The study population was predominantly male and 
mean age was 67 ± 11 years (Table 1). Mean eGFR was 
80 ± 31 ml/min/1.73 m2. Normal renal function was 
assessed in 318 patients (57%), mild renal dysfunction 
in 105 patients (19%), moderate renal dysfunction in 68 
patients (12%) and severe renal dysfunction in 67 
patients (12%). Minor troponin T elevation was 
observed in 25 patients (5%) and major troponin T 
elevations in 46 patients (8%).  
 
 
 
 
Figure 1. Survival and freedom from major adverse cardiac events 
(MACE) in 558 patients who survived major non-cardiac vascular 
surgery according to perioperative troponin T release. 
 
During a mean follow-up time of 4 ± 2 years, 116 
patients (21%) died. MACE were observed in 82 
patients (15%) (cardiac death in 62 patients and non-
fatal myocardial infarction in 20). Kaplan-Meier curves 
stratified according to the level of troponin T release 
revealed that patients with minor and major troponin T 
release had a significantly decreased survival and 
MACE free survival, compared to patients with troponin 
T release <0.03 ng/ml (p<0.001 and p<0.001, 
respectively) (Figure 1). A decreased survival and 
MACE free survival was also observed in patients with 
more severe renal dysfunction (p<0.001 and p<0.001, 
respectively) (Figure 2). Multivariate analysis with 
adjustment for clinical characteristics and eGFR 
revealed that patients with minor (HR: 3.43, 95% CI: 
1.79-6.58, p<0.001) and major troponin T release (HR: 
3.72, 95% CI: 2.37-5.85, p<0.001) were both at 
comparable increased risk for late mortality compared 
to patients with troponin T release <0.03 ng/ml. Patients 
with minor (HR: 5.47, 95% CI: 2.60-11.48, p<0.001) 
and major troponin T release (HR: 6.32, 95% CI: 3.82-
10.48, p<0.001) were also at increased risk for MACE, 
compared to patient with troponin T release <0.03 
ng/ml.  
 
 
 
 
 
Figure 2. Survival and freedom from major adverse cardiac events 
(MACE) in 558 patients who survived major non-cardiac vascular 
surgery according to renal function. 
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In a subgroup analysis of patients with 
moderate or severe renal dysfunction (n=135), minor 
and major troponin T release remained significantly 
associated with late mortality (HR: 4.27, 95% CI: 1.75-
10.40, p<0.001, and HR: 5.54, 95% CI: 2.92-10.52, 
p<0.001) and MACE (HR: 8.09, 95% CI: 2.72-24.05, 
p<0.001, and HR: 7.05, 95% CI: 3.44-14.47, p<0.001). 
Moreover, tests for heterogeneity revealed no evidence 
for a differential effect of troponin T release in patients 
with different eGFR (p=0.19 for the endpoint all-cause 
mortality and p=0.79 for the endpoint MACE), 
indicating that minor and major elevations of troponin T 
predicted the risk of late mortality and MACE across 
the entire spectrum of renal function.  
 
DISCUSSION 
 
The troponin complex is a group of 3 proteins 
(troponin T, troponin I and troponin C) that act together 
through the tropomyosin complex to regulate muscle 
contraction. Cardiac troponin T levels are detectable in 
3 to 12 hours after myocardial injury, and the 
concentration is in direct proportion to the extent of 
myocardial injury [6]. Because of its high cardiac 
specificity, we have used troponin T as biomarker for 
myocardial damage instead of troponin I, troponin C, or 
creatine kinase and its MB subfraction. No consensus 
exists about optimal threshold levels of troponin T. 
 The ACC/ESC task force expressed in their 
consensus document that all elevated values of troponin 
T in the setting of documented myocardial ischemia 
should be considered myocardial infarction, using a 
upper value which corresponds to the 99th percentile of 
a reference group [7]. In our study, the Roche elecsys 
2010 immunoanalyzer, which does not cross-react with 
skeletal troponin, allowed a lower limit of 0.03 ng/ml 
with an acceptable imprecision (coefficient of variation) 
of ≤10%. The prognostic usefulness of small troponin T 
elevations has been studied previously among patients 
who presented to the emergency department with 
suspected myocardial ischemia. Hendrikson and 
colleagues showed that patients with small elevations of 
troponin T between 0.01 and 0.09 ng/ml were at 
significantly increased risk of death, myocardial 
infarction and coronary revascularization, compared to 
patients with undetectable troponin T release [8]. In 
patients who underwent major vascular procedures, 
Landesberg and colleagues demonstrated that at low 
cut-off levels, elevations in cardiac troponins (troponin I 
>0.6 ng/ml and/or troponin T >0.03 ng/ml) 
independently predicted increased risk of long-term 
mortality [9]. In this study, it was less clear whether a 
subgroup of patients with small troponin T elevations 
were at increased risk of late cardiac events and whether 
renal function interfered with the prognostic value of 
troponin T.  
The current study showed that after adjustment 
for eGFR, minor elevations in troponin T between 0.03 
and 0.09 ng/ml were strongly associated with adverse 
outcome. The hazard ratio for late all-cause mortality in 
patients with troponin T release between 0.03 and 0.09 
ng/ml was comparable to the hazard ratio of patients 
with troponin T release of 0.10 ng/ml or more. Tests of 
heterogeneity confirmed that both minor and major 
elevations of troponin T predicted the risk of late 
mortality across the entire spectrum of renal function.  
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Purpose of review Cardiovascular disease is the 
leading cause of death after anesthesia and surgery. The 
preoperative identification of patients with underlying 
coronary artery disease is important to initiate 
appropriate treatment strategies in order to reduce the 
risk of perioperative complications. The current review 
will discuss new insights in the field of perioperative 
medicine that can be applied to clinical practice or 
stimulate further investigation. 
Recent findings Recent findings in the past year have 
developed preoperative risk stratification in terms of 
simplicity, safety, accuracy and cost-effectiveness. 
Natriuretic peptides have been demonstrated to be 
promising new preoperative risk markers. Although 
recommended in high-risk patients, non-invasive 
cardiac stress testing may be safely omitted in patients 
at intermediate risk. The anti-ischemic properties of 
beta-blockers have been well described. In clinical 
practice however, adequate beta-blocker dosage, tight 
perioperative heart rate control and continuation of beta-
blockers after surgery may be important factors too. 
Statins have emerged as promising drugs with 
perioperative cardioprotective properties. However, 
before recommending routine administration of statin 
therapy, more clinical trials are needed. 
Summary New perceptions in perioperative medical 
management and novel developments in surgical and 
anaesthesiologic techniques continue to improve the 
cardiovascular outcome of patents undergoing major 
non-cardiac surgery. 
____________________________________________________________________________________________ 
 
DURING THE LAST FEW decades, tremendous 
efforts have been made to decrease cardiac morbidity 
and mortality associated with non-cardiac surgery. 
Firstly, preoperative evaluation of the surgical patient 
has been refined to identify those at increased risk of 
adverse cardiac events. In addition to medical history 
and physical examination, preoperative 
electrocardiography and functional testing have been 
demonstrated to be effective tools in predicting cardiac 
outcome after surgery. Secondly, developments in 
surgical and anesthesiological techniques, i.e. 
endovascular surgery and loco-regional anesthesia, have 
improved postoperative outcome considerably. Thirdly, 
several cardiovascular drugs have been shown to reduce 
the incidence of cardiovascular events after major non-
cardiac surgery. Consensus guidelines now recommend 
beta-blocker therapy in high-risk patients undergoing 
major non-cardiac surgery. More recently, evidence 
suggests that statins have cardioprotective properties 
that can be useful in surgical patients at increased 
perioperative risk. The current review will discuss new 
insights in the field of perioperative medicine that can 
be applied to clinical practice or stimulate further 
scientific investigation. 
 
 
 
Ischemic heart disease; a continuing problem in 
major surgery 
 
It has been estimated that 71.3 million people in the 
United States suffered from cardiovascular disease and 
that 13.2 million people suffered from coronary heart 
disease (history of angina pectoris or myocardial 
infarction) in the year 2003 [1**]. Since 1919, 
cardiovascular disease has been the single leading cause 
of death in the United States. It is the underlying or 
contributing cause of death in about 58% of all cases. In 
the 30 million patients undergoing non-cardiac surgery 
in the United States annually, cardiac complications also 
remain the leading cause of perioperative morbidity and 
mortality. A pooled analysis of several large studies 
found an incidence of 2.5% for the composite endpoint 
of perioperative myocardial infarction or cardiac death 
in unselected patients over the age of 40 (range: 2.0% to 
3.7%) [2]. These complications were higher in vascular 
surgery patients who had an incidence of 6.2% for 
cardiac events (range: 2.2% to 19.0%) [3]. The high 
frequency of perioperative complications reflects the 
high prevalence of underlying coronary artery disease. 
According to the World Health Organization, the global 
epidemic of cardiovascular disease will not only 
increase, but will also shift from developed to 
developing nations. It is further estimated that in the 
second half of the 21st century, more than one in four 
individuals will be 65 years of age or older. In the past, 
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major surgery was rarely performed on patients in their 
eighties or nineties. Nowadays, many major surgical 
interventions are performed in this very elderly 
population. A recent study performed in 1351 patients 
undergoing non-cardiac surgery showed that the rate of 
cardiac events increased with advanced age, 
independent of other clinical variables, in those patients 
with myocardial perfusion abnormalities during stress 
scintigraphy [4*]. With the growing elderly population, 
with the increasing incidence of cardiovascular disease 
and with the availability of more advanced surgical 
techniques to a higher-risk patient population, 
underlying ischemic heart disease in surgical patients 
continues to demand our attention. 
 
Towards simple, safe, inexpensive and accurate 
preoperative screening 
 
The first step in perioperative medical management is to 
identify the patient at increased risk of cardiovascular 
events. Based on a set of clinical risk factors that allows 
an estimate of the weighted risk of perioperative cardiac 
complications, several risk indices have been developed, 
including the Goldman cardiac risk index [5], the 
Detsky modified multifactorial risk index [6] and 
Eagle’s risk score [7]. It was shown that some of these 
existing risk indices, including the Goldman risk index, 
the modified Detsky index, the American Society of 
Anesthesiologists index and the Canadian 
Cardiovascular Society index, performed better than 
chance, but that no index was significantly superior to 
the other [8]. However, after the revision of the 
Goldman risk index by Lee and colleagues, the 
predictive value of this risk index improved 
substantially [9]. This index identifies 6 predictors of 
major cardiac complications: 1) high-risk surgery, 2) 
ischemic heart disease, 3) congestive heart failure, 4) 
cerebrovascular disease, 5) diabetes and 6) renal failure. 
Based on the presence of 0, 1, 2, or ≥3 of these 
predictors, the rate of major cardiac complications was 
estimated to be 0.4%, 0.9%, 7% and 11%, respectively. 
Clinicians and researchers have applied this revised 
cardiac risk index to a large extent. Moreover, it was 
demonstrated that the risk index could be improved 
substantially by adding the type of surgical procedure. 
Boersma and colleagues validated the Lee risk index in 
a large cohort (n=108.593) of patients undergoing all 
types of non-cardiac surgical procedures and 
demonstrated a substantial improvement by adding the 
surgical risk of the various surgical procedures (C-
statistic improved form 0.63 to 0.85) [10].  
 
A simple evaluation based on clinical risk factors and 
type of surgery is the cornerstone of rational 
preoperative cardiac risk assessment that can guide 
subsequent cardiac evaluation (Figure 1). According to 
the American College of Cardiology/American Heart 
Association guidelines, preoperative cardiac exercise or 
pharmacological stress testing is recommended in all 
patients at increased cardiac risk based on clinical risk 
profile, functional capacity and type of surgery [12].  A 
few studies have compared the prognostic accuracy of 
various non-invasive tests used for preoperative cardiac 
risk assessment. Among ambulatory and exercise 
electrocardiography, myocardial perfusion scintigraphy, 
radionuclide ventriculography and dobutamine or 
dipyridamole stress echocardiography, stress 
echocardiography has been favored consistently as test 
of choice [13,14,15,16]. In addition to the detection of 
stress induced myocardial ischemia, resting 
echocardiography detects valvular heart disease or left 
ventricular dysfunction. This may be important since 
heart murmurs are frequently observed during the 
preoperative evaluation [17*] and aortic stenosis is 
associated with a fivefold increased risk of perioperative 
cardiac events [18]. 
 
Accurate screening with all available techniques may be 
risky, may increase costs, may delay surgery and may 
not influence perioperative management. This situation 
has led to commentaries that emphasis should be shifted 
from risk stratification to risk modification [19*]. 
Indeed, the DECREASE-II study questioned the value 
of cardiac testing in patients at intermediate risk, since 
only a minority of these patients experience stress-
induced myocardial ischemia. The recently published 
results showed that cardiac testing could safely be 
omitted in these patients, provided that beta-blockers 
aiming at tight heart rate control are prescribed [20**]. 
The study further showed that no testing brought 
surgery almost 3 weeks forward [20**].   
 
 
Figure 1. Risk evaluation and cardiac complications in patients 
undergoing major vascular surgery. BB = beta-blockers. The 
proportions are the incidence of cardiac death or myocardial 
infarction. Derived from Boersma and colleagues [11]. 
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New laboratory markers in risk stratification 
 
In the search for simple, safe, inexpensive and accurate 
preoperative screening, blood serum markers have 
emerged as promising preoperative risk measures. The 
use of absolute serum creatinine levels and serum 
glucose levels can refine risk stratification and can 
guide further management [21,22]. A promising marker 
that has been investigated more recently is the 
natriuretic peptide. Natriuretic peptides are endogenous 
cardiac hormones that include atrial natriuretic peptide 
(A-type), brain natriuretic peptide (B-type or BNP), and 
its amino-terminal portion N-terminal pro-B-type 
natriuretic peptide (NT-proBNP) [23,24]. NT-proBNP 
is synthesized in the ventricular myocardium and 
released in response to ventricular wall stress [25,26]. 
NT-proBNP has been demonstrated to be an important 
diagnostic and prognostic marker in patients with heart 
failure [27,28]. The diagnostic and prognostic value of 
elevated levels of NT-proBNP has more recently been 
shown in patients with acute coronary syndromes and 
stable coronary artery disease [29,30]. Three studies 
published last year have consistently demonstrated that 
elevated natriuretic peptide levels predict short-term 
adverse cardiovascular events in patients undergoing 
elective non-cardiac surgery [31,32*, 33*]. Optimal cut-
off values as determined with receiver operating curve 
characteristics analysis in the three studies were 450 
ng/l and 533 ng/l for N-terminal pro-B-type natriuretic 
peptide and 189 ng/l for brain natriuretic peptide. The 
prognostic value of preoperative natriuretic peptides 
was also sustained for long-term events, as 
demonstrated in a study involving 335 patients who 
were followed for a mean duration of 14 months (Figure 
2) [34*]. The optimal cut-off value to predict late events 
was 319 ng/l [34*]. Natriuretic peptide measurements 
are objective, easily obtainable and inexpensive and are 
therefore promising markers for routine first-line 
cardiac risk assessment. 
 
The controversy surrounding perioperative beta-
blocker therapy 
 
The application of appropriate cardiac risk reduction 
strategies is one of the most important steps in 
perioperative medical management. Numerous clinical 
trials have shown that perioperative use of beta-blockers 
can reduce the incidence of postoperative myocardial 
ischemia, myocardial infarction and cardiac mortality 
[35,36,37,38,39,40]. Randomized trials have 
demonstrated that perioperative ischemia as detected by 
continuous 12-lead electrocardiographic monitoring was 
significantly reduced by beta-blocker therapy 
[35,36,37]. Two randomized trials have demonstrated 
that beta-blockers were also effective for the prevention  
 
Figure 2.  An increase in preoperative N-terminal pro-B-type 
natriuretic peptide (NT-proBNP) level can predict long-term major 
adverse cardiac events (MACE) after major vascular surgery. Derived 
from Feringa and colleagues [34*].  
 
of cardiac death and myocardial infarction in the 
perioperative period [39,40]. The first trial evaluated the 
effect of atenolol in 200 high-risk patients undergoing 
non-cardiac surgery and demonstrated no difference in 
perioperative mortality, but a significantly lower 
mortality rate at 6 months after discharge (0% versus 
8%, p<0.001), over the first year (3% versus 14%, 
p=0.005) and over 2 years of follow-up (10% versus 
21%, p=0.2) [39]. The second trial showed in 112 high-
risk patients with stress-induced myocardial ischemia a 
10-fold reduction in the incidence of perioperative 
cardiac death and myocardial infarction in patients 
receiving bisoprolol, compared to patients receiving 
placebo [40]. On the basis of these trials, the guidelines 
of the American College of Cardiology/American Heart 
Association have recommended beta-blocker therapy in 
all vascular surgery patients with a positive stress test 
[12].  
 
However, controversy still surrounds the clinical benefit 
of perioperative beta-blocker therapy [41,42,43**]. A 
very recently published trial randomized patients to 
receive either placebo or metoprolol, which was started 
2 hours before vascular surgery until hospital discharge 
or a maximum of 5 days postoperatively [43**]. No 
reduction in 30-day and 6-month cardiac event rate was 
observed in patients receiving metoprolol compared to 
placebo [43**]. The DIPOM trial that randomized 
diabetic patients to receive metoprolol or placebo from 
the day before surgery to a maximum of eight days after 
also failed to demonstrate a beneficial effect in favor of 
beta-blockers [44**].  
 
The mechanism by which β-blockers exert their 
cardioprotective effect remains not completely 
understood. Proposed mechanisms include reduction in 
heart rate, restoration of the myocardial oxygen supply-
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demand balance and prolongation of coronary diastolic 
filling time [45,46]. Inadequate dosage of β-blockers 
and insufficient reduction of heart rate during the 
perioperative period may possibly explain the 
occurrence of adverse cardiac events and may explain 
why several studies failed to show a beneficial effect. A 
recently published study demonstrated in 272 vascular 
surgery patients that higher doses of beta-blockers and 
tight heart rate control were associated with reduced 
perioperative myocardial ischemia and troponin T 
release and improved long-term outcome (Figure 3) 
[47**]. Another study also demonstrated that a lower 
heart rate before surgery was associated with a 
significantly lower risk of perioperative cardiac events 
[20**]. In addition to adequate beta-blocker dosage and 
heart rate control, continuation of beta-blocker therapy 
in the postoperative period may also be recommended. 
Withdrawal of beta-blocker therapy in the perioperative 
period has been associated with a 2.6-fold increased risk 
of 1-year mortality [48**].   
 
 
Figure 3. A higher perioperative heart rate is associated with increased 
perioperative myocardial ischemia during continuous 12-lead 
electrocardiographic monitoring and troponin T release. Derived from 
Feringa and colleagues [47**]. 
 
Furthermore, the efficacy of beta-blocker therapy in 
intermediate-risk patients in comparison to high-risk 
patients has been questioned. The incidence of 
cardiovascular complications in intermediate risk 
patients is low, therefore, the number needed to treat to 
prevent a major cardiovascular complication may be 
exceedingly high [49*]. In the general population, beta-
blockers have been proven to prolong survival in 
patients with a history of myocardial infarction, with 
hypertension or with left ventricular dysfunction. In line 
with this evidence, beta-blockers may especially benefit 
patients presenting with these cardiovascular conditions. 
Indeed, a recent study showed that short- and long-term 
survival was significantly improved in patients with 
severe left ventricular dysfunction undergoing major 
vascular surgery who were using chronic beta-blocker 
therapy, compared to patients not using beta-blockers 
[50*].  
 
The emerging benefits of statin treatment 
 
Now thought to have properties beyond the lipid-
lowering effects, statins have emerged as promising 
cardioprotective drugs in the perioperative setting. 
Observational studies and clinical trials have 
demonstrated marked reductions in cardiovascular 
events among statin users undergoing major vascular 
surgery [51]. The beneficial properties of statins beyond 
the lipid-lowering effect include oxidative stress 
reduction and decrease in vascular inflammation, 
suggesting a plaque-stabilizing effect [52]. In human 
carotid plaques, statins have been demonstrated to 
decrease lipids, lipid oxidation, inflammation, matrix 
metalloproteinase-2 and cell death and increase tissue 
inhibitor of metalloproteinase 1 and collagen [53]. 
Intensive statin therapy may even result in significant 
regression of atherosclerosis as demonstrated in the 
ASTEROID trial [54**]. The many reports published 
last year in literature reflect the increasing interest in 
statin therapy as cardioprotective drug. Leurs and 
colleagues have published the data from the 
EUROSTAR Data Registry and reported that in patients 
who underwent endovascular abdominal aortic 
aneurysm repair, overall mortality rate at 5 years of 
follow-up was lower in those using statins, compared to 
those not using statins [55*]. Recent studies not only 
suggested that statins can lower cardiac events, but that 
it can also reduce in-hospital length of stay [56*], 
preserve renal function after suprarenal aortic clamping 
[57**] and can lower the incidence of stroke after 
carotid angioplasty and stent placement in patients with 
symptomatic carotid stenosis [58*]. Finally, several 
systematic review articles found supportive evidence in 
favor of statin therapy [59*,60**]. A pooled analysis of 
2 randomized studies, 15 cohort studies and 1 case-
control study demonstrated that the odds for death or 
acute coronary syndrome during the perioperative 
period was significantly lower in statin users, compared 
to patients not using statins [60**]. However, due to the 
relative paucity of data, more randomized trials are 
needed before recommending routine administration of 
statin therapy in all patients undergoing major surgery. 
 
Other agents with potential cardioprotective effect 
 
Other agents that have been studied for their potential 
cardioprotective effect in non-cardiac surgery include 
the α-2-adrenergic agonists (clonidine, 
dexmedetomidine, mivazerol), calcium-channel 
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blockers (diltiazem, verapamil) and nitroglycerin. The 
small-scale studies on calcium-channel blockers and 
nitroglycerin failed to demonstrate a cardioprotective 
effect after non-cardiac surgery. In contrast, the α-2-
adrenergic agonists have gained much interest, since it 
has been hypothesized that the α-2-agonist properties, 
which reduces post-ganglionic noradrenalin output, can 
moderate the catecholamine response to surgery and 
anesthesia and therefore the myocardial, hemodynamic 
and metabolic instability associated with cardiovascular 
events. The most convincing evidence to date has come 
from the European Mivazerol Trial, showing no overall 
effect of mivazerol on the prespecified combined 
endpoint of cardiac death and myocardial infarction in a 
study population of 2854 patients [61]. Post hoc 
analysis in 904 patients who underwent major vascular 
surgery, however, revealed that mivazerol use was 
associated with a significantly lower incidence of the 
combined endpoint. A reduction in perioperative 
mortality with the use of clonidine, another α-2-
adrenergic agonist, has been demonstrated in one 
prospective, randomized, placebo-controlled clinical 
trial involving 190 patients with or at risk for coronary 
artery disease and undergoing non-cardiac surgery [62]. 
Despite these encouraging findings, evidence in favor of 
α-2-adrenergic agonists is based on a few studies. In 
addition, the long-term benefits of short-term 
perioperative α-2-adrenergic agonist therapy are not yet 
known. Finally, it remains a question whether α-2-
adrenergic agonists are superior to beta-blockers and 
statins or whether it can complement each other.  
 
Anesthetic management and cardioprotection  
 
It has been speculated that improvements in anesthetic 
management can reduce the cardiac risk during major 
non-cardiac surgery. A pulmonary artery catheter and 
subsequent hemodynamic optimization, for example, 
has been proposed to improve cardiovascular outcome. 
A large randomized clinical trial of 1994 high-risk 
patients, older than 60 years of age, in American 
Society of Anesthesiologists class III or IV risk and 
undergoing major non-cardiac surgery, showed no 
significant benefits of a pulmonary artery catheter over 
standard care in terms of reduced in-hospital mortality, 
improved 6- and 12-month survival and reduced length 
of hospital stay [63]. The application of epidural 
anesthesia and analgesia is another example which was 
proposed to improve cardiovascular outcome. Rogers 
and colleagues demonstrated in a meta-analysis that 
neuraxial blockade (spinal or epidural) could reduce all-
cause mortality by 30% and myocardial infarction by 
33%. Recent randomized trials however showed no 
overall reduction in the incidence of death and major 
complications between patients with and without 
neuraxial blockade [64,65]. However, subgroup analysis 
revealed that patients undergoing abdominal aortic 
surgery with neuraxial blockade do have a lower 
incidence of cardiovascular, pulmonary and cerebral 
complications [64]. Finally, it has been suggested that 
perioperative hypothermia can result in increased 
postoperative myocardial ischemia. A recent study 
demonstrated that maintenance of normothermia could 
significantly lower the incidence of cardiac events 
(unstable angina pectoris, cardiac arrest, myocardial 
infarction) [66]. These studies showed that some 
improvements in anesthetic management can reduce 
cardiovascular morbidity, however, it remains unknown 
to what extent and by which mechanism anesthesiology 
contributes to perioperative cardiovascular morbidity 
and mortality. 
  
Conclusion 
 
Despite the impressive progress made in the past to 
diminish cardiac mortality and morbidity associated 
with major non-cardiac surgery, the epidemic of 
cardiovascular disease remains a significant contributor 
to perioperative morbidity and mortality. New insights 
in the past year have developed preoperative risk 
stratification in terms of simplicity, safety, accuracy and 
cost-effectiveness. The anti-ischemic properties of beta-
blockers have been well described. In clinical practice 
however, adequate beta-blocker dosage, tight 
perioperative heart rate control and continuation of beta-
blockers after surgery may be important factors too. 
Statins have emerged as promising drugs with 
perioperative cardioprotective properties. However, 
before recommending routine administration of statins, 
more clinical trials are needed to support existing 
evidence. Perioperative management should not only 
focus on the short-term outcome, every attempt to 
improve long-term survival should be welcomed. New 
perceptions in perioperative medical management and 
novel developments in surgical and anesthesiologic 
techniques should continue to benefit the many patients 
undergoing non-cardiac surgery every year. 
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Protecting the Heart with Cardiac Medication in 
Patients with Left Ventricular Dysfunction 
Undergoing Major Noncardiac Vascular Surgery 
Harm H. H. Feringa, MD (1), Jeroen J. Bax, MD (2), O. Schouten, MD (3), and D. Poldermans, MD (4) 
 
 
Patients with left ventricular dysfunction who are 
undergoing major noncardiac vascular surgery are at 
increased risk of adverse postoperative events. We 
sought to evaluate whether perioperative medication 
use, including angiotensin-converting enzyme (ACE) 
inhibitors, b-blockers, statins, and aspirin, was 
associated with a reduced incidence of postoperative in-
hospital mortality in these high-risk patients. The study 
enrolled 511 patients with left ventricular dysfunction 
(left ventricular ejection fraction <30%) who were 
undergoing major noncardiac vascular surgery. Cardiac 
risk factors and medication use were noted before 
surgery. Preoperative dobutamine stress 
echocardiography (DSE) was performed to identify 
patients with stress-induced myocardial ischemia. The 
end point was postoperative in-hospital mortality. 
Univariate and multivariate logistic regression analyses 
were performed to evaluate the relation between 
perioperative medication use and mortality. The mean 
age of the study population was 64 ± 11 years, and 75% 
were men. Perioperative use of ACE inhibitors, b 
blockers, statins, and aspirin was recorded in 215 
(48%), 139 (27%), 107 (21%), and 125 patients (24%), 
respectively. Stress-induced myocardial ischemia 
occurred in 82 patients (16%). Sixty-four patients (13%) 
died. Perioperative use of ACE inhibitors (odds ratio 
[OR], 0.33; 95% confidence interval [CI], 0.12-0.91), b- 
blockers (OR, 0.03; 95% CI, 0.01-0.26), statins (OR, 
0.06; 95% CI, 0.01-0.53), and aspirin (OR, 0.13; 95% 
CI, 0.03-0.55), was significantly associated with a 
reduced incidence of mortality, after adjusting for 
cardiac risk factors and DSE results. In conclusion, the 
present study showed that the perioperative use of ACE 
inhibitors, b-blockers, statins, and aspirin is 
independently associated with a reduced incidence of 
in-hospital mortality in patients with left ventricular 
dysfunction who are undergoing major noncardiac 
vascular surgery. 
___________________________________________________________________________________________ 
 
 
 
From the Departments of (1) Anesthesiology, (3) Vascular Surgery, 
and (4) Cardiology, Erasmus MC, Rotterdam; and the (2) Department 
of Cardiology, Leiden University Medical Center, Leiden, The 
Netherlands 
 
CONGESTIVE HEART FAILURE is a disorder 
characterized by an abnormal cardiac ventricular 
performance that develops as a consequence of many 
forms of heart disease. The prevalence of congestive 
heart failure ranges from 1.2% in the adult population to 
8.0% in the population of individuals 
older than 75 years of age.1,2 Angiotensin- converting 
enzyme (ACE) inhibitors and b- blockers have been 
shown to improve morbidity and mortality in patients 
with left ventricular dysfunction. 3,4 Statins and aspirin 
may also be of benefit in patients with left ventricular 
dysfunction because these patients frequently have 
coronary artery disease as a comorbidity. 
Patients with left ventricular dysfunction who are 
undergoing major noncardiac vascular surgery are at 
increased risk for postoperative mortality.5-7 
Perioperative management of these patients is aimed at 
maximizing hemodynamic status and providing 
intensive postoperative surveillance. However, limited 
information is available about whether concomitant 
perioperative cardiac medication use reduces the 
postoperative mortality rate in these high-risk patients. 
We therefore conducted this study to evaluate whether 
perioperative use of cardiac medication, including ACE-
inhibitors, b-blockers, statins, and aspirin, was 
associated with a reduced incidence of in-hospital 
mortality in patients with left ventricular dysfunction 
undergoing major noncardiac 
vascular surgery. 
 
METHODS 
 
Study Population 
We enrolled patients with left ventricular dysfunction 
who were undergoing major noncardiac vascular 
surgery at the Erasmus Medical Center, Rotterdam, 
during the period 1990 to 2004. Left ventricular 
dysfunction was defined as an ejection fraction of 30% 
or less, or by a rest wall motion score of 1.70 or more, 
as assessed by preoperative two-dimensional (2D) 
echocardiography. The left ventricular ejection fraction 
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was calculated by using the Simpson’s rule formula, 
after left ventricular end-diastolic and end-systolic 
volumes were obtained from the apical four- and two-
chamber views. The major noncardiac vascular surgery 
procedures were abdominal aortic repair, lower-
extremity revascularization, and carotid artery surgery. 
Before surgery, patients were screened for cardiac risk 
factors (history of coronary artery disease, 
cerebrovascular disease, diabetes mellitus, renal 
dysfunction, hypertension, hypercholesterolemia, 
smoking, and chronic obstructive pulmonary disease) 
and medication use (ACE inhibitors, b-blockers, statins, 
aspirin, calcium channel blockers, coumarin, diuretics, 
digoxin, and nitrates). A baseline 12-lead 
electrocardiogram was obtained. A preoperative 
dobutamine stress echocardiography (DSE) was 
performed to identify patients with stress-induced 
myocardial ischemia. 
 
Dobutamine Stress Echocardiography 
Patients underwent a resting 2D precordial 
echocardiographic examination. Dobutamine 
hydrochloride was then administered intravenously by 
infusion pump, starting at 5 μg/ kg/min for 5 minutes, 
followed by 10 μg/kg/ min for 5 minutes and increasing 
by 10 μg/ kg/min every 3 minutes to a maximum of 40 
μg/kg/min, and continued for 6 minutes. The 
dobutamine infusion was stopped if a target heart rate 
(85% of the age- and gender-corrected maximal heart 
rate) was achieved. If the target heart rate was not 
achieved and patients had no symptoms or signs of 
ischemia, atropine sulphate (0.25 to 2.0 mg 
intravenously) was given while the administration of 
dobutamine was continued. Metoprolol was 
administered (1.0 to 5.0 mg intravenously) to reverse 
the side effects of the administration of dobutamine or 
the dobutamine-atropine combination if the side effects 
did not revert spontaneously and quickly. Two 
experienced investigators, blinded to the clinical data, 
performed off-line assessment of echocardiographic 
images. A standard 16-segment model was used to score 
wall motion on a 5-point scale (a score of 1 indicating 
normal; 2, mild hypokinesis; 3, severe hypokinesis; 4, 
akinesis; and 5, dyskinesis), and a wall-motion score 
index was calculated (total score divided by the number 
of segments scored).8 The results of DSE were 
considered positive if new wall-motion abnormalities 
occurred, that is, if wall motion in any segment 
worsened by 1 or more grades during the test, with the 
exception of akinesis becoming dyskinesis. 
 
End Point 
The end point was in-hospital mortality, which was 
defined as death occurring during the postoperative in-
hospital stay or occurring after discharge but within the 
first 30 days after surgery. 
 
Statistical Analysis 
Continuous data are expressed as mean ± SD and 
compared with the Student t test. Categorical data are 
presented as percent frequencies. Univariate and 
multivariate logistic regression models were used to 
analyze the relation between the use of perioperative 
medication and in-hospital mortality. In multivariate 
analyses, adjustments were made for baseline clinical 
variables and stress-induced myocardial ischemia, 
irrespective of the significance level in univariate 
analysis. Odds ratios (OR) are given with 95% 
confidence intervals (CI). For all tests, P < .05 (two-
sided) was considered significant. 
 
RESULTS 
 
 
Table 1. Baseline Characteristics of the 511 Patients with Left 
Ventricular Dysfunction 
Characteristic N 
Age (years) (mean ± SD)   64 ± 11 
Gender (male) (%)    383 (75) 
History of coronary artery disease (%)  308 (60) 
History of cerebrovascular disease (%)  80 (16) 
Hypertension (%)    203 (40) 
Hypercholesterolemia (%)   126 (25) 
Diabetes Mellitus (%)   72 (14) 
Renal failure (%)    57 (11) 
Current smoker (%)    168 (33) 
COPD (%)    88 (17) 
Electrocardiography 
Left ventricular hypertrophy (%)   37 (7) 
Q-waves (%)    183 (36) 
ST-segment changes (%)   105 (21) 
Left bundle branch block (%)   20 (4) 
Right bundle branch block (%)   28 (5) 
Atrial fibrillation (%)    37 (7) 
Cardiac medication 
Aspirin (%)    125 (24) 
ACE inhibitors (%)    215 (48) 
b-blockers (%)    139 (27) 
Calcium channel blockers (%)   162 (32) 
Coumarin (%)    111 (22) 
Digoxin (%)    41 (8) 
Diuretic (%)    136 (27) 
Nitrates (%)    163 (32) 
Statins (%)    107 (21) 
COPD = chronic obstructive pulmonary disease; ACE = angiotensin-
converting enzyme. 
 
 
 
The study enrolled 511 patients with left ventricular 
dysfunction. Their mean age was 64 ± 11 years, and 383 
patients (75%) were men. Perioperative use of ACE 
inhibitors, b-blockers, statins, and aspirin was recorded 
in 215 (48%), 139 (27%), 107 (21%), and 125 patients 
(24%), respectively. Baseline characteristics of the 
study population are presented in Table 1. The mean 
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rest wall motion score index was 2.11 ± 0.37. Stress-
induced myocardial ischemia occurred in 82 patients 
(16%). No fatal complications occurred during 
preoperative DSE. Abdominal aortic repair was 
performed in 237 patients (46%), lower-extremity 
revascularization in 221 patients (43%), and carotid 
artery surgery in 53 patients (10%). Sixty-four patients 
(13%) died. Table 2 presents the univariate association 
between perioperative medication and in-hospital 
mortality. Table 3 presents the association between 
perioperative medication and in-hospital mortality, after 
adjusting for cardiac risk factors and DSE results. ACE 
inhibitors (OR, 0.33; 95% CI, 0.12-0.91), b-blockers 
(OR, 0.03; 95% CI, 0.01-0.26), statins (OR, 0.06; 95% 
CI, 0.01-0.53), and aspirin (OR, 0.13; 95% CI, 0.03-
0.55), were significantly and independently associated 
with a reduced incidence of inhospital mortality. 
 
DISCUSSION 
 
This study shows that perioperative use of ACE 
inhibitors, b-blockers, statins, and aspirin was 
associated with a reduced incidence of in-hospital 
mortality in patients with left ventricular dysfunction 
undergoing major noncardiac vascular surgery. These 
associations were independent of cardiac risk factors 
and stress-induced myocardial ischemia during 
preoperative DSE.  
 
ACE Inhibitors 
Blockade of the renin-angiotensin system with ACE 
inhibitors has been shown to improve survival in 
patients with reduced left ventricular function.9-12 
Recently, randomized, placebo controlled studies have 
suggested that ACE inhibitors reduce cardiovascular 
events in patients at high risk for coronary events who 
were not known to have heart failure.13,14 There is 
evidence that activation of the renin-angiotensin system 
stimulates atherosclerosis and contributes to ischemic 
events.15 ACE inhibitors have been shown to exert their 
vasculoprotective properties through several 
mechanisms. There is a growing body of evidence that 
ACE inhibitors improve the endogenous fibrinolytic 
balance, an important determinant in the defense 
mechanism against intravascular thrombus formation 
that is implicated in the pathogenesis of myocardial 
infarction and other acute vascular syndromes.16 In 
addition, ACE inhibitors may positively influence 
vasoactive substances, such as nitric oxide and 
angiotensin II, which have been shown to be involved in 
adverse vascular remodeling processes.17 These 
observations suggest that patients with reduced left 
ventricular function undergoing major noncardiac 
vascular surgery, who are at increased risk for 
postoperative adverse cardiac events, may benefit from 
perioperative ACE inhibitor therapy. In these patients 
who frequently present with concomitant coronary 
artery disease, ACE inhibitors may not only improve the 
perioperative hemodynamic status but may also prevent 
acute coronary events through their vasoprotective 
properties. To our knowledge, no previously published 
studies have investigated the protective effect of ACE 
inhibitors in patients with left ventricular dysfunction 
undergoing major noncardiac 
vascular surgery. Our results suggest that these patients 
may benefit from perioperative ACE inhibitor 
therapy; however, large randomized controlled 
trials are needed to confirm our conclusion. 
 
Table 2. Univariate Relation Between Medication and In-hospital 
Mortality 
Medication   OR* 95% CI  P 
Aspirin    1.36 0.76-2.42  .3 
ACE inhibitors   1.44 0.85-2.44  .2 
b-Blockers   0.24 0.10-0.58  <.001 
Calcium-channel blockers  1.57 0.91-2.68  .1 
Coumarin    1.12 0.60-2.08  .7 
Digoxin    0.43 0.10-1.86  .3 
Diuretic    2.10 1.21-3.61  .008 
Nitrates    1.44 0.84-2.47  .2 
Statins    0.36 0.15-0.85  .02 
OR = odds ratio; CI = confidence interval; ACE = angiotensin-
converting enzyme. 
*Adjusted for the following baseline characteristics: age, gender, 
history of coronary artery disease, cerebrovascular disease, 
hypertension, hypercholesterolemia, diabetes mellitus, renal 
dysfunction, smoking, chronic obstructive pulmonary disease, 
electrocardiographic abnormalities and stress induced ischemia during 
dobutamine stress echocardiography. 
 
Table 3. Multivariate Analysis Between Medication and In-hospital 
Mortality 
Medication   OR* 95% CI  P 
Aspirin    0.13 0.03-0.55  .005 
ACE inhibitors   0.33 0.12-0.91  .03 
b-Blockers   0.03 0.01-0.26  .002 
Calcium-channel blockers  0.89 0.35-2.27  .8 
Coumarin    1.22 0.42-3.58  .7 
Digoxin    0.27 0.05-1.62  .2 
Diuretic    0.46 0.16-1.32  .2 
Nitrates    0.66 0.26-1.67  .4 
Statins    0.06 0.01-0.53  .01 
OR = odds ratio; CI = confidence interval; ACE = angiotensin-
converting enzyme. 
*Adjusted for the following baseline characteristics: age, gender, 
history of coronary artery disease, cerebrovascular disease, 
hypertension, hypercholesterolemia, diabetes mellitus, renal 
dysfunction, smoking, chronic obstructive pulmonary disease, 
electrocardiographic abnormalities and stress induced ischemia during 
dobutamine stress echocardiography. 
 
 
b-Blockers 
Large randomized trials have demonstrated the 
usefulness of b-blockers in nonsurgical patients with 
reduced left ventricular function. The Metoprolol in 
Dilated Cardiomyopathy Trial, Metoprolol CR/XL 
Randomized Intervention Trial in Congestive Heart 
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Failure trial, Cardiac Insufficiency Bisoprolol Study I 
and II, and Carvedilol Prospective Randomized 
Cumulative Survival Study Group, have all 
demonstrated the benefits of metoprolol, bisoprolol, and 
carvedilol for survival in stable advanced patients with 
heart failure.18-21 As a result, consensus guidelines 
strongly recommended the use of b-blockers in these 
patients, unless there is a strong contraindication.22 
Several randomized trials have demonstrated that 
patients with coronary artery disease undergoing major 
noncardiac surgery benefit from perioperative b-blocker 
therapy in terms of reduced postoperative morbidity and 
mortality.23,24 Our results suggest that the 
perioperative use of b-blocker therapy may also be 
beneficial in patients with left ventricular dysfunction 
undergoing major noncardiac vascular surgery. It has 
been shown that b-blockers reverse the process of left 
ventricular remodeling, leading to improved 
hemodynamics with favorable effects on prognosis.25 
In addition, b-blockers may also have beneficial effects 
through their heart rate-regulating, anti-arrhythmic, and 
anti-inflammatory effects. 26 It might be suggested that 
these mechanisms may explain the cardioprotective 
effect of b-blockers. 
 
Statins 
Statins (3-hydroxy 3-methylglutaryl-coenzyme A 
[HMG-CoA] reductase inhibitors) have been shown to 
reduce cardiac events and improve survival in patients 
with hypercholesterolemia coronary artery disease, or 
both.27-31 Statins also have been associated with a 
lower perioperative and long-term mortality rate after 
major noncardiac vascular surgery.32,33 In addition to 
their lipid-lowering effects, the pleiotropic effects of 
statins, which include inflammation reduction, reduction 
in free-radical production in the vascular wall, 
improvement in endothelial function, and stabilization 
of atheromatous plaques, may contribute to its 
beneficial properties.34 An issue of debate is whether 
statins should be given to patients with congestive heart 
failure. Higher cholesterol levels in patients with heart 
failure predict a better outcome.35 Lower cholesterol 
levels may not be directly responsible for a worse 
outcome, however, but may reflect developing cachexia. 
Furthermore, it remains unknown whether patients with 
nonischemic heart failure will also benefit from statin 
therapy. Future large-scale mortality trials will tell us 
whether we should give statins to patients with 
congestive heart failure. Until the safety and efficacy of 
statin therapy in heart failure patients who are or are not 
undergoing major noncardiac vascular surgery is 
established, we do not recommend statin therapy to be 
prescribed in a standard fashion in this patient 
population. 
 
Antiplatelet Drugs 
Antiplatelet drugs are now established agents for 
preventing cardiovascular and cerebrovascular ischemic 
events. The meta-analysis of the antithrombotic trialists 
collaboration showed a proportional reduction of 23% 
in serious vascular events among 9214 patients with 
peripheral arterial disease using antiplatelet therapy 
(primarily aspirin) compared with those using no 
antiplatelet therapy (5.8 vs. 7.1%, P <.04).36 Current 
evidence indicates that aspirin or clopidogrel seem to be 
the first-line oral antiplatelet drugs of choice. 
Antiplatelet drugs may be recommended in patients 
with heart failure who have concomitant atrial 
fibrillation for the prevention of possible acute vascular 
occlusions. 
 
Should patients with left ventricular dysfunction 
undergoing major noncardiac vascular surgery be 
treated with perioperative aspirin therapy? 
Firstly, no evidence exists to suggest antiplatelet therapy 
in patients with heart failure who are in sinus rhythm. 
Secondly, there is no convincing evidence that aspirin 
reduces perioperative cardiac complications in patients 
with or without left ventricular dysfunction undergoing 
noncardiac surgery. Moreover, patients with heart 
failure might be at increased risk for bleeding 
complications because of difficult anticoagulant control, 
which may be explained by variable hepatic congestion 
and various drug interactions. However, it remains a 
matter of debate whether aspirin treatment is associated 
with an increased risk of bleeding complications. Our 
results support the use of perioperative aspirin therapy 
in reducing in-hospital mortality in patients with left 
ventricular dysfunction undergoing major vascular 
surgery. Unfortunately, bleeding complications were not 
investigated in this study. Before routine aspirin 
treatment is recommended in this patient population, 
more studies are needed to investigate the efficacy and 
safety of perioperative aspirin treatment. 
 
Limitations and Conclusion 
A major limitation in this study is that the medications 
were not assigned in a randomly, controlled setting. In 
addition, patients and physicians were not masked to the 
different medical treatments. We used multivariate 
regression analysis to adjust for cardiac risk factors and 
DSE results; however, other factors may have played a 
role in the cause of death. This study is one of the first 
in its kind to investigate the effect of different 
medication on postoperative outcome in patients with 
left ventricular dysfunction who are undergoing major 
noncardiac vascular surgery. 
 
Based on our results, we conclude that in these patients, 
perioperative ACE inhibitor, b- blocker, aspirin, and 
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statin therapy is significantly and independently 
associated with a reduced incidence of in-hospital 
mortality. However, before standard ACE inhibitor, b-
blocker, aspirin, and statin treatment are recommended 
in this patient population, randomized studies are 
needed to establish its safety and efficacy. 
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High dose β-blockers and tight heart rate control 
reduce myocardial ischemia and troponin T release in 
vascular surgery patients 
Harm H.H. Feringa, M.D.*, Jeroen J. Bax, M.D.†, Eric Boersma, Ph.D. ‡, Miklos D. Kertai, M.D.*, Simon H. Meij, 
M.Sc‡, Wael Galal, M.D.*, Olaf Schouten, M.D.§, Ian R. Thomson, M.D.**, Peter Klootwijk, M.D.‡, Marc R.H.M. 
van Sambeek, M.D.§, Jan Klein, M.D.*, Don Poldermans, M.D.* 
 
 
Background:  Adverse perioperative cardiac events occur frequently despite the use of β-blockers. We examined 
whether higher doses of β-blockers and tight heart rate control was associated with reduced perioperative 
myocardial ischemia and troponin T release and improved long-term outcome. 
Methods and Results:  In an observational cohort study, 272 vascular surgery patients were preoperatively 
screened for cardiac risk factors and β-blocker dose. Beta-blocker dose was converted to a percentage of maximum 
recommended therapeutic dose. Heart rate and ischemic episodes were recorded by continuous 12-lead 
electrocardiography, starting one day before to 2 days after surgery. Serial troponin T levels were measured after 
surgery. All-cause mortality was noted during follow-up.  
Myocardial ischemia was detected in 85/272 (31%) patients and troponin T release in 44/272 (16.2%). Long-term 
mortality occurred in 66/272 (24.2%) patients. In multivariate analysis, higher β-blocker doses (per 10% increase) 
were significantly associated with a lower incidence of myocardial ischemia (HR: 0.62, 95% CI: 0.51-0.75), 
troponin T release (HR: 0.63, 95% CI: 0.49-0.80) and long-term mortality (HR: 0.86, 95% CI: 0.76-0.97). Higher 
heart rates during electrocardiographic monitoring (per 10 bpm increase) were significantly associated with an 
increased incidence of myocardial ischemia (HR: 2.49, 95% CI: 1.79-3.48), troponin T release (HR: 1.53, 95% CI: 
1.16-2.03) and long-term mortality (HR: 1.42, 95% CI: 1.14-1.76).   
Conclusion: This study showed that higher doses of β-blockers and tight heart rate control are associated with 
reduced perioperative myocardial ischemia and troponin T release and improved long-term outcome in vascular 
surgery patients. 
__________________________________________________________________________________________ 
 
 
LARGE CLINICAL TRIALS have demonstrated the 
beneficial effect of β-adrenoreceptor blocking agents in 
preventing perioperative cardiac morbidity and 
mortality in patients undergoing major non-cardiac 
vascular surgery [1-3]. The ACC/AHA has therefore 
recommended the use of β-blockers in surgical patients 
who are at increased risk for postoperative adverse 
events [4]. The mechanism by which β-blockers exert 
their cardioprotective effect remains not completely 
understood, but proposed mechanisms include reduction 
in heart rate, restoration of the myocardial oxygen 
supply-demand balance, and prolongation of coronary 
diastolic filling time [5,6]. Despite the presumed 
benefits of perioperative β-blocker therapy, 
cardiovascular mortality and non-fatal myocardial 
infarction may still occur in patients using β-blockers, 
especially during the stressful perioperative period 
characterized by rapidly changing physiologic responses 
[7,8]. Inadequate dosage of β-blockers and insufficient 
reduction of heart rate during the perioperative period 
may possibly explain the occurrence of adverse cardiac 
events in these patients. 
Early postoperative episodes of myocardial ischemia, 
i.e. during the first 48 hours after surgery, are an 
important correlate of adverse cardiac outcome after 
surgery [2]. Continuous 12-lead electrocardiographic 
monitoring and measurement of cardiac troponins are 
accurate and reliable methods for the detection of 
perioperative myocardial ischemia. We conducted this 
study to assess whether higher doses of β-blockers and 
tight heart rate control during surgery are associated 
with a reduced incidence of perioperative myocardial 
ischemia as detected by continuous 12-lead 
electrocardiographic monitoring,  with reduced troponin 
T release and with a reduced incidence of long-term 
mortality and cardiac events. 
 
*Department of Anesthesiology, Erasmus Medical Center, Rotterdam, 
the Netherlands. †Department of Cardiology, Leiden University 
Medical Center, Leiden, the Netherlands. ‡Department of Cardiology, 
Erasmus Medical Center, Rotterdam, the Netherlands. §Department of 
Vascular Surgery, Erasmus Medical Center, Rotterdam, the 
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METHODS 
 
Patients  
The study population consisted of 273 patients, 
undergoing elective major vascular surgery at the 
Erasmus MC in Rotterdam, the Netherlands, during the 
period July 2001 to August 2005. The study was 
performed with informed consent of all patients. 
Patients with a cardiac pacemaker, left ventricular 
hypertrophy, left or right bundle branch block and atrial 
fibrillation were excluded. Prior to surgery, a detailed 
cardiac history was obtained and patients were screened 
for hypertension (blood pressure ≥140/90 mmHg), 
diabetes mellitus (fasting glucose level ≥7.0 mmol/L, or 
insulin therapy), hypercholesterolemia (plasma 
cholesterol level ≥5.5 mmol/L or cholesterol-lowering 
medication) and renal failure (serum creatinine level ≥ 
2.0 mg/dL (177 μmol/L)). The presence of definite 
coronary artery disease was indicated by a previous 
myocardial infarction, previous coronary intervention, 
or present stable angina pectoris. The use of chronic β-
blocker therapy was noted and β-blocker dose was 
converted to a percentage of maximum recommended 
therapeutic dose (MRTD) according to the FDA's 
Center for Drug Evaluation and Research database. The 
MRTD for atenolol was 3.330 mg/kg (body-
weight)/day, for bisoprolol 0.330 mg/kg (body-
weight)/day, for metoprolol 6.670 mg/kg (body-
weight)/day, for carvedilol 0.417 mg/kg (body-
weight)/day, for propranolol 10.700 mg/kg (body-
weight)/day, and for labetolol 40.700 mg/kg (body-
weight)/day.   
 
Dobutamine stress echocardiography 
Before surgery, all patients underwent dobutamine 
stress echocardiography for preoperative risk 
stratification, which was performed according to 
established protocols [10]. The left ventricle was 
divided into 17 segments and wall motion was scored 
on a 5-point scale (a score of 1 indicating normal, 2 
mild hypokinesis, 3 severe hypokinesis, 4 akinesis, and 
5 dyskinesis). The results were considered positive if 
wall motion in any segment decreased by one or more 
grades during testing. Patients who had a positive result 
on dobutamine stress echocardiography were considered 
to be at high risk of developing myocardial ischemia in 
the perioperative period.  
 
 
 
 
Table 1. Baseline characteristics of the study population. 
 No 
β-blockers (n=97) 
Low dose β-
blockers (n=97) 
High dose β-
blockers (n=78) 
p-value 
Age (years) 68.4 +/-9.9 67.3 +/-10.0 66.3 +/-10.3 0.39 
Male gender 74 (76.3) 80 (82.5) 64 (82.1) 0.49 
Current stable angina pectoris 13 (13.4) 15 (15.5) 19 (24.4) 0.14 
History of myocardial infarction 41 (42.3) 40 (41.2) 40 (51.3) 0.36 
Previous coronary artery revascularization 17 (17.5) 14 (14.4) 17 (21.8) 0.45 
Coronary artery disease (summary variable) 43 (44.3) 45 (46.4) 45 (57.7) 0.18 
History of congestive heart failure 4 (4.1) 2 (2.1) 2 (2.6) 0.68 
History of cerebrovascular event 25 (25.8) 29 (29.9) 19 (24.4) 0.68 
Renal failure 7 (7.2) 2 (2.1) 1 (1.3) 0.069 
Diabetes mellitus 15 (15.5) 15 (15.5) 13 (16.7) 0.97 
Hypertension 42 (43.3) 38 (39.2) 38 (48.7) 0.45 
Hypercholesterolemia 35 (36.1) 39 (40.2) 34 (43.6) 0.60 
Current or past smoking 74 (76.3) 62 (63.9) 56 (71.8) 0.16 
Aspirin  46 (47.4) 54 (55.7) 46 (59.0) 0.28 
Angiotensin-converting enzyme inhibitors 24 (24.7) 24 (24.7) 25 (32.1) 0.47 
Statins 46 (47.4) 59 (60.8) 42 (53.8) 0.17 
Calcium channel blockers 31 (32.0) 22 (22.7) 26 (33.3) 0.22 
Preoperative heart rate 76.0 +/-12.9 66.2+/-11.9 64.1 +/-11.3 <0.001 
Atenolol - 5 (5.2) 4 (5.1) 0.74 
Bisoprolol - 67 (69.1) 47 (60.3) 0.29 
Metoprolol - 15 (15.5) 19 (24.4) 0.20 
Carvedilol - 9 (9.3) 3 (3.8) 0.27 
Propranolol - 2 (2.1) 1 (1.3) 0.85 
Labetolol - 1 (1.0) 1 (1.3) 0.58 
Values are given in number (%), or in mean +/- standard deviation 
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The baseline ST segment level was defined as the 
average ST segment during a stable period (duration of 
20 minutes) preceding each ischemic episode. ST 
segment change was measured 60 ms after the J point. If 
the J point fell within the T-wave, the ST segment 
change was measured 40 ms after that point. Heart rate 
was recorded and means of heart rate before, during and 
after surgery were calculated. A measure of absolute 
heart rate change was used and expressed as the sum of 
the differences between the mean heart rate before,  
Holter electrocardiography 
Patients were continuously monitored with a 10-
electrode, 12-lead digital ECG recorder (DR180+ 
Digital Recorder, NorthEast Monitoring Inc. 
Massachusetts), starting one day before surgery up to 2 
days after. Recordings were performed in the 
continuous 12-lead mode with a recording length of 10 
seconds every minute. The frequency response was 0.05 
– 150Hz. Electrocardiographic data were initially 
processed by a technician and analyzed by two 
experienced investigators, who were blinded to the 
patient’s clinical data. After excluding all abnormal 
QRS complexes, the ambulatory ECG recordings were 
analyzed for ST-segment deviations. A continuous ST 
segment trend was generated and all potential ischemic 
episodes were identified. Episodes of ischemia were 
defined as reversible ST-segment changes, lasting at 
least one minute and shifting from baseline to more than 
0.1 mV (1 mm). during and after surgery. The mean 
heart rate after surgery was calculated from a standard 
24-hour time period. For example, a patient with a mean 
heart rate of 75, 80 and 85 before, during and after 
surgery, respectively, had an absolute heart rate change 
of 5+5=10 bmp. 
 
Perioperative management and follow-up 
Prior to surgery, patients with beta-blockers were asked 
about medication adherence. Beta-blockers were 
withheld if patients presented with a systolic blood 
pressure <100 mmHg or with a heart rate <50 bpm. The 
dosage of beta-blockers on the day of surgery and after 
surgery was kept similar to the preoperative beta-
blocker dose. It was ascertained that beta-blockers were 
administered on the morning of surgery and on each day 
after surgery until discharge. Beta-blockers were 
administered orally or by naso-gastric tube in patients 
who were not able to take medication orally. All 
patients received standard perioperative pain 
management. Surgical procedures were classified as 
abdominal aortic aneurysm repair (129 patients, 47%), 
lower extremity revascularization (100 patients, 37%) 
and carotid artery surgery (43 patients, 16%). In all 
patients, troponine T levels were measured on 
postoperative day 1, 3 and 7 and whenever clinically 
indicated by ECG changes, consistent with myocardial 
ischemia or infarction. Troponin T level was measured 
using a whole blood rapid test (TropT version 2, Roche 
Diagnostics, Mannheim, Germany). A value of >0.1 
ng/ml was used to define positive troponin T levels. 
During a median follow-up of 2.6 years, outpatient 
visits were scheduled every 3 months after discharge. 
Endpoints were mortality and cardiac events (cardiac 
death and non-fatal myocardial infarction). Non-fatal 
myocardial infarction was diagnosed when at least two 
of the following were present: elevated cardiac enzyme 
levels (CK level > 190 U/L and CK-MB >14 U/L, or 
CK-MB fraction >10% of total CK, or cardiac troponin 
T >0.1 ng/ml), development of typical 
electrocardiographic changes (new Q waves >1 mm or > 
30 ms), and typical symptoms of angina pectoris. In 
case of death, the cause of death was identified. Cardiac 
death was defined as death caused by acute myocardial 
infarction, cardiac arrhythmias, congestive heart failure, 
or sudden death. No patients were lost to follow-up. 
 
Statistical analysis 
Continuous data were expressed as mean (+/- SD) and 
analysis of variance (ANOVA) was used to compare 
means in different groups of β-blockers. Categorical 
data are presented as percentages and analyzed using the 
chi-square test with Yates’ correction. The study group 
was divided in patients receiving no, low dose (1-25% 
of MRTD) and high dose (>25% of MRTD) β-blockers. 
Binary logistic regression analysis was used to study the 
effect of β-blockers and heart rate on the occurrence of 
myocardial ischemia and troponin T release. The C-
index for the different multivariate logistic regression 
models was calculated to evaluate how well the model 
performed. Cox proportional hazards models were used 
to analyze the effect of β-blockers and heart rate control 
on postoperative survival and cardiac events. In 
multivariate analysis, adjustments were made for age, 
gender, cardiac risk factors according to the Revised 
Cardiac Risk Index (coronary artery disease, history of 
congestive heart failure, cerebrovascular disease, 
diabetes mellitus and renal failure), dobutamine stress 
test results, hypertension, statins and angiotensin 
converting enzyme inhibitors. Odds and hazard ratios 
are given with 95% confidence intervals. For all tests, a 
p value <0.05 (two-sided) was considered significant. 
All analysis was performed using SPSS 12.0 statistical 
software (SPSS Inc., Chicago, Illinois). 
 
RESULTS 
 
Baseline characteristics 
The baseline characteristics of the 272 patients (mean 
age 67.4 +/- 10.0, 80% male) are presented in Table 1. 
No significant differences were observed between 
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baseline characteristics in the groups of patients with 
different doses of β-blockers. A total of 175 patients 
(64%) were using β-blockers; 3 of these patients (1.7%) 
presented with renal failure. Dobutamine stress 
echocardiography prior to surgery detected myocardial 
ischemia in 78 patients (29%). The majority of the 78 
patients with a positive preoperative stress test received 
β-blockers (n=69, 88%). Mean duration of surgery 
(from intubation to skin closure) was 5.4 +/-2.1 hours. 
Mean duration of continuous 12-lead ECG registration 
was 62.9 +/-13.8 hours. The mean heart rate during 12-
lead ECG monitoring was 72.7 +/-12.4 bpm. Mean 
absolute heart rate change was 9.7 +/- 7.1 bmp. Higher 
doses of β-blockers were significantly associated with 
lower heart rates during 12-lead ECG monitoring (78.8 
+/-11.8, 73.1 +/- 11.1, and 68.0 +/-10.9 bpm in patients 
with no, low dose and high dose β-blockers, 
respectively p<0.0001), and non-significantly with 
lower absolute heart rate change (11.3 +/-8.8, 9.6 +/-7.2, 
and 8.5 +/-9.7 bpm in patients with no, low dose and 
high dose β-blockers, respectively, p=0.092). 
 
Predictors for myocardial ischemia and troponin T 
release 
Myocardial ischemia was detected in 85 patients (31%). 
A total of 141 periods of myocardial ischemia were 
detected (33, 61 and 47 periods before, during and after 
surgery, respectively). The number of ischemic events 
per patient ranged from 1 to 5. The median duration of 
ischemic events was 64.5 minutes (range 9-1020 
minutes) and the median ST-segment deviation was 1.5 
mm (range 1.0-5.4 mm). Troponin T levels >0.1 ng/ml 
were measured in 44 patients (16.2%). Troponin T 
values ranged from 0.1 to 8.14 ng/ml (median: 1.1 
ng/ml). 
In univariate analysis, higher β-blockers doses, lower 
heart rates and lower absolute heart rate change were 
associated with a lower incidence of myocardial 
ischemia (for all: p<0.0001), and with a lower incidence 
of troponin T release (for all: p<0.0001) (Figure 1). In 
multivariate analysis, these associations remained 
significant (Table 2). In a final multivariate model 
including β-blocker dose, heart rate, absolute heart rate 
change and baseline clinical variables, we found that 
these variables remained independently associated with 
myocardial ischemia (β-blocker dose per 10% increase: 
HR: 0.66, 95% CI: 0.55-0.79, p<0.0001; heart rate per 
10 bpm increase: HR: 2.10, 95% CI: 1.52-2.91, 
p<0.0001; absolute heart rate change per 10 bpm 
increase: HR: 1.46, 95% CI: 1.03-2.07, p=0.032) (C-
index: 0.86).  
 
 
 
Predictors for long-term mortality and cardiac 
events 
During long-term follow-up, mortality, cardiac death 
and non-fatal myocardial infarction occurred in 66 
(24.2%), 48 (17.6%), and 6 (2.2%) patients, 
respectively. Multivariate results are summarized in 
Table 3. In multivariate analysis, higher doses of β- 
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Figure 1. The dose of β-blockers, mean heart rate and absolute heart 
rate change in relation to myocardial ischemia and troponin T release. 
 
 
  179
Table 2. Multivariate models to predict myocardial ischemia (detected by continuous 12-lead electrocardiographic monitoring) and myocardial 
damage (troponin T release). 
* Adjusted for age, gender, coronary artery disease, history of congestive heart failure, history of cerebrovascular events, diabetes mellitus, renal 
failure, hypertension, dobutamine stress echocardiography results, statins and angiotensin converting enzyme inhibitors.  
 
Table 3. Multivariate models to predict postoperative mortality and cardiac events (cardiac death or non-fatal myocardial infarction). 
 
Long-term mortality Long-term cardiac events Characteristic 
Hazards ratio  
(95% CI) 
p-value Hazards ratio (95% 
CI) 
p-value 
Dose of β-blockers per 10% increase* 0.86 (0.76-0.97) 0.0080 0.71 (0.60-0.84) <0.0001 
Heart rate (per 10 bpm increase)* 1.42 (1.14-1.76) 0.002 1.56 (1.22-2.00) <0.001 
    - Heart rate prior to surgery (per 10 bpm increase)* 1.21 (0.99-1.45) 0.052 1.28 (1.02-1.59) 0.030 
    - Heart rate during surgery (per 10 bpm increase)* 1.37 (1.09-1.70) 0.005 1.53 (1.20-1.97) <0.001 
    - Heart rate after surgery (per 10 bpm increase)* 1.45 (1.16-1.67) <0.001 1.62 (1.31-2.02) <0.001 
Absolute heart rate change (per 10 bpm increase)* 1.37 (1.06-1.77) 0.016 1.60 (1.20-2.13) 0.0013 
Myocardial ischemia during ECG monitoring* 2.23 (1.25-3.62) 0.0054 4.84 (2.38-9.84) <0.0001 
Troponin T release* 2.60 (1.49-4.55) <0.001 3.95 (2.11-7.42) <0.0001 
Adjusted for age, gender, coronary artery disease, history of congestive heart failure, history of cerebrovascular events, diabetes mellitus, renal 
failure, hypertension, dobutamine stress echocardiography results, statins and angiotensin converting enzyme inhibitors. 
 
  
 
blockers were significantly associated with a reduced 
incidence of mortality and cardiac events. Higher heart 
rates and higher absolute heart rate changes were 
associated with an increased incidence of long-term 
mortality and cardiac events. We also demonstrated that 
myocardial ischemia and troponin T release were 
significant predictors of adverse long-term outcome. 
Interestingly, higher levels of troponin T release were 
associated with a higher incidence of mortality (HR per 
1.0 ng/ml increase: 1.30, 95% CI: 1.03-1.68, p=0.037) 
and cardiac events (HR per 1.0 ng/ml increase: 1.40, 
95% CI: 1.05-1.85, p=0.027) 
 
DISCUSSION 
 
The clinical characteristics of our study population 
demonstrate that coronary artery disease is highly 
prevalent among patients undergoing major vascular 
surgery. These patients are therefore at increased risk of 
adverse postoperative cardiac events and may benefit 
from perioperative β-blocker therapy [1-3]. Several 
studies have demonstrated the association between 
perioperative β-blockers and myocardial ischemia 
reduction. In the study of Mangano et al., up to 10 mg 
atenolol or placebo was intravenously administered 30 
min before and after surgery and up to 100 mg/day was 
orally given throughout the hospital stay (up to 7 days) 
to 200 non-cardiac surgical patients. Continuous 3-lead 
Holter monitoring showed a 50% reduction of 
myocardial ischemia in the atenolol treated group 
during the first 2 postoperative days [2,11]. Another 
study demonstrated in 26 patients with preoperative 
myocardial ischemia that strict heart rate control (heart 
rate of 20% below the ischemic threshold) using 
continuous esmolol infusion significantly decreased the 
rate of postoperative myocardial ischemia during Holter 
monitoring [12]. Two patients experienced a cardiac 
event; one in the placebo and one in the esmolol group. 
Both patients had extensive myocardial ischemia and 
were unable to maintain target heart rate control, 
suggesting that heart rate control, more than β-blocker 
therapy, may be the key element in reducing 
postoperative ischemia and adverse postoperative 
events.  
 
Myocardial ischemia and troponin T release are markers 
for coronary artery disease and have been identified as 
predictors of adverse cardiac events after non-cardiac 
surgery [2,13]. This finding has been confirmed in our 
study. Moreover, our study also demonstrates that a 
higher level of troponin T was associated with worse 
outcome. During the last decades, much attention has 
been given to the prevention of postoperative cardiac 
events. The development of cardiac risk scores has 
Myocardial ischemia  Troponin T release Characteristic 
Odds ratio (95% CI) P-value C-index Odds ratio (95% CI) P-value C-index 
Dose of β-blockers per 10% increase* 0.62 (0.51-0.75) <0.0001 0.80 0.63 (0.49-0.80) <0.0001 0.77 
Heart rate  (per 10 bpm increase)* 2.49 (1.79-3.48) <0.001 0.80 1.53 (1.16-2.03) 0.003 0.76 
  - Mean HR prior to surgery (per 10 bpm increase)* 1.51 (1.19-1.92) <0.001 0.73 1.06 (0.82-1.38) 0.64 0.63 
  - Mean HR during surgery (per 10 bpm increase)* 2.62 (1.88-3.66) <0.0001 0.82 1.57 (1.21-2.03) <0.001 0.74 
  - Mean HR after surgery (per 10 bpm increase)* 2.12 (1.62-2.77) <0.0001 0.81 1.41 (1.12-1.77) 0.003 0.73 
Absolute heart rate change (per 10 bpm increase)* 1.75 (1.25-2.45) <0.001 0.73 1.37 (1.04-1.89) 0.030 0.69 
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allowed clinicians to identify patients at increased risk 
for adverse postoperative events [14]. Coronary artery 
revascularization before elective major vascular surgery 
has been proposed as preventive measure, but does not 
seem to significantly alter the long-term outcome [15]. 
Cumulating evidence suggests encouraging effects of 
perioperative β-blocker therapy. However, most studies 
have not included heart rate, absolute heart rate change 
and dosage of β-blockers into their analyses, omitting 
several important potential determinants of 
postoperative outcome. Our results suggest that higher 
doses of β-blockers, lower mean heart rates and lower 
absolute heart rate changes were all important in the 
reduction of myocardial ischemia, troponin T release 
and long-term events. 
 
Reductions in heart rate lead to restoration of the 
myocardial oxygen supply-demand balance and 
prolongation of coronary diastolic filling time, being of 
benefit to the surgical patient with a compromised 
coronary circulation, exposed to the stressful period of 
surgery [5,6]. In addition, it might be hypothesized that 
β-blockers improve outcome after major non-cardiac 
surgery by its anti-inflammatory effect [16]. It also has 
been demonstrated that elevated heart rates are 
associated with an increased risk of vulnerable coronary 
plaque disruption and that β-blockers could reduce the 
risk of disruption [17]. We defined absolute heart rate 
change by the cumulative difference between the mean 
heart rate before, during, and after surgery. It might be 
suggested that achieving continuous low levels of heart 
rate during the whole perioperative period may yield the 
optimal physiological condition to prevent adverse 
events. However, further studies are needed to confirm 
and validate the effect of perioperative heart rate change 
on postoperative outcome. 
 
Although this study demonstrates strong evidence in 
favor of high doses of β-blockers, low heart rates and 
low absolute heart rate changes, several limitations 
should be addressed. The major limitation in this study 
is that β-blockers were not randomly assigned to the 
patients. We used multivariate analysis to adjust for 
known possible confounding factors, such as cardiac 
risk factors according the Revised Cardiac Risk index, 
indications for beta-blocker therapy and 
cardioprotective medication. Although our study 
focused on beta-blockers, heart rate and heart rate 
changes, future studies should evaluate the relation 
between blood pressure, cardiac output and 
postoperative cardiac events. Our results may explain 
why several previously published studies failed to show 
a beneficial effect of β-blockers [7,8]. Administration of 
β-blockers alone might not be sufficient for 
postoperative risk reduction. Close perioperative heart 
rate monitoring and heart rate control together with 
adequate doses of oral or intravenous β-blockers may 
improve prognosis and may therefore be recommended 
in all patients undergoing major vascular surgery.  
 
“All authors had full access to the data and take full 
responsibility for its integrity. All authors have read and 
agree to the manuscript as written” 
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β-Blockers Improve In-hospital and Long-term 
Survival in Patients with Severe Left Ventricular 
Dysfunction Undergoing Major Vascular Surgery 
H.H.H. Feringa (a), J.J. Bax (b), O. Schouten (c), M.D. Kertai (a), L.L.M. van de Ven (a), S. Hoeks (d), M.R.H.M. 
van Sambeek (c), J. Klein (a) and D. Poldermans (a) 
 
 
Objectives: To study whether β-blockers reduce in-
hospital and long-term mortality in patients with severe 
left ventricular dysfunction (LVD) undergoing major 
vascular surgery.  
Design: Observational cohort study.  
Materials: Five hundred and eleven patients with severe 
LVD (ejection fraction<30%) undergoing major non-
cardiac vascular surgery.  
Methods: In all patients, cardiac risk factors, 
medication (including β-blockers), and dobutamine 
stress echocardiography (DSE) results were noted prior 
to surgery. DSE was evaluated for rest and stress-
induced new wall motion abnormalities. Endpoint was 
in-hospital and long-term mortality. Propensity scores 
for β-blockers were calculated and regression models 
were used to analyse the relation between β-blockers 
and mortality.  
Results: Mean age was 64±11 years and 383 patients 
(75%) were male. 139 patients (27%) used β-blockers. 
Stress-induced ischemia occurred in 82 patients (16%). 
Median follow-up was 7 years (interquartile range: 3–
10). In-hospital and long-term mortality was observed in 
64 (13%) and 171 (33%) patients, respectively. After 
adjusting for clinical variables, DSE results and 
propensity scores, β-blockers were significantly 
associated with reduced in-hospital and long-term 
mortality (OR: 0.18, 95% CI: 0.04–0.74 and HR: 0.38, 
95% CI: 0.22–0.65, respectively).  
Conclusion: In patients with severe LVD undergoing 
major vascular surgery, the use of β-blockers is 
associated with a reduced incidence of in-hospital and 
long-term postoperative mortality.  
____________________________________________________________________________________________ 
 
 
THE PREVALENCE OF congestive heart failure in 
the adult population in the United States and United 
Kingdom has been estimated to be 1.2 and 1.8%, 
respectively, and has been demonstrated to be higher 
among the older population with prevalence values of 
5.5 and 8.0%, respectively, in patients aged 75 years or 
older.1 and 2 Both congestive heart failure and coronary 
artery disease have been identified as significant 
predictors of postoperative morbidity and mortality in 
patients undergoing major non-cardiac surgery.3, 4 and 5 
Because patients who are at increased risk of 
postoperative events may benefit from medical 
treatment or other preoperative interventions, the 
identification of these patients has been an important 
goal in preoperative screening strategies. Tools for 
preoperative screening include cardiac risk scores, such 
as the revised cardiac risk index, resting 
echocardiography, and dobutamine stress 
echocardiography, which may detect both left 
ventricular dysfunction and stress induced myocardial 
ischemia.4, 6 and 7  
β-Blockers are established therapeutic agents for 
patients with hypertension and coronary artery disease. 
In addition, β-blockers have been shown to reduce 
morbidity and mortality in patients with mild, moderate 
and severe chronic heart failure.8, 9 and 10 As a result, 
consensus guidelines strongly recommended the use of 
β-blockers in heart failure patients, unless there is a 
strong contraindication.11 and 12 Several randomized trials 
have demonstrated that patients with coronary artery 
disease benefit from perioperative β-blocker therapy in 
terms of reduced postoperative morbidity and 
mortality.13 and 14  
We conducted this study to assess whether 
chronic β-blocker therapy reduces the incidence of in-
hospital and long-term mortality in patients with severe 
left ventricular dysfunction undergoing major non-
cardiac vascular surgery. In this cohort study, we used 
propensity analysis to adjust for selection bias in the 
comparison of treatments.  
aDepartment of Anesthesiology, Erasmus MC, Rotterdam, The 
Netherlands. bDepartment of Cardiology, Leiden University Medical 
Center, Leiden, The Netherlands. cDepartment of Vascular Surgery, 
Erasmus MC, Rotterdam, The Netherlands. dDepartment of Clinical 
Epidemiology, Erasmus MC, Rotterdam, The Netherlands. 
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1. MATERIALS AND METHODS 
1.1. Study cohort  
Patients who were referred to the Erasmus Medical 
Centre between January 1990 and January 2004 for 
elective major vascular surgery were routinely screened 
for cardiac risk factors and underwent resting 
echocardiography and dobutamine stress 
echocardiography (DSE) for pre-operative risk 
stratification. A total of 511 consecutive patients with 
markedly decreased left ventricular function were 
retrospectively identified and were included in this 
study. Left ventricular systolic dysfunction was defined 
as an ejection fraction of 30% or less by preoperative 
two-dimensional echocardiography, or as a resting wall 
motion-score index of 1.70 or more. Left ventricular 
end-diastolic and end-systolic volumes were obtained 
from the apical four- and two-chamber views by using 
the Simpson's rule formula, from which the ejection 
fraction was calculated. Wall motion score index was 
calculated according to the guidelines of the American 
Society of Echocardiography (ASE), using a 16-
segment model.15  
β-Blocker therapy was recorded when β-blockers were 
started at least 1 month prior and continued to at least 2 
months after surgery. Diabetes mellitus was recorded if 
patients presented with a fasting glucose level of 
≥7.0 mmol/L, or in those who required treatment. 
Hypertension was recorded if patients presented with a 
blood pressure ≥140/90 mmHg or if patients were 
medically treated for hypertension. 
Hypercholesterolemia was recorded if patients 
presented with a plasma cholesterol level ≥5.5 mmol/L, 
or if patients were taking lipid-lowering agents. Renal 
dysfunction was recorded if patients presented with a 
serum creatinine level ≥2.0 mg/dL (177 μmol/L) or in 
those who required dialysis. A baseline 12-lead 
electrocardiography was obtained and was considered 
abnormal in the presence of one or more of the 
following; Q-waves, ST-segment depression or 
elevation, left ventricular hypertrophy, right or left 
bundle branch block and atrial fibrillation. Surgical 
procedures included elective aortic abdominal repair, 
lower extremity revascularization and carotid artery 
surgery.  
1.2. Dobutamine stress echocardiography  
All patients underwent a resting two-dimensional 
precordial echocardiographic examination and a 12-lead 
electrocardiogram was recorded. Dobutamine 
hydrochloride was then administered intravenously by 
infusion pump, starting at 5 μg/kg/min for 5 min, 
followed by 10 μg/kg/min for 5 min and increasing by 
10 μg/kg/min every 3 min to a maximum of 
40 μg/kg/min, and continued for 6 min. The dobutamine 
infusion was stopped if a target heart rate (85% of the 
age and gender corrected maximal heart rate) was 
achieved. If the target heart rate was not achieved and 
patients had no symptoms or signs of ischemia, atropine 
sulphate (0.25–2.0 mg intravenously) was given while 
the administration of dobutamine was continued. 
Metoprolol was administered (1.0–5.0 mg 
intravenously) to reverse the side effects of the 
administration of dobutamine or the dobutamine–
atropine combination if the side effects did not revert 
spontaneously and quickly. Two experienced 
investigators performed off-line assessment of 
echocardiographic images, and were blinded to the 
clinical data in order to give an objective interpretation. 
Using a standard 16-segment model, wall motion was 
scored on a 5-point scale (a score of 1 indicating 
normal, 2 mild hypokinesis, 3 severe hypokinesis, 4 
akinesis, and 5 dyskinesis) and a wall motion score 
index was calculated (total score divided by the number 
of segments scored). The results of DSE were 
considered positive if new wall-motion abnormalities 
occurred (i.e. if wall motion in any segment worsened 
by ≥1 grades during the test, with the exception of 
akinesis becoming dyskinesis). This criterion was used 
consistently during the whole study period.  
1.3. Postoperative outcome  
End-point was mortality. In-hospital mortality was 
defined as death occurring during postoperative in-
hospital stay or as death occurring after hospital 
discharge but within the first 30 days after surgery. 
Long-term mortality was defined as death occurring at 
any time from day 1 after surgery. Information about the 
patient's vital status was obtained by reviewing the 
hospital's medical records, by approaching the patient's 
general physician and by approaching the Office of 
Civil Registry. The date of the last review or the date 
that an endpoint was reached was used to calculate 
follow-up time. Median follow-up time was 7 years 
(interquartile range: 3–10 years). Follow-up was 
completed in all patients.  
1.4. Statistical analysis  
Continuous data are expressed as mean (±SD) or 
median (±interquartile range) and compared using the 
Student t-test or Mann–Whitney U-test when 
appropriate. Categorical data are presented as percent 
frequencies and differences between proportions were 
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Table 1.  Baseline characteristics of the 511 patients  
 β-Blockers (n=139) No β-blockers (n=372) p-Value 
Age (years) 64±11 65±12 0.35 
Male gender 97 (70%) 286 (77%) 0.19 
Angina pectoris 53 (38%) 107 (29%) 0.05 
Previous myocardial infarction 85 (61%) 182 (49%) 0.02 
Previous coronary revascularization 51 (37%) 62 (17%) <0.001 
Previous stroke or transient ischemic attack 26 (19%) 54 (15%) 0.31 
Hypertension 88 (63%) 115 (31%) <0.001 
Current smoker 42 (30%) 126 (34%) 0.50 
Chronic obstructive pulmonary disease 28 (20%) 60 (16%) 0.35 
Hypercholesterolemia 57 (41%) 69 (19%) <0.001 
Diabetes mellitus 29 (21%) 43 (12%) 0.01 
Renal failure 21 (15%) 36 (10%) 0.11 
Electrocardiography 
 Left ventricular hypertrophy 8 (6%) 29 (8%) 0.55 
 Q-waves 58 (42%) 125 (34%) 0.11 
 ST-segment changes 39 (28%) 66 (18%) 0.01 
 Left bundle branch block 8 (6%) 12 (3%) 0.29 
 Right bundle branch block 6 (4%) 22 (6%) 0.63 
 Atrial fibrillation 16 (12%) 21 (6%) 0.04 
Type of surgery 
 Abdominal aortic repair 71 (51%) 166 (45%) 0.23 
 Lower extremity revascularization 55 (40%) 166 (45%) 0.35 
 Carotid artery surgery 13 (9%) 40 (11%) 0.76 
Cardiac medication 
 Aspirin 51 (37%) 74 (20%) <0.001 
 Angiotensin-converting enzyme inhibitors 74 (53%) 141 (38%) 0.002 
 Calcium channel blockers 65 (47%) 97 (26%) <0.001 
 Coumarin 38 (27%) 73 (20%) 0.08 
 Digoxin 15 (11%) 26 (7%) 0.22 
 Diuretic 44 (32%) 92 (25%) 0.14 
 Nitrates 66 (48%) 97 (26%) <0.001 
 Statins 61 (44%) 46 (12%) <0.001 
    
compared using the chi-square test with Yates' 
correction. The Kaplan–Meier method with log-rank 
test was used to compare survival curves in two or more 
groups. Because β-blockers were not assigned in a 
random fashion and selection bias may distort the 
results of our study, a propensity score for β-blockers 
was constructed using multiple logistic regression 
analyses. Propensity analyses are reliable tools to 
correct for selection bias and the rationale for using 
propensity scores has been described previously.16 and 17 
A propensity score is generally defined as the 
conditional probability of assignment to a particular 
treatment given a vector of observed covariates. To 
assess the effect of a treatment in a situation in which 
randomization is difficult or impossible, propensity 
scores are a useful method for matching members of 
different groups. Comparisons of different groups reveal 
reliable information on the impact of the treatment of 
interest with a small residual bias.17 Clinical variables 
and medication that were independently associated with 
the decision to prescribe β-blockers (p-value<0.25) were 
included in the multivariate propensity score. Important 
determinants to prescribe β-blockers were angina 
pectoris, previous myocardial infarction, hypertension, 
and hypercholesterolemia (p<0.05). Propensity scores 
ranged from 0.007 to 0.97.  
Logistic regression models were used to analyse the 
relation between β-blocker therapy and in-hospital 
mortality. Cox hazards regression models were used to 
analyse the relation between β-blocker therapy and 
long-term mortality. In multivariate analyses, 
adjustments were made for baseline clinical variables, 
DSE results, and propensity scores, irrespective of the 
significance level in univariate analysis. In order to 
reveal possible heterogeneity between intermediate risk 
procedures (carotid artery surgery) and high-risk 
procedures (abdominal aortic aneurysm repair and lower 
extremity revascularization procedures), an interaction 
term was evaluated. Interaction was considered  
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Table 2.  Univariate predictors of 30-day and long-term mortality  
 30-Day mortality (n=64)  Long-term mortality (n=171)  
 Odds ratio (95% CI) p-Value Hazard ratio (95% CI) p-Value 
Age>70 years 2.11 (1.24–3.57) 0.006 1.64 (1.21–2.23) 0.002 
Male gender 1.52 (0.78–2.95) 0.22 1.28 (0.88–1.87) 0.19 
Angina pectoris 1.27 (0.73–2.20) 0.39 1.32 (0.96–1.82) 0.09 
Previous MI 4.19 (2.22–7.92) <0.001 3.07 (2.19–4.34) <0.001 
Previous stroke or TIA 5.43 (2.06–9.62) <0.001 2.06 (1.42–2.99) <0.001 
Hypertension 1.61 (0.95–2.73) 0.07 1.05 (0.79–1.44) 0.84 
Current smoker 0.74 (0.32–1.70) 0.47 1.15 (0.81–1.65) 0.38 
Hypercholesterolemia 0.53 (0.23–1.21) 0.22 1.21 (0.85–1.72) 0.31 
Diabetes mellitus 1.00 (0.47–2.12) 0.99 1.61 (1.08–2.40) 0.02 
Renal failure 4.54 (2.42–8.54) <0.001 2.72 (1.84–4.03) <0.001 
COPD 1.56 (0.83–2.93) 0.17 1.27 (0.87–1.87) 0.16 
Abnormal ECG 0.83 (0.49–1.40) 0.49 1.74 (1.25–2.43) <0.001 
NWMA 3.23 (1.84–5.66) <0.001 4.11 (2.99–5.67) <0.001 
β-Blockers 0.24 (0.10–0.58) 0.001 0.49 (0.32–0.75) <0.001 
MI, myocardial infarction; TIA, transient ischemic attack; COPD, chronic obstructive pulmonary disease; ECG, electrocardiogram; NWMA, new 
wall motion abnormalities 
 
statistically significant at the 0.05 probability level. 
Odds ratios (OR) and hazard ratios (HR) are given with 
95% confidence intervals. For all tests, a p-value<0.05 
(two-sided) was considered significant. All analyses 
were performed using SPSS-11.0 statistical software 
(SPSS Inc., Chicago, Illinois).  
2. RESULTS 
Mean age was 64±11 years and 383 patients (75%) were 
male. A total of 139 patients (27%) were using chronic 
β-blockers; 99 patients (71%) used a selective β-blocker 
and 40 patients (29%) a non-selective β-blocker. 
Selective β-blockers included atenolol (n=8), bisoprolol 
(n=41) and metoprolol (n=50). Non-selective β-blockers 
included carvedilol (n=26) and sotalol (n=14). Baseline 
characteristics of the patients subdivided according to 
the use of β-blockers are summarized in Table 1. During 
preoperative DSE, heart rate increased from 
72±15 beats/min at rest to 132±18 beats/min at peak 
stress. The maximum dose of dobutamine infusion was 
37.6±8 μg/kg/min. Atropine was administered in 312 
patients (61%) to achieve target heart rate. The mean 
wall motion score index at rest was 2.11±0.37. The 
mean wall motion score index at rest was 2.07±0.28 in 
patients using beta-blockers and of 2.11±0.36 in patients 
who did not (p=0.52). The mean wall motion score 
index at peak stress was 1.80±0.47. Stress induced 
myocardial ischemia occurred in 82 patients (16%). No 
fatal complications occurred during or immediately after 
the stress test. Abdominal aortic repair was performed 
in 237 patients (46%), lower extremity revascularization 
in 221 patients (43%), and carotid artery surgery in 53 
patients (10%). 
In-hospital mortality occurred in 64 patients (13%) and 
long-term mortality in 171 patients (33%). Univariate 
associations between clinical variables and mortality are 
summarized in Table 2. Age above 70 years, previous 
myocardial infarction, history of stroke or transient 
ischemic attack, renal failure and stress induced 
myocardial ischemia were significant unadjusted 
determinants for in-hospital and long-term mortality. 
The use of β-blockers was associated with a significant 
reduction of in-hospital and long-term mortality (OR: 
0.24, 95% CI: 0.10–0.58 and HR: 0.49, 95% CI: 0.32–
0.75, respectively). Kaplan–Meier estimates for long-
term mortality, stratified according to the use of β-
blockers, showed a better survival for those patients 
using β-blocker therapy (p<0.001) (Fig. 1). In 
multivariate analysis, the relation between β-blocker 
therapy and post-operative mortality was adjusted for 
clinical variables, DSE results and propensity scores for 
β-blockers. The use of β-blockers remained significantly 
associated with a reduced incidence of in-hospital and 
long-term mortality (OR: 0.18, 95% CI: 0.04–0.74 and 
HR: 0.38, 95% CI: 0.22–0.65, respectively) (Fig. 2).  
In patients using β-blockers (n=139), we observed no 
significant effect of selective β-blockers as compared to 
non-selective β-blockers on postoperative mortality (in-
hospital mortality: OR: 0.4, 95% CI: 0.1–2.0; long-term 
mortality: HR: 0.7, 95% CI: 0.3–1.4); in multivariate 
analyses, this association was also non-significant (in-
hospital mortality: OR: 0.6, 95% CI: 0.1–3.5; long-term 
mortality: HR: 0.6, 95% CI: 0.3–1.3). Tests for 
heterogeneity revealed no evidence for a differential 
effect of β-blockers in patients undergoing intermediate 
risk procedures (carotid artery surgery) and high-risk 
procedures (abdominal aortic aneurysm repair and lower 
extremity revascularization) (p-value for interaction 
=0.96). 
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 Fig. 1. Kaplan–Meier estimates of all-cause mortality, stratified 
according to the use of β-blockers. Dashed line denotes β-blocker use; 
solid line denotes no β-blocker use.  
3. DISCUSSION 
This study shows that β-blockers improve in-hospital 
and long-term survival in patients with severe left 
ventricular dysfunction undergoing major non-cardiac 
vascular surgery. This association was independent of 
clinical risk factors, stress induced myocardial ischemia 
during DSE, and propensity scores for β-blockers.  
Congestive heart failure has been identified as an 
important risk factor for adverse events after major non-
cardiac surgery. In 1977, Goldman developed the 
multifactorial cardiac risk index, which allows 
preoperative estimation of cardiac risk in non-cardiac 
surgical procedures.3 They demonstrated that clinical 
signs of congestive heart failure such as a preoperative 
third heart sound and jugular venous distension were 
strongly associated with the development of 
postoperative life threatening or fatal cardiac 
complications. Twelve years later, Lee et al. developed 
and validated the revised cardiac risk index, which 
included congestive heart failure as an important 
predictor for postoperative cardiac events, among other  
 
Fig. 2. Multivariate models to predict 30-day (A) and long-term (B) 
mortality after major vascular surgery. ECG, electrocardiogram; 
COPD, chronic obstructive pulmonary disease; NWMA, new wall 
motion abnormalities; TIA, transient ischemic attack; MI, myocardial 
infarction.  
predictors, such as ischemic artery disease, high-risk 
type of surgery, a history of cerebrovascular disease, 
insulin therapy for diabetes mellitus, and preoperative 
serum creatinine levels of more than 2.0 mg/dL.4 
Although decompensated and compensated heart failure 
have been identified as, respectively, a major and 
intermediate determinant of increased perioperative 
cardiovascular risk, resting left ventricular dysfunction 
as measured by invasive and non-invasive tests has not 
been demonstrated to be a consistent predictor of 
perioperative cardiac events.18, 19, 20 and 21 Therefore, the 
ACC/AHA guidelines for perioperative cardiovascular 
evaluation for non-cardiac surgery do not recommend 
routine testing of left ventricular function in patients 
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without a history of congestive heart failure.6 However, 
the identification of patients with an ejection fraction of 
30% or less might be important, especially because 
these patients may benefit from β-blocker therapy.  
Large randomized trials have demonstrated the 
usefulness of β-blockers in non-surgical patients with 
reduced left ventricular function. The MDC-trial 
(Metoprolol in Dilated Cardiomyopathy Trial), MERIT-
HF trial (Metoprolol CR/XL Randomized Intervention 
Trial in Congestive Heart Failure), CIBIS-I and II trial 
(Cardiac Insufficiency Bisoprolol Study I and II), and 
COPERNICUS (Carvedilol Prospective Randomized 
Cumulative Survival Study Group), all have 
demonstrated the benefits of metoprolol, bisoprolol and 
carvedilol for survival in stable advanced heart-failure 
patients.22, 23, 24 and 25 The CAPRICORN study 
demonstrated that patients with left ventricular 
dysfunction following a recent acute myocardial 
infarction also benefit from β-blockers (carvedilol) in 
addition to angiotensin-converting enzyme inhibitors.26 
Meta-analyses have confirmed the usefulness of β-
blockers in patients with reduced left ventricular 
function, demonstrating that β-blockers reduced all-
cause mortality by around 30%.27, 28 and 29 As a result, 
consensus guidelines strongly support and 
recommended the use of β-blockers in a-symptomatic to 
severe symptomatic heart failure patients, unless there is 
an absolute contraindication to the use of these drugs.11 
and 12  
Perioperative management of patients with dilated or 
hypertrophic cardiomyopathy undergoing major surgery 
is aimed at maximizing preoperative hemodynamic 
status and providing intensive postoperative medical 
therapy and surveillance.6 Although randomized trials 
have demonstrated that patients who are at risk for 
coronary artery disease and who undergo major vascular 
surgery benefit from perioperative β-blocker therapy in 
terms of reduced postoperative morbidity and mortality, 
limited is known about the role of β-blocker therapy in 
patients with left ventricular dysfunction to improve 
early and long-term outcome after major vascular 
surgery.13 and 14 In the present study, we demonstrated 
the beneficial effect of β-blockers on in-hospital and 
long-term survival in patients with left ventricular 
dysfunction, independent of the presence or absence of 
coronary artery disease or other possible confounding 
factors. These results suggest that the effect of beta-
blockers is not only due to its long-term protective 
effect, but also due to its myocardial protective effect 
during the perioperative period of surgery. Preoperative 
screening of patients with left ventricular dysfunction 
might, therefore, be recommended. However, 
randomized controlled trials should be conducted before 
recommending this approach.  
It is known that an increase in cardiac adrenergic drive 
is an early compensatory mechanism for the failing 
heart and that chronic activation of the adrenergic 
nervous system results in increased cardiac output and 
heart rate with increased myocardial oxygen demand, 
ischemia and oxidative stress. This may result in 
histopathologic changes with subsequent ventricular 
remodeling. β-Blockers reverse the process of left 
ventricular remodeling, leading to improved 
hemodynamics with favorable effects on prognosis.30 In 
addition, β-blockers may also have beneficial effects 
through their heart rate regulating, anti-arrhythmic and 
anti-inflammatory effects.31, 32 and 33 We speculate that 
the same mechanisms may be responsible for the 
reduction in postoperative mortality in patients with left 
ventricular dysfunction undergoing major non-cardiac 
vascular surgery using concomitant β-blocker therapy. It 
may take a prolonged period for β-blockers to exert its 
cardioprotective effect and, therefore, β-blockers should 
be started at least several weeks before elective major 
non-cardiac surgery, when possible.  
The major limitation in this study is that β-blockers 
were not administered in a randomized controlled 
fashion. Selection bias is a major determinant for 
distorted results. However, we applied propensity 
analysis, which has been shown to be a reliable method 
to adjust for selection bias.16 and 17 Another limitation 
which should be considered when interpreting the 
results is that some patients with severe left ventricular 
dysfunction and especially those with extensive co-
morbidity, such as renal dysfunction and chronic 
obstructive pulmonary disease, were not referred to our 
clinic for major surgery, and, therefore, were not 
included in our study.  
Based on our results we conclude that β-blockers are 
independently associated with a reduced incidence of 
in-hospital and long-term mortality in patients with 
severe left ventricular dysfunction. 
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Hemodynamic responses and long-term follow-up 
results in patients using chronic β1-selective and non-
selective β-blockers during dobutamine stress 
echocardiography 
Harm H.H. Feringa, M.D.a, Jeroen J. Bax, M.D.b, Abdou Elhendy M.D., Ph.D. c, Ron T. van Domburg, Ph.D.d, Olaf 
Schouten, M.D.e, Boudewijn Krenning, M.D.d, Don Poldermans, M.D.d 
 
Objective: This study was undertaken to determine to 
what extent hemodynamic responses to dobutamine 
infusion between patients using concomitant β1-
selective or non-selective β-blockers differ and whether 
this difference affects the long-term prognostic value of 
dobutamine stress echocardiography (DSE) with respect 
to cardiac events. 
Design: Single centre, observational study. 
Methods: A total of 1234 patients using chronic β-
blockers underwent DSE and were prospectively 
included in the study. Heart rate and blood pressure 
responses were measured during the DSE protocol. 
During a median follow-up time of 4 years (range: 0.5-
14 years), overall and cardiac mortality and non-fatal 
myocardial infarction were noted.  
Results; A total of 954 and 280 patients were using β1-
selective and non-selective β-blockers, respectively. 
During DSE, the heart rate response was significantly 
higher, systolic and diastolic blood pressure responses 
were significantly lower and the double product of heart 
rate and systolic blood pressure was similar in patients 
using β1-selective, compared to patients using non-
selective β-blockers. In patients with and without new 
wall motion abnormalities during DSE, a similar cardiac 
event-free survival was observed irrespective of the 
selectivity of β-blockers (p=0.9 and p=0.3, respectively) 
Conclusion: During DSE, heart rate and blood pressure 
response was different, but the double product was 
similar in patients using β1-selective or non-selective β-
blockers, which may explain why the long-term 
prognostic value of DSE is similar in these two groups.
_____________________________________________________________________________________________ 
 
 
STRESS ECHOCARDIOGRAPHY is a widely used 
non-invasive technique for the long-term risk 
assessment in patients with known or suspected 
coronary artery disease [1,2]. Dobutamine, a synthetic 
catecholamine with predominant β1-adrenergic receptor 
activity and with mild agonistic effects on β2- and α1-
adrenergic receptors, is commonly used as a 
pharmacologic stressor in stress echocardiography [1,3]. 
Escalating doses of dobutamine are administered in 
conjunction with echocardiography to increase 
myocardial oxygen demand through positive inotropic 
and chronotropic effects and to detect new wall motion 
abnormalities in regions with a mismatch between 
myocardial oxygen supply and demand.  
In patients referred for dobutamine stress 
echocardiography (DSE), β-blockers are commonly 
prescribed and are frequently continued during the 
stress test. Beta-blockers can be classified into β1-
selective, predominantly blocking β1-adrenergic 
receptors, and non-selective β-blockers, blocking both 
β1- and β2-adrenergic receptors [4-6]. β1-selective β-
blockers are established therapeutic agents for patients 
with hypertension, angina pectoris and heart failure [7]. 
The beneficial effect of non-selective β-blockers in 
patients with congestive heart failure has been 
established more recently [8,9]. During exercise and 
stress, both β1-selective and non-selective β-blockers 
attenuate the expected increase in heart rate and cardiac 
output [4-6]. It has been observed that during exercise 
and dobutamine induced stress the increase in heart rate 
was more attenuated in patients using non-selective, 
than in patients using β1-selective β-blockers [10-12].    
During DSE, the hemodynamic responses may 
be different in patients using either β1-selective or non-
selective β-blockers, and this may influence the 
prognostic value of DSE. The purpose of this study was 
to compare the hemodynamic effects of incremental 
dobutamine infusion rates during stress 
echocardiography in patients using β1-selective or non-
selective β-blockers, and to evaluate whether the use of 
each of these two agents during DSE has any influence 
on the long-term prognostic value of DSE with respect 
to cardiac mortality or cardiac events.  
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METHODS 
 
Study population 
During the period January 1990 through December 
2003, 3875 patients underwent DSE at the Erasmus 
Medical Center in Rotterdam, the Netherlands. A total 
of 1234 patients were receiving either chronic β1-
selective or non-selective β-blocker therapy and were 
prospectively included in the study after giving 
informed consent. Clinical risk factors (hypertension, 
smoking, hypercholesterolemia, diabetes mellitus, 
angina pectoris, a history of myocardial infarction, a 
history of congestive heart failure) and the use of 
cardiac medication were recorded at the time of DSE. 
Hypertension was recorded if patients presented with a 
blood pressure ≥140/90 mmHg or if patients were 
medically treated for hypertension. 
Hypercholesterolemia was recorded if patients 
presented with a plasma cholesterol level ≥5.5 mmol/L, 
or if patients were taking lipid-lowering agents. 
Diabetes mellitus was recorded if patients presented 
with a fasting glucose level of ≥7.8 mmol/L, or in those 
who required treatment. Follow-up data were obtained 
from all patients. 
 
Dobutamine stress echocardiography and assessment 
of hemodynamic response 
The DSE protocol was approved by the Hospital Ethical 
Committee and was performed in accordance with well-
established protocols [13,14]. Patients underwent a 
resting two-dimensional precordial echocardiographic 
examination and standard apical and parasternal views 
were recorded on videotape and a 12-lead ECG was 
recorded. Dobutamine hydrochloride was then 
administered intravenously by infusion pump with 
incremental doses of 10 μg/kg/min every 3 minutes to a 
maximum of 40 μg/kg/min (stage 4), and continued for 
6 minutes. The dobutamine infusion was stopped if a 
target heart rate (85% of a theoretic maximal heart rate 
(men: (220 – age) x 85%; women: (200 – age) x 85%) 
was achieved. If the target heart rate was not achieved 
and patients had no symptoms or signs of ischemia, 
atropine sulphate (starting with 0.25 mg, increased to a 
cumulative maximum of 2.0 mg) was given 
intravenously at the end of stage 4 while the dobutamine 
administration was continued. Βeta-blocker therapy was 
continued during the study. During the test, a 12-lead 
ECG was recorded every minute. Blood pressure was 
measured by sphygmomanometry every 3 minutes 
(Accutorr A1; Datascope Corp., Paramus, NY, U.S.A.). 
Metoprolol was administered (1,0 to 5,0 mg 
intravenously) to reverse the side effects of the 
administration of dobutamine or the dobutamine-
atropine combination if the side effects did not revert 
spontaneously and quickly. Atropine was administered 
as an antidote if bradycardia and hypotension occurred. 
The criteria for stopping the test were: (1) severe new 
echocardiographic wall motion abnormalities in 
multiple locations, (2) horizontal or downsloping 
electrocardiographic ST depression of ≥0.2 mV 
measured 80 ms after the J point, or ST-segment 
elevation of ≥0.2 mV in the absence of Q waves, (3) 
symptomatic decline in systolic blood pressure of more 
than 40 mmHg from the resting value, or a systolic 
blood pressure of less than 100 mmHg, (4) hypertension 
(blood pressure >240/140 mmHg), (5) the occurrence of 
cardiac arrhythmias, (6) severe angina pectoris, and (7) 
intolerable adverse effects considered to be the result of 
dobutamine or atropine.  
Off-line assessment of echocardiographic 
images was performed by two experienced investigators 
without knowledge of the patient’s clinical data, but 
with knowledge of the doses of dobutamine and 
atropine used. From 1990 to 1993, the left ventricle was 
divided into 14 segments and wall motion was scored 
on a 4-point ordinal scale [15]. After 1993 a 16-segment 
5-point score was used [16]. The results of DSE were 
considered positive if new wall motion abnormalities 
occurred (i.e., if wall motion in any segment worsened 
by ≥1 grade(s) during the test, with the exception of 
akinesis becoming dyskinesis). The extent and location 
of ischemia were evaluated and a wall-motion score 
index (total score divided by the number of segments 
scored) was calculated, both at rest and during peak 
stress. When there was disagreement between the two 
assessors, a third investigator viewed the images 
without knowledge of the previous assessments, and a 
majority decision was reached.  
 
Clinical follow-up 
Follow-up data were obtained in January 2004. The 
patient’s status was determined by contacting the 
patient’s general physician and/or by reviewing hospital 
records. The date of the last interview or review was 
used to calculate follow-up time. Endpoints were as 
follows: death from all causes, cardiac death, non-fatal 
myocardial infarction and coronary revascularization 
(performed >2 months after DSE). After reaching an 
endpoint, follow-up was discontinued. Cardiac death 
was defined as death caused by acute myocardial 
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infarction, cardiac arrhythmias, or congestive heart 
failure. Non-fatal myocardial infarction was diagnosed 
when at least two of the following were present: 
elevated levels of CK, CK-MB and cardiac troponin T 
(CK level >190 U/L and CK-MB >14 U/L, or CK-MB 
fraction >6% of total CK, or cardiac troponin T >0.1 
ng/mL), development of typical electrocardiographic 
changes (new Q waves >1 mm or >30 ms), and typical 
symptoms of angina pectoris. Coronary 
revascularization included coronary angioplasty or 
coronary artery bypass surgery.   
 
Statistical analysis 
The study population was divided in two subgroups 
according to the type of β-blocker therapy. Continuous 
data are expressed as means (+/- SD) and compared 
using the Independent-samples t test or Paired-samples t 
test when appropriate. Categorical data are presented as 
percent frequencies and differences between proportions 
were compared using the chi-square test with Yates’ 
correction. ANOVA for repeated measurements was 
used to compare the hemodynamic responses between 
the two subgroups during the DSE protocol. Univariate 
Cox regression analysis was performed to study the 
prognostic value of the selected clinical characteristics 
and DSE results with respect to the endpoints. To 
investigate the prognostic value of β1-selective β-
blockers with respect to cardiac death or non-fatal 
myocardial infarction, multivariate Cox regression 
analysis was used to adjust for baseline characteristics 
and DSE results. Hazard ratios (HR) are given with 95% 
confidence intervals (95% CI). The cardiac event-free 
survival was compared using Kaplan-Meier curves. 
Differences between cardiac event-free survival curves 
were tested with the log-rank chi-square statistic. For all 
tests, a p-value <0.05 (two-sided) was considered 
significant.  
 
RESULTS 
 
Patient characteristics 
The study population consisted of 1234 consecutive 
patients undergoing dobutamine stress 
echocardiography (mean age: 61 +/-12 years, 68% 
male); 954 patients (77%) used a β1-selective β-blocker 
and 280 patients (23%) used a non-selective β-blocker. 
Beta1-selective β-blockers included atenolol, bisoprolol, 
celiprolol, metoprolol and nebivolol. Non-selective β-
blockers included carvedilol, pindolol, propranolol, 
sotalol and labetalol.  
 
 
Table 1. Baseline characteristics of patients using β1-selective β-blockers and non-selective β-blockers. 
Characteristics Patients with β1-
selective  β-blockers  
(n=954) 
Patients with non-
selective β-blockers 
(n=280) 
p-value 
Demographics    
    Age (years) (mean +/- SD) 60 +/-12 62 +/-11 0.053 
    Gender (male) (%) 68 66 0.5 
    Weight (kg) (mean +/- SD) 77 +/-13 76 +/-14 0.3 
    Length (m) (mean +/- SD) 1.71 +/-0.09 1.73 +/-0.1 0.07 
Hemodynamics    
    Heart rate (bpm) (mean +/- SD) 70 +/- 13 71 +/-13 0.3 
    Systolic blood pressure (mmHg) (mean +/- SD) 132 +/-24 130 +/-24 0.3 
    Diastolic blood pressure (mmHg) (mean +/- SD) 74 +/-13 75+/-13 0.6 
    Double product (bpm x mmHg) (mean +/- SD) 9213 +/- 2447 9233 +/- 2390 0.9 
Clinical characteristics    
    History of myocardial infarction (%) 49 44 0.3 
    History of congestive heart failure (%) 14 23 <0.001 
    Previous CABG (%) 19 22 0.2 
    Previous PTCA (%) 25 17 0.4 
    Stable angina pectoris (%) 41 36 0.4 
    Hypertension (%) 38 30 0.02 
    Smoking (%) 28 26 0.5 
    Hypercholesterolemia (%) 35 31 0.2 
    Diabetes Mellitus (%) 16 11 0.06 
Medication    
    Calcium antagonist (%) 33 34 0.9 
    Digitalis (%) 4 14 <0.001 
    Diuretic (%) 17 32 <0.001 
    ACE inhibitor  (%) 31 36 0.1 
 
CABG, coronary artery bypass grafting; PTCA, percutaneous transluminal coronary angioplasty; ACE inhibitor, angiotensin converting enzyme 
inhibitor
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Table 2. Dobutamine stress echocardiography results in patients using β1-selective β-blockers and non-selective β-blockers 
 Patients with β1-
selective β-blockers  
(n=954) 
Patients with non-
selective β-blockers 
(n=280) 
p-value 
Maximal dose of dobutamine (μg/kg/min) (mean +/- SD) 37 +/- 7 36 +/- 8 0.4 
Use of atropine (%) 64 64 1.0 
New arrhythmias during DSE (%)    
   SVT (%) 3 5 0.1 
    VT (<10 consecutive complexes) (%) 2 4 0.06 
    VT (>10 consecutive complexes) (%) 1 2 0.2 
    Atrial fibrillation (%) 1 1 1.0 
ST-segment changes during DSE (%) 39 39 1.0 
Heart rate at rest (bpm§) (mean +/- SD) 70 +/-13 70 +/-13 0.7 
Heart rate at peak stress (bpm§) (mean +/- SD) 129 +/-17 127 +/-18 0.1 
Test endpoints    
    Target heart rate achieved (%) 80 78 0.5 
    Angina pectoris (%) 3 3 1.0 
    ST changes (%) 5 5 1.0 
    Arrhythmias (%) 2 3 0.5 
    Abnormal blood pressure response (%) 1 0 0.7 
    Adverse effects of drugs (%) 39 39 1.0 
Rest wall motion abnormalities (%) 62 68 0.07 
New wall motion abnormalities (%) 54 53 0.7 
Rest wall motion score index (mean +/- SD) 1.31 +/-0.37 1.36 +/-0.44 0.5 
Peak wall motion score index (mean +/- SD) 1.51 +/-0.57 1.62 +/-0.65 0.006 
DSE, dobutamine stress echocardiography; SVT, supraventricular tachycardia; VT, ventricular tachycardia 
 
The maximum difference of mean systolic blood 
pressure (+/-SEM) between patients with selective and 
non-selective beta-blockers was observed during 
atropine administration (-0.6 +/-1.1 vs. 13.6 +/-2.4 
mmHg, respectively). The maximum difference of mean 
diastolic blood pressure (+/-SEM) between patients with 
selective and non-selective beta-blockers was also 
observed during atropine administration (-2.1 +/-0.6 vs. 
4.5 +/- 1.3 mmHg, respectively). In our study, the 
presence of congestive heart failure was significantly 
higher in patients using non-selective β-blockers, 
compared to selective beta-blockers. Congestive heart 
failure may blunt the hemodynamic response to 
dobutamine through β1-adrenergic receptor down-
regulation. We have repeated our analysis after the 
exclusion of patients with chronic congestive heart 
failure and we observed that the hemodynamic 
responses to dobutamine infusion was comparable with 
the hemodynamic responses in the total study 
population. We have therefore presented only the results 
for the total study population.    
 
Dobutamine stress echocardiography and follow-up 
results 
Dobutamine stress data are presented in Table 2. No 
fatal complications occurred during DSE. The maximal 
dose of dobutamine administration, the additional 
administration of atropine and the percentage of patients 
who achieved target heart rate were comparable 
between patients using β1-selective β-blockers and non-
selective β-blockers. No significant differences were 
observed between the two groups with regard to the 
development of cardiac arrhythmias, the achievement of 
test endpoints and the development of 
electrocardiographic ST segment changes. Finally, the 
incidence of rest wall motion abnormalities and the 
incidence of new wall motion abnormalities during DSE 
were similar in both groups.  
During a mean follow-up of 4 years (range: 
0.5-14 years), death from all causes occurred in 280 
(23%) patients. Cardiac death occurred in 169 (14%) 
and non-cardiac death in 111 (9%) patients. Non-fatal 
myocardial infarction occurred in 85 (7%) patients and 
coronary revascularization was performed in 441 (36%) 
patients. Adverse cardiac outcomes occurred with 
similar incidence in patients using β1-selective and non-
selective β-blockers (overall death: 23% vs. 22% 
respectively (p=0.7); cardiac death: 14% vs. 12% 
respectively (p=0.3), cardiac death or non-fatal 
myocardial infarction: 21% vs. 19% respectively 
(p=0.4); coronary revascularization: 36% vs. 36% 
respectively (p=0.9). Univariate and multivariate 
predictors of the composite endpoint of cardiac death or 
non-fatal myocardial infarction are presented in Table 3.  
After adjustment for clinical risk factors and rest wall 
motion abnormalities, new wall motion abnormalities 
during DSE remained a strong significant predictor of 
long-term cardiac death or non-fatal myocardial 
infarction (HR: 2.1, 95% CI: 1.5-3.0). In univariate and 
multivariate analyses, there was no significant relation  
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Figure 1. Line plots showing responses of heart rate, systolic blood 
pressure, diastolic blood pressure and heart rate-systolic blood 
pressure double product in patients using β1-selective (solid line) or 
non-selective β-blockers (dashed line) during dobutamine stress 
echocardiography (DSE). HR denotes heart rate, SBP and DBP denote 
systolic and diastolic blood pressure, Atr denotes atropine, ns denotes 
non significant. Values are means +/-SEM. 
 
between the selectivity of β-blockers with regard to 
long-term cardiac death or myocardial infarction. 
Kaplan-Meier curves for the prediction of the 
composite endpoint cardiac death or non-fatal 
myocardial infarction are presented in Figure 2. In 
summary, a similar cardiac event-free survival was 
observed between patients using β1-selective and non-
selective β-blockers in patients with (p=0.9) and in 
patients without new wall motion abnormalities (p=0.3) 
during DSE. A lower cardiac event-free survival was  
Figure 2. Kaplan-Meier curves for the prediction of the composite 
endpoint of cardiac death or non-fatal myocardial infarction (MI) in 
patients with or without new wall motion abnormalities during 
dobutamine stress echocardiography (DSE), stratified according to the 
use of β1-selective or non-selective β-blockers. 
 
 
 
 
observed in patients with, than in patients without new 
wall motion abnormalities in the group of patients using 
β1-selective (p<0.001) or non-selective β-blockers 
(p=0.02). 
 
DISCUSSION 
 
The results of this study demonstrate that the 
hemodynamic response to dobutamine during DSE is 
different for patients using β1-selective versus non-
selective β-blockers. The heart rate response was 
significantly higher and the responses of systolic and 
diastolic blood pressure were significantly lower in 
patients using β1-selective β-blockers, compared to 
those using non-selective β-blockers. The additional use 
of atropine, a competitive antagonist of muscarinic 
cholinergic receptors, at peak dobutamine infusion rate 
abolished the difference in heart rate response. Due to 
the reciprocal differences in heart rate and blood 
pressure in patients using β1-selective and non-selective 
β-blockers, the double product of heart rate and systolic 
blood pressure in response to dobutamine infusion was 
similar. The percentage of patients who achieved target 
heart rate was similar for the two groups. Importantly, 
the long-term predictive value of DSE for adverse 
cardiac events was also similar in patients using β1-
selective or non-selective β-blockers, although a non-
significant higher risk was observed in patients using 
selective beta-blockers. These findings indicate that the 
selectivity of concomitant β-blocker therapy during 
DSE does not influence the ability of DSE to predict the 
composite endpoint of cardiac death or non-fatal 
myocardial infarction.    
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Table 3. Univariate and multivariate predictors of the composite endpoint of cardiac death or non-fatal myocardial infarction. 
 Univariate 
HR (95% CI) 
Multivariate  
HR (95% CI) 
Age <70 years 1.03 (1.02-1.05) 1.04 (1.03-1.05) 
Gender (male) 1.8 (1.3-2.5) 1.4 (1.0-1.9) 
History of myocardial infarction 1.1 (0.8-1.4) 1.1 (0.8-1.4) 
History of congestive heart failure 2.1 (1.4-2.9) 1.9 (1.4-2.6) 
Angina pectoris 0.6 (0.4-0.9) 0.7 (0.5-0.9) 
Hypertension 0.9 (0.7-1.2) 1.1 (0.8-1.4) 
Smoking 1.3 (0.9-1.7) 1.0 (0.8-1.4) 
Hypercholesterolemia 0.4 (0.3-0.6) 1.1 (0.8-1.4) 
Diabetes Mellitus 1.6 (1.1-2.2) 1.9 (1.4-2.5) 
Rest wall motion abnormalities 1.0 (0.7-1.3) 1.1 (0.8-1.4) 
New wall motion abnormalities 1.4 (1.1-1.9) 2.1 (1.5-3.0) 
β1-selective β-blockers 1.1 (0.8-1.5) 1.3 (0.9-1.7) 
Hemodynamic response 
Beta-blockers can be classified into β1-selective and 
non-selective β-blockers. β1-selective β-blockers have 
predominant affinity for the β1-adrenergic receptors. 
Non-selective β-blockers produce a competitive 
blockade of both β1- and β2-adrenergic receptors [4-6]. 
Both β1-selective and non-selective β-blockers have 
negative chronotropic and negative inotropic effects, 
resulting in a decrease in cardiac output [4-6]. β-
blockers cause peripheral vasoconstriction in response 
to this decrease [17]. In addition, non-selective β-
blockers also block β2-adrenergic receptors, mediating 
peripheral vasodilatation [17]. Dobutamine, a synthetic 
catecholamine, has been approved for short-term 
positive inotropic support in circulatory decompensation 
secondary to depressed myocardial contractility and is 
used as a pharmacologic stressor in stress 
echocardiography [1,3]. The positive inotropic and 
chronotropic effects of dobutamine are predominantly 
mediated by β1-receptor stimulation [3]. At therapeutic  
doses, dobutamine also has mild β2 and α1 agonist 
effects [3]. 
The lower systolic and diastolic blood pressure 
response to dobutamine infusion in patients using β1-
selective β-blockers may be explained by unopposed 
β2-adrenergic receptor stimulation and subsequent 
peripheral vasodilatation. This fall in blood pressure 
may cause a baroreflex-mediated withdrawal of vagal 
tone that may explain the greater increase in heart rate 
in patients using β1-selective β-blockers. The 
hypothesis that a different heart rate response in patients 
using β1-selective or non-selective β-blockers is 
mediated by a difference in cardiac vagal tone, is 
supported by the current observation that this difference 
was abolished during infusion of an anticholinergic 
agent (atropine) at peak dose of dobutamine infusion. 
Other causes of difference in hemodynamic response 
should be considered. Beta-2 adrenergic receptors have 
a positive chronotropic effect and at therapeutic doses, 
dobutamine has mild beta-2 adrenergic effects. 
Therefore, during dobutamine infusion, a lower heart 
rate response may be observed in patients using non-
selective β-blockers compared to selective β-blockers 
[18]. Furthermore, it might be hypothesized that 
carvedilol has a tighter binding to beta-1 adrenergic 
receptors, compared to metoprolol and that a more 
effective degree of blockade of the beta-1 adrenergic 
receptor may explain the lower chronotropic response to 
dobutamine with non-selective, compared to selective 
agents [19,20].   
Although different in design, our hemodynamic 
results are supported by previously published studies 
evaluating the effect of β1-selective and non-selective 
β-blockers during dobutamine infusion. In the 
prospective crossover study reported by Maack et al. 
[11], comparing carvedilol (non-selective β-blocker) 
and metoprolol (β1-selective β-blocker) treatment in 44 
patients with heart failure, the increase in heart rate 
during DSE (with incremental dobutamine infusion 
rates up to 40 μg/kg/min) was more pronounced in 
patients receiving metoprolol treatment. Systolic and 
mean blood pressure increased in patients receiving 
carvedilol, while it remained unchanged in patients 
receiving metoprolol. In another published study 
comparing hemodynamic responses between carvedilol 
and metoprolol treatment in 10 patients with congestive 
heart failure, a higher heart rate, a higher cardiac output 
and a lower mean arterial pressure were observed in 
patients with metoprolol, compared to patients 
with carvedilol treatment during low infusion rates of 
dobutamine (5 and 15 μg/kg/min) [12].  
 
Clinical implications 
DSE is an established non-invasive technique for the 
long-term risk assessment in patients with known or 
suspected coronary artery disease [1,2]. In patients 
referred for DSE, β-blockers are commonly prescribed. 
Several studies have demonstrated that concomitant β-
blocker therapy lowers the sensitivity of pharmacologic 
stress echocardiography, but institutional policies for 
withholding β-blockade for patients undergoing DSE 
vary [21,22]. Beta-blockers are frequently continued 
during the stress test, because β-blocker withdrawal 
prior to the test can evoke adverse cardiac events in 
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patients with coronary artery disease and left ventricular 
dysfunction [23,24]. Atropine has been demonstrated to 
increase the diagnostic sensitivity for ischemia and for 
coronary artery disease, especially in patients receiving 
β-blockers [25]. Therefore, our protocol did not 
included withdrawal of ongoing beta-blocker therapy. 
Unfortunately, our study did not allow us to compare 
the prognostic value of DSE in patients with and 
without β-blockers. To our knowledge, the impact of the 
selectivity of β-blockers on the prognostic value of DSE 
has not been reported before. This study provides 
evidence that the selectivity of β-blockers does not 
influence the long-term prognostic value of DSE and we 
propose that the hospital policy for patients undergoing 
DSE should not be different for patients receiving a β1-
selective or a non-selective β-blocker.  
 
Conclusion 
In this study, heart rate and blood pressure response to 
higher doses of dobutamine infusion differed 
significantly in patients using β1-selective β-blockers, 
compared to patients using non-selective β-blockers. 
The difference in heart rate was abolished after the 
addition of atropine. Importantly, the long-term 
prognostic value of DSE with regard to adverse cardiac 
events appeared to be similar for patients using either 
β1-selective or non-selective β-blockers, although a 
non-significant higher risk was observed in patients 
using selective beta-blockers. 
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Objectives: To examine whether higher statin doses 
and lower low-density lipoprotein (LDL)-cholesterol are 
associated with improved cardiac outcome in vascular 
surgery patients. 
Background: Statins may have cardioprotective effects 
during major vascular surgery.  
Methods: In a prospective study of 359 vascular 
surgery patients, statin dose and cholesterol levels were 
recorded preoperatively. Myocardial ischemia and heart 
rate variability were assessed by 72-hour 12-lead 
electrocardiography starting 1 day before to 2 days after 
surgery. Troponin T was measured on postoperative day 
1, 3, 7 and before discharge. Cardiac events included 
cardiac death or non-fatal Q-wave myocardial infarction 
at 30 days and follow-up (mean: 2.3 years).  
Results: Perioperative myocardial ischemia, troponin T 
release, 30-day and late cardiac events occurred in 29%, 
23%, 4% and 18%, respectively. In multivariate 
analysis, lower LDL-cholesterol (per 10 mg/dL) 
correlated with lower myocardial ischemia (OR: 0.87, 
95% CI: 0.80-0.95), troponin T release (OR: 0.89, 95% 
CI: 0.82-0.96), 30-day (OR: 0.89, 95% CI: 0.78-1.00) 
and late cardiac events (HR: 0.91, 95% CI: 0.84-0.96). 
Higher statin doses (per 10% of maximum 
recommended dose) correlated with lower myocardial 
ischemia (OR: 0.85, 95% CI: 0.76-0.93), troponin T 
release (OR: 0.84, 95% CI: 0.76-0.93), 30-day (OR: 
0.62, 95% CI: 0.40-0.96) and late cardiac events (HR: 
0.76, 95% CI: 0.65-0.89), even after adjusting for LDL-
cholesterol. Significantly higher perioperative heart rate 
variability was observed in patients with higher statin 
doses. 
Conclusions: Higher statin doses and lower LDL-
cholesterol correlate with lower perioperative 
myocardial ischemia, perioperative troponin T release, 
30-day and late cardiac events in major vascular 
surgery. 
___________________________________________________________________________________ 
 
 
IN THE THIRTY MILLION individuals undergoing 
non-cardiac vascular surgery in the United States 
annually, cardiac complications remain the leading 
cause of perioperative morbidity and mortality. A 
pooled analysis found an incidence of 6.2% (range: 
2.2% to 19.0%) for the composite endpoint of 
perioperative myocardial infarction or cardiac death in 
unselected patients >40 years of age [1]. Ischemic 
myocardial injury also remains a common complication, 
which is observed in up to 41% of patients as detected 
by continuous 12-lead electrocardiographic monitoring 
and in up to 25% of patients as detected by elevated 
troponin T levels [2]. During recent years, HMG-CoA 
reductase inhibitors (statins) have emerged as promising 
cardioprotective drugs in the primary prevention of 
cardiac events and mortality in patients undergoing 
major vascular surgery [3,4,5]. 
Although studies showed that lower cholesterol 
levels are associated with improved outcome, optimal 
cholesterol levels in patients scheduled for major 
vascular surgery are not well known [6]. The main 
effect of statins is believed to be a reduction in 
cholesterol levels which attenuates the atherosclerotic 
process, however, statins may also have effects beyond 
its lipid-lowering properties [7]. Controversy exists 
whether statins have a positive effect on the cardiac 
autonomous nervous system [8]. Since decreased heart 
rate variability may trigger ischemic events, an 
improvement of heart rate variability by statins may be 
a potential mechanism of cardioprotection [9].  
The current prospective study was conducted to 
clarify the following: 1) are higher statin doses and 
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lower cholesterol levels associated with reduced 
myocardial compromise on subclinical level, i.e. 
myocardial ischemia assessed with continuous 12-lead 
electrocardiographic monitoring and troponin T release, 
2) are higher statin doses and lower cholesterol levels 
associated with improved clinical cardiac outcome, 3) 
are statins cardioprotective independent of cholesterol 
levels, 4) are statins associated with perioperative heart 
rate variability. 
  
METHODS 
 
Patients 
The study population consisted of 359 patients 
undergoing elective abdominal aortic aneurysm repair 
(n=175), peripheral artery bypass surgery (n=127) and 
carotid artery surgery (n=57) at the Erasmus Medical 
Center in Rotterdam, the Netherlands, during the period 
2002 to 2006. The study was approved by the hospital’s 
ethical committee and performed with informed consent 
of all patients. Patients with a cardiac pacemaker, left 
ventricular hypertrophy, left or right bundle branch 
block and atrial fibrillation were excluded. No patient 
presented with a myocardial infarction within 6 months 
prior to surgery Patients who participated in clinical 
intervention trials at or outside the Erasmus MC (i.e. the 
DECREASE-II, III and V trial) were also excluded. 
Patients were enrolled up to 3 months prior to surgery at 
the outpatient clinic. At study enrolment, a detailed 
cardiac history was obtained and patients were screened 
for hypertension (blood pressure ≥140/90 mmHg), 
diabetes (fasting glucose ≥7.0 mmol/L, or insulin 
therapy), renal failure (serum creatinine ≥ 2.0 mg/dL 
(177 μmol/L)), smoking and a history of 
cerebrovascular events. In all patients, beta-blockers 
were considered prior to surgery to obtain perioperative 
heart rates of 60-65 beats per minute. 
 
Dobutamine stress echocardiography 
Before surgery, all patients underwent dobutamine 
stress echocardiography for the assessment of coronary 
artery disease. Dobutamine stress echocardiography was 
performed according to established protocols. The left 
ventricle was divided into 17 segments and wall motion 
was scored on a 5-point scale (a score of 1 indicating 
normal, 2 mild hypokinesis, 3 severe hypokinesis, 4 
akinesis, and 5 dyskinesis). The results were considered 
positive if wall motion in any segment decreased by ≥1 
grades during testing. Patients with positive dobutamine 
stress echocardiography results were referred for further 
cardiac management. It was not standard policy to 
perform prophylactic preoperative coronary artery 
revascularization in patients with stress-induced 
ischemia, with the exception of patients in whom results 
were suggestive for left main stenosis.    
 
Statin dose and cholesterol measurements 
Type, dose and duration of statins were noted at 
enrolment in all statin users. The dose of statin therapy 
was converted to the percentage of maximum 
recommended therapeutic dose (MRTD) according to 
the FDA's Center for Drug Evaluation and Research 
database [10]. The MRTD for simvastatin, pravastatin 
and fluvastatin was 0.667 mg/kg/day. A MRTD of 
0.333 mg/kg/day was used  for atorvastatin and 
rosuvastatin. The duration of statin therapy was 
calculated from time of prescription to time of surgery. 
Long-term statin therapy was defined as statin treatment 
≥3 months prior to surgery.  All patients who presented 
with hypercholesterolemia at enrolment (plasma LDL-
cholesterol >200 mg/dL) received statins. After 2003, 
LDL-cholesterol levels were targeted to levels less than 
100 mg/dL. During the study period, high-risk surgery 
has not been a standard indication for statin treatment. 
Patients continued statin treatment after hospital 
discharge. Cholesterol levels were measured at 
enrolment and 1 day prior to surgery. For the current 
analysis, measurements obtained at the day before 
surgery were used. Measurements were obtained with 
an automated enzymatic method and included low-
density lipoprotein (LDL)-cholesterol, high-density 
lipoprotein (HDL)-cholesterol, triglycerides and total 
cholesterol.  
 
Assessment of perioperative myocardial ischemia 
Patients were continuously monitored with a 10-
electrode, 12-lead digital ECG recorder (DR180+ 
Digital Recorder, NorthEast Monitoring Inc. 
Massachusetts), starting 1 day before surgery up to 2 
days after. Recordings were performed in the 
continuous 12-lead mode with a recording length of 10 
seconds every minute. The frequency response was 0.05 
– 150Hz. Electrocardiographic data were initially 
processed by a technician and analyzed by 2 
experienced cardiologists who were blinded to the 
patient’s clinical data. After excluding all abnormal 
QRS complexes, the ambulatory electrocardiography 
recordings were analyzed for ST-segment deviations. A 
continuous ST segment trend was generated and all 
potential ischemic episodes were identified. Episodes of 
ischemia were defined as reversible ST-segment 
changes, lasting at least one minute and shifting from 
baseline to more than 0.1 mV (1 mm). The baseline ST 
segment level was defined as the average ST segment 
during a stable period (duration of 20 minutes) 
preceding each ischemic episode. ST segment change 
was measured 60 ms after the J point. If the J point fell 
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Table 1. Baseline characteristics of the study population according to statin therapy (n=359). 
Characteristic Statins  
(n=187) 
No statins (n=172) p-value 
Age (years) 66 ±  10 67 ±  10 0.8 
Male gender 141 (75.4) 143 (83.1) 0.07 
Angina pectoris 35 (18.7) 27 (15.7) 0.5 
History of myocardial infarction 68 (36.4) 68 (39.5) 0.5 
Previous coronary revascularization 33 (17.6) 21 (12.2) 0.2 
History of congestive heart failure 9 (4.8) 5 (2.9) 0.4 
History of cerebrovascular event 64 (34.2) 33 (19.2) 0.001 
Renal failure 11 (5.9) 6 (3.5) 0.3 
Diabetes 30 (16.0) 25 (14.5) 0.7 
Hypertension 87 (46.5) 59 (34.4) 0.02 
Hypercholesterolemia  107 (57.2) 22 (12.8) <0.001 
Current or past smoking 113 (60.4) 105 (61.0) 1.0 
Aspirin  102 (54.5) 93 (54.1) 1.0 
Angiotensin-converting enzyme  inhibitors 52 (27.8) 40 (23.3) 0.4 
β-Blockers 139 (74.3) 124 (72.7) 0.8 
Calcium channel blockers  45 (24.1) 49 (28.5) 0.3 
Stress-induced myocardial ischemia 36 (19.3) 42 (24.4) 0.2 
Low-density lipoprotein cholesterol 106 ±  38 136 ±  43 <0.001 
High-density lipoprotein cholesterol  50 ±  16 45 ±  17 0.02 
Triglycerides 152 ±  71 190 ±  101 <0.001 
Total cholesterol 175 ±  42 212 ±  51 <0.001 
Values are expressed as mean (± SD) or number (%). 
 
within the T-wave, the ST segment change was 
measured 40 ms after that point.  
 
Assessment of perioperative troponin T release 
Troponin T levels were measured on postoperative day 
1, 3, 7, before discharge and whenever clinically 
indicated by ECG changes, consistent with myocardial 
ischemia or infarction. Troponin T level was measured 
by an electrochemiluminescence immunoassay on the 
Elecsys 2010 (Roche Diagnostics, Mannheim, 
Germany). The recommended lower limit of 0.03 ng/ml 
was used to define positive troponin T levels since 
lower levels do not meet the imprecision criteria of 
<10%. 
 
Clinical cardiac outcome 
Study endpoints were major cardiac events (cardiac 
death and non-fatal Q-wave myocardial infarction) 
during the perioperative period (30-day period after 
surgery) and during follow-up (mean: 2.3 years). During 
follow-up, outpatient visits were scheduled every 3 
months after discharge. Cardiac death was defined as 
death caused by acute myocardial infarction, cardiac 
arrhythmias, congestive heart failure, or sudden death. 
Non-fatal myocardial infarction was diagnosed when at 
least the following were present: elevated cardiac 
enzyme levels, development of new Q waves (>1 mm or 
> 30 ms), and typical symptoms of angina pectoris. No 
patients were lost to follow-up. 
 
Assessment of perioperative heart rate variability 
Heart rate variability was computed for each subject 
using time-domain analysis of short-term 5-minute 
preoperative, intraoperative and postoperative 
recordings. Consecutive 5-minute recordings of 2-hour 
periods were obtained in a standard fashion at the 
evening before surgery, during the first 2-hours of 
surgery and at the second evening after surgery. The 
average heart rate variability of the 5-minute recordings 
during the 2-hour period was calculated. We used 
standard time domain measures including the standard 
deviation of the normal-to-normal (NN) intervals 
(SDNN) and the square root of the mean squared 
differences of successive NN intervals (rMSSD). The 
standard deviation of the average NN intervals 
(SDANN) and the mean of the 5-minute standard 
deviations (SDNN index) were also calculated for the 
first 24-hour recording. This 24-hour recording started 
at the evening prior to surgery and included night time 
and surgical period.  
 
Statistical analysis 
Continuous data were compared using the Student t test 
and categorical data were analyzed using the chi-square 
test with Yates’ correction. Binary logistic regression 
analysis was used to evaluate the association of statin 
dose and cholesterol levels on perioperative myocardial 
ischemia, troponin T release and 30-day clinical cardiac 
outcome. Cox proportional hazard analysis was used to 
assess the association of statin dose and cholesterol 
levels with late cardiac events. Propensity analysis is a 
reliable tool to correct for selection bias [11]. A 
propensity score for statin therapy was calculated, 
which was constructed using multiple logistic regression 
analysis. In multivariate analysis, adjustments were 
made for age, gender, coronary artery disease 
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(according to medical history or stress test results), 
history of congestive heart failure, cerebrovascular 
disease, diabetes, renal failure, hypertension, type of 
surgery, cardiovascular medication (beta-blockers, 
aspirin, angiotensin-converting enzyme inhibitors and 
calcium-channel blockers) and propensity scores. 
Analysis of variance (ANOVA) techniques were used to 
compare heart rate variability between groups of 
patients with different statin doses. Tests for 
heterogeneity were used to reveal a differential effect of 
statins between patients with or without perioperative 
myocardial ischemia and/or troponin T release. Odds 
and hazard ratios are given with 95% confidence 
intervals. For all tests, a p value <0.05 (two-sided) was 
considered significant. All analysis was performed 
using SPSS 12.0 statistical software (SPSS Inc., 
Chicago, Illinois).  
 
RESULTS 
 
Baseline characteristics 
The mean age of the study population was 67 ± 10 years 
and 79% were male. A total of 187 (52%) patients 
received statin therapy. The following statins were used: 
simvastatin in 54, pravastatin in 42, fluvastatin in 35, 
atorvastatin in 49 and rosuvastatin in 7 patients. Long-
term statin therapy was recorded in 150 patients (42%). 
Statins were newly prescribed in 37 patients (10%). The 
mean dose of statins was 41 ± 32% of MRTD. Patients 
with statins more frequently had a history of 
cerebrovascular events, hypertension and 
hypercholesterolemia, as compared to patients without 
statins (Table 1). Propensity analysis demonstrated that 
patients were more likely to have statins if they had a 
history of cerebrovascular events (p<0.001) and  
hypercholesterolemia (p<0.001). Propensity score 
ranged from 0.11 to 0.94. No differences in coronary 
artery disease, renal failure, diabetes, smoking and 
dobutamine stress test results were observed between 
the two groups.  
 
Statin dose and cholesterol levels in relation to 
myocardial ischemia 
A total of 187 ischemic episodes in 103 patients (29%) 
were detected during continuous 72-hour 12-lead 
electrocardiography. The median duration of an 
ischemic episode was 72 minutes (interquartile range: 
49-235 minutes). The median ST-segment deviation 
was 1.4 mm (interquartile range: 1.0-2.4 mm). The 
highest incidence of myocardial ischemia was detected 
in patients undergoing abdominal aortic repair (34%), 
followed by patients with lower extremity bypass 
surgery (25%) and carotid surgery (19%) (p=0.003). 
Univariate (Figure 1 and 2, Table 2) and multivariate  
 Figure 1. Incidence of myocardial ischemia and troponin T release. 
The lowest incidence of myocardial ischemia and troponin T release 
in the perioperative period was observed in patients with statin doses 
of more than 50% of the maximum recommended therapeutic dose. 
 
 Figure 2. Incidence of myocardial ischemia and troponin T release.  
The incidence of myocardial ischemia and troponine T release in the 
perioperative period was lowest in patients with baseline low-density 
lipoprotein (LDL)-cholesterol levels below 80 mg/dL. 
 
analysis (Table 2) revealed that higher statin doses and 
lower LDL-cholesterol levels were both significantly 
associated with a lower incidence of myocardial 
ischemia. Higher statin doses remained significantly 
associated with a lower incidence of perioperative 
myocardial ischemia, after adjusting for baseline 
cholesterol levels (Table 2).  
 
Statin dose and cholesterol levels in relation to 
troponin T release 
Troponin T release was detected in 83 patients (23%). 
The median troponin T value was 0.5 ng/ml 
(interquartile range 0.1-0.8 ng/ml). The highest 
incidence of troponin T release was observed in patients 
undergoing abdominal aortic repair (29%), followed by 
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Table 2. Statin therapy in relation to perioperative ischemia and troponin T release in patients undergoing major vascular surgery. 
Perioperative myocardial ischemia 
(n=103) 
OR (95% CI)  
Perioperative troponin T release (n=83) 
OR (95% CI) 
Characteristic 
Univariate Multivariate* Univariate Multivariate* 
Statins     
Statin therapy (n=187) 0.29 (0.17-0.47) 0.33 (0.18-0.60) 0.33 (0.19-0.55) 0.24 (0.12-0.47) 
Statin treatment <3 months† (n=37) 0.22 (0.08-0.58) 0.52 (0.13-2.03) 0.25 (0.08-0.72) 0.75 (0.19-2.96) 
Statin treatment ≥3 months† (n=150) 0.31 (0.18-0.51) 0.30 (0.17-0.53) 0.35 (0.18-0.62) 0.32 (0.17-0.59) 
Statin dose per 10% increase of MRTD 0.82 (0.75-0.89) 0.85 (0.76-0.93) 0.85 (0.77-0.94) 0.84 (0.76-0.93) 
Statin dose per 10% increase of MRTD (with 
adjustment for baseline LDL-cholesterol) 
0.87 (0.80-0.95) 0.88 (0.80-0.96) 0.90 (0.81-0.98) 0.87 (0.79-0.95) 
Level of baseline cholesterol*     
LDL-cholesterol (per 10 mg/dL decrease) 0.89 (0.83-0.96) 0.87 (0.80-0.95) 0.93 (0.87-1.00) 0.89 (0.82-0.96) 
HDL-cholesterol  (per 10 mg/dL decrease) 1.07 (0.91-1.25) 1.06 (0.88-1.28) 1.14 (0.95-1.37) 1.19 (0.96-1.47) 
Triglycerides (per 10 mg/dL decrease) 0.96 (0.93-0.99) 0.96 (0.93-0.98) 0.96 (0.93-0.98) 0.95 (0.93-0.98) 
Total cholesterol (per 10 mg/dL decrease) 0.87 (0.83-0.93) 0.86 (0.81-0.91) 0.93 (0.87-0.98) 0.91 (0.85-0.96) 
* Adjusted for age, gender, coronary artery disease (according to medical history or stress test results), history of congestive heart failure, 
cerebrovascular disease, diabetes, renal failure, hypertension, type of surgery and cardiovascular medication (beta-blockers, aspirin, angiotensin-
converting enzyme inhibitors and calcium-channel blockers) and propensity scores. 
† In comparison to patients with no statin treatment 
‡ No perioperative major cardiac events occurred in patients with statin treatment <3 months. 
MRTD =  maximum recommended therapeutic dose.  
 
Table 3. Statin therapy in relation to perioperative and late cardiac outcome in patients undergoing major vascular surgery.. 
Perioperative cardiac death or non-
fatal Q-wave myocardial infarction 
(n=15) 
OR (95% CI) 
Late cardiac death or non-fatal Q-wave 
myocardial infarction (n=64) 
HR (95% CI) 
Characteristic 
Univariate Multivariate* Univariate Multivariate* 
Statins     
Statin therapy (n=187) 0.31 (0.10-0.96) 0.32 (0.10-0.96) 0.42 (0.23-0.77) 0.41 (0.21-0.75) 
Statin treatment <3 months† (n=37) ‡ ‡ 0.75 (0.02-3.22) 0.81 (0.05-4.15) 
Statin treatment ≥3 months† (n=150) 0.24 (0.05-0.98) 0.25 (0.06-0.97) 0.50 (0.28-0.90) 0.52 (0.29-0.93) 
Statin dose per 10% increase of MRTD 0.60 (0.39-0.95) 0.62 (0.40-0.96) 0.75 (0.64-0.89) 0.76 (0.65-0.89) 
Statin dose per 10% increase of MRTD (with 
adjustment for baseline LDL-cholesterol) 
0.60 (0.37-0.95) 0.66 (0.42-0.98) 0.78 (0.65-0.96) 0.80 (0.67-0.94) 
Level of baseline cholesterol*     
LDL-cholesterol (per 10 mg/dL decrease) 0.86 (0.76-0.98) 0.89 (0.78-1.00) 0.93 (0.86-0.99) 0.91 (0.84-0.96) 
HDL-cholesterol  (per 10 mg/dL decrease) 1.05 (0.69-1.55) 1.10 (0.72-1.70) 0.92 (0.78-1.09) 1.05 (0.87-1.24) 
Triglycerides (per 10 mg/dL decrease) 1.01 (0.93-1.08) 1.01 (0.93-1.08) 0.99 (0.97-1.02) 1.01 (0.97-1.03) 
Total cholesterol (per 10 mg/dL decrease) 0.98 (0.87-1.12) 0.95 (0.85-1.07) 0.94 (0.90-1.01) 0.94 (0.88-1.00) 
* Adjusted for age, gender, coronary artery disease (according to medical history or stress test results), history of congestive heart failure, 
cerebrovascular disease, diabetes, renal failure, hypertension, type of surgery and cardiovascular medication (beta-blockers, aspirin, angiotensin-
converting enzyme inhibitors and calcium-channel blockers) and propensity scores. 
† In comparison to patients with no statin treatment 
‡ No perioperative major cardiac events occurred in patients with statin treatment <3 months. 
MRTD =  maximum recommended therapeutic dose.  
 
patients with lower extremity bypass surgery (22%) and 
carotid surgery (9%) (p<0.001). Univariate (Figure 1, 
Table 2) and multivariate analysis (Table 2) revealed 
that higher statin doses and lower LDL-cholesterol 
levels were both significantly associated with a lower 
incidence of troponin T release. Higher statin doses 
remained significantly associated with a lower incidence 
of troponin T release, irrespective of baseline 
cholesterol levels (Table 2).  
 
Statin dose and cholesterol levels in relation to 
clinical cardiac outcome 
Perioperative cardiac death and non-fatal Q-wave 
myocardial infarction occurred in 3% and 1% of 
patients, respectively. Late cardiac death and non-fatal 
Q-wave myocardial infarction occurred in 13% and 5% 
of patients, respectively. During follow-up, statins were 
discontinued in 2 patients (1%) due to side effects 
(myopathy in one patient and nausea and/or diarrhea in 
another). In multivariate analysis, higher statin doses 
and lower LDL-cholesterol levels were both 
significantly associated with a lower incidence of 30-
day and late cardiac events (Table 3). Higher statin 
doses remained significantly associated with lower 30-
day and late cardiac events, after adjusting for absolute 
baseline cholesterol levels. In subgroup analysis, the 
long-term benefit of statin therapy was also comparable 
between patients with and myocardial ischemia and/or 
troponin T release (p for interaction: 0.92) 
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Table 4. The association between heart rate variability and statin 
therapy. 
Characteristic Statins 
>50% of 
MRTD 
(n=53) 
Statins 1-
50% of 
MRTD 
(n=134) 
No 
statins 
(n=172) 
p-
value 
Prior to surgery     
SDNN (ms) 52 ± 29 48 ± 28 37 ± 19 <0.001 
rMSSD (ms) 40 ± 35 36 ± 31 28 ±  22 0.01 
Heart rate (bpm) 68 ± 11 67 ± 12 68 ± 12 0.7 
During surgery     
SDNN (ms) 39 ± 27 32 ±  21 29 ± 19 0.002 
rMSSD (ms) 32 ± 31 26 ± 19 25 ± 23 0.06 
Heart rate (bpm) 73 ± 13 71 ± 14 72 ± 13 0.4 
After surgery     
SDNN (ms) 48 ± 45 39 ± 24 36 ± 31 0.04 
rMSSD (ms) 34 ± 32 33 ± 30 29 ± 28 0.1 
Heart rate (bpm) 76 ± 13 77 ± 14 77 ± 14 0.8 
First 24-hour 
recording 
    
SDNN (ms) 139 ± 44 131 ± 45 119 ± 42 <0.001 
SDANN (ms) 116 ± 39 114 ± 39 88 ± 30 <0.001 
SDNN index (ms) 47 ± 28 40 ± 18 38± 17 0.002 
rMSSD (ms) 53 ± 47 49 ± 29 50 ± 37 0.3 
Heart rate (bpm) 72 ± 12 72 ± 13 72 ± 13 0.9 
MRTD = maximum recommended therapeutic dose. SDANN = 
standard deviation of the average normal-to-normal intervals. SDNN 
= standard deviation of the normal-to-normal intervals. rMSSD = 
square root of the mean squared differences of successive normal-to-
normal intervals. 
 
Statins and heart rate variability 
Heart rate variability was highest before and lowest 
during surgery (SNDD: 47±28, 34 ±23 and 39±29 ms 
before, during and after surgery, respectively 
(p=0.007)). We found that lower heart rate variability 
prior to surgery (SDNN per 10 ms decrease) 
significantly predicted myocardial ischemia during or 
after surgery (OR: 1.59, 95% CI: 1.19-2.13) and 
troponin T release after surgery (OR: 1.54, 95% CI: 
1.17-2.01). Lower heart rate variability during surgery 
(SDNN per 10 ms decrease) also significantly predicted 
myocardial ischemia after surgery (OR: 1.71, 95% CI: 
1.14-2.57) and troponin T release after surgery (OR: 
1.55, 95% CI: 1.13-2.11). Higher statin doses correlated 
significantly with higher SDNN  prior to, during and 
after surgery (Table 4).  
 
DISCUSSION 
 
This study found that higher statin doses and lower 
LDL-cholesterol levels were both significantly 
associated with a lower incidence of perioperative 
myocardial ischemia, perioperative troponin T release 
and 30-day and late cardiac events in patients 
undergoing major vascular surgery. Higher statin doses 
remained significantly associated with improved cardiac 
outcome, irrespective of baseline cholesterol levels. 
Higher statin doses also correlated significantly with 
higher perioperative heart rate variability. These results 
suggest that statins are cardioprotective on clinical and 
subclinical level and that they should be considered in 
all patients undergoing major vascular surgery. 
 
Statins and  myocardial ischemia 
The association between statin treatment and 
temporarily or prolonged myocardial ischemia is not 
well known. Myocardial ischemia in the perioperative 
setting may arise either from increased myocardial 
oxygen demand or reduced supply. Factors that increase 
myocardial oxygen demand are mainly tachycardia and 
hypertension resulting from surgical stress, 
postoperative pain, interruption of β-blocker use, or the 
use of sympathomimetic drugs. In contrast, decreased 
supply may be the result of hypotension, vasospasm, 
anemia, hypoxia, or coronary artery plaque rupture. 
Experimental animal studies have demonstrated that 
administration of statins before induction of myocardial 
ischemia improved myocardial viability, reduced the 
extent of inflammatory cell accumulation in the 
ischemic myocardium and preserved coronary blood 
flow which was attributed to a reduction in adhesion 
molecule expression of the endothelial monolayer and 
to an increase in the bioavailability of nitric oxide [12]. 
The results of the current study support the view that 
myocardial ischemia is not only limited by cholesterol-
lowering properties of statin therapy, but also by 
potential mechanisms such as endothelial function 
improvement and increase in nitric oxide with 
preservation of coronary blood flow [13].  
 
Statins and clinical cardiac outcome 
Large trials have consistently demonstrated that statins 
reduce cardiovascular morbidity and mortality in high-
risk patients [14,15,16,17]. Marked reductions in 
perioperative cardiovascular events have also been 
demonstrated in patients undergoing major vascular 
surgery [3,4,5]. The reduction of acute thrombotic 
events may be explained by atherosclerotic plaque 
attenuation and stabilization. Intensive statin therapy 
can result in significant regression of atherosclerosis as 
demonstrated in the ASTEROID trial [18]. In human 
carotid plaques, statins have been demonstrated to 
decrease lipids, lipid oxidation, inflammation, matrix 
metalloproteinase-2 and cell death and increase tissue 
inhibitor of metalloproteinase 1 and collagen [7]. 
According to the current results, every 10 mg/dL 
reduction in baseline LDL-cholesterol was significantly 
associated with a 13% lower risk of perioperative 
cardiac events. Moreover, a sustained beneficial effect 
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of high-dose statins and low LDL-cholesterol levels was 
observed  for late cardiac events. 
  
Statins and heart rate variability 
Reduced heart rate variability during surgery is most 
probably the result of anesthetic agents and can be a 
sign of increased sympathetic or reduced vagal activity. 
Reduced heart rate variability has been associated with 
sudden, arrhythmic, cardiovascular and non-
cardiovascular mortality in many studies. A recent study 
demonstrated that a temporal decrease in heart rate 
variability, i.e. vagal withdrawal, can act as a 
precipitating factor for myocardial ischemia [9]. High 
frequency components of heart rate variability showed a 
consistent decrease prior to an ischemic event and prior 
to the electrocardiographic appearance suggestive of 
coronary spasm [9]. We also observed that lower heart 
rate variability in the period preceding myocardial 
ischemia and troponin T release significantly predicted 
its occurrence in the period after this measurement. The 
beneficial effect of statins on autonomic function has 
been suggested in previously published studies 
[8,19,20]. Our results demonstrated that higher statin 
doses were significantly associated with higher SDNN. 
Heart rate, a determinant of heart rate variability, was 
similar between patients with different statin doses. 
These observations generate the hypothesis that in 
situations of decreased heart rate variability and 
increased myocardial oxygen demand, statins may exert 
an anti-ischemic effect by modulating the autonomic 
nervous system.  
 
Clinical implications 
An important observation in this study  was that statins 
were only prescribed in 52% of patients. This reflects 
the need for evidence supporting the benefit of statin 
treatment in patients undergoing major vascular surgery 
and the need for awareness among physicians. Statins 
have not yet been recommended as perioperative 
medical treatment by the American College of 
Cardiology/American Heart Association [21]. Coronary 
atherosclerosis is highly prevalent among patients 
undergoing major vascular surgery, with angiographic 
coronary abnormalities observed in up to 92% of 
patients [22]. Surgery poses the patient at additional 
increased risk of perioperative events [23]. Therefore, 
the recommendations to achieve LDL cholesterol 
levels<100 mg/dL in people with (risk equivalents of) 
coronary artery disease according to the guidelines of 
the National Cholesterol Education Program Adult 
Treatment Panel III and the European guidelines on 
cardiovascular disease prevention in clinical practice 
should be extrapolated to patients undergoing major 
vascular surgery [24,25]. The current study further 
provides evidence that additional risk reduction can be 
achieved by achieving LDL cholesterol levels <80 
mg/dL.   
 
Limitations 
Several limitations should be addressed. In this 
observational study, statins were not assigned randomly, 
however, the two groups were comparable in 
demographics and cardioprotective drugs. In addition, 
multivariate analysis and propensity scores were used to 
adjust for possible confounding factors. Second, the 
results apply to patients undergoing major non-cardiac 
vascular surgery, and our findings may not be 
generalized to patients undergoing general or low-risk 
surgery. Third, a lower cut-off level of 0.03 ng/ml was 
used to define positive troponin T levels. Lower 
troponin T levels were not used, since they do not meet 
the imprecision criteria (coefficient of variation) of 
<10%. Finally, carotid artery surgery has been 
associated with heart rate changed secondary to 
baroreceptor reflexes. The inclusion of these patients 
may potentially have confounded the heart rate 
variability results. 
 
In conclusion, higher statin doses are lower LDL-
cholesterol levels were both significantly associated 
with lower a lower incidence of perioperative 
myocardial ischemia during continuous 12-lead 
electrocardiographic monitoring, perioperative troponin 
T release, and 30-day and late cardiac events. Analysis 
of the 72-hour 12-lead electrocardiographic recordings 
further showed that perioperative heart rate variability 
was significantly higher in patients with higher statin 
doses. These results suggest that statins are 
cardioprotective on clinical and subclinical level. 
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___________________________________________________________________________________________ 
 
Introduction 
 
Cardiovascular diseases, including coronary artery disease, cerebrovascular disease, and peripheral arterial disease 
are the leading cause of morbidity and mortality in all age groups. However, its toll is heaviest among the elderly. 
Age is an important risk factor for cardiovascular disease, especially because pathophysiological mechanisms, such 
as atherosclerosis, are superimposed on the age-related degeneration of cardiovascular structures. Although age is 
considered to be a minor predictor of adverse postoperative outcome in patients undergoing major vascular surgery 
[1], elderly patients often presents with extensive co-morbidity and the surgeon is faced with the challenge to choose 
the optimal treatment strategy for the older individual. In this article, we will first discuss the growing problem of 
cardiovascular disease in the elderly and the association between age and atherosclerosis. Thereafter, the pre-
operative screening possibilities to identify elderly patients who are at increased risk for adverse postoperative 
events and the different options of perioperative management, which may be used in the elderly to improve their 
perioperative and long-term prognosis will be discussed. Finally, we discuss some important issues in risk factor 
control and life-style modification in elderly (non-)surgical patients for long-term mortality reduction.  
_____________________________________________________________________________________________ 
 
 
Cardiovascular disease in the elderly: A growing 
problem 
 
Cardiovascular disease is the leading cause of mortality 
for both men and women among all racial and ethnic 
groups in industrialised countries, accounting for over 
40% of deaths in those aged 35 years and older [2]. 
More than 80% of deaths attributed to cardiovascular 
disease occur in people over the age of 65 years. The 
elderly is a rapidly growing population in industrialized 
and less industrialized countries. It is estimated that in 
the second half of the 21st century, more than one in 
four individuals will be 65 years of age or older. In 
parallel, cardiovascular disease may reach epidemic 
proportions. It is expected that morbidity and mortality 
from cardiovascular disease, together with degenerative 
cognitive dysfunction and physical disability, which are 
more prevalent among the elderly, will account for a 
substantially increased burden for community 
healthcare and social services.  
During the last decades, however, the mortality rate for 
cardiovascular disease has progressively decreased in 
industrialised countries. Preventive strategies, risk 
factor modifications, and improvement in the diagnosis 
and treatment of atherosclerosis may have contributed 
to this trend. 
In the past, major non-cardiac surgery was rarely 
performed on patients in their eighties or nineties. 
Nowadays, many major surgical interventions are 
performed in this very elderly population. Pre-operative 
risk assessment is therefore warranted in elderly patients 
to facilitate decision-making about major surgery, and 
to identify those at increased risk for postoperative 
adverse events, who might benefit from preventive 
treatment strategies. 
 
Should we concern about elderly patients 
undergoing major vascular surgery? 
 
Many studies have demonstrated that the frequency of 
perioperative complications increases with age [3,4]. 
This finding may be attributed to the prevalence of co-
morbidities, such as atherosclerosis, that increases with 
increasing chronological age. However, even in the 
absence of confounding influences of disease, advanced 
age itself may be an independent risk factor. An age-
dependent increase in central arterial stiffness, 
independent of blood pressure and other risk factors, has 
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been confirmed in several studies [5]. A 
pathophysiological explanation for this may be 
mechanical fracture and fragmentation of elastin fibers 
after repetitive stress cycles, resulting in progressive 
fibrosis of the arterial wall and arterial stiffening. In 
addition, intimal and medial thickening, the occurrence 
of elastic lamina discontinuities due to elastin 
degradation, and deviations in the morphologic 
orientation of smooth muscular cells, have been 
demonstrated to be typical age-associated changes in 
large arteries [6]. These age-related changes are similar 
to underlying mechanisms that lead to atherosclerosis. 
Atherosclerosis is characterized by stiffening of the 
intimal and medial layers of arteries and plaque 
formation within the inner wall of the artery. Rupture of 
the plaque, with subsequent thrombosis and vessel 
occlusion causes significant cardiovascular morbidity 
and mortality. In addition to vascular changes, advanced 
age is associated with a general decline in cardiac 
function and with diminished cardiac reserve in times of 
increased cardiovascular stress [6]. Thus, age-related 
cardiovascular changes, in combination with the 
increased prevalence and severity of risk factors in the 
elderly population, probably explain the increased 
incidence of (perioperative) mortality in this segment of 
the population. The primary and secondary prevention 
of cardiovascular disease is the cornerstone of reducing 
mortality in the elderly population and in elderly 
patients undergoing major non-cardiac surgery.   
 
Preoperative risk stratification in elderly patients 
scheduled for major noncardiac surgery 
 
Cardiac complications, such as myocardial infarction 
and congestive heart failure are the major cause of 
perioperative mortality in elderly patients undergoing 
major non-cardiac surgery. Pre-operative risk 
stratification should be based on the identification of 
risk factors for perioperative morbidity and mortality. 
High-risk type of surgery, history of ischemic heart 
disease, history of congestive heart failure, history of 
cerebrovascular disease, preoperative treatment with 
insulin, and preoperative serum creatinine >2.0 mg/dL 
have been identified as independent predictors of 
adverse perioperative events in the surgical population 
[7,8]. Advanced age has not been identified as an 
independent predictor. Moreover, current practice 
guidelines for perioperative cardiovascular evaluation 
by the American College of Cardiology and the 
American Heart Association (ACC/AHA) have listed 
age as a minor clinical predictor of perioperative 
cardiovascular risk [1]. In addition, several studies have 
demonstrated relative low perioperative complication 
rates in the elderly, although the overall frequency of 
perioperative complications is increased [9-11]. Thus, 
the preoperative evaluation and perioperative 
management of the elderly patient should be directed by 
the presence and extent of possible co-morbidity, such 
as coronary artery disease, renal dysfunction, diabetes 
mellitus, and aortic valve stenosis. Aortic valve stenosis 
has been recognized as a major independent risk factor 
for perioperative cardiac events in patients undergoing 
non-cardiac surgery [7,12]. In a study by Kertai et al., 
patients with aortic valve stenosis had a 5-fold increased 
risk of perioperative complications, in comparison to 
patients without aortic stenosis [12]. Although several 
studies have reported promising results and low 
postoperative event rates in selected patients with aortic 
valve stenosis undergoing noncardiac surgery [13,14], 
aortic valve replacement prior to non-cardiac surgery is 
recommended with indications similar to those in the 
non-preoperative setting [1]. Aortic valve sclerosis is 
common in the elderly and it has the potential to 
progress to clinically significant aortic valve stenosis. 
Recently, it has been demonstrated that aortic valve 
sclerosis, even in the absence of hemodynamically 
significant obstruction of left ventricular outflow, is 
associated with an increased risk of cardiovascular 
death in patients 65 years of age or older [15]. 
Preoperative assessment of the aortic valve may 
especially be beneficial in the elderly, and future studies 
are needed to identify aortic valve sclerosis as possible 
independent risk factor for adverse postoperative 
cardiac events.   
The stepwise approach to preoperative cardiac 
assessment, as suggested by the ACC/AHA practice 
guidelines, include history, physical examination and 
electrocardiographic assessment to assess age, 
functional capacity, and type of surgery and to identify 
potentially serious cardiac disorders and co-morbid 
conditions [1]. Recommendations for supplemental 
preoperative evaluations have to be individualized to the 
specific patient and may include one or more of the 
following: echocardiography (assessment of resting left 
ventricular function and aortic valve), exercise or 
pharmacologic stress testing, ambulatory 
electrocardiographic monitoring, and coronary 
angiography [1].  
 
Perioperative medical treatment possibilities 
 
Perioperative medical treatment in the elderly is aimed 
at reducing the incidence of postoperative cardiac 
complications. Medical treatment possibilities include 
the use of β-blockers, α-2-adrenergic agonists, statins, 
calcium channel blockers and myocardial 
revascularization.  
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Beta-blockers  
Beta-blockers are established therapeutic agents for 
hypertension, coronary artery disease, and heart failure, 
since they improve the prognosis in these patients. The 
mechanism by which β-blockers exert their 
cardioprotective effect remains not completely 
understood, but proposed mechanisms include the 
following: reduction in heart rate and contractility and 
restoration of the myocardial oxygen supply-demand 
balance, prolongation of coronary diastolic filling time, 
anti-arrhythmic properties, anti-renin/angiotensin 
properties, and inhibition of catecholamine induced 
cardiac necrosis (apoptosis) [16,17]. Randomized, 
placebo-controlled trials have demonstrated that patients 
who are at risk for coronary artery disease and who 
undergo major vascular surgery benefit from 
perioperative β-blocker therapy in terms of reduced 
postoperative morbidity and mortality [18,19]. 
Observational studies in elderly patients undergoing 
non-cardiac surgery show consistent findings and show 
that β-blockers reduce the incidence of perioperative 
myocardial infarction [20]. Therefore, β-blockers are 
now recommended by the ACC/AHA in patients 
undergoing major vascular surgery, who are at increased 
risk for postoperative adverse events, based on the 
finding of ischemia on preoperative testing.  
Serious side effects of β-blockers are bradycardia, 
hypotension, dyspnoea and (worsening of) intermittent 
claudication. Physicians have been reluctant in 
prescribing β-blockers to patients with presumed 
contraindications to their use, especially to elderly 
patients and patients with impaired left ventricular 
function, transient heart failure, and chronic obstructive 
pulmonary disease [21]. However, these patients may 
derive the greatest benefit from β-blocker therapy, as 
has been demonstrated in a recent study in which β-
blockers had significant benefit in patients who had a 
myocardial infarction and who presented with presumed 
contraindications to β-blocker use (elderly, heart failure, 
pulmonary disease) [22].  
 
Alpha-2-adrenergic agonists 
Alpha-2-adrenergic agonists are used for the treatment 
of hypertension, migraine, for the suppression of 
autonomically mediated signs and symptoms in opioid 
withdrawal, and as anesthetic premedication, providing 
sedative, anxiolytic, and analgesic effects. These drugs 
prevent tachycardia and hypertension and have both 
sympatholytic and anti-ischemic properties. It was 
therefore proposed that these drugs might be beneficial 
in perioperative cardiac protection. In a randomized, 
placebo-controlled, double blind study, the Multicenter 
Study of Perioperative Ischemia European Study Group 
evaluated the safety and efficacy of mivazerol 
hydrochloride in patients with coronary artery disease 
undergoing non-cardiac surgery [23]. Mivazerol has 
been shown to be relatively safe, and to be associated 
with a decreased incidence of perioperative tachycardia, 
hypertension, and myocardial ischemia. However, no 
differences in perioperative death or myocardial 
infarction were observed [23]. More recently, the 
European Mivazerol Trial demonstrated no differences 
in perioperative cardiac death or myocardial infarction 
in patients with coronary artery disease undergoing non-
cardiac surgery [24]. However, in a subgroup of patients 
with coronary artery disease undergoing major vascular 
surgery, mivazerol was associated with a significant 
reduced incidence in perioperative cardiac death and 
myocardial infarction [24].  
Side effects of α-2-adrenergic agonists are bradycardia 
and hypotension and may limit its use. Although the 
evidence is conflicting, α-2-adrenergic agonists may be 
recommended as perioperative medical therapy for 
perioperative control of hypertension or known 
coronary artery disease, and may be considered as an 
alternative therapy in patients with contraindications for 
perioperative β-blockers [1]. The response of α-2-
adrenergic agonists may be different in elderly patients. 
However, no studies have yet evaluated the safety and 
efficacy of α-2-adrenergic agonists in elderly patients 
undergoing major non-cardiac surgery.  
 
Statins  
Statins (HMG-CoA reductase inhibitors) are effective 
drugs for reducing LDL-cholesterol levels and have 
been shown to reduce cardiac events and improve 
survival in patients with hypercholesterolemia and/or 
coronary artery disease [25-29]. In addition to the lipid-
lowering effect of statins, the pleiotropic effects of 
statins, which includes inflammation reduction, 
reduction in free-radical production in the vascular wall, 
improvement in endothelial function, and stabilization 
of atheromatous plaques, may contribute to its 
beneficial properties [30]. Statins have been associated 
with a lower perioperative and long-term mortality rate 
after major non-cardiac vascular surgery [31-34]. In a 
case-controlled study among patients who underwent 
major vascular surgery, nonusers were at 4.5-fold 
increased risk of perioperative mortality, as compared to 
statin users [31]. A prospective randomized, placebo-
controlled trial confirmed that statin use was 
significantly associated with a reduced incidence of 
major adverse cardiovascular events up to 6 months 
after non-cardiac vascular surgery [32]. The long-term 
beneficial effect of statin use after abdominal aortic 
surgery was confirmed in a retrospective study, which 
demonstrated reduced all-cause and cardiovascular 
mortality during a median follow-up of 4.7 years [33]. 
The protective effect of statin use has been 
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demonstrated to be independent of clinical risk factors, 
β-blocker use, and hypercholesterolemia [33,34].  
Side effects of peri-operative statin therapy are elevated 
serum transaminases, myopathy, rhabdomyolysis, and 
proteinuria. Analgesia and postoperative pain may mask 
signs of myopathy, with failure to recognize it, leading 
to the development of rhabdomyolysis and acute renal 
failure. Most trials on statin therapy have been 
published after 2003, and perioperative statin therapy 
has not (yet) been implemented in clinical guidelines. 
However, the results from one randomized clinical trial 
and several retrospective trials provide a condition for 
general agreement for perioperative statin use. Limited 
is known about perioperative statin therapy in the 
elderly population. In a post hoc analysis, tests for 
heterogeneity showed that perioperative mortality 
reduction by statins was stronger in patients below the 
age of 70 years, as compared to patients above 70 years 
of age [31]. However, statin use in patients above 70 
years of age was still associated with a reduced 
incidence of perioperative mortality (Odds ratio: 0.27, 
95% confidence interval: 0.09-0.76). It appears that 
statin therapy is well tolerated and safe in elderly 
patients [35,36]. In addition, statins have been shown to 
reduce the risk of adverse cardiovascular events in 
elderly high-risk patients [37,38]. Elderly patients, who 
have a high absolute risk of events, may show the 
greatest benefit of perioperative statin use. 
 
Calcium-channel blockers 
Calcium-channel blockers are used in the treatment of 
hypertension, and prophylaxis of angina pectoris or 
coronary artery spasm. Verapamil and diltiazem are also 
used as antiarrhythmics. Calcium channel blockers 
block calcium entry into cells of vascular smooth 
muscle and myocardium. By reducing heart rate, 
myocardial contractility and blood pressure, calcium 
channel blockers can reverse the myocardial oxygen 
supply-demand mismatch. In addition, they dilate 
coronary arteries in both normal and ischemic 
myocardium and inhibit coronary artery spasm. A recent 
meta-analysis reviewed the efficacy of calcium channel 
blockers during non-cardiac surgery [39]. Eleven 
studies (1007 patients) were included and it was 
demonstrated that calcium channel blockers 
significantly reduced perioperative ischemia and 
supraventricular tachyarrhythmias in patients 
undergoing non-cardiac surgery. In a post hoc analysis, 
diltiazem significantly reduced perioperative ischemia, 
supraventricular tachyarrhythmias, death and 
myocardial infarction.  
Side effects of calcium channel blockers are ankle 
edema, flushing, headache, and postural hypotension, 
and may be more frequently observed in the elderly. 
Greater reductions in blood pressure usually occur in the 
elderly, compared with younger patients receiving the 
same dosages of calcium antagonists. Compared with 
younger patients, greater heart rate suppression may be 
seen in older patients treated with verapamil and 
diltiazem [40]. Future studies are needed to prove the 
safety and efficacy of calcium channel blockers in 
elderly patients undergoing major non-cardiac surgery. 
 
Myocardial revascularization 
Myocardial revascularization prior to surgery may 
prevent myocardial ischemia and adverse outcome in 
patients with significant coronary artery disease, and 
therefore may be considered in high-risk patients 
undergoing major non-cardiac surgery. The Coronary 
Artery Revascularization Prophylaxis trial showed that 
long-term outcome after elective major vascular surgery 
was not significantly altered by coronary artery 
revascularization before surgery in 510 patients with 
stable coronary artery disease randomly assigned to 
either revascularization or no revascularization [41]. 
Although the primary end-point was late mortality, 30-
days findings did also not show any differences in 
mortality or non-fatal myocardial infarction. Therefore, 
the criteria for coronary revascularization in major 
vascular surgery patients should be similar to the non-
surgical population.  
 
Risk factor control in elderly (non-)surgical patients 
 
It is unclear to what extent the increased frequency of 
perioperative complications in the elderly is attributed 
to co-morbidities, or to advanced age itself. Patients 
with co-morbidities may not only benefit from adequate 
specific perioperative management, as have been 
discussed previously, but may also benefit from more 
general measures, such as adequate control of risk 
factors and life-style modifications. Lifestyle changes 
include reduction of overweight, physical activity, 
dietary modifications (a low-fat, low-cholesterol, and 
high-fiber diet), cessation of smoking, and blood 
pressure control. Medical treatment is also efficient for 
control of risk factors including hypertension, 
hypercholesterolemia, and diabetes mellitus. Although 
these measures have not yet been studied specifically 
for perioperative outcome, it has been demonstrated that 
functional status (behaviors necessary to maintain daily 
life and encompassing areas of physical, cognitive, and 
social functioning) is a strong predictor of 90-day and 2-
year mortality after hospitalization [42]. Risk factor 
control and life-style modification should be considered 
in (non-)surgical elderly patients for improving long-
term survival 
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Should obesity be treated in the elderly? 
The relationship between overweight and mortality in 
the elderly remains controversial. Higher values of the 
body mass index have been associated with both 
increased and decreased mortality rates [43-45]. In a 
review of 13 studies evaluating the relation between 
overweight and mortality in the elderly, Heiat et al 
showed that most studies failed to show a significant 
association between high body mass index and 
increased mortality in elderly patients, despite the large 
number of participants [46]. They demonstrated that 
current data did not support mild to moderate 
overweight (body mass index between 25 and 27) to be 
associated with higher mortality in the elderly. Although 
some studies demonstrated that body mass index values 
above 27 were associated with increased mortality, the 
relative risks were not large. In addition, they 
demonstrated that higher body mass index values were 
consistent with a smaller relative mortality risk in 
elderly persons compared with young and middle-aged 
populations. The loss of muscle mass and the gain of fat 
that occurs with aging is called sarcopenia, and has been 
associated with an increase in mortality. The above 
mentioned conflicting results may be due to the use of 
the body mass index as surrogate of body fat, since the 
body mass index does not account for changes in the 
body composition. The body mass index also does not 
account for weight fluctuations over time, for stable 
weight has been associated with lower mortality rate 
[47,48]. It has been demonstrated that weight loss is 
associated with better glucose tolerance and increased 
insulin sensitivity, and with improvement in blood 
pressure [49-52]. Therefore, elderly (non-) surgical 
patients with impaired glucose tolerance or elderly 
hypertensive patients may indeed benefit from 
intentional weight loss.  
 
How important is physical activity in the elderly? 
Frequent and occasional physical activity decreases the 
risk of mortality among elderly people [53,54]. 
Physicians should especially recommend physical 
activity to sedentary older individuals. Moderate 
exercise programs suitable for the elderly involve 
walking, climbing stairs, bicycling or swimming. 
Cardio-respiratory fitness seems to be more important 
than the amount of body fat in predicting the risk of 
mortality. Lee et al have evaluated the separate and joint 
effects of obesity and cardio-respiratory fitness in a 
study population of middle-aged men [55]. They 
demonstrated a higher all-cause and cardiovascular 
mortality rate in unfit obese individuals, compared to fit 
lean individuals and a higher all-cause and 
cardiovascular mortality rate in fit obese individuals, 
compared to unfit lean individuals. These results still 
have to be confirmed in elderly (non-)surgical patients. 
Physical activity is not only important for the reduction 
of cardiovascular related morbidity and mortality in the 
elderly, it also has been demonstrated to reduce the risk 
of morbidity and mortality due to diabetes mellitus, 
cancer and osteoporosis [56].  
 
Smoking cessation should be encouraged in the elderly 
Both nicotine and carbon monoxide harm the 
cardiovascular system. Autopsy studies have shown an 
association between cigarette smoking and the presence 
of coronary atherosclerosis. In addition, cigarette 
smoking is associated with a decreased serum HDL-C 
level and acts synergically with other risk factors to 
increase the risk of cardiovascular disease. Large studies 
have shown that smoking is a significant risk factory for 
cardiac and overall death in elderly men and women 
[57]. In addition, ex-smokers have risks similar to 
individuals who never smoked, which are significantly 
lower than risks in individuals who continue smoking 
[58]. Therefore, elderly (non-)surgical patients should 
be strongly encouraged to quit smoking. 
 
Dietary modifications – the mediterranean diet 
Potential cardiovascular benefits of dietary fibers 
include effects on serum lipid levels, triglyceride levels 
and blood pressure. Cereal fiber consumption in the 
elderly has been associated with a lower incidence of 
cardiovascular disease. In addition, several studies have 
demonstrated the beneficial effect of healthy dietary 
patterns on overall survival [59,60]. The Mediterranean 
diet may meet the characteristics necessary for 
beneficial effects on health and survival. Components of 
the traditional mediterranean diet include high 
monounsaturated: saturated fat ratio, moderate ethanol 
consumption, high consumption of legumes, high 
consumption of cereals, high consumption of fruits, 
high consumption of vegetables, low consumption of 
meat and meat products, low consumption of milk and 
dairy products. Elderly (non-)surgical patients, 
combining adherence to a Mediterranean diet with life-
style modifications (not smoking, physical activity, 
moderate alcohol consumption), may expect to have 
more than 50% reduction in all-cause and cause-specific 
mortality in comparison to those who did not [61]. 
 
Diabetes mellitus in the elderly  
It is estimated that almost 1 out of 5 elderly individuals 
have diabetes. Among those with diabetes, 
approximately 90% have type II diabetes mellitus. It is 
widely known that diabetes is a powerful predictor of 
cardiovascular disease. The risk of cardiovascular 
disease is 2-fold in men, whereas the risk is 5 to 10 fold 
in women. Obesity and physical inactivity can 
accelerate the progression of impaired glucose tolerance 
to disease. A major obstacle in treating patients with 
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diabetes mellitus and coronary artery disease is that 
diabetes is undiagnosed in many patients. 
Cardiovascular progression may accelerate before the 
onset of diabetes mellitus. In addition, it remains 
difficult to modify life-style factors involved in the 
aetiology of diabetes and coronary artery disease.  The 
Diabetes Prevention Program examined the effects of 
lifestyle interventions and metformin in persons with 
impaired glucose tolerance in preventing or delaying the 
onset of diabetes [62]. It was demonstrated that among 
patients over 60 years of age, the development of 
diabetes was prevented or delayed by 71% in the 
intensive lifestyle intervention group and by 11% in the 
metformin group as compared to the placebo group. 
Strict glycemic control has been associated with 
improved outcomes among critically ill patients 
(primarily cardiac surgery patients) in the surgical 
intensive care unit [63], among diabetic patients with 
acute myocardial infarction [64], and among diabetic 
patients undergoing coronary artery bypass surgery 
[65]. These findings suggest that in elderly patients, 
attention should not only be focused on the detection of 
diabetes mellitus and on lifestyle modifications, but also 
on strict (perioperative) glycemic control. 
 
Antihypertensive treatment in the elderly 
The prevalence of systolic hypertension rises with 
increasing age. Several large trials have suggested that 
treating elderly patients for diastolic and systolic 
hypertension, and isolated systolic hypertension was 
beneficial in terms of a decrease in overall mortality rate 
[66-68]. Drug treatment is recommended if life style 
modifications have been proved to be unsuccessful 
during a 3-6 month period. Drugs, which have been 
proven to reduce morbidity and mortality in the elderly, 
are diuretics and β-blockers and are therefore the first 
choice drugs recommended by national guidelines [69].  
 
Lipid-lowering drugs in the elderly  
Dyslipidemia is a very powerful predictor of 
cardiovascular disease. Alone, it predicts all major 
clinical manifestations of atherosclerorosis, with the 
possible exception of cerebrovascular disease. The 
landmark publication of Kannel et al from the 
Framingham study, publicated in 1961, identified serum 
cholesterol and blood pressure as the most important 
risk factors for cardiovascular disease except for age 
and sex [70]. The ratio of total cholesterol and high-
density lipoprotein-C has been demonstrated as 
probably the best risk estimate. Serum triglycerides are 
far less consistent to have predictive value. Lipid 
lowering diets, comprising high polyunsaturated fat-and 
low saturated fats, are probably beneficial in elderly 
patients to reduce mortality from cardiovascular 
diseases, Drug therapy should be considered for elderly 
(non-)surgical patients, since several studies have 
clearly established its beneficial effects. Bile acid 
sequestrates appear to be effective in the elderly 
persons; however, gastrointestinal side effects may be a 
major reason for poor acceptance in older patients. 
Nicotinic acid is associated with multiple side effects 
and may not be the first drug of choice. HMG-CoA 
reductase inhibitors are well tolerated by older patients 
and are effective for lowering LDL-C and even produce 
modest increased in HDL-C. Reductions in LDL 
cholesterol of 35 to 40% seem to be sufficient for 
achieving lipid-lowering goals [fair]. Additional use of 
cereals, vegetables and fruits may result in an additional 
6 to 10% lowering in LDL cholesterol levels, an 
equivalent to doubling or quadrupling the dose of a 
statin drug [71].   
 
Summary 
 
Cardiovascular disease is the leading cause of mortality 
in industrialised countries. The prevalence of 
cardiovascular disease and its risk factors increases with 
age. Age itself is associated with age-related 
degeneration of cardiovascular structures. The 
preoperative evaluation and perioperative management 
of the elderly patient should be directed by the presence 
and extent of possible co-morbidity. The 
recommendation of perioperative treatment with β-
blockers to prevent postoperative adverse cardiac events 
in high-risk patients is based on a firm scientific basis. 
Statins, α-2-adrenergic receptor agonists, and calcium 
channel blockers may also have potential benefit in 
high-risk elderly patients. In addition to specific 
perioperative medical treatment, general measures for 
risk factor reduction and life-style modifications have 
been proven to favor long-term survival in the general 
population, and should also be considered in the elderly 
surgical patient.  
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This study assesses risk factors in elderly vascular 
surgery patients and evaluates whether perioperative 
cardiac medication can reduce postoperative mortality 
rate. In a cohort study, 1693 consecutive patients ≥65 
years undergoing major non-cardiac vascular surgery 
were preoperatively screened for cardiac risk factors 
and medication. During follow-up (median: 8.2 years), 
mortality was noted. Hospital mortality occurred in 
8.1% and long-term mortality in 28.5%. In multivariate 
analysis, age, coronary artery disease, heart failure, 
cerebrovascular disease, renal failure and diabetes were 
significantly associated with increased hospital and 
long-term mortality. Perioperative aspirin (OR [95% 
CI]: 0.53 [0.34-0.83]), β-blockers (OR 0.32,[0.19-0.54]) 
and statins (OR 0.35, [0.18-0.68]) were significantly 
associated with reduced hospital mortality. In addition, 
aspirin (HR 0.65, [0.53-0.81]), angiotensin-converting 
enzyme (ACE)-inhibitors (HR 0.74, [0.59-0.92]), β-
blockers (HR 0.61, [0.48-0.76]) and statins (HR 0.65, 
[0.49-0.87]) were significantly associated with reduced 
long-term mortality. Heterogeneity tests revealed a 
gradient decrease of mortality risk in patients from low 
to high age using statins (P = .03). In conclusion, age is 
an independent predictor of hospital and long-term 
mortality in elderly patients undergoing major vascular 
surgery. Aspirin, ACE-inhibitors, β-blockers and statins 
reduce long-term mortality risk. Especially the very 
elderly may benefit from statin therapy. 
_____________________________________________________________________________________________ 
 
THE ELDERLY IS A rapidly growing population, 
often undergoing surgery. Many studies have 
demonstrated that the frequency of perioperative 
complications increases with age, which may possibly 
be related to co-morbidity, such as atherosclerosis, that 
increases with advanced age (Mangano, 1990; Tiret et 
al., 1986). However, even in the absence of confounding 
influences of disease, advanced age itself may be an 
independent risk factor. Cardiac complications are the 
major cause of perioperative mortality in elderly 
patients undergoing major surgery. High-risk surgery, 
ischemic heart disease, heart failure, cerebrovascular 
disease, diabetes mellitus, and renal dysfunction, as 
summarized in the Revised Cardiac Risk Index, have 
been identified as independent predictors of adverse 
perioperative events in the surgical population 
(Goldman et al., 1977; Lee et al., 1999). Limited 
information is available whether advanced age itself 
independently predicts hospital and long-term mortality 
in elderly surgical patients (Eagle et al., 2002).  
Several medications may potentially be 
beneficial in elderly patients undergoing major vascular 
surgery. β-blockers, statins and calcium channel 
blockers have been demonstrated to reduce adverse 
cardiac events in patients undergoing non-cardiac 
surgery (Poldermans et al., 1999; Mangano et al., 1990; 
Poldermans et al., 2003; Durazzo et al., 2004; Kertai et 
al., 2004; Wijeysundera and Beattie, 2003). 
Angiotensin-converting enzyme (ACE) inhibitors and 
antiplatelet drugs have been demonstrated to prevent 
cardiovascular events in high-risk non-surgical patients 
(Hirsch and Duprez, 2003; Yusuf et al., 2000; 
Antithrombotic Trialists’Collaboration, 2002). Data 
whether these medications may reduce postoperative 
and long-term mortality in elderly surgical patients are 
limited.  
The goal of this study was to evaluate whether 
age and cardiac risk factors according to the Revised 
Cardiac Risk Index are significant independent 
predictors of hospital and long-term mortality in elderly 
patients undergoing major non-cardiac vascular surgery 
and whether perioperative medication use, including 
ACE-inhibitors, aspirin, β-blockers, calcium channel 
blockers and statins may reduce hospital and long-term 
mortality risk. 
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2. METHODS 
 
2.1 Patient population 
A total of 1 693 consecutive patients aged 65 years and 
older who underwent major non-emergent non-cardiac 
vascular surgical procedures at the Erasmus Medical 
Centre in Rotterdam, the Netherlands, from January 
1990 to January 2004 were enrolled in this cohort study. 
Major non-cardiac vascular surgical procedures 
included the following: abdominal aortic aneurysm 
repair, lower extremity revascularization and carotid 
artery surgery. The hospital’s Medical Ethical 
Committee was informed about the study protocol, and 
for this observational cohort study no official approval 
was required.   
Prior to surgery, a detailed cardiac history was obtained 
and patients were screened for hypertension (blood 
pressure ≥140/90 mmHg or antihypertensive treatment), 
diabetes mellitus (fasting glucose level ≥7.0 mmol/L, or 
treatment for diabetes mellitus), hypercholesterolemia 
(plasma cholesterol level ≥5.5 mmol/L or cholesterol-
lowering treatment), and renal failure (serum creatinine 
level ≥ 2.0 mg/dl (177 μmol/L) or renal dialysis). The 
presence of definite coronary artery disease was 
indicated by a previous myocardial infarction, by a 
previous coronary intervention, or by the presence of 
stable angina pectoris. Data were stored in the 
computerized hospital database and in medical records, 
Cardiac risk factors according to the Revised Cardiac 
Risk Index by Lee (high-risk type of surgery, coronary 
artery disease, history of congestive heart failure, 
history of cerebrovascular disease, diabetes mellitus, 
and renal failure) were identified in all patients (Lee et 
al., 1999). Perioperative use of medication was recorded 
and included the following: ACE inhibitors, aspirin, β-
blockers, calcium channel blockers and statins. Cardiac 
medication was continued during the perioperative 
period; however, aspirin was discontinued 5-7 days 
prior to surgery in patients undergoing aortic aneurysm 
repair and lower extremity revascularization procedures, 
and restarted 1-5 days after surgery. Chronic medication 
use was ascertained if medication was documented at 
least one to three months prior to hospital admission for 
surgery and at discharge after hospital stay. 
2.2 Follow-up and outcome 
The median follow-up period was 8.2 years 
(interquartile range: 5.1-10.9). Endpoint was mortality. 
Hospital mortality was defined as death occurring 
during postoperative in-hospital stay or as death 
occurring after hospital discharge but within the first 30 
days after surgery. Long-term mortality was defined as 
death occurring in the period after surgery. Mortality 
data were collected by reviewing the medical records 
and by approaching the Office of Civil Registry. The 
cause of death was ascertained by reviewing medical 
records, the computerized hospital database, autopsy 
reports, or by contacting the referring physician or 
general practitioner.  
 
2.3 Analysis of data 
Continuous data were expressed as mean (+/-SD) and 
categorical data were presented as percent frequencies. 
Analysis of variance (ANOVA) techniques were used to 
evaluate the association between the mean number of 
cardiac risk factors and age. Univariate and multivariate 
logistic regression was used to analyse the relation 
between baseline characteristics and in-hospital 
mortality, and Cox proportional-hazards regression to 
analyse the relation between baseline characteristics and 
long-term mortality. In multivariate analysis, pre-
selected variables were age, gender, cardiac risk factors 
according to the Revised Cardiac Risk Index, 
irrespective of the significance level in univariate 
analysis, hypertension, hypercholesterolemia, smoking, 
chronic obstructive pulmonary disease and propensity 
scores for medication use. Propensity scores were 
calculated for statins, beta-blockers, aspirin, ACE-
inhibitors and calcium channel blockers, which were 
constructed using multiple logistic regression analysis. 
Variables that were independently associated with the 
decision to prescribe the medications were included in 
the multivariate propensity score. The Kaplan-Meier 
method with the log-rank test was used to assess 
differences in survival. The effect of perioperative 
medication use may be different across the range of age. 
Therefore, tests for heterogeneity were used to evaluate 
interaction between perioperative medication and age. 
Odds ratios and hazards ratios are reported with 
corresponding 95% confidence intervals. For all tests, a 
P-value <.050 (two-sided) was considered significant.  
 
3. RESULTS 
 
3.1 Cardiac risk factors and age 
The baseline characteristics, including the prevalence of 
cardiac risk factors according to the Revised Cardiac 
Risk Index, are presented in Table 1. Mean age was 73 
(+/-5) years and 76.0% were male. Perioperative aspirin, 
ACE inhibitors, β-blockers, calcium channel blockers 
and statins were used in 548 (32.4%), 404 (23.8%), 447 
(26.4%), 456 (26.9%), and 274 (16.2%) patients, 
respectively. Propensity analysis demonstrated that 
patients were more likely (p<0.001) to be prescribed 
statins if they had hypercholesterolemia and coronary 
artery disease, β –blockers if they had hypertension or 
coronary artery disease, aspirin if they had coronary 
artery disease or cerebrovascular disease, ACE 
inhibitors if they had a history of heart failure and 
calcium channel blockers if they had hypertension.  
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Table1. Baseline Characteristics of the Study Population. 
Characteristic N=1 693  
Age (years) 73.0 +/-5.4 
Male gender 1 287 (76.0) 
Coronary artery disease* 613 (36.2) 
History of congestive heart failure* 104 (6.1) 
History of cerebrovascular accident* 254 (15.0) 
Renal failure* 97 (5.7) 
Diabetes mellitus* 161 (9.5) 
Hypertension 668 (39.5) 
Hypercholesterolemia 270 (15.9) 
Smoking 457 (27.0) 
Chronic obstructive pulmonary disease 290 (17.1) 
Abnormal electrocardiography 668 (49.5) 
Aspirin use 548 (32.4) 
Angiotensin-converting enzyme inhibitors use 404 (23.8) 
Βeta-blocker use 447 (26.4) 
Calcium channel blocker use 456 (26.9) 
Statin use 274 (16.2) 
Values are expressed as mean (+/-SD) or as number (%). 
 
 
Aortic abdominal aneurysm repair was performed in 
42.4%, lower extremity revascularization in 37.0%, and 
carotid artery surgery in 20.6%. The mean number of 
cardiac risk factors according to the Revised Cardiac 
Risk Index was 1.7 +/-0.8. The number of cardiac risk 
factors increased with increasing age (mean number of 
cardiac risk factors: 1.6, 1.8, 1.8, and 1.9 in patients 
aged 65 to 70, 70 to 75, 75 to 80 and ≥80 years, 
respectively, P for trend .005) (Figure 1).  
 
3.2 Predictors of mortality 
Hospital mortality occurred in 137 patients (8.1%), and 
long-term mortality occurred in 482 (28.5%). The most 
common cause of death was cardiac disease, which 
accounted for 48.0% of all deaths (Figure 2). Survival 
analysis, stratified according to the number of cardiac 
risk factors according to the Revised Cardiac Risk 
Index, showed a significant worse survival for patients 
with an increased number of cardiac risk factors (log 
rank: P  < .001). In multivariate analysis, age and 
cardiac risk factors according to the Revised cardiac risk 
index were significantly and independently associated 
with increased hospital and long-term mortality (Table 
2).  
In multivariate analysis, perioperative use of 
aspirin, β-blockers and statins was significantly 
associated with a 47%, 68%, and 65% lower risk of 
hospital mortality, respectively (Table 2). In addition, 
perioperative use of aspirin, ACE inhibitors, β-blockers 
and statins was significantly associated with a 35%, 
26%, 39%, and 35% lower risk of long-term mortality, 
respectively (Table 2). Tests for heterogeneity revealed 
no significant interaction between age and medication 
use. However, in patients using statins, it was observed 
that the risk for overall mortality was decreasing in a 
gradient manner from patients with the lowest age to 
patients with the highest age (P  = .03) (Figure 3). Tests 
for heterogeneity were repeated for the endpoint 
cardiovascular mortality and a significant interaction 
remained between age and statin use (P  = .02). For the 
endpoint non-cardiovascular mortality, no significant 
interaction was observed between age and statin use (P  
= .36) 
 
1.5
1.6
1.7
1.8
1.9
2
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(n=593)
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(n=538)
75 to 80
(n=372)
>80 (n=190)
Age group (number)
 
Figure 1. The association between the number of cardiac risk factors 
according to the Revised Cardiac Risk Index by Lee (high-risk type of 
surgery, coronary artery disease, history of congestive heart failure, 
history of cerebrovascular disease, diabetes mellitus, and renal failure) 
and age (P for trend: .005). 
 
 
Figure 2. The different causes of long-term mortality. Values are 
presented as percentages. 
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Figure 3. Graph illustrating heterogeneity between age and statin use. 
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Table 2. Multivariate Model to Predict Long-term Mortality, Including Age, Gender and Cardiac Risk Factors According to the Revised Cardiac 
Risk Index by Lee. 
Characteristic In-hospital mortality 
(n=137) 
 Long-term mortality 
(n=482) 
 
 OR (95%CI) P -value HR (95%CI) P -value 
Age (per year increase) 1.05 (1.02-1.09) <.001 1.04 (1.01-1.05) <.001 
Male gender 1.15 (0.72-1.84) .64 1.24 (0.99-1.54) .06 
Coronary artery disease 1.93 (1.31-2.85) <.001 1.37 (1.14-1.66) <.001 
History of congestive heart failure 3.64 (2.15-6.16) <.001 2.22 (1.68-2.95) <.001 
History of cerebrovascular accident 2.81 (1.85-4.26) <.001 1.32 (1.04-1.67) .02 
Renal failure 5.54 (3.33-9.21) <.001 2.63 (2.00-3.48) <.001 
Diabetes mellitus 1.87 (1.12-3.13) .001 1.46 (1.11-1.90) .006 
β-Blocker use 0.32 (0.19-0.54) <.001 0.61 (0.48-0.76) <.001 
Statin use 0.35 (0.18-0.68) <.001 0.65 (0.49-0.87) .004 
Aspirin use 0.53 (0.34-0.83) .006 0.65 (0.53-0.81) <.001 
ACE inhibitors use 0.69 (0.44-1.09) .09 0.74 (0.59-0.92) .008 
Ca-channel blocker  0.92 (0.60-1.40) .76 0.80 (0.61-1.05) .12 
 
 
 
4. DISCUSSION 
 
In this cohort study of 1 693 elderly patients undergoing 
major vascular surgery, the number of cardiac risk 
factors increased with increasing age. This study further 
showed that cardiac risk factors according to the 
Revised Cardiac Risk Index were significant predictors 
of hospital and long-term mortality in elderly surgical 
patients.  
Age itself was also identified as an independent 
predictor of hospital and long-term mortality. 
Importantly, this study demonstrated that perioperative 
use of aspirin, β-blockers and statins was significantly 
associated with a 47%, 68%, and 65% lower risk of 
hospital mortality, respectively. The use of aspirin, ACE 
inhibitors, β-blockers and statins was associated with a 
35%, 26%, 39%, and 35% lower risk of long-term 
mortality, respectively. Especially in the very elderly, 
perioperative use of statins may be beneficial in 
reducing long-term mortality. 
Beta-blockers are established therapeutic 
agents for hypertension, coronary artery disease, and 
heart failure, since they improve the prognosis in these 
patients (Lopez-Sendon et al., 2004). Proposed 
mechanisms by which β-blockers exert their 
cardioprotective effect include reduction in heart rate 
and contractility and restoration of the myocardial 
oxygen supply-demand balance (Cruickshank, 2000).  
Randomized, placebo-controlled trials have 
demonstrated that high-risk patients undergoing major 
vascular surgery benefit from perioperative β-blocker 
therapy in terms of reduced postoperative morbidity and 
mortality (Poldermans et al., 1999; Mangano et al., 
1990). Physicians have been reluctant in prescribing β-
blockers to patients with presumed contraindications to 
their use, especially to elderly patients and patients with 
impaired left ventricular function, transient heart failure, 
and chronic obstructive pulmonary disease (Viskin et 
al., 1995). However, it has been suggested that these 
patients may derive the greatest benefit from β-blocker 
therapy (Gottlieb et al., 1998). 
Statins (HMG-CoA reductase inhibitors) are 
effective drugs for reducing LDL-cholesterol levels and 
have been shown to reduce the risk of adverse 
cardiovascular events in elderly high-risk patients 
(Miettinen et al., 1997; Shepherd et al., 2002). Statins 
have also been associated with a lower perioperative 
and long-term mortality rate after major vascular 
surgery (Poldermans et al., 1999; Durazzo et al., 2004; 
Kertai et al., 2004). In addition to the lipid-lowering 
effect of statins, the pleiotropic effects of statins, which 
includes inflammation reduction and stabilization of 
atheromatous plaques may contribute to its beneficial 
properties (Moreno and Fuster, 2004). Not much is 
known about perioperative statin therapy in the elderly 
population. It appears that statin therapy may be well 
tolerated and safe (Santinga et al., 1994). The present 
study demonstrated the beneficial effect of statins in the 
elderly. Moreover, especially the very elderly seemed to 
benefit from statins in terms of reduced cardiac death. 
No interaction was observed between age and statin use 
in terms of reduced mortality from other causes, such as 
cancer. 
The meta-analysis of the anti-thrombotic 
trialists collaboration showed a proportional reduction 
of 23% in serious vascular events among 9 214 patients 
with peripheral arterial disease using antiplatelet therapy 
(primarily aspirin), compared with those using no 
antiplatelet therapy (5.8 vs. 7.1%, P  = .004) 
(Antithrombotic Trialists’ Collaboration, 2002). To our 
knowledge, no randomised studies have been published 
evaluating perioperative aspirin therapy in elderly 
surgical patients. The results in this study support the 
use of aspirin therapy in reducing hospital and long-
term mortality in elderly undergoing major vascular 
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surgery. It remains a matter of debate whether 
perioperative aspirin treatment is associated with an 
increased risk of bleeding complications. Unfortunately, 
bleeding complications were not investigated in this 
study. Prior to recommending routine aspirin treatment 
in this patient population, more studies are needed to 
investigate the efficacy and safety of this drug. 
Growing evidence suggest that ACE-inhibitors 
directly inhibit the atherosclerotic process and improve 
vascular endothelial function (Lonn et al., 1994). The 
HOPE study investigators showed that ramipril 
significantly reduced the rate of mortality, myocardial 
infarction and stroke in 9,297 high-risk patients without 
a low ejection fraction or heart failure (Yusuf et al., 
2000). Activation of the renin-angiotensin system seems 
to be associated with an increased risk of cardiovascular 
events. It may be hypothesized that the beneficial 
effects of ACE inhibitors on vascular endothelial 
function and its beneficial effects on hemodynamic 
status are responsible for postoperative long-term 
mortality reduction, as demonstrated in the present 
study. 
Calcium-channel blockers are used in the 
treatment of hypertension, and prophylaxis of angina 
pectoris or coronary artery spasm. By reducing heart 
rate, myocardial contractility and blood pressure, 
calcium channel blockers can reverse the myocardial 
oxygen supply-demand mismatch. In addition, they 
dilate coronary arteries in both normal and ischemic 
myocardium and inhibit coronary artery spasm. These 
properties might render them potentially 
cardioprotective during major surgery. A recent meta-
analysis reviewed the efficacy of calcium channel 
blockers during non-cardiac surgery, and demonstrated 
that calcium channel blockers significantly reduced 
perioperative ischemia and supraventricular 
tachyarrhythmia but not mortality (Wijeysundera and 
Beattie, 2003). This is in line with our study, which 
failed to show a beneficial effect of calcium-channel 
blockers on hospital and long-term mortality in elderly 
patients.  
A major limitation in this study is that 
medication was not assigned in a randomly, controlled 
setting. In addition, patients and physicians were not 
masked to the different medical treatments. However, 
properly conducted observational studies might not 
produce misleading or biased results (Concato et al., 
2000). Although multivariate regression analysis was 
used to adjust for cardiac risk factors, other factors may 
have played a role in the cause of death.  However, we 
used propensity scores to adjust for selection bias. To 
assess the effect of a treatment in a situation in which 
randomization is difficult or impossible, propensity 
scores are a useful method for matching members of 
different groups.  
This large cohort study demonstrated in 
patients aged 65 years and older undergoing major non-
cardiac vascular surgery that age itself is an independent 
and significant risk factor of hospital and long-term 
mortality, along with the cardiac risk factors according 
to the Revised Cardiac Risk Index. Furthermore, this 
study demonstrates that β -blockers, statins, aspirin and 
ACE inhibitors are associated with lower postoperative 
mortality rates in this particular patient population. 
Especially the very elderly may benefit from statin 
therapy. Further trials and safety studies are needed to 
explore and confirm the beneficial effects of β -
blockers, statins, aspirin and ACE inhibitors in this 
patient population. 
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WE WOULD LIKE TO thank Dr. Steg for his interest 
regarding our recent study [1]. The more widespread 
use of drug-eluting stents will have its implications in 
perioperative management of patients undergoing non 
cardiac surgery. Especially in the early phase after stent 
implantation patients are at increased risk, either due to 
bleeding complications in those who continued dual 
antiplatelet therapy or because of in-stent thrombosis 
after antiplatelet discontinuation. These patients might 
be identified by troponin elevation and abrupt ST-
segment elevation in the territory of a recently 
implanted stent. Although it is recommended to 
continue antiplatelet therapy in this period during 
surgery, no convincing safety data exists.  
Our report demonstrates that preoperative coronary 
revascularization in 49 high-risk patients was not 
associated with an improved outcome, compared to 
medical therapy. Of this group, a percutaneous coronary 
intervention was performed in 32 patients, a drug-
eluting stent was used in 30 patients. Of these patients, a 
Q-wave myocardial infarction occurred in 11. 
Continuous 12-lead electrocardiographic monitoring 
was performed in a sub-study for the detection of non 
Q-wave ST-segment changes, which may be present in 
up to 41% of patients and have prognostic implications 
[2,3]. Of the 11 patients with Q-wave myocardial 
infarction, ST-elevation occurred in 7/11 patients. The 
location of ST-elevation corresponded to the recently 
stented coronary artery territory in 5/7 patients. 
Importantly, all stented patients underwent surgery 
using dual antiplatelet therapy. 
One might speculate that the increased thrombotic 
risk during surgery as a result of cytokine response, 
catecholamine surge, platelet activation and reduced 
fibrinolytic activity can not be prevented by dual 
platelet therapy. As cardiac outcome is not improved 
after revascularization in this small study, a switch to 
postoperative coronary revascularization could be 
considered in this high-risk population. 
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Background. Carotid artery stenting (CAS) is less 
invasive than endarterectomy. This study examined 
differences in perioperative myocardial ischemia, 
troponin T release and clinical cardiac events in patients 
undergoing CAS compared to endarterectomy.  
Methods. In an observational study, CAS was 
performed in 24 and carotid endarterectomy in  44 
patients. Prior to surgery, clinical risk factors were 
noted and dobutamine stress echocardiography was 
performed for cardiac risk assessment. Perioperative 
continuous 72-hour 12-lead electrocardiographic 
monitoring was used for myocardial ischemia detection. 
Troponin T (>0.03 ng/ml) was measured on 
postoperative day 1, 3, 7 or before discharge. Cardiac 
events (cardiac death or Q-wave myocardial infarction) 
were noted during hospital stay and during follow-up 
(mean: 1.2 years).  
Results. No significant differences were observed 
between patients with CAS and endarterectomy in terms 
of baseline clinical characteristics, dobutamine stress 
echocardiography results and cardiovascular 
medication. Perioperative myocardial ischemia was 
detected in 9 patients (13%), perioperative troponin T 
release in 7 patients (10%), early cardiac events in 1 
patient (1%) and late cardiac events in 3 patients (4%). 
Significantly less perioperative myocardial ischemia 
was observed in patients with CAS compared to 
endarterectomy (0% versus 21%, p=0.02). Troponin T 
release was also significantly lower in CAS, compared 
to endarterectomy (0% versus 16%, p=0.04). Early (0% 
versus 2%, p=0.5) and late (0% versus 7%, p=0.2) 
cardiac events were lower after CAS, compared to 
endarterectomy, although these differences were not 
significant. 
 Conclusions: CAS is associated with a lower incidence 
of perioperative myocardial ischemia and troponin T 
release, compared to endarterectomy. 
____________________________________________________________________________________ 
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STROKE IS THE THIRD leading cause of death in 
the United States, behind heart disease and cancer [1]. 
In the year 2003, about 273 000 Americans died due to 
stroke as underlying or contributing cause [1]. 
Randomized clinical trials have established the efficacy 
of carotid endarterectomy in preventing stroke in 
patients with atherosclerotic carotid stenosis [2-8]. 
However, carotid endarterectomy has been 
contraindicated in patients at increased predicted 
perioperative risk of stroke or death [9]. In these 
patients, stenting of the carotid artery is a reasonable 
alternative.  
The advantages of carotid artery stenting 
(CAS) compared to endarterectomy include the use of 
locoregional anesthesia, reduced tissue injury, reduced 
wound complications and shorter hospital stay [10]. In 
addition, the incidence of procedure-related stroke 
during CAS has reduced considerably with advances in 
embolic protection devices, [11-15]. Limited 
information is available about cardiovascular outcome 
in patients undergoing either CAS or endarterectomy. 
More invasive surgery and surgical stress may be 
associated with increased perioperative myocardial 
ischemia due to a mismatch in myocardial oxygen 
supply and demand. Prolonged myocardial ischemia 
may lead to myocardial injury that poses the patient at 
subsequent increased risk of cardiovascular events [16]. 
Therefore, CAS may be superior to carotid artery 
endarterectomy in the prevention of cardiovascular 
events. 
 This study reports the differences in 
perioperative myocardial ischemia, perioperative 
troponin T release and early and late cardiovascular 
events in patients with CAS as compared to carotid 
artery endarterectomy. 
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METHODS 
 
A total of 68 intermediate to high risk cardiovascular 
patients underwent elective CAS or endarterectomy at 
the Erasmus Medical Center in Rotterdam, the 
Netherlands, during the period 2005 to 2006. The study 
was performed with informed consent of all patients and 
approved by the hospital’s ethics committee. Patients 
with a cardiac pacemaker, left ventricular hypertrophy, 
left or right bundle branch block and atrial fibrillation 
were excluded. Patients who participated in clinical 
intervention trials in or outside the Erasmus Medical 
Center were also excluded. At study enrolment, a 
detailed cardiac history was obtained and patients were 
screened for hypertension (blood pressure ≥140/90 
mmHg), diabetes (fasting glucose ≥7.0 mmol/L, or 
insulin therapy), renal failure (serum creatinine ≥ 2.0 
mg/dL (177 μmol/L)), smoking and a history of 
cerebrovascular events. β-Blockers were considered to 
achieve resting heart rates of 60-65 beats per minute. 
Before surgery, patients underwent dobutamine stress 
echocardiography for the assessment of coronary artery 
disease.  
 
Surgery 
Surgery was performed by experienced surgeons and 
interventional physicians. Patients with transient 
ischemic attack or non-disabling stroke within 3 months 
before enrolment and/or with carotid artery stenosis 
≥70% as confirmed by catheter angiography or 
magnetic resonance angiography were considered for 
CAS or carotid endarterectomy. CAS was carried out 
through the femoral route with generally available stents 
and protection devices. Locoregional and a combination 
of locoregional and general anesthesia were used for 
CAS and carotid endarterectomy, respectively. Inotropic 
agents were used in patients presenting with 
perioperative bradycardia. All patients received standard 
perioperative pain management. β-Blockers were 
continued postoperatively.  
 
Assessment of perioperative myocardial ischemia and 
troponin T release 
Patients were continuously monitored with a 10-
electrode, 12-lead digital ECG recorder (DR180+ 
Digital Recorder, NorthEast Monitoring Inc. 
Massachusetts), starting 1 day before up to 2 days after 
surgery. Recording lengths were 10 seconds every 
minute. The frequency response was 0.05 – 150Hz. 
Electrocardiographic data were processed by a 
technician and analyzed by 2 experienced cardiologists 
blinded to the patient’s clinical data. After excluding all 
abnormal QRS complexes, the recordings were 
analyzed for ST-segment deviations. A continuous ST 
segment trend was generated and all potential ischemic 
episodes were identified. Episodes of ischemia were 
defined as reversible ST-segment changes, lasting >1 
minute and shifting from baseline to >0.1 mV (1 mm).  
 
 
Table 1. Baseline characteristics of the study population (n=68). 
Carotid artery stenosis (n=68) Characteristic 
Stenting (n=24) Open (n=44) P value 
Age (years) 66 ± 11 64 ± 11 0.5 
Male gender 14 (58.3%) 34 (77.3%) 0.1 
Angina pectoris 2 (8.3%) 6 (13.6%) 0.5 
History of myocardial infarction 6 (25.0%) 10 (22.7%) 0.9 
Previous coronary revascularization 1 (4.2%) 2 (4.5%) 0.9 
History of congestive heart failure 0 (0%) 0 (0%) - 
History of cerebrovascular accident 12 (50.0%) 23 (52.3%) 0.9 
History of transient ischemic attack 12 (50.0%) 21 (47.7%) 0.9 
Renal failure 0 (0%) 1 (2.3%) 0.5 
Diabetes 3 (12.5%) 6 (13.6%) 0.9 
Hypertension 9 (37.5%) 18 (40.9%) 0.8 
Hypercholesterolemia 10 (41.7%) 21 (47.7%) 0.6 
Current or past smoking 15 (62.5%) 29 (65.9%) 0.8 
Aspirin  22 (91.6%) 41 (93.2%) 0.8 
Angiotensin-converting enzyme inhibitors 6 (25.0%) 7 (15.9%) 0.4 
Beta-blockers 12 (50.0%) 31 (70.5%) 0.1 
Calcium channel blockers 5 (20.8%) 10 (22.7%) 0.9 
Statins 13 (54.2%) 29 (65.9%) 0.3 
Stress-induced myocardial ischemia 2 (8.3%) 2 (4.5%) 0.5 
Duration of surgery (hours) 1.9 ± 0.6 3.0 ± 0.9 <0.001 
Fluid infusion during surgery (liters) 0.06 ± 0.1 0.2 ± 0.4 <0.001 
Heart rate (beats/minute) 70 ± 14 69 ± 13 0.9 
Values are expressed as mean (± SD) or number (%). 
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The baseline ST segment level was defined as the 
average ST segment during a stable period (duration of 
20 minutes) preceding each ischemic episode. ST 
segment change was measured 60 ms after the J point. If 
the J point fell within the T-wave, the ST segment 
change was measured 40 ms after that point.  
Troponin T levels were measured on postoperative day 
1, 3, 7 or before discharge and whenever clinically 
indicated by ECG changes, consistent with myocardial 
ischemia or infarction. Troponin T level was measured 
by an electrochemiluminescence immunoassay on the 
Elecsys 2010 (Roche Diagnostics, Mannheim, 
Germany). The recommended lower limit of 0.03 ng/ml 
was used to define positive troponin T levels since 
lower levels do not meet the imprecision criteria of 
<10%. 
 
Heart rate and heart rate variability 
Mean heart rate was calculated before, during and after 
surgery. Heart rate variability was computed using time-
domain analysis of short-term 5-minute recordings. 
Consecutive 5-minute recordings of 2-hour periods were 
obtained in a standard fashion at the evening before 
surgery, during the first 2-hours of surgery and at the 
second evening after surgery. The standard deviation of 
the NN intervals (SDNN (ms)) was calculated. 
 
Clinical outcome 
During a mean follow-up of 1.2 years, outpatient visits 
were scheduled every 3 months after discharge. Study 
end points were all-cause mortality and major cardiac 
events (cardiac death and non-fatal Q-wave myocardial 
infarction) during hospital stay and follow-up.  
 
Non-fatal Q-wave myocardial infarction was diagnosed 
when at least the following were present: elevated 
cardiac enzyme levels, development of new Q waves 
(>1 mm or >30 ms), and typical symptoms of angina 
pectoris. Cardiac death was defined as death caused by 
acute myocardial infarction, cardiac arrhythmias, 
congestive heart failure, or sudden death. No patients 
were lost to follow-up.  
 
Statistical analysis 
The study group was divided according to CAS and 
open repair. Baseline characteristics and outcome 
between the two types of procedure were compared 
using the Student t test or chi-square test. For all tests, a 
p value <0.05 (two-sided) was considered significant. 
All analysis was performed using SPSS 12.0 statistical 
software (SPSS Inc., Chicago, Illinois).  
 
 
 
 
RESULTS 
 
Out of 68 patients, 44 patients (65%) received carotid 
artery endarterectomy and 24 patients (35%) underwent 
CAS. No significant differences were observed between 
CAS and carotid endarterectomy in terms of baseline 
clinical characteristics, dobutamine stress 
echocardiography results and cardiovascular medication 
therapy (Table 1). Mean preoperative heart rate and 
heart rate variability was similar between CAS and 
carotid endarterectomy (Table 2). Duration of surgery 
and total fluid infusion, however, were significantly 
lower in patients with CAS (Table 1).  
 
Myocardial ischemia and troponin T release 
Myocardial ischemia during continuous 12-lead 
electrocardiography was detected in 9 patients (13%). A 
total of 11 episodes of myocardial ischemia were 
detected. The median duration of ischemic events was 
61 minutes (interquartile range: 52-145 minutes) and the 
median ST-segment deviation was 1.9 mm (interquartile 
range: 1.0-3.5 mm). Troponin T release was detected in 
7 patients (10%). The median troponin T value was 0.09 
ng/ml (interquartile range 0.04-1.2 ng/ml). Perioperative 
myocardial ischemia was significantly lower in patients 
with CAS, compared to carotid artery endarterectomy 
(Table 3). Troponin T release was also significantly 
lower in patients with CAS, compared to carotid artery 
endarterectomy (Table 3).  
 
Table 2. Perioperative heart rate and heart rate variability. 
Carotid artery stenosis (n=68)  
Stenting 
(n=24) 
Open 
(n=44) 
P value 
Heart rate  70 ± 13 72 ± 13 0.7 
- Before surgery (bpm) 69 ± 14 70 ± 12 0.9 
- During surgery (bpm) 71 ± 15 75 ± 14 0.4 
- After surgery (bpm) 70 ± 15 72 ± 13 0.8 
Heart rate variability 
(SDNN*) 
   
- Before surgery (ms) 49 ± 32 51 ± 29 0.9 
- During surgery (ms) 56 ± 40  50 ± 27 0.7 
- After surgery (ms) 59 ± 29 49 ± 56 0.5 
*SDNN = standard deviation of the normal-to-normal RR intervals. 
Values are expressed as mean (± SD) 
 
Clinical cardiac outcome 
Perioperative mortality did not occur in the study 
population. A perioperative non-fatal myocardial 
infarction was observed in one patient who received 
endarterectomy. A major perioperative stroke with right 
hemiplegia occurred in one patient who received CAS. 
During follow-up, mortality, cardiac death, non-fatal 
myocardial infarction and stroke occurred in 3 (4.4%), 1 
(1.5%), 2 (2.9%) and 3 (4.4%) patients, respectively. 
Major cardiac events during follow-up were observed in 
3 patients with carotid endarterectomy, while no major 
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cardiac events during follow-up were observed in 
patients with CAS (Table 3). Two out of 3 patients with 
late cardiac events (67%) had perioperative myocardial 
ischemia as detected by continuous 12-lead 
electrocardiography. 
 
Table 3. Myocardial ischemia, troponin T release and clinical outcome 
after carotid artery stenting or carotid artery endarterectomy.   
Carotid artery stenosis (n=68)  
Stenting  
(n=24) 
Open  
(n=44) 
P value 
 ST-segment changes* 0 (0%) 9 (20.5%) 0.02 
- Before surgery 0 (0%) 1 (2.3%) 0.5 
- During surgery 0 (0%) 5 (11.4%) 0.09 
- After surgery 0 (0%) 5 (11.4%) 0.09 
Troponin T release 0 (0%) 7 (15.9%) 0.04 
Myocardial injury† 0 (0%) 9 (20.5%) 0.02 
Perioperative mortality 0 (0%) 0 (0%) - 
Late mortality 1 (4.2%) 2 (4.5%) 0.9 
Perioperative cardiac 
events 
0 (0%) 1 (2.3%) 0.5 
Late cardiac events 0 (0%) 3 (6.8%) 0.2 
Perioperative stroke 1 (4.2%) 0 (0%) 0.2 
Late stroke 2 (8.3%) 1 (2.3%) 0.2 
*During continuous 72-hour 12-lead electrocardiography. †Composite 
of myocardial ischemia and troponin T release. 
 
DISCUSSION 
 
In this study, a lower incidence of perioperative 
myocardial ischemia and troponin T release was 
observed in patients with CAS compared to 
endarterectomy, despite comparable baseline 
characteristics. Perioperative and late cardiac events 
were not observed in patients with CAS, but did occur 
in patients with carotid endarterectomy. 
 
The dominance held by carotid artery endarterectomy is 
currently challenged by CAS. Numerous studies have 
expressed concerns about the safety of CAS. Although 
perioperative stroke in CAS is a leading complication, 
substantial progress in safety has been made due to 
embolic protection devices. At our institution, patients 
scheduled for CAS more often presented with a history 
of myocardial infarction and stress induced ischemia, 
while patients scheduled for endarterectomy more 
commonly presented with angina pectoris. These 
differences, however, were not significant. Most of the 
intermediate to high-risk cardiovascular patients at our 
institution received endarterectomy, which is still 
considered as gold-standard.   
 
An important finding of this study was that the 
incidence of subclinical myocardial ischemia and injury 
was lower in patients undergoing CAS, compared to 
endarterectomy. Favorable results have been reported of 
CAS among patients with severe cardiac disease. In a 
study of 170 patients, in whom 92% had 
angiographically proven coronary artery disease, no 
deaths or myocardial infarctions were observed at 30 
days [17]. In a retrospective study of 167 patients with 
cardiac disease, CAS  followed by open heart surgery 
was associated with a lower incidence of myocardial 
infarction, compared to combined endarterectomy and 
open heart surgery (3% versus 13%, p=0.06) [18] . 
Finally, a lower incidence of troponin I release has also 
been shown in patients undergoing CAS, as compared 
to endarterectomy [19]. 
 
These results are in contrast to a study that included 21 
high cardiac risk patients, in whom the incidence of 
perioperative myocardial infarction and congestive heart 
failure was non-significantly higher in CAS, compared 
to endarterectomy [20]. The authors discussed that 
additional strain on the heart due to bradycardia and 
lower coronary perfusion pressure may have resulted in 
adverse cardiac events in the CAS treatment group. We 
observed similar perioperative heart rates between the 
two treatment groups. Inotropic agents were used in 
patients presenting with perioperative bradycardia. 
However, surgery duration and total fluid infusion were 
significantly increased in patients undergoing 
endarterectomy. Invasive surgical procedures have been 
associated with significant changes in mean arterial 
pressure, cardiac output, systemic vascular resistance 
and significant increases in blood lactate, catecholamine 
and arterial pH [21,22]. Increased sympathetic activity 
associated with invasive procedures may lead to a 
mismatch in oxygen supply and demand. Prolonged 
myocardial ischemia can lead to myocardial injury and 
subsequent cardiac events [16]. Indeed, 2 out of 3 
patients with late cardiac events had perioperative 
myocardial ischemia during continuous 12-lead 
electrocardiographic monitoring.  
 
Several limitations should be noted. First, owing to the 
small number of patients in each treatment group, the 
results should be interpreted cautiously. Second, 
treatment was not randomly assigned to patients. 
However, the two treatment groups were comparable in 
baseline characteristics and may not explain the large 
differences in perioperative myocardial ischemia and 
troponin T release. Third, because no cardiovascular 
events occurred in patients with CAS, adjusted relative 
risk ratios could not be calculated. Fourth, follow-up 
was relatively short. Future studies should assess 
cardiovascular outcome beyond 1.2 years of follow-up. 
 
In conclusion, the results of this contemporary study 
showed that patients with CAS have a lower incidence 
of perioperative myocardial ischemia and troponin T 
release, compared to carotid endarterectomy. 
 
 
 
230
REFERENCES 
 
1. Thom T, Haase N, Rosamond W, Howard VJ, Rumsfeld J, 
Manolio T, et al. Heart disease and stroke statistics--2006 
update: a report from the American Heart Association Statistics 
Committee and Stroke Statistics Subcommittee. Circulation. 
2006;113:e85-151. 
2. North American Symptomatic Carotid Endarterectomy Trial 
Collaborators. Beneficial effect of carotid endarterectomy in 
symptomatic patients with high-grade carotid stenosis. N Engl J 
Med. 1991;325:445-453. 
3. Barnett HJ, Taylor DW, Eliasziw M, Fox AJ, Ferguson GG, 
Haynes RB, et al. Benefit of carotid endarterectomy in patients 
with symptomatic moderate or severe stenosis. N Engl J Med. 
1998;339:1415-1425. 
4. Hobson RW 2nd, Weiss DG, Fields WS, Goldstone J, Moore 
WS, Towne JB, et al. Efficacy of carotid endarterectomy for 
asymptomatic carotid stenosis. N Engl J Med. 1993;328:221-
227. 
5. Executive Committee for the Asymptomatic Carotid 
Atherosclerosis Study. Endarterectomy for asymptomatic carotid 
artery stenosis. JAMA. 1995;273:1421-1428. 
6. Mayberg MR, Wilson SE, Yatsu F, Weiss DG, Messina L, 
Hershey LA, et al. Carotid endarterectomy and prevention of 
cerebral ischemia in symptomatic carotid stenosis. JAMA. 
1991;266:3289-3294. 
7. Halliday A, Mansfield A, Marro J, Peto C, Peto R, Potter J, et al. 
Prevention of disabling and fatal strokes by successful carotid 
endarterectomy in patients without recent neurological 
symptoms: randomised controlled trial. Lancet. 2004;363:1491-
1502. 
8. European Carotid Surgery Trial. Randomised trial of 
endarterectomy for recently symptomatic carotid stenosis: final 
results of the MRC ECST. Lancet. 1998;351:1379-1387. 
9. Biller J, Feinberg WM, Castaldo JE, Whittemore AD, Harbaugh 
RE, Dempsey RJ, et al. Guidelines for carotid endarterectomy: a 
statement for healthcare professionals from a Special Writing 
Group of the Stroke Council, American Heart Association. 
Circulation. 1998;97:501-509. 
10. Coward LJ, Featherstone RL, Brown MM. Safety and efficacy 
of endovascular treatment of carotid artery stenosis compared 
with carotid endarterectomy: a Cochrane systematic review of 
the randomized evidence. Stroke. 2005;36:905-911. 
11. Yadav JS, Wholey MH, Kuntz RE, Fayad P, Katzen BT, 
Mishkel GJ, et al. Stenting and Angioplasty with Protection in 
Patients at High Risk for Endarterectomy Investigators. 
Protected carotid-artery stenting versus endarterectomy in high-
risk patients. N Engl J Med. 2004;351:1493-1501. 
12. Mas JL, Chatellier G, Beyssen B. Carotid angioplasty and 
stenting with and without cerebral protection: clinical alert from 
the Endarterectomy Versus Angioplasty in Patients With 
Symptomatic Severe Carotid Stenosis (EVA-3S) trial. Stroke. 
2004;35:e18-20. 
13. CaRESS Steering Committee. Carotid Revascularization Using 
Endarterectomy or Stenting Systems (CaRESS) phase I clinical 
trial: 1-year results. J Vasc Surg. 2005;42:213-219. 
14. Kastrup A, Groschel K, Krapf H, Brehm BR, Dichgans J, Schulz 
JB. Early outcome of carotid angioplasty and stenting with and 
without cerebral protection devices: a systematic review of the 
literature. Stroke. 2003;34:813-819. 
15. Zahn R, Mark B, Niedermaier N, Zeymer U, Limbourg P, 
Ischinger T, et al. Embolic protection devices for carotid artery 
stenting: better results than stenting without protection? Eur 
Heart J. 2004;25:1550-1558. 
16. Landesberg G, Luria MH, Cotev S, Eidelman LA, Anner H, 
Mosseri M, et al. Importance of long-duration postoperative ST-
segment depression in cardiac morbidity after vascular surgery. 
Lancet. 1993;341:715-719. 
17. Shawl F, Kadro W, Domanski MJ, Lapetina FL, Iqbal AA, 
Dougherty KG, et al. Safety and efficacy of elective carotid 
artery stenting in high-risk patients. J Am Coll Cardiol. 
2000;35:1721-1728. 
18. Ziada KM, Yadav JS, Mukherjee D, Lauer MS, Bhatt DL, 
Kapadia S, et al. Comparison of results of carotid stenting 
followed by open heart surgery versus combined carotid 
endarterectomy and open heart surgery (coronary bypass with or 
without another procedure). Am J Cardiol. 2005;96:519-523. 
19. Motamed C, Motamed-Kazerounian G, Merle JC, Dumerat M, 
Yakhou L, Vodinh J, et al. Cardiac troponin I assessment and 
late cardiac complications after carotid stenting or 
endarterectomy. J Vasc Surg. 2005;41:769-774. 
20. Kasirajan K, Matteson B, Marek JM, Langsfeld M. Comparison 
of nonneurological events in high-risk patients treated by carotid 
angioplasty versus endarterectomy. Am J Surg. 2003;185:301-
304. 
21. Baxendale BR, Baker DM, Hutchinson A, Chuter TA, Wenham 
PW, Hopkinson BR. Haemodynamic and metabolic response to 
endovascular repair of infra-renal aortic aneurysms. Br J 
Anaesth. 1996;77:581-585. 
22. Thompson JP, Boyle JR, Thompson MM, Strupish J, Bell PR, 
Smith G. Cardiovascular and catecholamine responses during 
endovascular and conventional abdominal aortic aneurysm 
repair. Eur J Vasc Endovasc Surg. 1999;17:326-333. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
231
Chapter 30 
 
Endovascular versus open surgical repair of abdominal aortic 
aneurysms and the incidence of cardiac arrhythmias, myocardial 
ischemia and clinical cardiac events 
 
American Journal of Cardiology. 2007;100:1479-1484 
 
Harm H.H. Feringa  
Stefanos E. Karagiannis  
Radosav Vidakovic 
Peter G. Noordzij 
Jasper J. Brugts  
Olaf Schouten 
Marc R.H.M. van Sambeek 
Jeroen J. Bax 
Don Poldermans 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
232
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This study examines differences in cardiac arrhythmias, 
perioperative myocardial ischemia, troponin T release 
and cardiovascular events between endovascular and 
open repair of abdominal aortic aneurysms. In 175 
patients, 126 underwent open and 49 underwent 
endovascular repair of abdominal aortic aneurysms. 
Continuous 12-lead electrocardiographic monitoring, 
starting 1 day before to 2 days after surgery, was used 
for cardiac arrhythmia and myocardial ischemia 
detection. Troponin T was measured on postoperative 
day 1, 3, 7 and before discharge. Cardiac events (cardiac 
death or Q-wave myocardial infarction) were noted at 
30-days and follow-up (mean: 2.3 years). Newly onset 
atrial fibrillation, non-sustained ventricular tachycardia, 
sustained ventricular tachycardia and ventricular 
fibrillation occurred in 5%, 17%, 2% and 1% of 
patients, respectively. Myocardial ischemia, troponin T 
release, 30-day and long-term cardiac events occurred in 
34%, 29% , 6% and 10% of patients, respectively. 
Significantly higher heart rates and lower heart rate 
variability were observed in the open repair group. 
Cardiac arrhythmias were lower in endovascular repair 
group (14% vs. 29%, p=0.04). Endovascular repair was 
also significantly associated with lower myocardial 
ischemia (OR: 0.14, 95% CI: 0.05-0.40, p<0.001), 
troponin T release (OR: 0.10, 95% CI: 0.02-0.32, 
p<0.001), 30-day mortality (0% versus 8.7%, p=0.03) 
and 30-day cardiac events (0% versus 7.9%, p=0.04). 
Long-term mortality and cardiac events were not 
significantly lower in the endovascular group. In 
conclusion, endovascular repair is associated with a 
lower incidence of perioperative cardiac arrhythmias, 
myocardial ischemia, troponin T release, cardiac events 
and all-cause mortality, compared to open repair of 
abdominal aortic aneurysms. 
_____________________________________________________________________________________________ 
 
 
THIS PROSPECTIVE OBSERVATIONAL study was 
conducted to assess whether endovascular repair of 
abdominal aortic aneurysms (AAA) is associated with a 
lower incidence of perioperative myocardial ischemia, 
perioperative troponin T release and 30-day and long-
term cardiac events as compared to open repair. In 
addition, perioperative heart rate, heart rate variability 
and the incidence of cardiac arrhythmias were compared 
between the 2 types of procedures. 
 
Departments of Cardiology (a), Anesthesiology (b) and Vascular 
Surgery (c), Erasmus MC, Rotterdam, the Netherlands. Department of 
Cardiology, Leiden University Medical Center, Leiden, the 
Netherlands (d). 
 
METHODS 
 
A total of 175 patients underwent elective open or 
endovascular repair for infrarenal AAA at the Erasmus 
Medical Center in Rotterdam, the Netherlands, during 
the period 2002 to 2006. The study was performed with 
informed consent of all patients and approved by the 
hospital’s medical ethics committee. Patients with a 
cardiac pacemaker, left ventricular hypertrophy, left or 
right bundle branch block or atrial fibrillation were 
excluded. Patients who participated in clinical 
intervention trials in or outside the Erasmus Medical 
Center were also excluded. At study enrollment, a 
detailed cardiac history was obtained and patients were 
screened for hypertension (blood pressure ≥140/90 
mmHg), diabetes (fasting glucose ≥7.0 mmol/L, or 
insulin therapy), renal failure (serum creatinine ≥ 2.0 
mg/dL (177 μmol/L)), smoking and a history of 
cerebrovascular events. β-Blockers were considered to 
achieve resting heart rates of 60-65 beats per minute. 
Before surgery, high-risk patients underwent 
dobutamine stress echocardiography for the assessment 
of coronary artery disease. Dobutamine stress 
echocardiography was performed according to 
established protocols. The left ventricle was divided into 
17 segments and wall motion was scored on a 5-point 
scale (a score of 1 indicating normal, 2 mild 
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hypokinesis, 3 severe hypokinesis, 4 akinesis, and 5 
dyskinesis). The results were considered positive if wall 
motion in any segment decreased by ≥ 1 grades during 
testing.  
Surgery was performed by experienced 
surgeons and interventional physicians. Patients with an 
infrarenal abdominal aortic aneurysm ≥5.5 cm in 
diameter as indicated by computed tomography were 
considered for endovascular or open aneurysm repair. 
Hospital guidelines recommended endovascular repair 
in patients at increased cardiac risk. However, the 
choice of procedure was left to the discretion of the 
vascular surgeon and was mainly based on patient 
preference. Endovascular repair was carried out through 
the femoral route with generally available stents and 
protection devices. Locoregional anesthesia was used 
for endovascular repair and a combination of 
locoregional and general anesthesia was used for open 
repair. All patients received standard perioperative pain 
management. β-Blockers were continued 
postoperatively. In patients who were unable to take β-
blockers orally or by nasogastric tube, intravenous 
metoprolol was administered. β-Blockers were withheld 
if the heart rate was <50 beats per minute or if the 
systolic blood pressure was <100 mmHg.  
Patients were continuously monitored with a 
10-electrode, 12-lead digital electrocardiography 
recorder (DR180+ Digital Recorder, NorthEast 
Monitoring Inc. Massachusetts), starting 1 day before 
surgery up to 2 days after. Recording lengths were 10 
seconds every minute. The frequency response was 0.05 
– 150Hz. Electrocardiographic data were processed by a 
technician and analyzed by 2 experienced cardiologists 
blinded to the patient’s clinical data. After excluding all 
abnormal QRS complexes, the recordings were 
analyzed for ST-segment deviations. A continuous ST 
segment trend was generated and all potential ischemic 
episodes were identified. Episodes of ischemia were 
defined as reversible ST-segment changes, lasting >1 
minute and shifting from baseline to >0.1 mV (1 mm). 
The baseline ST segment level was defined as the 
average ST segment during a stable period (duration of 
20 minutes) preceding each ischemic episode. ST 
segment change was measured 60 ms after the J point. If 
the J point fell within the T-wave, the ST segment 
change was measured 40 ms after that point. The 
ischemic burden was calculated by multiplying ischemia 
duration with ST-segment deviation. 
Troponin T levels were measured on 
postoperative day 1, 3, 7, before discharge and 
whenever clinically indicated by electrocardiographic 
changes, consistent with myocardial ischemia or 
infarction. Troponin T level was measured by an 
electrochemiluminescence immunoassay on the Elecsys 
2010 (Roche Diagnostics, Mannheim, Germany). For 
the definition of positive troponin T levels, 0.03 ng/ml 
was used as cut-off value, since lower values do not 
meet the imprecision criteria of <10%. 
Mean heart rate was calculated before, during 
and after surgery. Heart rate variability was computed 
using time-domain analysis of short-term 5-minute 
recordings. Consecutive 5-minute recordings of 2-hour 
periods were obtained in a standard fashion at the 
evening before surgery, during the first 2-hours of 
surgery and at the second evening after surgery. The 
standard deviation of the NN intervals (SDNN (ms)) 
was calculated. All electrocardiographic recordings 
were analyzed for newly onset atrial fibrillation, 
monomorphic or polymorphic ventricular tachycardia 
and ventricular fibrillation. Non-sustained ventricular 
tachycardia was defined as an episode of ≥3 consecutive 
ventricular premature beats at a rate of ≥120 beats/min, 
lasting <30 seconds. Sustained ventricular tachycardia 
lasted >30 seconds. 
During a mean follow-up of 2.3 years, 
outpatient visits were scheduled every 3 months after 
discharge. Study endpoints were all-cause mortality and 
major cardiac events (cardiac death and non-fatal Q-
wave myocardial infarction) during hospital stay and 
follow-up. Non-fatal Q-wave myocardial infarction was 
diagnosed when at least the following were present: 
elevated cardiac enzyme levels, development of typical 
electrocardiographic changes (new Q waves >1 mm or 
>30 ms), and typical symptoms of angina pectoris. 
Cardiac death was defined as death caused by acute 
myocardial infarction, cardiac arrhythmias, congestive 
heart failure, or sudden death. No patients were lost to 
follow-up.  
The study group was divided according to 
endovascular or open repair. Continuous data were 
expressed as mean (±SD) or median (interquartile 
range) and compared using the Student t test or Mann-
Whitney test. Categorical data were analyzed using the 
chi-square test. Binary logistic regression analysis and 
Cox proportional hazard models were used for 
perioperative and long-term outcome analysis, 
respectively. A propensity score for surgical procedure 
was calculated, which was constructed using multiple 
logistic regression analysis [1]. Variables associated 
with the decision to perform endovascular repair were 
included in the multivariate propensity score. In 
multivariate analysis, adjustments were made for age, 
gender, diabetes, renal failure, coronary artery disease 
(history of angina or myocardial infarction or stress 
induced ischemia), history of cerebrovascular disease, 
hypertension, β-blockers, statins and propensity scores. 
For all tests, a p value <0.05 (two-sided) was considered 
significant. All analysis was performed using SPSS 12.0 
statistical software (SPSS Inc., Chicago, Illinois).  
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Table 1. Baseline characteristics of the study population. 
Abdominal aortic aneurysm (n=175) Characteristic 
Endovascular 
(n=49) 
Open  
(n=126) 
P value 
Age >70 years 32 (65%) 65 (52%) 0.1 
Men 42 (86%) 105 (83%) 0.7 
Angina pectoris 12 (24%) 21 (17%) 0.2 
Previous myocardial infarction 17 (35%) 54 (43%) 0.3 
Previous coronary revascularization 9 (18%) 18 (14%) 0.5 
Prior congestive heart failure 1 (2%) 5 (4%) 0.5 
Prior cerebrovascular events 6 (12%) 20 (16%) 0.5 
Renal failure 2 (4%) 5 (4%) 1.0 
Diabetes mellitus 4 (8%) 19 (15%) 0.2 
Hypertension 16 (33%) 50 (40%) 0.4 
Hypercholesterolemia* 14 (29%) 40 (32%) 0.7 
Current or past smoker 25 (51%) 81 (64%) 0.1 
Aspirin  27 (55%) 53 (42%) 0.1 
Angiotensin-converting enzyme inhibitors 10 (20%) 35 (28%) 0.3 
β-Blockers 39 (80%) 93 (74%) 0.4 
Calcium channel blockers 10 (20%) 35 (28%) 0.3 
Statins 22 (45%) 59 (47%) 0.8 
Stress-induced myocardial ischemia 13 (27%) 29 (23%) 0.8 
Duration of operation (hours) 3.0 ± 1.1 5.6 ± 1.4 <0.001 
Fluid infusion during operation (liters) 0.4 ± 0.3 2.8 ± 1.7 <0.001 
Heart rate 1 day prior to surgery (beats/minute) 69 ± 11 70 ± 15 0.3 
Values are expressed as mean (± SD) or number (%). * Defined as LDL-cholesterol >130 mg/dL or the use of lipid-lowering medication. 
 
 
RESULTS 
 
Out of 175 patients, open repair was performed in 126 
patients and endovascular repair in 49 patients. No 
significant differences were observed between open and 
endovascular repair in terms of baseline clinical 
characteristics, dobutamine stress echocardiography 
results and cardiovascular medication (Table 1). Mean 
preoperative heart rate was similar between open and 
endovascular repair. Duration of surgery and total fluid 
infusion, however, were significantly higher in patients 
with open repair, compared to endovascular repair 
(Table 1). Propensity analysis demonstrated that 
patients were more likely to undergo endovascular 
abdominal aortic repair if they were older (p=0.04) and 
if they had a history of angina pectoris (p=0.052). 
Propensity score ranged from 0.35 to 0.95. 
Myocardial ischemia during continuous 12-
lead electrocardiography was detected in 60 patients 
(34%). A total of 109 episodes of myocardial ischemia 
were detected. The median duration of ischemic events 
was 81 minutes (interquartile range: 60-269 minutes) 
and the median ST-segment deviation was 1.4 mm 
(interquartile range: 1.0-2.7 mm). Myocardial ischemia 
was significantly lower in patients with endovascular 
repair of abdominal aortic aneurysm, compared to open 
repair (Table 2). The ischemic burden was also 
significantly lower in patients with endovascular repair 
(median 67 mm*min) compared to open repair (median: 
209 mm*min) (p=0.003). In multivariate analysis,  
 
 
 
Figure 1. The incidence of perioperative myocardial ischemia (a) and 
troponin T release (b) in patients with and without perioperative 
cardiac arrhythmias.
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Table 2. Myocardial ischemia, troponin T release and clinical outcome in patients with endovascular or open repair.  
Abdominal aortic aneurysm (n=175) Variable 
 
 
Endovascular 
(n=49) 
Open (n=126) Relative risk 
(95% CI)‡ 
P value 
Ischemia and troponin T     
 ST-segment changes 5 (10.2%) 55 (43.7%) 0.14 (0.05-0.40) <0.001 
- Before operation 4 (8.2%) 7 (5.6%) 2.10 (0.50-8.61) 0.3 
- During operation 5 (10.2%) 41 (32.5%) 0.24 (0.09-0.68) 0.007 
- After operation 3 (6.1%) 35 (27.8%) 0.18 (0.05-0.62) 0.006 
Troponin T release 3 (6.1%) 48 (38.1%) 0.10 (0.02-0.32) <0.001 
Myocardial injury* 5 (10.2%) 64 (50.8%) 0.11 (0.03-0.26) <0.001 
Outcome     
30-day all-cause mortality 0 (0%)  11 (8.7%) - 0.03** 
30-day cardiac events 0 (0%)  10 (7.9%) - 0.04** 
Long-term all-cause mortality 4 (8.2%) 17 (13.5%) 0.52 (0.17-1.63) 0.2 
Long-term cardiac events 3 (6.1%) 15 (11.9%) 0.45 (0.12-1.81) 0.3 
*Composite of myocardial ischemia and troponin T release. ‡ Adjusted for age, gender, diabetes, renal failure, coronary artery disease, history of 
heart failure, history of cerebrovascular disease, hypertension, β-blockers, statins and propensity score. ** Calculated by chi-square test.  
 
Table 3. Perioperative heart rate, heart rate variability and arrhythmias in patients with endovascular or open repair. 
Abdominal aortic aneurysm (n=175) Variable 
Endovascular 
(n=49) 
Open  
(n=126) 
P value 
Heart rate (bpm)  69 ± 10 75 ± 14 0.01 
- Before operation (bpm) 69 ± 11 70 ± 15 0.3 
- During operation (bpm) 68 ±  9 74 ± 13 0.009 
- After operation (bpm) 72 ± 13 81 ± 15 0.004 
Heart rate variability (SDNN*)    
- Before operation (ms) 48 ± 20 49 ± 21 0.7 
- During operation (ms) 42 ± 20 26 ± 18 0.001 
- After operation (ms) 44 ± 20 28 ±  21 0.004 
Arrhythmias    
- Any 7 (14.3%) 37 (29.3%) 0.04 
- Non-sustained ventricular tachycardia 6 (12.2%) 23 (18.3%) 0.3 
- Sustained ventricular tachycardia 0 (0%) 4 (3.1%) 0.2 
- Newly onset atrial fibrillation 1 (2.0%) 8 (6.3%) 0.2 
- Ventricular fibrillation 0 (0%) 2 (1.6%) 0.4 
*SDNN = standard deviation of the normal-to-normal RR intervals. Values are expressed as mean (± SD) or number (%). 
 
 
endovascular repair remained significantly associated 
with lower myocardial ischemia (Table 2).  
Troponin T release was detected in 51 patients 
(29%). The median troponin T value was 0.45 ng/ml 
(interquartile range 0.08-0.75ng/ml). In univariate and 
multivariate analysis, endovascular repair of abdominal 
aortic aneurysm was significantly associated with lower 
troponin T release (Table 2). In patients with 
myocardial damage, the level of troponin T release was 
significantly lower after endovascular repair (median 
0.17 ng/ml), compared to open repair (0.45 ng/ml) 
(p<0.001).  
Mean preoperative heart rate and heart rate 
variability were comparable between open and stenting 
procedures. During and after surgery, however, heart 
rate was significantly higher and heart rate variability 
significantly lower in open repair, compared to 
endovascular repair (Table 3). Interestingly, patients 
with myocardial ischemia after surgery had a lower 
heart rate variability before (SDNN: 32±29 versus 
50±26, p=0.002), during (SDNN: 23±19 versus 36±24, 
p=0.01) and after surgery (SDNN: 21±19 versus 46±42, 
p=0.008), compared to patients with no myocardial 
ischemia. Patients with troponin T release also had a 
lower heart rate variability before (SDNN: 49±25 versus 
32±29, p=0.002), during (SDNN: 23±21 versus 37±23, 
p=0.004) and after surgery (SDNN: 21±18 versus 
47±39, p<0.001), compared to patients with no troponin 
T release.  
Newly onset atrial fibrillation, non-sustained ventricular 
tachycardia, sustained ventricular tachycardia and 
ventricular fibrillation occurred in 9 (5%), 29 (17%), 4 
(2%) and 2 (1%) of patients, respectively. Patients with 
perioperative cardiac arrhythmias were more likely to 
have perioperative ischemia and troponin T release, 
compared to patients without arrhythmias (Figure 1). In 
addition, heart rate during and after surgery was 
significantly higher and heart rate variability during and 
after surgery was significantly lower in patients with 
cardiac arrhythmias (Figure 2). Sustained ventricular 
tachycardia and ventricular fibrillation were not 
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Figure 2. Mean heart rate (a) and heart rate variability (± standard 
error of the mean) (b) in patients with and without perioperative 
cardiac arrhythmias. 
 
observed in patients with endovascular repair, but 
occurred in 4 (3%) and 2 patients (2%), respectively, 
with open surgical repair. The incidence of atrial 
fibrillation and non-sustained ventricular tachycardia 
was also non-significantly lower in patients with 
endovascular repair (Table 3). The cumulative incidence 
of cardiac arrhythmias was significantly lower in 
endovascular repair, compared to open surgery (Table 
3). 
All-cause mortality and cardiac events occurred 
in 11 (6.3%) and 10 (5.7%) patients, respectively, 
during hospital stay. In-hospital mortality and cardiac 
events were not observed after endovascular repair, but 
occurred in 11 (9%) and 10 (8%) patients with open 
surgical repair (Table 2). During follow-up, all-cause 
mortality and cardiac events occurred in 21 (12%) and 
18 (10%) patients, respectively. Patients with 
endovascular repair were at non-significantly lower risk 
of long-term mortality and cardiac events, compared to 
open repair (Table 2).  
 
DISCUSSION 
 
Several studies have demonstrated that endovascular 
procedures can significantly decrease cardiovascular 
events in the perioperative period, in comparison to 
open repair [2-7]. Long-term studies have suggested no 
sustained survival benefit after the first postoperative 
year for endovascular stenting [8]. In a previous study, 
we demonstrated that endovascular stent grafting was 
associated with a reduced incidence of perioperative 
complications, but with comparable long-term cardiac 
outcome. [7]. In the current study, perioperative 72-hour 
12-lead electrocardiographic monitoring was applied in 
a contemporary patient cohort. Endovascular repair was 
significantly associated with lower perioperative heart 
rate and higher perioperative heart rate variability. 
Patients with endovascular repair also had a lower 
incidence of perioperative cardiac arrhythmias, 
myocardial ischemia, troponin T release, mortality and 
cardiac events. We confirmed that long-term mortality 
and cardiac events were non-significantly lower in 
patients with endovascular repair.  
In previous studies, myocardial ischemia 
during major vascular surgery has been observed in up 
to 41% of patients and has been demonstrated to be a 
strong predictor of subsequent clinical cardiovascular 
events [9]. The current study detected perioperative 
myocardial ischemia in 34% of patients. Myocardial 
ischemia in the perioperative setting may arise either 
from increased myocardial oxygen demand or reduced 
supply. Factors that increase myocardial oxygen 
demand are mainly tachycardia and hypertension 
resulting from surgical stress, postoperative pain, 
interruption of β-blocker use, or the use of 
sympathomimetic drugs. In contrast, decreased supply 
may be the result of hypotension, vasospasm, anemia, 
hypoxia, or coronary artery plaque rupture. Invasive 
procedures have been associated with significant 
changes in arterial pressure, cardiac output and 
increases in blood lactate, catecholamine and arterial pH 
[10,11]. Therefore, the higher heart rate in patients 
undergoing open repair is likely the result of increased 
surgical stress and sympathetic tone.  
Heart rate variability has been used as a 
measure of cardiac autonomic function and mostly 
reflects vagal tone. Increased anesthetic depth and 
sympathetic tone most likely explain the lower 
perioperative heart rate variability in patients with open 
repair, compared to endovascular repair [12]. It has been 
suggested that decreased heart rate variability could 
trigger ischemic events [13,14]. Indeed, in the current 
study, myocardial ischemia and troponin T release was 
preceded by significantly lower heart rate variability. 
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The current results, therefore, support the view that 
ischemic events predominantly occur in situations with 
increased sympathetic activity.  
This study further revealed a higher incidence 
of cardiac arrhythmias in patients with open repair. In 
addition, patients with perioperative cardiac arrhythmias 
had a higher incidence of myocardial ischemia and 
troponin T release. They also had significantly higher 
heart rates and lower heart rate variability during and 
after surgery. These results therefore suggest that 
surgical stress, higher heart rates and lower heart rate 
variability in association with myocardial oxygen 
supply-demand mismatch causes the higher incidence of 
sustained and non-sustained ventricular tachycardias, 
newly onset atrial fibrillation and ventricular fibrillation 
in patients with open repair, compared to endovascular 
repair. 
 Cardiac complications remain a leading cause 
of morbidity and mortality among vascular surgery 
patients. Due to the lack of long-term data, the choice 
between stenting and open repair now heavily relies on 
surgeon experience and patient preference. Concerns 
have been raised about the long-term efficacy and safety 
of endovascular grafts. Not only endoleaks become 
increasingly common as duration of follow-up is 
extended, aneurysm-related deaths after successful 
endograft therapy have also been reported [15]. 
The major limitation in this study is that the 
surgical procedures were not randomly assigned to the 
patients. However, baseline clinical characteristics were 
comparable and detailed cardiac assessment with 
dobutamine stress test echocardiography revealed no 
significant baseline differences between the two types 
of surgery. In addition, we used multivariate analysis 
and propensity analysis to adjust for known possible 
confounding factors. Unfortunately, no data were 
available regarding the incidence of repeat procedures 
for graft leaks in patients with endovascular surgery.  
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Summary and Conclusions 
 
 
IN THE NEXT FEW DECADES, cardiovascular 
disease will remain the dominant cause of death and 
disability in the world. Until recently, atherosclerotic 
disease of the lower extremities has been regarded as a 
local problem, which required local treatment. Now, the 
association between peripheral arterial disease and 
cardiovascular mortality is well appreciated and 
treatment strategies focus on the systemic nature of 
atherosclerosis. Strategies include primary prevention of 
atherosclerotic disease, secondary prevention of disease 
complications and tertiary prevention in patients with 
established disease. This thesis proposes strategies to 
improve management and outcome in patients with 
peripheral arterial disease. 
The recognition of risk factors in patients with 
peripheral arterial disease is important since many of 
these risk factors can be modified. In patients with 
peripheral arterial disease, the following risk factors 
were associated with increased 10-year mortality: renal 
dysfunction, heart failure, ST-changes, age above 65, 
hypercholesterolemia, ankle-brachial index values 
below 0.60, Q-waves, diabetes, cerebrovascular disease 
and pulmonary disease (Chapter 2). A risk index based 
on these variables can provide an overall framework for 
risk assessment and medical decision making (Chapter 
2). In addition to these classic risk factors, low post-
exercise ankle-brachial index values (Chapter 3), stress-
induced myocardial ischemia and left ventricular 
dysfunction during dobutamine stress echocardiography 
(Chapter 4) are correlated with poor outcome. During 
follow-up, patients with declining ankle-brachial index 
values, i.e. progressive atherosclerotic disease, will 
experience more mortality, cardiac events and kidney 
dysfunction, compared to patients with no declines in 
ankle-brachial index (Chapter 5).  
Fortunately, mortality and morbidity in these 
patients can be reduced by cardioprotective medication, 
such as statins, aspirin, beta-blockers and angiotensin-
converting enzyme inhibitors (Chapter 6). Especially 
intensified lipid-lowering therapy with low target LDL-
cholesterol levels will improve the prognosis of 
peripheral arterial disease (Chapter 7). Renal 
dysfunction is both a major risk factor and complication 
in patients with peripheral arterial disease. Improved 
renal outcome can be accomplished with statins and 
angiotensin converting enzyme-inhibitors; both are 
associated with less progression towards end-stage renal 
disease (Chapter 8). Diabetes is another major risk 
factor in peripheral arterial disease and poor glycemic 
control contributes to mortality and morbidity (Chapter 
9). The beneficial effect of statins in patients with 
peripheral arterial disease can be attributed to both 
improved lipid metabolism and improved glycemic 
control (Chapter 9).  
Patients with advanced peripheral 
atherosclerotic disease can present with many symptoms 
including claudication, gangrene, angina pectoris, stroke 
and myocardial infarction. These patients are also at 
increased risk of abdominal aortic aneurysms, renal 
artery stenosis and carotid stenosis, which may present 
without any symptoms. Patients may require surgery for 
symptomatic relief or for preventive purposes in order 
to increase overall survival. Unfortunately, surgery is 
associated with substantial perioperative myocardial 
ischemia and cardiac events (Chapter 10). Therefore, 
the indication for surgery should outweigh its risk. A 
substantial proportion of patients have perioperative ST-
elevation, which can occur in non-culprit related 
coronary arteries (Chapter 10). This finding complicates 
its prediction and may explain why preoperative 
preventive coronary artery revascularization does not 
improve perioperative outcome.  
Risk assessment is an essential step in 
perioperative management. Risk factors in addition to 
traditional risk factors are unrecognized myocardial 
infarction and silent myocardial ischemia (Chapter 11), 
impaired fasting glucose and poor glycemic control 
(Chapter 12), marginal troponin T elevations (Chapter 
19) and elevated N-terminal pro-B-type natriuretic 
peptide (NT-proBNP) levels (Chapter 13 and 14). The 
positive correlation between elevated NT-proBNP with 
the extent of stress induced myocardial ischemia during 
dobutamine stress echocardiography (Chapter 15) and 
with perioperative ischemia (Chapter 16) provides 
addition support for its use as marker of coronary artery 
disease. NT-proBNP levels also reflect left ventricular 
function and functional status after cardiac surgery 
(Chapter 17).  
Perioperative risk stratification is important, 
since it guides perioperative management (Chapter 18 
and 20). For example, high risk patients with left 
ventricular dysfunction should receive angiotensin-
converting enzyme-inhibitors, statins and beta-blockers 
in order to improve not only long-term outcome, but 
also perioperative outcome (Chapter 21). Although the 
benefit of perioperative beta-blockers in high-risk 
patients has been established by large randomized trials, 
recent studies have demonstrated conflicting results and 
have questioned its routine use. Chapter 22 argues an 
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individual patient approach, in which cardioprotection 
can be achieved by tight heart rate control with adequate 
beta-blocker dosage (Chapter 22). The benefit of beta-
blockers in patients with left ventricular dysfunction is 
suggested in Chapter 23. In addition to beta-blockers, 
statins have emerged as promising drugs with 
cardioprotective properties. Chapter 25 shows that 
statins have perioperative cardioprotective effects, 
which go beyond its lipid-lowering properties.  
With recent advances in perioperative 
management, higher-risk patients, such as the (very) 
elderly, are now considered for major surgery (Chapter 
26 and 27). Surgical procedures with minimal cardiac 
stress should be appreciated. Chapters 29 and 30 study 
cardiac outcome in patients who are undergoing less 
invasive surgical procedures, such as carotid stenting or 
endovascular abdominal aortic repair. These studies 
show that less-invasive procedures correlate with lower 
cardiac events, compared to more invasive surgery. 
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Samenvatting en Conclusies 
 
WERELDWIJD blijven hart- en vaat- aandoendingen 
de komende jaren de primaire oorzaak voor morbiditeit 
en mortality. Perifeer atherosclerose van de onderste 
extremiteiten werd ooit beschouwd als locaal probleem. 
Op dit moment is het welbekend dat perifeer 
atherosclerotisch vaatlijden een systemisch probeem is 
dat een systemische behandeling vergt. Met name 
coronaire vaataandoeningen zijn geassocieerd met 
perifeer atherosclerotisch vaatleiden. Behandeling is 
gericht op primaire preventie, secundaire preventie van 
ziektecomplicaties en tertiaire preventie in patiënten die 
reeds ziektecomplicaties hebben. In dit proefschrift 
worden verschillende strategien voorgesteld die tot doel 
hebben een verbetering te brengen in de prognose van 
patienten met perifeer en coronair atherosclerotische 
vaataandoeningen. 
Identificatie van risicofactoren in patiënten met 
perifeer atherosclerotische aandoeningen is belangrijk 
zodat deze risicofactoren aggressiev behandeld kunnen 
worden. De volgende risicofactoren zijn geassocieerd 
met verhoogde mortaliteit: nierinsufficiëncie, hartfalen, 
ST-segment afwijkingen, leeftijd boven 65 jaar, 
hypercholesterolemie, enkel-arm index kleiner dan 0.60, 
Q’s op de electrocardiogram, diabetes mellitus, 
cerebrovasculaire aandoeningen en longaandoeningen 
(hoofdstuk 2). Deze risicofactoren kunnen samengevat 
worden in een risico-index dat gebruikt kan worden om 
het risico op mortaliteit te schatten. Op basis van deze 
index kan vervolgens een optimaal preventief beleid 
bepaald worden (hoofdstuk 2). Naast de traditionele 
risicofactoren zijn een lage enkel-arm index na 
inspanning (hoofdstuk 3), stress-geïnduceerd 
myocardischemie en linker ventrikel dysfunctie 
(hoofdstuk 4) geassocieerd met een slechte prognose. 
Een verslechtering in enkle-arm index gedurende de tijd 
is ook geassocieerd met een verhoogd risico op 
mortaliteit, cardiale complicaties en nierfalen  
(hoofdstuk 5). 
Ondanks dit somber perspectief kan mortaliteit 
aanzienlijk verbeterd worden door het voorschrijven van 
verschillende cardiovasculaire medicaties, zoals 
statines, aspirine, beta-blokkers en ACE-remmers 
(hoofdstuk 6). Intensief statine gebruik en lage LDL-
cholesterol waardes verbetert de prognose aanzienlijk 
(hoofdstuk 7). Hoofdstuk 8 laat zien dat statines en 
ACE-remmers ook een verlaging kunnen geven in de 
incidentie van nierfalen. Hoofdstuk 9, tenslotte, 
suggereeert dat het effect van statines gerelateerd is aan 
een verbeterde glucosemetabolisme.  
Patiënten met gevorderd atherosclerotisch 
vaatleiden kunnen zich symptomatisch presenteren of 
zich presenteren met asymptomatische aandoeningen 
zoals abdominale aneurysmata, nierslagader-
vernauwingen en halsslagadervernauwingen. Zowel het 
verlichten van symptomen als het verbeteren van 
prognose zijn indicatoren voor chirurgisch ingrijpen. 
Helaas zijn hoog-risico operaties geassocieerd met 
perioperatieve ST-afwijkingen en cardiale complicaties, 
met name in hoog-risico patiënten (hoofdstuk 10). 
Volgens de resultaten in hoofdsuk 11 correleert de 
locatie van ST-elevatie slecht met de locatie van de 
kritieke coronairvernauwing. Deze observatie kan 
verklaren waarom preventieve coronaire revascularisatie 
geen verbeterde perioperatieve prognose geeft.  
Een weloverwogen beslissing moet gemaakt 
worden tussen de voor- en nadelen van chirurgie. 
Bekende risicofactoren voor het ontwikkelen van 
perioperatieve complicaties zijn diabetes mellitus, 
cerebrovasculaire aandoeningen, nierfunctiestoornissen, 
coronair atherosclerotische aandoeningen en hartfalen. 
Ook een stil mycardinfarct en asymptomatisch coronair 
atherosclerotische aandoeningen (hoofdstuk 11), slechte 
glucoseregulatie (hoofdstuk 12), een verhoging in het 
natriuretisch hormoon (hoofdstuk 13 en 14) en 
marginale perioperative troponinestijgingen (hoofdstuk 
19) hebben prognostische waarde. De positieve 
associatie tussen verhoogde natriuretisch hormoon 
concentraties en stress-geïnduceerd myocardischemie 
tijdens dobutamine stress echocardiografie (hoofdstuk 
15) en myocardischemie tijdens operatie (hoofdstuk 16) 
ondersteund de hypothese dat verhoogde natriuretisch 
hormoon concentraties gebruikt kunnen worden als 
prognostisch middel. Ook kan het natriuretisch hormoon 
een indicator zijn voor linkerventrikel functie en 
functionele status na mitraalklepchirurgie (hoofdstuk 
17). 
Risicostratificatie bepaalt het perioperatieve 
beleid (hoofdstuk 20). Chirurgische patiënten met 
linkerventrikeldysfunctie kunnen hun overlevingskans 
vergroten door het gebruik van perioperatieve ACE-
remmers, statines en beta-blokkers (hoofdstuk 21). 
Hoofdstuk 22 suggereert dat het voorschrijven van beta-
blokkers een individuele patiëntenbenadering vereist 
waarin cardioprotectie verkregen wordt door stricte 
hartslagfrequentiecontrole en adequate beta-
blokkerdosering. De effectiviteit van beta-blokkers in 
patienten met hartfalen word verondersteld in hoofdstuk 
23. Naast beta-blokkers hebben ook statines een positief 
effect in het voorkomen van cardiale complicaties 
(hoofdstuk 24). 
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Door verbeteringen in perioperatief beleid 
komen patiënten met een hoger risico, zoals patiënten 
met een hogere leeftijd, in aanmerking voor chirurgie. 
In hoog-risico patiënten kan een voorkeur gegeven 
worden aan chirurgische ingrepen met minimale 
cardiale stress. Hoofdstukken 29 en 30 laten zien dat 
minimaal invasieve chirurgische ingrepen, zoals het 
gebruik van endoscopische procedures en stents, een 
vermindering kunnen geven in myocardcelschade en 
cardiale complicaties, in vergelijking tot meer invasieve 
ingrepen. 
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Addendum: Perioperatieve risicostratificatie en beleid 
in vaatchirurgische patiënten 
Harm H.H. Feringa, MD 
 
Het risico op cardiale complicaties is hoog bij patiënten 
die een vaatchirurgische operatie ondergaan. Deze 
complicaties ontstaan door aanhoudende 
myocardischemie of door ruptuur van de coronaire 
plaque in de perioperatieve periode. Preoperatieve 
risico-inschatting in deze patiënten is belangrijk voor 
het bepalen van een optimaal medisch beleid dat gericht 
is op risicoreductie. β-Blokkers verminderen dit risico 
aanzienlijk, waarbij adequate dosering van de β-blokker, 
nauwkeurige perioperatieve controle van de hartslag en 
continuering van de β-blokker na ontslag uit het 
ziekenhuis belangrijk zijn. Recent is ook bewezen dat 
ook statines een perioperatief cardioprotectief effect 
hebben. Het perioperatief beleid dient niet alleen gericht 
te zijn op kortetermijnuitkomsten, elke poging om 
langetermijnprognose te verbeteren moet worden 
verwelkomd.  
___________________________________________________________________________________________ 
 
 
HET PROBLEEM 
 
IN NEDERLAND ONDERGAAT jaarlijks 3.8% van 
de bevolking een niet-cardiaal chirurgische ingreep 
(www.prismant.nl). Ongeveer 6% van deze ingrepen 
bestaat uit vaatchirurgische operaties [1]. Jaarlijks 
overlijden er ongeveer 1.500 patiënten tijdens of na een 
vaatchirurgische operatie, uitgaande van de schatting 
dat de perioperatieve sterfte in Nederland 4.4% is [1]. 
Meer dan de helft van deze sterftegevallen is het gevolg 
van primaire of secundaire cardiale complicaties [2]. 
Daarmee kent de vaatchirurgie het hoogste risico op 
cardiovasculaire sterfte, in vergelijking met andere niet-
cardiaal chirurgische ingrepen [2]. De incidentie van 
perioperatieve cardiovasculaire complicaties op 
mondiaal niveau is vergelijkbaar: 2.5% van de patiënten 
die een niet-cardiale niet-vaatchirurgische operatie 
ondergaan en 6.2% van de patiënten die een perifeer 
vaatchirurgische operatie ondergaan [3]. De hoge 
incidentie van cardiovasculaire complicaties 
weerspiegelt de hoge prevalentie van onderliggend 
coronairlijden. Volgens de Wereld Gezondheids 
Organisatie zal de wereldwijde epidemie van hartziekte 
niet alleen toenemen in de westerse wereld, maar zal 
deze zich ook uitbreiden naar onderontwikkelde landen. 
Verder zullen door nieuwe chirurgische technieken, 
zoals endovasculaire ingrepen, patiënten met een hogere 
leeftijd en een hoger risicoprofiel in aanmerking komen 
voor vaatchirurgie. Ondanks de verbetering in 
perioperatieve zorg gedurende de laatste decennia, blijft 
het daarom noodzakelijk aandacht te geven aan reductie 
van perioperatieve morbiditeit en mortaliteit. In deze 
beschouwing zal ingegaan worden op de 
pathofysiologie van perioperatieve cardiale 
complicaties. Verder zullen de preoperatieve 
beoordeling van het cardiale risicoprofiel en de 
risicoreductie door middel van medicamenteuze 
therapie aan bod komen. 
 
PATHOFYSIOLOGIE 
 
Perioperatieve cardiale complicaties kunnen ontstaan 
door aanhoudende myocardischemie of door ruptuur 
van een atherosclerotische plaque in een van de coronair 
arteriën (Figuur 1) [4]. Aanhoudende perioperatieve 
ischemie van het myocard ontstaat door een locaal 
toegenomen behoefte aan zuurstof of een verlaagde 
zuurstoftoevoer. Verhoogde zuurstofbehoefte kan 
ontstaan door de stress van de operatie (pijnsensaties, 
tachycardie, hypertensie) of door de toediening van 
sympathicomimetische geneesmiddelen. Een verlaagd  
 
 
Figuur 1. Pathologie van een perioperatief myocardinfarct. 
 
aanbod van zuurstof aan het myocard kan ontstaan door 
hypotensie, vasospasme, anemie, hypoxie of een 
significante coronaire stenose of obstructie. 
Verschillende studies hebben aangetoond dat 
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Tabel 1. Een schematisch stappenplan voor perioperatief beleid. 
Stap  Omschrijving Bewijs 
klasse  
1. Identificeer cardiale 
risicofactoren 
Ischemische hartziekte, hartfalen, cerebrovasculaire aandoening, 
diabetes mellitus, nierfunctiestoornissen (Lee-score) 
I-B 
2. Schat risico in van de 
betreffende chirurgische 
ingreep 
Laag risico: gynaecologie, oogheelkunde, carotischirurgie, 
mammachirurgie; Intermediair-laag risico: orthopedie, urologie; 
Intermediair-hoog risico: abdominale chirurgie, keel-, neus-, 
oorheelkunde, neurochirurgie, longchirurgie; Hoog-risico: 
aortachirurgie, perifere vaatchirurgie. 
I-B 
3. Elektrocardiografie Ritme- en geleidingsstoornissen voorspellen perioperatieve cardiale 
complicaties. 
I-B 
4. Bloedserum analyse Verhoging in concentraties van natriuretisch hormoon, glucose, 
geglycosyleerd hemoglobine en creatinine voorspellen cardiale 
complicaties.  
I-B 
5. Overweeg rust echocartografie Linkelventrikelfunctie bepaling bij hartfalen. Diagnostiseren van 
hartklepafwijkingen. 
I-B 
6. Overweeg stress 
echocartografie 
Screening voor ischemische hartziekte in hoogrisico patiënten. I-B 
7. Optimaliseer medisch beleid β-Blokkers in adequate dosis and van zekere duur (start minimaal 1 
maand voor de operatie tot minimaal 1 maand na de operatie) bij 
patiënten met een hoog risico.  
Overweeg statines bij patiënten met een hoog risico. 
I-A 
 
 
 
I-B 
 
8. Overweeg coronair 
revascularisatie 
Nut van preoperatieve coronair revascularisatie is controversieel. IIb-A 
9. Perioperatieve ischemie 
detectie 
(Sub)klinische myocardischemie en myocardcelschade bepaald door 
middel van perioperatieve Holter registratie of troponine T metingen is 
geassocieerd met een verhoogde korte en lange-termijn mortaliteit. 
I-B 
10. Optimaliseer postoperatief 
beleid 
Overweeg continuering van β-blokker en statine na ontslag uit het 
ziekenhuis. Overweeg cardiologisch consult bij complicaties. 
I-B 
*Klasse  I: Er is bewijs of algemene overeenstemming dat de procedure of behandeling effectief en nuttig is  
Klasse II: Er is tegenstrijdig bewijs en/of uiteenlopende mening dat de procedure of behandeling effectief en nuttig is.  
Klasse IIa: Er is gunstig bewijs voor effect en nut 
Klasse IIb: Er is minder gunstig bewijs voor effect en nut 
Klasse III: Er is bewijs of algemene overeenstemming dat de procedure of behandeling niet effectief en nuttig is en in sommige 
gevallen zelfs schadelijk 
A: Data verkregen door middel van meerdere gerandomiseerde onderzoeken 
B: Data verkregen door middel van een gerandomiseerd onderzoek of ongerandomiseerde onderzoeken 
C: Gebaseerd op de opinie van experts of case studies 
 
 
aanhoudende ischemie van het myocard kan leiden tot 
myocardcelschade en vervolgens tot cardiale 
complicaties [5]. Pathologische studies laten zien dat 
bijna alle patiënten met een fataal perioperatief 
myocardinfarct significante afwijkingen hebben in de 
coronair arteriën en dat ongeveer de helft een ruptuur 
van de coronaire plaque heeft gehad [6]. Perioperatief 
beleid bestaat zowel uit het inschatten van het risico van 
deze complicaties als uit interventies gericht om het 
pathologische proces positief te beïnvloeden.   
 
PREOPERATIEVE RISICOSTRATIFICATIE 
 
Verschillende risico-indicatoren zijn ontwikkeld om het 
risico op perioperatieve complicaties te kunnen 
inschatten. Lee’s gereviseerde cardiale risico-index 
wordt het meest gebruikt [7]. Deze risico-index was 
ontwikkeld bij patiënten ≥50 jaar die een niet-cardiale, 
electieve chirurgische ingreep ondergingen waarvan de 
verwachte ziekenhuis duur twee dagen of langer was. 
Deze index gebruikt 6 voorspellers voor cardiale 
complicaties: 1) hoogrisico chirurgie, 2) ischemische 
hartziekte, 3) hartfalen, 4) cerebrovasculaire 
aandoeningen, 5) diabetes mellitus en 6) een gestoorde 
nierfunctie. De geschatte prevalentie van cardiale 
complicaties bij aanwezigheid van 0, 1, 2, of ≥3 van 
deze voorspellers was respectievelijk 0.4%, 0.9%, 7% 
en 11%. Recente studies hebben aangetoond dat 
inschatting van het risico verbeterd kan worden door 
preoperatieve bepaling van het natriuretisch hormoon 
[8-11]. Verder is rust echocardiografie geïndiceerd voor 
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het detecteren van linkerventrikeldysfunctie bij 
patiënten met hartfalen. Ook kunnen 
hartklepaandoeningen opgespoord worden, zoals 
aortaklepstenose, welke geassocieerd zijn met 
verhoogde perioperatieve sterfte. [12]. Richtlijnen 
adviseren verder een niet-invasieve cardiale stress test 
bij patiënten met een hoog risico [13]. Gezien de 
prognostische nauwkeurigheid kan in dit verband een 
voorkeur gegeven worden aan farmacologische stress 
echocardiografie [14]. Een schematische stappenplan 
voor het perioperatief beleid is weergegeven in Tabel 1. 
 
β-BLOKKERS 
 
Meerdere studies hebben aangetoond dat β-blokkers de 
incidentie van perioperatieve myocardischemie en 
cardiale complicaties kunnen reduceren [15,16,17]. Het 
stroomdiagram (figuur 2) bijvoorbeeld laat de incidentie 
in perioperatieve cardiale complicaties zien in laag-, 
intermediair- en hoogrisico patiënten met of zonder β-
blokkers. Overtuigend zijn twee gerandomiseerde 
studies bij hoogrisico patiënten. De eerste studie 
evalueerde het effect van atenolol bij 200 hoogrisico 
patiënten die een niet-cardiale ingreep ondergingen. 
Hoewel er geen verschil was in perioperatieve sterfte, 
was er een significant lager sterftecijfer 6 maanden na 
ontslag (0 vs. 8%, P < 0.001), in het eerste jaar (3 vs. 
14%, P = 0.005) en na 2 jaar follow-up (10 vs. 21%, P 
= 0.2) [16]. De tweede studie toonde bij 112 hoogrisico 
patiënten met stressgeïnduceerde myocardischemie aan 
dat het gebruik van bisoprolol geassocieerd was met een 
10-voudige reductie in de gecombineerde eindpunten 
perioperatieve cardiale sterfte en het optreden van 
myocardinfarct, in vergelijking met placebo [17].  
 
Recent gepubliceerde studies vermelden echter 
tegenstrijdige resultaten [18,19]. In een studie waarbij
 
 
 
 
Figuur 2. Incidentie van perioperatieve cardiale sterfte of niet-fataal myocardinfarct in vaatchirurgische patiënten [zie referentie 15]. 
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metoprolol of placebo gegeven werd aan vasculair 
chirurgische patiënten 2 uur voor operatie tot een 
maximum van 5 dagen na de operatie werd geen 
verschil waargenomen in cardiale complicaties na 30 
dagen en 6 maanden [18]. In een studie waarbij 1 dag 
voor operatie tot maximaal 8 dagen erna metoprolol of 
placebo gegeven werd aan chirurgische patiënten met 
diabetes mellitus werd ook geen verschil waargenomen 
[19]. Deze negatieve resultaten kunnen verklaard 
worden door een onvoldoende dosering in β-blokker en 
een onvoldoende verlaging in hartslagfrequentie (Figuur 
3) [20]. Ook kunnen deze resultaten verklaard worden 
door de relatief korte duur van β-blokker toediening. 
Een studie heeft laten zien dat de prognose significant 
verbeterd wordt wanneer β-blokkers gecontinueerd 
worden na ontslag uit het ziekenhuis [21]. Tevens zijn 
er aanwijzingen dat kortwerkende β-blokkers (zoals 
metoprolol) minder cardioprotectief zijn dan 
langwerkende β-blokkers (zoals atenolol) [22]. 
Toekomstige studies zullen moeten uitwijzen of β-
blokkers de perioperatieve sterfte verminderen in laag-
intermediair risico patiënten. 
 
Figuur 3. Incidentie van perioperatieve myocardischemie en troponine 
T stijging in relatie tot β-blokker dosering en hartslagfrequentie [zie 
referentie 20]. 
 
STATINES 
 
Recente studies hebben laten zien dat statines de kans 
op perioperatieve cardiovasculaire complicaties kunnen 
verlagen [23]. De gunstige eigenschappen van statines 
kunnen naast het lipide-verlagend effect verklaard 
worden door de zogenoemde pleiotrope effecten, zoals 
oxidatieve stress reductie, ontstekingsreductie en plaque 
stabilisatie [24]. Ook zijn er aanwijzingen dat 
perioperatieve toediening van statines de verblijfsduur 
in het ziekenhuis verkorten en postoperatieve 
nierfunctieverslechtering na suprarenale afklemming 
van de aorta kan voorkomen [25,26]. De DECREASE 
III studie is een gerandomiseerd onderzoek in 
vaatchirurgische patiënten dat het effect van statines op 
onstekingsparameters en perioperatieve mortaliteit 
evalueert. De DECREASE IV studie is een 
gerandomiseerd onderzoek in laagintermediair risico 
patiënten met een niet-cardiaal, niet-vasculair 
chirurgische ingreep dat het effect van β-blokkers en 
statines op perioperatieve sterfte evalueert [27]. Deze 
studies zullen meer inzicht geven in het effect van 
statines op perioperatieve ontstekings-mediatoren en op 
cardiovasculaire uitkomst in niet-cardiaal chirurgische 
patiënten.  
 
OVERIGE MEDICATIE 
 
Andere middelen met potentieel cardioprotectieve 
effecten zijn calcium antagonisten (dihydropyridines en 
non-dihydropyridines), nitroglycerine en a2-receptor 
agonisten (clonidine, dexmedetomidine, mivazerol). Er 
zijn enkele studies met relatief weinig patiënten verricht 
die gekeken hebben naar de effecten van non-
dihydropyridines (diltiazem) in de perioperatieve 
periode [28]. Hoewel bradycardie relatief vaker voor 
kwam in patiënten met diltiazem, leek het de 
perioperatieve incidentie op myocardinfarct niet te 
reduceren [28]. α2-Receptor agonisten lijken 
perioperatief wel cardioprotectieve eigenschappen te 
hebben. Het is aangetoond dat zowel mivazerol als 
clonidine de incidentie van perioperatieve 
cardiovasculaire complicaties kan reduceren [29,30]. 
α2-Receptor agonisten verminderen het vrijkomen van 
endogeen noradrenaline. Hierdoor zou cardiale 
ischemie tijdens chirurgie voorkomen kunnen worden. 
Het bewijs ten gunste van α2-receptor agonisten is 
echter nog gebaseerd op te weinig onderzoek, waardoor 
een eventuele gunstige invloed op de lange termijn 
vooralsnog onopgehelderd blijft. Verder is het de vraag 
of α2-receptor agonisten superieur zijn in vergelijking 
met β-blokkers en statines en of deze medicamenten 
elkaar in werking kunnen complementeren.  
 
CONCLUSIE 
 
Vaatchirurgische patiënten hebben een hoog risico op 
cardiale complicaties. Risico-inschatting in deze 
patiënten is belangrijk zodat optimaal medisch beleid 
 
 
246
toegepast kan worden voor risicoreductie. β-Blokkers 
worden geadviseerd in hoogrisico patiënten en statines 
zouden overwogen moeten worden. Risico reductie 
moet gericht zijn zowel op de korte-termijn als lange-
termijn periode.  
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